

1  
2 **Association between Bisphosphonate use and COVID-19 related outcomes: a**  
3 **retrospective cohort study**  
4  
5

6 Jeffrey Thompson<sup>1\*</sup>, Yidi Wang<sup>2\*</sup>, Tobias Dreischulte<sup>3</sup>, Olga Barreiro<sup>2</sup>, Rodrigo J. Gonzalez<sup>2</sup>,  
7 Pavel Hanč<sup>2</sup>, Colette Matysiak<sup>2</sup>, Harold R. Neely<sup>2</sup>, Marietta Rottenkolber<sup>3</sup>, Tom Haskell<sup>1</sup>,  
8 Stefan Endres<sup>4,5</sup>, and Ulrich H. von Andrian<sup>2,6,\$</sup>  
9

10  
11  
12 *Author Information*  
13

14 <sup>1</sup> Cerner Enviza, 51 Valley Stream Pkwy, Malvern, PA 19355

15 <sup>2</sup> Dept. of Immunology, Harvard Medical School, Boston, MA 02115

16 <sup>3</sup> Institute of General Practice and Family Medicine, University Hospital of Ludwig-  
17 Maximilians-University Munich, Pettenkofenstr. 10, 80336 Munich, Germany

18 <sup>4</sup> Center of Integrated Protein Science Munich and Division of Clinical Pharmacology,  
19 University Hospital, LMU Munich, Germany

20 <sup>5</sup> Einheit für Klinische Pharmakologie (EKLiP), Helmholtz Zentrum München, German  
21 Research Center for Environmental Health, Neuherberg, Germany

22 <sup>6</sup> The Ragon Institute of MGH, MIT and Harvard, Cambridge, MA  
23

24  
25 \* Equal contribution  
26  
27

28  
29 \$ Send correspondence to:  
30

31 Ulrich H. von Andrian, M.D.

32 Dept. of Immunology

33 Harvard Medical School

34 Boston, MA 02115, USA  
35

36 Ph: +617-432-6827

37 Fax: +617-432-6828  
38

39 Email: [uva@hms.harvard.edu](mailto:uva@hms.harvard.edu)  
40

41 **ABSTRACT**

42

43 *Background:*

44 Although there are several efficacious vaccines against COVID-19, vaccination rates in many  
45 regions around the world remain insufficient to prevent continued high disease burden and  
46 emergence of viral variants. Repurposing of existing therapeutics that prevent or mitigate  
47 severe COVID-19 could help to address these challenges. The objective of this study was to  
48 determine whether prior use of bisphosphonates is associated with reduced incidence and/or  
49 severity of COVID-19.

50

51 *Methods:*

52 A retrospective cohort study utilizing payer-complete health insurance claims data from  
53 8,239,790 patients with continuous medical and prescription insurance from 1-1-2019 to 6-  
54 30-2020 was performed. The primary exposure of interest was use of any bisphosphonate  
55 from 1-1-2019 to 2-29-2020. Outcomes of interest included: (a) testing for SARS-CoV-2  
56 infection; (b) COVID-19 diagnosis; and (c) hospitalization with COVID-19 diagnosis between  
57 3-1-2020 and 6-30-2020.

58

59 *Results:*

60 7,906,603 patients for whom continuous medical and prescription insurance information was  
61 available were selected. 450,366 bisphosphonate users were identified and 1:1 propensity  
62 score-matched to bisphosphonate non-users by age, gender, insurance type, primary-care-  
63 provider visit in 2019, and comorbidity burden. Bisphosphonate users had lower odds ratios  
64 (OR) of testing for SARS-CoV-2 infection (OR=0.22; 95%CI:0.21-0.23; p<0.001), COVID-19  
65 diagnosis (OR=0.23; 95%CI:0.22-0.24; p<0.001), and COVID-19-related hospitalization  
66 (OR=0.26; 95%CI:0.24-0.29; p<0.001). Sensitivity analyses yielded results consistent with  
67 the primary analysis. Bisphosphonate-use was also associated with decreased odds of acute  
68 bronchitis (OR=0.23; 95%CI:0.22-0.23; p<0.001) or pneumonia (OR=0.32; 95%CI:0.31-0.34;  
69 p<0.001) in 2019, suggesting that bisphosphonates may protect against respiratory infections  
70 by a variety of pathogens, including but not limited to SARS-CoV-2.

71

72 *Conclusions:*

73 Prior bisphosphonate-use was associated with dramatically reduced odds of SARS-CoV-2  
74 testing, COVID-19 diagnosis, and COVID-19-related hospitalizations. Prospective clinical  
75 trials will be required to establish a causal role for bisphosphonate-use in COVID-19-related  
76 outcomes.

77

78 *Funding:*

79 This study was supported by NIH grants, AR068383 and AI155865, a grant from MassCPR  
80 (to U.H.v.A.) and a CRI Irvington postdoctoral fellowship, CRI2453 (to P.H.).

81

## 82 INTRODUCTION

83

84 Throughout the COVID-19 pandemic, massive global efforts to repurpose existing drugs as  
85 potential therapeutic options for COVID-19 have been undertaken. Drug repurposing,  
86 whereby a drug already proven to be safe and effective in humans for another approved  
87 clinical indication is evaluated for novel clinical use, may allow for faster identification and  
88 deployment of therapeutic agents compared to traditional drug discovery pipelines. Using *in*  
89 *silico* and *in vitro* analyses, a growing list of drugs have been suggested to be potentially  
90 efficacious in treating COVID-19 by either direct or indirect antiviral actions<sup>1</sup>. Another  
91 potentially beneficial class of drugs may be agents that boost or modulate anti-viral immune  
92 responses to SARS-CoV-2 infection to reduce clinical symptoms and/or mitigate disease  
93 progression. Regardless of the mechanism of action, ultimately, randomized prospective  
94 clinical studies are needed to test the safety and efficacy of each candidate in treating or  
95 preventing COVID-19. Observational studies can help prioritize candidates for prospective  
96 clinical testing, by examining associations between the use of a candidate drug and the  
97 incidence or severity of disease in users compared to a matched group of non-users. Drugs  
98 with strong observational evidence for potential effectiveness against COVID-19 may then be  
99 considered for prospective trials<sup>1</sup>.

100

101 Here, we have investigated bisphosphonates (BPs), a class of small-molecule drugs that  
102 inhibit bone resorption by osteoclasts<sup>2</sup>. BPs are widely prescribed as either oral or  
103 intravenous formulations to treat osteoporosis, Paget disease, and malignancy-induced  
104 hypercalcemia. Additionally, BPs are used as adjuvant therapy for breast cancer<sup>3</sup>. BPs are  
105 subdivided into two classes, nitrogen-containing (amino-BPs) and nitrogen-free BPs (non-  
106 amino-BPs)<sup>4</sup>. Both accumulate in bone but have distinct molecular mechanisms by which  
107 they kill osteoclasts to prevent bone resorption<sup>2</sup>.

108

109 Aside from depleting osteoclasts, clinical and experimental studies indicate that BPs exert a  
110 plethora of immunomodulatory effects, providing a rationale for exploring BPs as potential  
111 repurposed drug candidates for COVID-19 (ref. <sup>5</sup>). Indeed, amino-BPs regulate the activation,  
112 expansion, and/or function of a major subset of human  $\gamma\delta$ T cells<sup>6-8</sup> as well as neutrophils<sup>9</sup>,  
113 monocytes<sup>10</sup>, and macrophages<sup>11,12</sup>; they can modulate the antigen-presentation capacity of  
114 dendritic cells<sup>13</sup>; and in animal studies, both amino-BPs and non-amino-BPs exerted potent  
115 adjuvant-like activity to boost antibody and T cells responses to viral antigens<sup>14</sup>. Furthermore,  
116 observational studies have reported decreased in-hospital mortality for patients in the ICU<sup>15</sup>,  
117 and reduced incidence of pneumoniae and pneumonia-related mortality in patients treated  
118 with amino-BPs versus controls<sup>16</sup>. These immunological and clinical effects of BPs combine  
119 with several other characteristics that make BPs well-suited as repurposed drug candidates  
120 in the context of a pandemic: they are globally accessible as generics, affordable,  
121 straightforward to administer, and have known safety profiles in adult<sup>17</sup> and paediatric  
122 populations<sup>18,19</sup>.

123

124 In light of these considerations, we have analysed a database of health insurance claims in  
125 the U.S. to determine if prior BP-use is associated with a differential incidence and/or severity  
126 of COVID-19-related outcomes. Specifically, we assessed the relationship between use of  
127 BPs and COVID-19-related hospitalizations and COVID-19 diagnosis, as well as testing for  
128 SARS-CoV-2 infection (as a proxy for severe COVID-19 symptoms given the restricted  
129 access to testing during the initial surge). Outcomes were measured from March 1, 2020 to

130 June 30, 2020, a period that roughly coincided with the first wave of COVID-19 in the U.S.  
131 and predated the advent of potential outcome modifiers, such as vaccines or other effective  
132 treatment options.

## 133 **METHODS**

### 134 *Study Design*

135 A retrospective cohort study was performed using health insurance claims data from January  
136 1, 2019 to June 30, 2020 (study period) in order to assess the relationship between use of  
137 BPs and three COVID-19-related outcomes: (a) testing for SARS-CoV-2 infection; (b)  
138 COVID-19 diagnosis; and (c) hospitalization with a COVID-19 diagnosis, whereby COVID-19-  
139 related hospitalization was deemed the primary endpoint and COVID-19 diagnosis and  
140 testing were secondary endpoints. Primary and secondary endpoints were assessed during  
141 the observation period of March 1, 2020 to June 30, 2020, roughly corresponding to the first  
142 nation-wide surge of COVID-19 in the U.S. (**Fig. 1A**). In the primary analysis, the risk of  
143 COVID-19-related outcomes was assessed among BP users compared to a matched sample  
144 of BP non-users with similar demographic and clinical characteristics.

### 145 146 *Data Source*

147 Data used for this study included closed medical (inpatient and outpatient) and outpatient-  
148 pharmacy-dispensed claims between January 1, 2019 and June 30, 2020, from the Komodo  
149 Health payer-complete dataset (<https://www.komodohealth.com>). This dataset is derived from  
150 over 150 private insurers in the U.S. and includes patients with commercial, individual, state  
151 exchange-purchased, Medicare Advantage, and Medicaid managed-care insurance coverage.  
152 The dataset also provides information on insurance eligibility periods. Closed claims within  
153 this dataset represent those that had undergone insurance adjudication. In total, the Komodo  
154 Health payer-complete dataset includes health insurance claims data from over 140 million  
155 individuals in the U.S. from 2015 to 2020.

### 156 157 *Cohort Definition*

158 All patients were required to have continuous medical and prescription insurance eligibility  
159 during the entire study period. Patients with missing information for age, gender, insurance  
160 type, or state/region were excluded.

### 161 162 *Exposures of Interest*



163 The primary exposure of interest was the use of any amino- or non-amino BP medication.  
164 Exposure to BPs and all other medications of interest were assessed over a 14-month pre-  
165 observation period preceding the COVID-19 pandemic in the U.S. This long duration was  
166 chosen because of the extended bioavailability of BPs, which accumulate in bone where they  
167 are retained and slowly released for up to several years<sup>20</sup>. Patients were classified as BP  
168 users if they had any claim at any time during the pre-observation period for one of the  
169 following: alendronate, alendronic acid, etidronate, ibandronate, ibandronic acid, pamidronate,  
170 risedronate, and zoledronic acid (full details in **Appendix 1**).

### 171 172 *Timing of BP Dose*

173 The effect of timing and formulation of BPs on COVID-19-related outcomes was more closely  
174 examined by varying the window between BP exposure and outcome measurement. The  
175 primary analysis BP user cohort, along with their propensity-score matched (see below for  
176 cohort matching) BP non-user cohort, were stratified as follows: two cohorts were used as the  
177 reference comparator with known BP-exposure during all or most of the pre-observation and  
178 the entire observation period, specifically (i) BP users who took oral alendronic acid (dosed  
179 daily or weekly) throughout the pre-observation period (i.e. at least one claim or drug-on-hand

180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232

A  
B



**Figure 1: Study Periods, Cohort Selection, and Analyses of BP use on COVID-19-Related Outcomes**

**A.** Schematic overview of the study timeline. **B.** Schematic flow diagram illustrating the identification of the study population and matched control populations for primary analysis and sensitivity analyses cohorts. *BP*: bisphosphonate; *CA*: California; *CCI*: Charlson comorbidity index; *CI*: confidence interval; *COPD*: chronic obstructive pulmonary disease; *FL*: Florida; *IL*: Illinois; *NY*: New York; *OR*: odds ratio; *PCP*: primary care physician; *PS*: propensity score; *PSM*: propensity score match

233 in each quarter in 2019 and in Jan/Feb. 2020) that also had a days-supply extending past  
234 June 30, 2020, and (ii) users of infusion zoledronic acid (dosed annually) with a claim in Q3  
235 or Q4 2019; two cohorts with BP-exposure only during the pre-observation period, namely (iii)  
236 users of alendronic acid occurring during the first six months of 2019 with days-covered  
237 ending prior to June 30, 2019 and no other BP claims thereafter, and (iv) users of zoledronic  
238 acid in January or February 2019 with no other BP claims during the remainder of the study  
239 period; and, two cohorts with short-term BP exposure, specifically new users of (v) alendronic  
240 acid or (vi) zoledronic acid in February 2020, with no prior BP claims during the pre-  
241 observation period.

242

### 243 *Covariates*

244 As covariates, we considered factors that may influence either the use of BPs or potential  
245 modulators of primary or secondary study endpoints. These included: age; gender; insurance  
246 type (commercial, dual, Medicaid, Medicare); having had any primary care physician (PCP)  
247 visit in 2019; and comorbidity burden. The variable 'PCP visit in 2019' was used to control for  
248 prior healthcare-use behaviour and was assigned based on any physician office claim from  
249 January 1, 2019 to December 31, 2019 with one of the following provider types: family  
250 practice, general practice, geriatric medicine, internal medicine, and preventive medicine.  
251 Comorbidity score assignment was calculated following the Charlson Comorbidity Index (CCI)  
252 methodology<sup>21</sup>, and was based on diagnosis codes present on any medical claim (inpatient or  
253 outpatient) occurring during the pre-observation period. The assigned CCI score was used as  
254 the comorbidity covariate for the primary cohort propensity score matching, but to better  
255 control for differences in comorbidity burden when assessing outcomes, all regression  
256 analyses involving the primary analysis cohort included the following individual comorbidity  
257 covariates in lieu of the aggregate CCI score: osteoporosis, cancer, chronic obstructive  
258 pulmonary disease (COPD), depression, dyslipidaemia, hypertension, obesity, type 2  
259 diabetes, cardiovascular disease overall, sickle cell anemia, stroke, dementia, HIV/AIDS,  
260 chronic kidney disease/end-stage renal disease (CKD/ESRD), and liver disease (**Appendix**  
261 **1**).

262

### 263 *Cohort Matching*

264 For the primary analysis, BP users were propensity-score (PS) matched to BP non-users via  
265 a PS calculated using multiple variables, including age, gender, insurance type, CCI, and any  
266 PCP visit in 2019, to yield comparable populations by demographics and clinical  
267 characteristics (**Fig. 1B**). To account for the differential geographic spread of COVID-19  
268 across the U.S. during the observation period, matching was performed within each  
269 geographic region separately (Northeast, Midwest, South, West) and then combined. In  
270 addition to this within-region stratified match, a cohort build was also performed after  
271 restricting to patients from New York (NY) state only, since this state was the site of the  
272 largest outbreak in the initial COVID-19 surge in the U.S. All matching algorithms used a  
273 greedy-match propensity score technique<sup>22</sup> to match BP users to non-users with a maximum  
274 permitted propensity-score difference of 0.015.

275

### 276 *Definition of Endpoints*

277 Primary and secondary endpoints were assigned using inpatient and outpatient medical  
278 claims that occurred during the four-month observation period. The primary endpoint, COVID-  
279 19-related hospitalization, was assigned based on the presence of an International

280 Classification of Diseases, Tenth Revision (ICD-10) code on any inpatient medical service  
281 claim indicating test-confirmed 2019 Novel Coronavirus (2019-nCoV) acute respiratory  
282 disease, specifically U07.1. The first secondary endpoint, SARS-CoV-2 testing, was assigned  
283 using Current Procedural Terminology (CPT) codes indicating a test for active infection,  
284 specifically 87635, 87636, and 87637. The second secondary endpoint, COVID-19-related  
285 diagnosis, was assigned based on any medical service claim with the ICD-10 diagnosis code  
286 U07.1.

287

### 288 *Statistical Analysis*

289 To analyze data, MySQL, Excel, and SAS 9.4 was used on a secure hosted environment  
290 provided by Komodo Health. All data used in this study was subject to data restrictions per  
291 working agreements with Komodo Health, which dictated that only aggregate results can be  
292 exported (no patient-level data), so no deidentified data can be shared.

293 Unadjusted analyses assessing the association between BP-use and COVID-19-related  
294 outcomes were performed for the primary analysis cohort using chi-square tests for  
295 categorical variables and calculation of the crude unadjusted odds ratio (OR) in the matched  
296 cohort groups overall, when stratified by region and in NY state alone, and when further  
297 stratified by age group and gender. Chi-square tests for categorical variables and t-tests for  
298 continuous variables were also performed to assess differences in demographic and clinical  
299 characteristics of BP users compared to BP non-users both pre-match and post-match to  
300 assess the success of the propensity-score match.

301 Multivariate logistic regression analyses, modelled separately to determine the adjusted OR  
302 for each COVID-19-related primary and secondary outcome while adjusting for demographic  
303 and clinical characteristics, were performed on the matched primary analysis cohort with all  
304 regions combined, when stratified by region, and in NY state alone. The primary exposure of  
305 interest was BP-use (yes/no) during the pre-observation period. Additional  
306 demographic/clinical characteristics also included as regression model covariates were: age  
307 group, gender, region (for all regions-combined analyses), insurance type, PCP visit in 2019,  
308 and the following comorbid conditions: osteoporosis, cancer, COPD, depression,  
309 dyslipidaemia, hypertension, obesity, type 2 diabetes, cardiovascular disease overall, sickle  
310 cell anaemia, stroke, dementia, HIV/AIDS, CKD/ESRD, and liver disease.

311 All tests were two-tailed, and  $p$ -values of less than 0.05 were considered significant. All  
312 analyses were performed using SAS 9.4 (Cary, NC).

313

### 314 *Sensitivity Analyses*

315 Multiple sensitivity analyses were performed to assess the reliability of the primary analysis  
316 results and/or to address potential unmeasured confounding (full details in **Appendix 1**).

317 [1] The first sensitivity analysis addressed potential confounding by indication (i.e. the  
318 possibility of the indication for BP use rather than BP use itself being responsible for  
319 differences in outcomes among BP users and non-users) by restricting the control  
320 group to an active comparator cohort of patients who had used non-BP anti-resorptive  
321 bone medications during the pre-observation period. Users of non-BP anti-resorptive  
322 bone medications, the smaller patient population, were then 1:1 matched to BP users,  
323 providing a sample where all patients had used bone health medications during the  
324 pre-observation period ("*Bone-Rx*" cohort) (**Fig. 1B**). Cohort matching and regression



325 modelling were performed following the same methodology employed for the primary  
326 analysis.

- 327 [2] The second sensitivity analysis further addressed potential baseline differences  
328 between users of BPs and users of non-BP anti-resorptive bone medications in terms  
329 of indication for treatment and risk of SARS-CoV-2 exposure. To homogenise  
330 indication for treatment, we restricted the “Bone-Rx” cohort to females aged older than  
331 50 years with an osteoporosis diagnosis (ICD-10: M80.x, M81.x, M82.x), which is the  
332 main (but not the only) indication for use of anti-resorptive bone medications. In order  
333 to homogenise risk of COVID-19 exposure, we additionally (a) restricted both groups  
334 to residents of New York, Illinois, Florida, and California (four states with a high  
335 incidence of COVID-19 cases during the observation period, with each representing a  
336 geographic region)<sup>23</sup>, and (b) matched within each state by insurance-type strata (i.e.  
337 BP non-users matched to BP users with Medicaid coverage residing in New York) to  
338 control for differences in socioeconomic characteristics. Non-BP anti-resorptive bone  
339 medication users were then matched to BP users by age, PCP visit in 2019, and the  
340 following select comorbid conditions that include those thought to impact COVID-19  
341 severity: cancer, COPD, depression, dyslipidaemia, heart failure, hypertension, obesity,  
342 and type 2 diabetes<sup>24</sup>. In addition to assessing COVID-19-related outcomes, the  
343 matched cohorts that resulted from this analysis, older female patients from New York,  
344 Illinois, Florida, or California with a diagnosis of osteoporosis who were users of BP or  
345 non-BP anti-resorptive medications (“*Osteo-Dx-Rx*” cohort), were used for the third  
346 and fourth sensitivity analyses (see below).
- 347 [3] The third sensitivity analysis evaluated the relationship between BP-use and  
348 exploratory negative control outcomes that were not anticipated to be impacted by the  
349 pharmacological mechanism of BPs. Separate comparisons were made in the primary  
350 cohort, the “*Bone-Rx*” cohort, and the “*Osteo-Dx-Rx*” cohort to evaluate the odds of  
351 any acute cholecystitis or acute pancreatitis-related inpatient/emergency-room (ER)  
352 service, which were chosen since both would present in an acute manner that require  
353 emergency intervention. These exploratory outcomes were assessed: (1) during the  
354 observation period among the already matched BP user/non-user populations; and (2)  
355 during a pre-pandemic period (the second half of 2019) when restricted to BP users in  
356 the first half of 2019 and their previously-assigned BP non-user matched pair to  
357 mitigate any COVID-19-related impacts on healthcare resource utilization.
- 358 [4] The fourth sensitivity analysis assessed the relationship between BP-use and  
359 exploratory positive control outcomes (anticipated to be impacted by the  
360 immunomodulatory pharmacological mechanism of BPs) occurring in 2019. For this  
361 analysis, the primary, “*Bone-Rx*”, and “*Osteo-Dx-Rx*” cohorts were restricted to BP  
362 users who had any BP claim during the first half of 2019 and their previously-assigned  
363 BP non-user matched pair to assess the relationship between BP-use and medical  
364 services for other respiratory infectious diseases (acute bronchitis, pneumonia).
- 365 [5] The fifth sensitivity analysis addressed potential bias due to the 'healthy adherer' effect,  
366 whereby users of a preventive drug may have better disease outcomes due to their  
367 healthier behaviours rather than due to drug treatment itself<sup>25</sup>. Two strategies were  
368 employed to validate the findings from our primary analysis while controlling for the  
369 potential impact of healthy adherer effect-associated bias. First, we tested whether  
370 effects observed with exposure to BPs were similarly observed with exposure to other  
371 preventive drugs, namely statins, antihypertensives, antidiabetics, and antidepressants.

372 Second, we assessed whether the association between BP-use and COVID-19-related  
373 outcomes was maintained among the matched user/non-user populations of these  
374 other preventive drugs, i.e. BP users were compared to BP non-users within, for  
375 example, the statin user population and separately within the matched statin non-user  
376 population.

377

378

## RESULTS

379

### *Study Population*

380

381

382

383

384

385

386

A total of 8,239,790 patients met the inclusion criterion of continuous medical and prescription insurance eligibility over the full study period, of which 333,107 were excluded due to missing demographic information, resulting in a total eligible sample of 7,906,603 patients (**Fig. 1B**). Of this full population, 452,051 (5.7%) and 7,454,552 (94.3%) patients were classified as BP users and BP non-users, respectively. Within BP users, more than 99% were prescribed an amino-BP, with oral alendronic acid (75.4%), zoledronic acid infusion (11.5%), and oral ibandronic acid (8.4%) as the most prevalent formulations (**Table S1**).

387

388

389

390

391

392

393

394

395

396

397

398

399

400

401

402

Prior to propensity-score matching, there were significant differences between BP users and non-users across all demographic and clinical characteristics. BP users were older (age >60: 82.7% versus 27.7%;  $p<0.001$ ), predominantly female (91.0% versus 57.2%;  $p<0.001$ ), with a higher comorbidity burden (mean CCI 0.95 versus 0.60;  $p<0.001$ ), with a larger proportion of patients residing in the Western U.S. (21.1% versus 15.4%;  $p<0.001$ ), covered by Medicare (43.3% versus 13.7%;  $p<0.001$ ), and having visited a PCP in 2019 (63.8% versus 44.7%;  $p<0.001$ ). Propensity-score matching yielded 450,366 BP users and 450,366 BP non-users with no significant differences across all characteristics used in matching (**Table 1**). Differences did exist, however, in the distribution of individual comorbid condition indicators that were used as covariates in the regression analysis, with the BP non-user cohort having a higher proportion of patients with COPD (10.2% versus 8.5%;  $p<0.001$ ), cardiovascular disease (25.1% versus 18.7%;  $p<0.001$ ), dyslipidemia (36.9% versus 34.6%;  $p<0.001$ ), hypertension (46.4% versus 38.8%;  $p<0.001$ ), obesity (10.3% versus 6.7%;  $p<0.001$ ), and type 2 diabetes (22.9% versus 18.2%;  $p<0.001$ ). Over 98% of all BP user/non-user matches for the primary analysis cohort were completed with differences in matched propensity scores  $<0.000001$  (overall mean difference of 0.000004, max difference of 0.0147).

403

404

405

406

407

408

Similar profiles in pre-match *versus* post-match characteristics were seen when patients were stratified by region or restricted to NY-state (**Tables S2A-E**). Demographic distributions, including differences between BP user *versus* BP non-user characteristics pre- and post-matching for all sensitivity analysis cohorts are detailed in **Appendix 2**.

409

410

411

412

413

414

### *BP use and COVID-19-Related Outcomes*

Among the full matched cohort, BP users had significantly lower rates and unadjusted (crude) odds of testing (1.2% vs. 5.1%; OR=0.22; 95%CI:0.21-0.22;  $p<0.001$ ), diagnosis (0.7% vs. 2.9%; OR=0.22; 95%CI:0.21-0.23;  $p<0.001$ ), and hospitalization (0.2% vs. 0.7%; OR=0.24; 95%CI:0.22-0.26;  $p<0.001$ ) as compared to BP non-users (**Fig. 2**). Consistent findings were seen when sub-stratifying the full matched cohort by age, gender, age\*gender, within grouped regions, by individual region, and in NY-state alone (**Tables S3A-F**).

415

416

417

Multivariate regression analyses yielded similar results for all outcomes while additionally controlling for patient demographic and comorbidity characteristics. In the full matched cohort, BP users had lower adjusted odds of testing (OR=0.22; 95%CI:0.21-0.23;  $p<0.001$ ),

418 diagnosis (OR=0.23; 95%CI:0.22-0.24; p<0.001), and hospitalizations (OR=0.26;  
419 95%CI:0.24-0.29; p<0.001). These findings were robust when comparing BP users with BP  
420 non-users when stratified by geographic region or NY-state alone.  
421

422  
423

**Table 1: Primary Analysis Cohort (All Regions), Patient Characteristics Pre/Post Match**

	All Observations Unmatched							All Observations Matched						
	All		BP Non-users		BP Users		p-value	All		BP Non-users		BP Users		p-value
	N	%	N	%	N	%		N	%	N	%	N	%	
<b>All Patients</b>	<b>7,906,603</b>	<b>100.0%</b>	<b>7,454,552</b>	<b>94.3%</b>	<b>452,051</b>	<b>5.7%</b>		<b>900,732</b>	<b>100.0%</b>	<b>450,366</b>	<b>50.0%</b>	<b>450,366</b>	<b>50.0%</b>	
<b>Demographics</b>														
<b>Age</b>														
≤20	1,840,050	23.3%	1,838,922	24.7%	1,128	0.2%	<0.001	2,253	0.3%	1,125	0.2%	1,128	0.3%	1.00
21-40	1,446,999	18.3%	1,443,908	19.4%	3,091	0.7%		6,195	0.7%	3,104	0.7%	3,091	0.7%	
41-50	925,309	11.7%	916,758	12.3%	8,551	1.9%		17,096	1.9%	8,545	1.9%	8,551	1.9%	
51-60	1,250,190	15.8%	1,184,469	15.9%	65,721	14.5%		131,445	14.6%	65,724	14.6%	65,721	14.6%	
61-70	1,181,261	14.9%	1,024,383	13.7%	156,878	34.7%		313,822	34.8%	156,944	34.8%	156,878	34.8%	
71-80	783,775	9.9%	642,050	8.6%	141,725	31.4%		280,803	31.2%	140,366	31.2%	140,437	31.2%	
≥81	479,019	6.1%	404,062	5.4%	74,957	16.6%		149,118	16.6%	74,558	16.6%	74,560	16.6%	
<b>Gender</b>														
Female	4,670,960	59.1%	4,263,524	57.2%	407,436	90.1%	<0.001	811,497	90.1%	405,746	90.1%	405,751	90.1%	0.99
Male	3,235,643	40.9%	3,191,028	42.8%	44,615	9.9%		89,235	9.9%	44,620	9.9%	44,615	9.9%	
<b>Region</b>														
Midwest	1,467,802	18.6%	1,391,835	18.7%	75,967	16.8%	<0.001	151,802	16.9%	75,901	16.9%	75,901	16.9%	1.00
Northeast	2,152,560	27.2%	2,032,832	27.3%	119,728	26.5%		238,988	26.5%	119,494	26.5%	119,494	26.5%	
South	3,042,604	38.5%	2,881,718	38.7%	160,886	35.6%		319,408	35.5%	159,704	35.5%	159,704	35.5%	
West	1,243,637	15.7%	1,148,167	15.4%	95,470	21.1%		190,534	21.2%	95,267	21.2%	95,267	21.2%	
<b>Insurance</b>														
Commercial	3,938,603	49.8%	3,791,545	50.9%	147,058	32.5%	<0.001	294,070	32.6%	147,012	32.6%	147,058	32.7%	1.00
Dual	156,497	2.0%	125,090	1.7%	31,407	6.9%		59,936	6.7%	29,980	6.7%	29,956	6.7%	
Medicaid	2,594,500	32.8%	2,517,020	33.8%	77,480	17.1%		154,519	17.2%	77,272	17.2%	77,247	17.2%	
Medicare	1,217,003	15.4%	1,020,897	13.7%	196,106	43.4%		392,207	43.5%	196,102	43.5%	196,105	43.5%	
<b>PCP Visit 2019</b>														
No	4,283,697	54.2%	4,119,831	55.3%	163,866	36.2%	<0.001	327,383	36.3%	163,659	36.3%	163,724	36.4%	0.89
Yes	3,622,906	45.8%	3,334,721	44.7%	288,185	63.8%		573,349	63.7%	286,707	63.7%	286,642	63.6%	
<b>Clinical Characteristics</b>														
	<b>mean</b>	<b>SD</b>	<b>mean</b>	<b>SD</b>	<b>mean</b>	<b>SD</b>	<b>p-value</b>	<b>mean</b>	<b>SD</b>	<b>mean</b>	<b>SD</b>	<b>mean</b>	<b>SD</b>	<b>p-value</b>
<b>CCI</b>	0.62	1.38	0.60	1.35	0.95	1.76	<0.001	0.95	1.76	0.95	1.76	0.95	1.76	0.70
<b>Regression Comorbidity Covariates</b>														
	<b>N</b>	<b>%</b>	<b>N</b>	<b>%</b>	<b>N</b>	<b>%</b>	<b>p-value</b>	<b>N</b>	<b>%</b>	<b>N</b>	<b>%</b>	<b>N</b>	<b>%</b>	<b>p-value</b>
Osteoporosis	267,020	3.4%	135,231	1.8%	131,789	29.2%	<0.001	163,814	18.2%	32,390	7.2%	131,424	29.2%	<0.001
Cancer	419,083	5.3%	366,786	4.9%	52,297	11.6%	<0.001	94,148	10.5%	41,861	9.3%	52,287	11.6%	<0.001
CKD/ESRD	361,451	4.6%	328,633	4.4%	32,818	7.3%	<0.001	68,999	7.7%	36,182	8.0%	32,817	7.3%	<0.001
COPD	466,094	5.9%	427,850	5.7%	38,244	8.5%	<0.001	84,234	9.4%	45,990	10.2%	38,244	8.5%	<0.001
CVD	1,084,031	13.7%	999,526	13.4%	84,505	18.7%	<0.001	197,243	21.9%	112,933	25.1%	84,310	18.7%	<0.001
Dementia	125,811	1.6%	113,778	1.5%	12,033	2.7%	<0.001	24,921	2.8%	12,889	2.9%	12,032	2.7%	<0.001
Depression	571,303	7.2%	531,355	7.1%	39,948	8.8%	<0.001	86,280	9.6%	46,431	10.3%	39,849	8.8%	<0.001
Dyslipidemia	1,532,254	19.4%	1,375,920	18.5%	156,334	34.6%	<0.001	322,125	35.8%	166,360	36.9%	155,765	34.6%	<0.001
HIV/AIDS	33,229	0.4%	31,711	0.4%	1,518	0.3%	<0.001	2,897	0.3%	1,379	0.3%	1,518	0.3%	0.01
Hypertension	1,899,063	24.0%	1,723,519	23.1%	175,544	38.8%	<0.001	384,059	42.6%	209,184	46.4%	174,875	38.8%	<0.001
Liver Disease	251,331	3.2%	231,664	3.1%	19,667	4.4%	<0.001	38,697	4.3%	19,031	4.2%	19,666	4.4%	0.001
Obesity	638,506	8.1%	608,083	8.2%	30,423	6.7%	<0.001	76,844	8.5%	46,498	10.3%	30,346	6.7%	<0.001
Sickle Cell Anemia	10,499	0.1%	10,292	0.1%	207	0.0%	<0.001	422	0.0%	215	0.0%	207	0.0%	0.70
Stroke	104,859	1.3%	97,001	1.3%	7,858	1.7%	<0.001	19,395	2.2%	11,569	2.6%	7,826	1.7%	<0.001
Type 2 Diabetes	978,239	12.4%	895,983	12.0%	82,256	18.2%	<0.001	184,978	20.5%	103,031	22.9%	81,947	18.2%	<0.001

424  
425  
426  
427

BP: bisphosphonate; CCI: Charlson Comorbidity Index; COPD: chronic obstructive pulmonary disease; CKD/ESRD: chronic kidney disease/end-stage renal disease; CVD: cardiovascular disease (overall); PCP: primary care physician; SD: standard deviation

428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484

	Incidence of outcome events by exposure to bisphosphonates		Odds of Event		Adjusted OR Forest Plot
	Number of events / non-user patients (%)	Number of events / user patients (%)	Crude OR (95%CI)	Adjusted OR (95%CI)	
<b>(i) All Regions Combined</b>					
SARS-CoV-2 Test	22,948 / 450,366 (5.1)	5,189 / 450,366 (1.2)	0.22 (0.21-0.22)	0.22 (0.21-0.23)	
COVID-19 Diagnosis	13,265 / 450,366 (2.9)	3,024 / 450,366 (0.7)	0.22 (0.21-0.23)	0.23 (0.22-0.24)	
COVID-19 Hospitalization	2,995 / 450,366 (0.7)	715 / 450,366 (0.2)	0.24 (0.22-0.26)	0.26 (0.24-0.29)	
<b>(ii) Region = Northeast</b>					
SARS-CoV-2 Test	7,147 / 119,494 (6.0)	1,684 / 119,494 (1.4)	0.22 (0.21-0.24)	0.23 (0.21-0.24)	
COVID-19 Diagnosis	6,242 / 119,494 (5.2)	1,578 / 119,494 (1.3)	0.24 (0.23-0.26)	0.25 (0.23-0.26)	
COVID-19 Hospitalization	1,191 / 119,494 (1.0)	314 / 119,494 (0.3)	0.26 (0.23-0.30)	0.29 (0.26-0.33)	
<b>(iii) Region = Midwest</b>					
SARS-CoV-2 Test	3,583 / 75,901 (4.7)	868 / 75,901 (1.1)	0.23 (0.22-0.25)	0.24 (0.22-0.26)	
COVID-19 Diagnosis	1,716 / 75,901 (2.3)	383 / 75,901 (0.5)	0.22 (0.20-0.25)	0.24 (0.22-0.27)	
COVID-19 Hospitalization	515 / 75,901 (0.7)	121 / 75,901 (0.2)	0.23 (0.19-0.29)	0.26 (0.21-0.32)	
<b>(iv) Region = South</b>					
SARS-CoV-2 Test	6,865 / 159,704 (4.3)	1,553 / 159,704 (1.0)	0.22 (0.21-0.23)	0.22 (0.21-0.23)	
COVID-19 Diagnosis	2,911 / 159,704 (1.8)	624 / 159,704 (0.4)	0.21 (0.19-0.23)	0.22 (0.20-0.24)	
COVID-19 Hospitalization	682 / 159,704 (0.4)	167 / 159,704 (0.1)	0.24 (0.21-0.29)	0.26 (0.23-0.30)	
<b>(v) Region = West</b>					
SARS-CoV-2 Test	5,353 / 95,267 (5.6)	1,084 / 95,267 (1.1)	0.19 (0.18-0.21)	0.20 (0.18-0.21)	
COVID-19 Diagnosis	2,396 / 95,267 (2.5)	439 / 95,267 (0.5)	0.18 (0.16-0.20)	0.19 (0.17-0.21)	
COVID-19 Hospitalization	607 / 95,267 (0.6)	113 / 95,267 (0.1)	0.19 (0.15-0.23)	0.20 (0.16-0.25)	
<b>(vi) Region = New York State</b>					
SARS-CoV-2 Test	2,826 / 49,862 (5.7)	772 / 49,862 (1.5)	0.26 (0.24-0.28)	0.26 (0.24-0.28)	
COVID-19 Diagnosis	2,796 / 49,862 (5.6)	811 / 49,862 (1.6)	0.27 (0.26-0.30)	0.28 (0.26-0.31)	
COVID-19 Hospitalization	486 / 49,862 (1.0)	136 / 49,862 (0.3)	0.28 (0.23-0.34)	0.33 (0.27-0.40)	

**Figure 2: Association of BP use and COVID-19-Related Outcomes**

Incidence (left) and regression-adjusted results for odds (right) of SARS-CoV-2 testing (blue), COVID-19 diagnosis (purple), and COVID-19-related hospitalizations (red) of BP users compared with BP non-users in the all-regions combined primary analysis cohort (i) and when stratified by region/state into: Northeast (ii), Midwest (iii), South (iv), West (v), and New York state (vi).

485 *Timing of last BP exposure and COVID-19-Related Outcomes*

486 The above results demonstrate that any BP exposure during the 14-months pre-observation  
487 period is associated with a marked reduction in each of the three COVID-19-related  
488 outcomes. To further investigate the relationship between COVID-19-related outcomes and  
489 the timing of BP exposure, we focused on the two most commonly prescribed BPs,  
490 alendronic acid (oral formulation dosed daily or weekly) and zoledronic acid (infusion dosed  
491 annually). For each BP type, COVID-19-related outcomes were assessed among users: (i-ii)  
492 with exposure or days covered (based on prescription frequency) during the pre-observation  
493 period and throughout the observation period; (iii-iv) with exposure or days covered ending  
494 prior to the observation period; and (v-vi) newly initiating therapy prior to the observation  
495 period (**Fig. 3A**). Strikingly, all subgroups of BP users had decreased odds of COVID-19-  
496 related outcomes (**Fig. 3B**) except for the odds of hospitalization among zoledronic acid  
497 users who were last dosed in January/February of 2019 (OR=0.52; 95%CI:0.20-1.40; p=0.20)  
498 or newly initiated in February of 2020 (OR=0.49; 95%CI:0.13-1.88; p=0.30).

500 *Sensitivity Analysis 1: COVID-19-Related Outcomes Among All Users of Anti-Resorptive*  
501 *Medications ("Bone-Rx" Cohort)*

502 The first sensitivity analysis was performed to address potential confounding by indication. To  
503 validate our primary findings in more comparable cohorts, analysis was restricted to  
504 comparing BP users to patients using non-BP anti-resorptive bone medications during the  
505 pre-observation period. Compared to non-BP users of anti-resorptive medications, BP users  
506 had decreased odds of testing (OR=0.31; 95%CI:0.28-0.33; p<0.001), diagnosis (OR=0.35;  
507 95%CI:0.31-0.38; p<0.001), and hospitalization (OR=0.45; 95%CI:0.36-0.56; p<0.001) (**Fig.**  
508 **4A**). Furthermore, these findings were robust when assessed separately across every  
509 geographic region as well as NY state for all outcomes except hospitalizations when  
510 restricted to the Western U.S. (p=0.08; **Table S4**).

512 *Sensitivity Analysis 2: COVID-19-Related Outcomes Among Users of Anti-Resorptive*  
513 *Medications with a Diagnosis of Osteoporosis ("Osteo-Dx-Rx" Cohort)*


514 The second sensitivity analysis was performed to address the fact that, even after restricting  
515 the comparator cohort to users of anti-resorptive medications, differences may still exist  
516 between patient cohorts that could affect COVID-19-related outcomes, including different  
517 indications for anti-resorptive medication use and other uncontrolled patient characteristics.  
518 To address this, the association between BP use and COVID-19 related outcomes were  
519 examined in a cohort restricted to female patients over 50 years old, with a diagnosis of  
520 osteoporosis, using either a BP or a non-BP anti-resorptive bone medication, matched within  
521 insurance-type as a proxy for socioeconomic status, and selected from four states (NY, IL, FL,  
522 CA) with high incidences of COVID-19 cases during the observation period<sup>23</sup> ("*Osteo-Dx-Rx*"  
523 cohort). In agreement with the results reported above, the decrease in odds of COVID-19-  
524 related outcomes in BP users remained robust for testing (OR=0.28; 95%CI:0.23-0.35;  
525 p<0.001), diagnosis (OR=0.40; 95%CI:0.32-0.49; p<0.001), and hospitalizations (OR=0.45;  
526 95%CI:0.26-0.75; p=0.003) (**Figure 4B**).

528 *Sensitivity Analysis 3: Association of BP-use with Exploratory Negative Control Outcomes*

529 While the above sensitivity analyses were performed to control for health status differences  
530 between BP users and BP non-users during the pre-observation period, it remained  
531 theoretically possible that BP users exhibited differential health care access that might have

532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580

**A**  
**B**



	Incidence of outcome events by exposure to bisphosphonates		Odds of Event		Adjusted OR Forest Plot	
	Number of events / non-user patients (%)	Number of events / user patients (%)	Crude OR (95%CI)	Adjusted OR (95%CI)		
<b>(i) Alendronic acid dosed full study period</b>						
SARS-CoV-2 Test	5,191 / 107,805 (4.8)	982 / 107,805 (0.9)	0.18 (0.17-0.19)	0.19 (0.17-0.20)		
COVID-19 Diagnosis	3,229 / 107,805 (3.0)	643 / 107,805 (0.6)	0.19 (0.18-0.21)	0.20 (0.18-0.22)		
COVID-19 Hospitalization	724 / 107,805 (0.7)	139 / 107,805 (0.1)	0.19 (0.16-0.23)	0.20 (0.17-0.25)		
<b>(ii) Zoledronic acid dosed Q3/Q4 2019</b>						
SARS-CoV-2 Test	1,831 / 30,718 (6.0)	560 / 30,718 (1.8)	0.29 (0.27-0.32)	0.29 (0.26-0.32)		
COVID-19 Diagnosis	955 / 30,718 (3.1)	181 / 30,718 (0.6)	0.18 (0.16-0.22)	0.23 (0.19-0.27)		
COVID-19 Hospitalization	218 / 30,718 (0.7)	41 / 30,718 (0.1)	0.19 (0.13-0.26)	0.28 (0.19-0.40)		
<b>(iii) Alendronic acid dosed Q1/Q2 2019</b>						
SARS-CoV-2 Test	1,518 / 30,306 (5.0)	382 / 30,306 (1.3)	0.24 (0.22-0.27)	0.24 (0.22-0.28)		
COVID-19 Diagnosis	886 / 30,306 (2.9)	210 / 30,306 (0.7)	0.23 (0.20-0.27)	0.24 (0.20-0.28)		
COVID-19 Hospitalization	206 / 30,306 (0.7)	49 / 30,306 (0.2)	0.24 (0.17-0.32)	0.26 (0.24-0.28)		
<b>(iv) Zoledronic acid dosed January/February 2019</b>						
SARS-CoV-2 Test	156 / 2,829 (5.5)	45 / 2,829 (1.6)	0.28 (0.20-0.39)	0.24 (0.17-0.36)		
COVID-19 Diagnosis	80 / 2,829 (2.8)	25 / 2,829 (0.9)	0.31 (0.19-0.48)	0.32 (0.19-0.54)		
COVID-19 Hospitalization	19 / 2,829 (0.7)	7 / 2,829 (0.2)	0.37 (0.15-0.87)	0.52 (0.20-1.40)		
<b>(v) Alendronic acid dosed February 2020</b>						
SARS-CoV-2 Test	416 / 8,465 (4.9)	95 / 8,465 (1.1)	0.22 (0.18-0.28)	0.22 (0.18-0.28)		
COVID-19 Diagnosis	247 / 8,465 (2.9)	62 / 8,465 (0.7)	0.25 (0.19-0.32)	0.25 (0.19-0.34)		
COVID-19 Hospitalization	52 / 8,465 (0.6)	11 / 8,465 (0.1)	0.21 (0.11-0.40)	0.25 (0.13-0.50)		
<b>(vi) Zoledronic acid dosed February 2020</b>						
SARS-CoV-2 Test	149 / 2,398 (6.2)	48 / 2,398 (2.0)	0.31 (0.22-0.43)	0.32 (0.22-0.46)		
COVID-19 Diagnosis	73 / 2,398 (3.0)	15 / 2,398 (0.6)	0.20 (0.11-0.35)	0.25 (0.13-0.46)		
COVID-19 Hospitalization	13 / 2,398 (0.5)	4 / 2,398 (0.2)	0.31 (0.10-0.94)	0.49 (0.13-1.88)		

**Figure 3: Timing of BP use and COVID-19-Related Outcomes. A.** Schematic of BP user sub-stratification by timing of exposure to alendronic acid or zoledronic acid prior to outcome assessment. Broken lines represent periods of active BP dosing. For zoledronic acid users, days covered was considered to extend 1 year past the dosing period based on dosing guidelines. **B.** Incidence (left) and regression-adjusted results (right) for odds of SARS-CoV-2 testing, COVID-19 diagnosis, and COVID-19-related hospitalizations of BP users compared with BP non-users in pre-specified subgroups. *CI: confidence interval; OR: odds ratio.*

581 **A** (“Bone-Rx” Cohort)

	Incidence of outcome events by exposure to bisphosphonates		Odds of Event		Adjusted OR Forest Plot
	Number of events / non-user patients (%)	Number of events / user patients (%)	Crude OR (95%CI)	Adjusted OR (95%CI)	
<b>All Regions Combined</b>					
SARS-CoV-2 Test	2,438 / 50,498 (4.8)	760 / 50,498 (1.5)	0.30 (0.28-0.33)	0.31 (0.28-0.33)	
COVID-19 Diagnosis	1,307 / 50,498 (2.6)	461 / 50,498 (0.9)	0.35 (0.31-0.39)	0.35 (0.31-0.38)	
COVID-19 Hospitalization	276 / 50,498 (0.5)	123 / 50,498 (0.2)	0.44 (0.36-0.55)	0.45 (0.36-0.56)	

596  
597  
598  
599 **B** (“Osteo-Dx-Rx” Cohort)

	Incidence of outcome events by exposure to bisphosphonates		Odds of Event		Adjusted OR Forest Plot
	Number of events / non-user patients (%)	Number of events / user patients (%)	Crude OR (95%CI)	Adjusted OR (95%CI)	
<b>All Regions Combined</b>					
SARS-CoV-2 Test	395 / 7,949 (5.0)	115 / 7,949 (1.4)	0.28 (0.23-0.35)	0.28 (0.23-0.35)	
COVID-19 Diagnosis	300 / 7,949 (3.8)	121 / 7,949 (1.5)	0.40 (0.32-0.49)	0.40 (0.32-0.49)	
COVID-19 Hospitalization	47 / 7,949 (0.6)	21 / 7,949 (0.3)	0.45 (0.27-0.75)	0.45 (0.26-0.75)	

614  
615 **Figure 4: COVID-19-Related Outcomes Among the Bone-RX and Osteo-Dx-Rx Restricted Cohorts.**  
616 Incidence and forest plots summarizing regression-adjusted odds ratios of SARS-CoV-2  
617 testing (blue), COVID-19 diagnosis (purple), ANDD COVID-19-related hospitalizations (red)  
618 in the (A) “Bone-Rx” and (B) “Osteo-Dx-Rx” sensitivity analysis cohorts.  
619



620 impacted COVID-19-related outcomes. To examine such residual confounding, the third  
621 sensitivity analysis evaluated the incidence of exploratory outcomes not hypothesized to be  
622 modulated by BP-use in the primary, “*Bone-Rx*”, and “*Osteo-Dx-Rx*” cohorts. Outcomes were  
623 measured during the observation period, as well as during a pre-pandemic period (the  
624 second half of 2019), to control for potential reduction in the use of healthcare services<sup>26,27</sup>  
625 during the COVID-19 pandemic. The associations between BP-use and the following  
626 exploratory outcomes, which were anticipated to not be impacted by BP-use, were assessed:  
627 any acute cholecystitis or acute pancreatitis-related inpatient/ER service. Regression  
628 modelling found BP users in the primary analysis cohort to have decreased odds of any  
629 inpatient/ER service for acute cholecystitis (OR=0.55; 95%CI:0.44-0.69; p<0.001) and acute  
630 pancreatitis (OR=0.58; 95%CI:0.49-0.69; p<0.001) during the observation period (**Fig. 5A**),  
631 as well as decreased odds of acute pancreatitis (OR=0.83; 95%CI:0.71-0.96; p=0.01) during  
632 the second half of 2019. BP users in the “*Bone-Rx*” cohort displayed a decreased odds of  
633 service for acute pancreatitis (OR=0.55; 95%CI:0.36-0.87; p=0.01) only during the study  
634 observation period and no significant difference in odds of service for acute cholecystitis  
635 during either periods. Lastly, there was no difference in any outcome between BP users and  
636 BP non-users in the “*Osteo-Dx-Rx*” cohort, although there were very few events in this cohort.

#### 637 638 *Sensitivity Analysis 4: Association of BP-use with Exploratory Positive Control Outcomes*


639 The fourth sensitivity analysis was performed to assess if there is an association between  
640 BP-use and incidence of other respiratory infections, which has been previously reported<sup>16</sup>.  
641 Medical services for acute bronchitis or pneumonia were measured during the second half of  
642 2019, prior to the advent of COVID-19, in the primary, “*Bone-Rx*”, and “*Osteo-Dx-Rx*” cohorts.  
643 Regression modelling found that, among all cohort variations modelled, BP users had a  
644 decreased odds of any medical service related to acute bronchitis (point estimates of ORs  
645 ranged from 0.23 to 0.28) and pneumonia (point estimates of ORs ranged from 0.32 to 0.36)  
646 (**Figure 5B**).

#### 647 648 *Sensitivity Analysis 5: Association of Other Preventive Drugs with COVID-19-Related Outcomes*


650 A potential pitfall in the interpretation of apparent effects of preventive medications on health  
651 outcomes is the so-called healthy adherer effect, whereby patients may have better  
652 outcomes due to their overall healthier behaviours and not due to active drug treatment  
653 itself<sup>25</sup>. To address this possibility of unmeasured confounding, a final sensitivity analysis was  
654 performed to evaluate the association between control exposures (i.e. use of other preventive  
655 medications such as statins, antihypertensives, antidiabetics, and antidepressants) and  
656 COVID-19-related outcomes (**Figure 6A**). In comparison to BPs, the impact of other  
657 preventive drug classes on COVID-19-related outcomes was much weaker overall (**Figure**  
658 **6B-E**) and varied between geographic regions in terms of magnitude or direction (**Table S5A-**  
659 **D**). Furthermore, when assessing the impact of BP-use within matched user/non-user  
660 preventive drug cohorts (e.g. BP users compared to BP non-users among the matched statin  
661 user and statin non-user populations), we found BP-use to be consistently associated with  
662 lower odds of testing (point estimates of ORs ranged from 0.21 to 0.27), diagnosis (point  
663 estimates of ORs ranged from 0.22 to 0.30), and hospitalizations (point estimates of ORs  
664 ranged from 0.25 to 0.33) across all stratified preventive user/non-user cohorts (**Figure 6B-E**).

665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717

A




B




**Figure 5: Exploratory Outcomes among BP Users versus BP Non-users.** Incidence and adjusted odds ratios of (A) expected negative exploratory outcomes and (B) other respiratory infections, in the primary, “Bone-Rx”, and “Osteo-Dx-Rx” cohorts. *CI*: confidence interval; *ER*: emergency room; *OR*: odds ratio.

718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775

A



B



776 C

777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803

	Incidence of outcome events by drug exposure		Odds of Event		Adjusted OR Forest Plot	
	Number of events / non-user patients (%)	Number of events / user patients (%)	Crude OR (95%CI)	Adjusted OR (95%CI)		
<b>Outcomes by Antihypertensive Use</b>						
SARS-CoV-2 Test	106,990 / 1,786,001 (6.0)	98,075 / 1,786,001 (5.5)	0.91 (0.90-0.92)	0.87 (0.86-0.88)		
COVID-19 Diagnosis	57,001 / 1,786,001 (3.2)	49,458 / 1,786,001 (2.8)	0.86 (0.85-0.87)	0.75 (0.74-0.76)		
COVID-19 Hospitalization	10,147 / 1,786,001 (0.6)	11,505 / 1,786,001 (0.6)	1.13 (1.10-1.17)	0.98 (0.95-1.00)		
<b>Outcomes by BP Use Among Antihypertensive Users</b>						
SARS-CoV-2 Test	9,665 / 204,396 (4.7)	2,316 / 204,396 (1.1)	0.23 (0.22-0.24)	0.23 (0.22-0.24)		
COVID-19 Diagnosis	5,748 / 204,396 (2.8)	1,529 / 204,396 (0.7)	0.26 (0.25-0.28)	0.26 (0.25-0.28)		
COVID-19 Hospitalization	1,474 / 204,396 (0.7)	385 / 204,396 (0.2)	0.26 (0.23-0.29)	0.27 (0.24-0.30)		
<b>Outcomes by BP Use Among Antihypertensive Non-users</b>						
SARS-CoV-2 Test	7,334 / 135,724 (5.4)	1,583 / 135,724 (1.2)	0.21 (0.20-0.22)	0.21 (0.20-0.22)		
COVID-19 Diagnosis	3,792 / 135,724 (2.8)	772 / 135,724 (0.6)	0.20 (0.18-0.22)	0.22 (0.20-0.24)		
COVID-19 Hospitalization	686 / 135,724 (0.5)	144 / 135,724 (0.1)	0.21 (0.17-0.25)	0.27 (0.22-0.32)		


804 D

805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832

	Incidence of outcome events by drug exposure		Odds of Event		Adjusted OR Forest Plot	
	Number of events / non-user patients (%)	Number of events / user patients (%)	Crude OR (95%CI)	Adjusted OR (95%CI)		
<b>Outcomes by Antidiabetic Use</b>						
SARS-CoV-2 Test	43,103 / 754,553 (5.7)	42,377 / 754,553 (5.6)	0.98 (0.97-1.00)	0.92 (0.90-0.93)		
COVID-19 Diagnosis	22,924 / 754,553 (3.0)	26,339 / 754,553 (3.5)	1.15 (1.13-1.18)	0.88 (0.86-0.90)		
COVID-19 Hospitalization	4,670 / 754,553 (0.6)	6,993 / 754,553 (0.9)	1.50 (1.45-1.56)	1.13 (1.08-1.18)		
<b>Outcomes by BP Use Among Antidiabetic Users</b>						
SARS-CoV-2 Test	3,536 / 79,500 (4.4)	943 / 79,500 (1.2)	0.26 (0.24-0.28)	0.26 (0.24-0.28)		
COVID-19 Diagnosis	2,732 / 79,500 (3.4)	818 / 79,500 (1.0)	0.29 (0.27-0.32)	0.29 (0.27-0.32)		
COVID-19 Hospitalization	832 / 79,500 (1.0)	237 / 79,500 (0.3)	0.28 (0.24-0.33)	0.29 (0.25-0.34)		
<b>Outcomes by BP Use Among Antidiabetic Non-users</b>						
SARS-CoV-2 Test	3,669 / 72,514 (5.1)	925 / 72,514 (1.3)	0.24 (0.23-0.26)	0.25 (0.23-0.27)		
COVID-19 Diagnosis	2,156 / 72,514 (3.0)	526 / 72,514 (0.7)	0.24 (0.22-0.26)	0.25 (0.23-0.28)		
COVID-19 Hospitalization	500 / 72,514 (0.7)	120 / 72,514 (0.2)	0.24 (0.20-0.29)	0.27 (0.22-0.33)		

833 E

834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858



859 **Figure 6: Association of Other Preventive Drugs with COVID-19-Related Outcomes**  
 860 **A.** Schematic illustrating the identification of study populations and matched controls for each  
 861 drug class. **B-E.** Incidence and adjusted odds ratios of SARS-CoV-2 testing (blue), COVID-19  
 862 diagnosis (purple), and COVID-19-related hospitalizations (red) in users and non-users of (**B**)  
 863 statins, (**C**) antihypertensive medications, (**D**) non-insulin antidiabetic medications, and (**E**)  
 864 antidepressant medications. For each class of preventive medications, further analysis was  
 865 performed comparing BP users and BP non-users within matched cohorts of medication  
 866 users (middle) and medication non-users (bottom). *BP: bisphosphonate; CCI: Charlson*  
 867 *comorbidity index; CI: confidence interval; COPD: chronic obstructive pulmonary disease; OR:*  
 868 *odds ratio; PCP: primary care physician; PS: propensity score; PSM: propensity score match*

## 869 DISCUSSION

870

871 This study examined the association between recent exposure to BPs and subsequent  
872 COVID-19-related outcomes during the initial outbreak of the COVID-19 pandemic in the U.S.  
873 Our findings demonstrate that amino-BP users experienced a three- to five-fold reduced  
874 incidence of SARS-CoV-2 testing, COVID-19 diagnosis, and COVID-19-related  
875 hospitalization during this period. This dramatic difference in outcomes was consistently  
876 observed when comparing BP users to BP non-users in a propensity score-matched general  
877 population, when comparing to users of other anti-resorptive bone medications, when further  
878 restricting the latter cohort to female osteoporosis patients that were matched by  
879 comorbidities within state of residence and by insurance type, and when comparing BP users  
880 to BP non-users stratified by use of other preventive medications. Therefore, although there  
881 are confounding-related limitations inherent within retrospective studies, the consistency and  
882 strength of our observed associations when using various methods to control for unmeasured  
883 confounding support the contention that further prospective research should be performed to  
884 determine the true magnitude of the potential immunomodulatory effects of BP use.

885 Our findings are consistent with previous observational studies, prior to the advent of COVID-  
886 19, that had reported associations between BP use and reduced incidence of pneumonia and  
887 pneumonia-related mortality<sup>16,28,29</sup>. Accordingly, we observed in our population that BP use  
888 was associated with decreased odds of medical services for acute bronchitis and pneumonia  
889 during the second half of 2019. Taken together, these findings suggest that BPs may play a  
890 protective role in respiratory tract infections from a variety of causes, including SARS-CoV-2.

891 Other recent retrospective studies have explored, to some extent, associations of anti-  
892 resorptive medication use and COVID-19-related outcomes, albeit in much smaller patient  
893 populations than were analysed here. One study found no differences in the COVID-19-  
894 related risk of hospitalization, ICU admission, and mortality among 1,997 female patients  
895 diagnosed with COVID-19 who received anti-osteoporosis medication as compared to  
896 propensity score-matched COVID-19 patients who were not receiving such drugs<sup>30</sup>. This  
897 study did not examine the incidence of COVID-19 among BP users, but it raises the  
898 possibility that the subset of BP users who do develop sufficient pathology to be diagnosed  
899 with COVID-19 may have a similar clinical course as BP non-users. Another retrospective  
900 cohort study in Italy examining the association of oral amino-BP use and incidence of COVID-  
901 19-related hospitalization and mortality found no difference between BP users and BP non-  
902 users or users of non-BP anti-resorptive medications<sup>31</sup>. However, the overall incidence of  
903 COVID-19 hospitalization in the primary cohort (151/126,370 patients, or 0.12%) of this study  
904 was markedly lower than in the present analysis (3,710/900,732 patients, or 0.41%). A third  
905 study examined the influence of various anti-osteoporosis drugs, including BPs, on the  
906 cumulative incidence of COVID-19 in 2,102 patients with non-inflammatory rheumatic  
907 conditions that were compared to population estimates in the same geographic region<sup>32</sup>. In  
908 this analysis, users of non-BP anti-resorptive medications and zoledronate, but not users of  
909 oral BPs, had a lower incidence and relative risk of COVID-19 diagnosis and hospitalization.  
910 The observations with zoledronate are consistent with the findings reported here. However,  
911 we did not detect a significant impact of non-BP anti-resorptive medications in comparison to  
912 BPs, and we found a robust association between oral BP use and lower odds of COVID-19  
913 diagnosis and related hospitalization. The reason for these discrepancies is unclear but could  
914 potentially reflect the large disparity in sample size between our study, which differed by more  
915 than three orders of magnitude. A fourth study, which used Israeli insurance data to perform

916 an analysis involving two separate case-control matched cohorts to assess the risk of  
917 COVID-19 hospitalizations when stratified by recent medication use, also found that the odds  
918 COVID-19-related hospitalizations were lower among users of BPs, and ranged from an OR  
919 of 0.705 (95%CI: 0.522 to 0.935) to 0.567 (95%CI:0.400 to 0.789)<sup>33</sup>.

920 The large size of our dataset allowed for a range of fully powered, stratified analyses to be  
921 performed to explore the robustness of our findings and to address unmeasured confounding  
922 factors and other sources of potential bias that can occur in retrospective studies using  
923 insurance claims data. These sensitivity analyses included: (1) comparing the effect of BP  
924 use and active control exposure, namely non-BP anti-resorptive bone medication; (2) further  
925 reducing unmeasured confounding by restricting sensitivity analysis (1) to females older than  
926 50 years, diagnosed with osteoporosis, matched within state and insurance type and  
927 matched by comorbid conditions thought to impact COVID-19 severity; (3) assessing the  
928 effect of BP-use on exploratory negative control outcomes (acute cholecystitis or pancreatitis  
929 related inpatient/ER service); (4) evaluating the effect of BP-use on exploratory positive  
930 control outcomes (other respiratory infections); and (5) evaluating the potential bias related to  
931 the 'healthy adherer effect' by assessing (a) the effect of other preventive medication use on  
932 COVID-19-related outcomes (as negative control exposures) and (b) the BP effect in users  
933 and non-users of other preventive medications.

934 Notwithstanding, a retrospective analysis of insurance claims data has inevitable limitations  
935 that should be considered. For example, the interpretation of our findings depends, in part, on  
936 the assumption that BP users and non-users had a similar risk of SARS-CoV-2 infection  
937 during the observation period. However, our dataset does not allow us to restrict patient  
938 observations to those with known exposure to SARS-CoV-2. Therefore, to minimize potential  
939 differences in SARS-CoV-2 exposure between BP users and non-users in our primary study  
940 cohort, we implemented additional analytical strategies, including the sensitivity analyses  
941 discussed above, as well as matching BP users to BP non-users within geographical regions  
942 and specific states.

943 Despite these efforts, it is important to note that we have limited information to assess and  
944 match BP users to BP non-users by sociodemographic risk factors, such as socio-economic  
945 status and racial/ethnic minority status, that are associated with COVID-19 incidence and  
946 mortality<sup>34,35</sup>. In particular, our dataset does not include information on patients' race or ethnic  
947 background. This is a relevant limitation given the documented impact of racial/ethnic  
948 disparities on COVID-19 related outcomes. Specifically, Black/African-American and Hispanic  
949 patients have been shown to have significantly higher test positivity rates<sup>36-39</sup> and severity of  
950 disease at the time of testing<sup>39</sup>. Furthermore, Black/African American<sup>40</sup> and Hispanic patients  
951 were found to have a higher incidence of COVID-19 infection<sup>37,41</sup> and odds of COVID-19  
952 related hospital admission even after adjustment for comorbidities<sup>42</sup>, residence in a low-  
953 income area<sup>38</sup>, and insurance plan<sup>40,43,44</sup>. The greater COVID-19 burden in these groups is  
954 likely due to a combination of systemic health inequities as well as a disproportionate  
955 representation among essential workers<sup>45,46</sup>, which could potentially increase their exposure  
956 risk to SARS-CoV-2. In addition, there are known variations in the prevalence of osteoporosis  
957 between different racial groups, which could potentially result in disproportionate frequencies  
958 of BP prescriptions<sup>47</sup>. The potential confounding due to socio-economic status and differential  
959 prevalence of osteoporosis among racial/ethnic groups was addressed in our analysis of the  
960 "Osteo-Dx-Rx" cohort where we compared BP users to non-users after restricting to female  
961 patients with a diagnosis of osteoporosis, all using anti-resorptive bone medications, and  
962 matched by insurance type (proportion of Medicaid and dual Medicare/Medicaid users) as a

963 proxy for social-economic status (**Figure 4B**). Nevertheless, this strategy cannot rigorously  
964 rule out a potential under-representation of groups with higher sociodemographic risk factors  
965 among BP users that could have contributed to the observed decreased odds of COVID-19  
966 related outcomes in our primary analyses.

967 The potential bias introduced by a putative differential racial/ethnic group composition of BP  
968 users *versus* BP non-users is at least partially addressed by a recent study of a large  
969 Californian cohort of female BP users<sup>48</sup>. Compared to the racial composition of California at-  
970 large (a proxy for BP non-users)<sup>49</sup>, BP users were predominantly Non-Hispanic White (36.5%  
971 in California *versus* 53.3% among BP users). The proportions of Black/African-Americans  
972 and Asians among BP users in that study were similar to those in California at-large, whereas  
973 Hispanic patients represented a smaller percentage (24%) of BP users as compared to  
974 Hispanics in the state's general population (39.4%). Based on these findings and the reported  
975 differential case rates of COVID-19 infections among racial groups in California<sup>50</sup>, we can  
976 estimate the race-adjusted incidence of COVID-19 in populations reflecting the composition  
977 of BP users and non-users<sup>48</sup> to be 1.7% and 2.1%, respectively. By comparison, in our study  
978 the actual rate of COVID-19 diagnosis in the Western US was 2.5% for BP non-users *versus*  
979 0.46% for BP users (**Fig. 2**), indicating that the uneven representation of ethnic/racial groups  
980 cannot fully explain the observed differences in COVID-19 related outcomes. Moreover, we  
981 note that racial/ethnic minorities are also under-represented among statin users<sup>51</sup>, but statin-  
982 users in our primary cohort had similar odds of COVID-19 hospitalization as statin non-users  
983 (**Figure 6B**). Similarly, Black/African-Americans and Hispanics have lower utilization rates of  
984 antidepressants<sup>52</sup> and Hispanics were also reported to be undertreated with antihypertensive  
985 medications<sup>53</sup>. Our analysis of COVID-19-related outcomes among users and non-users of  
986 antihypertensives showed a modest decrease in COVID-19 diagnosis and minimal  
987 association with COVID-19-related hospitalization (**Figure 6C**). By contrast, users of  
988 antidepressants had uniformly lower odds for both endpoints (**Figures 6E**), which is  
989 consistent with other recent studies<sup>33,54,55</sup>. However, regardless of the class of non-BP  
990 preventive drugs analysed, concomitant BP use was consistently associated with  
991 dramatically decreased odds of COVID-19 diagnosis and hospitalization as well as testing for  
992 SARS-CoV-2 (**Figure 6B-E**).

993 Furthermore, specifically looking at the rate of SARS-CoV-2 testing in California<sup>37,38</sup> or nation-  
994 wide<sup>36</sup>, the proportions of different racial and ethnic groups among tested patients were  
995 nearly identical to estimates for the state or national population. Thus, the observed  
996 association between BP use and reduced testing for SARS-CoV-2 infection in our nation-  
997 wide cohorts is unlikely to be explained by potential differences in racial composition between  
998 BP users and non-users. It also seems unlikely that exposure to BPs reduces the actual  
999 incidence of SARS-CoV-2 infections. More likely, we propose that immune-modulatory effects  
1000 of BPs may enhance the anti-viral response of BP users to SARS-CoV-2 and mitigate the  
1001 development of symptoms. Milder or absent symptoms may have caused infected BP users  
1002 to be less likely to seek testing. Moreover, because there was a nationwide shortage of  
1003 available tests for SARS-CoV-2 during the observation period, patients needed to present  
1004 with sufficiently severe disease symptoms to be eligible for testing, so fewer test-seeking BP  
1005 users may have qualified. Consequently, a larger proportion of uncaptured 'silent' infections  
1006 among BP users could explain why fewer diagnoses and hospitalizations were observed in  
1007 this group.

1008 The scarceness of COVID-19 tests combined with the strain on healthcare systems during  
1009 the observation period could potentially have resulted in a misclassification bias whereby



1010 some patients may have been falsely diagnosed and/or hospitalized with COVID-19 without  
1011 having received a confirmatory test. However, this bias should equally affect BP users and  
1012 BP non-users and bias our findings towards the null. Relatedly, limited hospital capacity  
1013 during the observation period could have led to rationing of inpatient hospital beds based on  
1014 severity of disease and likelihood to survive<sup>56</sup>. However, matching by age and comorbidities  
1015 should produce patient populations with similar characteristics used for rationing.

1016 A further limitation of our study is the lack of information on the result of COVID-19 tests  
1017 received by patients. Therefore, as discussed above, the incidence and odds of COVID-19  
1018 testing should not be viewed as a proxy for the rate of infection, but rather reflects the  
1019 incidence of patients with severe enough symptoms or exposure to warrant testing. Another  
1020 potential source of confounding is the possibility that some patients in our study were  
1021 classified as BP non-users due to the absence of BP exposure during the pre-observation  
1022 period but may have received a BP during the observation period. The potential  
1023 misclassification of BP non-users, however, would bias towards the null hypothesis, and was  
1024 only seen in 1.92% of the matched BP non-user population.

1025 An additional limitation is potential censoring of patients who died during the observation  
1026 period, resulting in truncated insurance eligibility and exclusion based on the continuous  
1027 insurance eligibility requirement. However, modelling the impact of censoring by using death  
1028 rates observed in BP users and non-users in the first six months of 2020 and attributing all  
1029 deaths as COVID-19-related did not significantly alter the decreased odds of COVID-19  
1030 diagnosis in BP users (see **Appendix 3**).

1031 Additional limitations could also arise from comorbidities and misclassification bias due to the  
1032 diagnostic and procedure codes used to identify study outcomes. Regarding comorbidities,  
1033 one potential limitation in both the primary and “*Bone-Rx*” cohorts is imbalanced comorbidity  
1034 burden in BP user and non-user cohorts post-match. **Table 1** shows there is differential  
1035 prevalence of most co-morbid diseases despite matched cumulative CCI score between BP  
1036 user and BP non-user cohorts. However, this limitation is in part addressed given (1) these  
1037 covariates were controlled for during regression analyses on study outcomes, and (2) that the  
1038 key study findings were also observed in the “*Osteo-Dx-Rx*” cohort, which matched based on  
1039 individual comorbidities. Another potential limitation, misclassification bias of study outcomes,  
1040 may be present due to the specific procedure/diagnostic codes used. For SARS-CoV-2  
1041 testing, procedure codes were limited to those testing for active infection, and therefore  
1042 observations could be missed if they were captured via antibody testing (CPT 86318, 86328).  
1043 These codes were excluded a priori due to the focus on the symptomatic COVID-19  
1044 population. Furthermore, for the COVID-19 diagnosis and hospitalization outcomes, all  
1045 events were identified using the ICD-10 code for lab-confirmed COVID-19 (U07.1), and  
1046 therefore events with an associated diagnosis code for suspected COVID-19 (U07.2) were  
1047 not included. This was done to have a more stringent algorithm when identifying COVID-19-  
1048 related events, and any impact of events identified using U07.2 is considered minimal, as  
1049 previous studies of the early COVID-19 outbreak have found that U07.1 alone has a positive  
1050 predictive value of 94%<sup>57</sup>, and for this study U07.1 captured 99.2%, 99.0%, and 97.5% of all  
1051 COVID-19 patient-diagnoses for the primary, “*Bone-Rx*”, and “*Osteo-Dx-Rx*” cohorts,  
1052 respectively.

1053 One large potential bias to consider when comparing BP users to BP non-users is the healthy  
1054 adherer effect, whereby adherence to drug therapy is associated with overall healthier  
1055 behavior<sup>58,59</sup>. During the COVID-19 pandemic, this could have potentially resulted in  
1056 differences between BP users and non-users such as, for example, adherence to mask-

1057 wearing, hand washing, or social distancing. However, if this effect accounted for the  
1058 observed association between BP use and COVID-19-related outcomes, one would expect  
1059 that BP users would have distinct odds for outcomes not predicted to be modulated by BPs  
1060 and/or that users of other preventive medications would show similar associations. The  
1061 sensitivity analysis of exploratory outcomes in our primary cohort indicates that BP users had  
1062 decreased odds of any ER/inpatient visit for acute pancreatitis or acute cholecystitis during  
1063 the observation period and decreased odds of ER/inpatient visits for acute pancreatitis prior  
1064 to the COVID-19 pandemic in 2019 (**Figure 5A**). Plausible (non-exclusive) explanations for  
1065 BP use association with decreased odds of these exploratory outcomes could be that: (1) BP  
1066 users may be healthier at baseline; (2) BP users may have fewer risk factors for cholecystitis  
1067 and pancreatitis such as smoking<sup>60</sup>, which can modify COVID-19-related outcomes<sup>61</sup> but was  
1068 not captured in our propensity score matching; (3) BPs directly decreased the risk of  
1069 hypercalcemia-induced cholecystitis<sup>62</sup> and pancreatitis<sup>63</sup>; and/or (4) BP users may have  
1070 preferentially avoided or postponed use of medical services during the pandemic.

1071 Thus, the healthy adherer effect could have potentially contributed to the association of BP  
1072 use with a lower incidence of exploratory outcomes. However, as discussed above, other  
1073 preventive drug classes had a variable directional impact on the odds of COVID-19-related  
1074 events, and sub-analyses within each drug class identified a strong association between  
1075 concomitant BP use and decreased COVID-19-related events (**Figures 6B-E**). Taken  
1076 together, these results suggest the observed association between BP use and COVID-19-  
1077 related outcomes cannot solely be attributed to general behaviors associated with the healthy  
1078 adherer effect.

1079 Notably, several observational studies have reported that the use of one of our comparator  
1080 preventive drug classes, statins, is associated with a lower risk of mortality in hospitalized  
1081 COVID-19 patients<sup>33 64,65</sup>. Indeed, statins are currently being tested as an adjunct therapy for  
1082 COVID-19 (NCT04380402). In our study population, statin use was associated with  
1083 moderately decreased odds of SARS-CoV-2 testing and COVID-19 diagnosis, though at a  
1084 much smaller magnitude than BPs, and was not consistently associated with reduced odds of  
1085 COVID-19-related hospitalizations. Our analysis did not address the clinical course of  
1086 hospitalized patients, so these results are not necessarily conflicting. However, we note that  
1087 in our primary cohort, as many as 15.2% of statin users concomitantly used a BP. Indeed,  
1088 within statin users, stratification by BP use revealed that the decreased odds of SARS-CoV-2  
1089 testing, COVID-19 diagnosis, and COVID-19-related hospitalizations remained regardless of  
1090 statin use. Future studies on disease outcomes of hospitalized COVID-19 patients with  
1091 antecedent use of BPs and statins alone or in combination are needed to clarify the effects of  
1092 each drug class.

1093 The differential association of amino-BPs *versus* statins with COVID-19 related outcomes is  
1094 somewhat unexpected because both target the same biochemical pathway, albeit at different  
1095 enzymatic steps<sup>13</sup>. Statins block HMG-CoA reductase, the first and key rate-limiting enzyme  
1096 in the mevalonate pathway<sup>66</sup>. Amino-BPs, which account for >99% of BPs prescribed in our  
1097 study, inhibit a downstream enzyme in the same metabolic pathway, farnesyl pyrophosphate  
1098 synthase (FPPS), which converts geranyl pyrophosphate to farnesyl pyrophosphate<sup>67</sup>. FPPS  
1099 blockade disrupts protein prenylation and interferes with cytoskeletal rearrangement,  
1100 membrane ruffling and vesicular trafficking in osteoclasts, thus preventing bone resorption<sup>68</sup>.  
1101 However, the anti-osteolytic activity of BPs *per se* is unlikely to account for the observed  
1102 association between BP use and decreased incidence of COVID-19 and, more broadly,

1103 respiratory tract infections, because patients treated with non-BP anti-resorptive bone health  
1104 medications have higher odds of respiratory infections (<sup>16</sup> and this study).

1105 Another consequence of mevalonate pathway inhibition by both statins and amino-BPs is  
1106 arrested endosomal maturation in antigen-presenting cells resulting in enhanced antigen  
1107 presentation, T cell activation and humoral immunity<sup>13</sup>. In addition to this adjuvant-like effect,  
1108 FPPS blockade by amino-BPs causes the intracellular accumulation of the enzyme's  
1109 substrate, isopentyl diphosphate (IPP), in myeloid leukocytes, which then stimulate V $\gamma$ 9V $\delta$ 2 T  
1110 cells<sup>69,70</sup>, a large population of migratory innate lymphocytes in humans that are thought to  
1111 play an important role in host defense against infectious pathogens<sup>71</sup>, including SARS-CoV-1  
1112 (ref. <sup>6</sup>). Experiments in humanized mice that were challenged with influenza viruses have  
1113 shown that amino-BP-induced expansion of V $\gamma$ 9V $\delta$ 2 T cells markedly improves viral control  
1114 and mitigates disease severity and mortality<sup>8,72</sup>. However, since statins act upstream of FPPS,  
1115 they are expected to inhibit IPP synthesis and, hence, have been shown to counteract the  
1116 stimulatory effect of amino-BPs on V $\gamma$ 9V $\delta$ 2 T cells<sup>69</sup>. However, statins and amino-BPs do not  
1117 always antagonize each other. *In vitro*, concomitant statin and amino-BP use has been  
1118 shown to be synergistic in inhibition of cancer cell growth, but mainly through downstream  
1119 inhibition of geranylgeranyl transferases and subsequent protein prenylation by statins<sup>73</sup>. The  
1120 fact that the observed reduction in COVID-19-related outcomes in BP users was not altered  
1121 by concomitant statin use implies that the apparent protective effects of amino-BPs may not  
1122 rely solely on stimulation of V $\gamma$ 9V $\delta$ 2 T cells. Indeed, in mice (in which BPs are not known to  
1123 stimulate  $\gamma\delta$  T cells), BPs potently boost systemic and mucosal antiviral antibody and T cell  
1124 responses<sup>14</sup>. This effect was also seen with non-nitrogenous BPs, which do not antagonize  
1125 FPPS<sup>14</sup>. In the present study, the number of patients who used non-nitrogenous BPs was  
1126 less than 20, and therefore too small to determine any impact on COVID-19-related  
1127 outcomes. Nevertheless, in aggregate, these clinical and pre-clinical findings raise the  
1128 possibility that BPs may exert (at least some) immuno-stimulatory effects by engaging an as  
1129 yet unidentified additional pathway, regardless of their nitrogen content.

1130 Irrespective of the precise molecular mechanism of action, BPs have been reported to exert a  
1131 plethora of effects on additional immune cell populations in humans, including NK cells<sup>74</sup> and  
1132 regulatory T cells<sup>75</sup>. Moreover, studies of patients treated with amino-BPs found impaired  
1133 chemotaxis and generation of reactive oxygen species by neutrophils<sup>76,77</sup>, a population of  
1134 inflammatory cells whose dysregulated recruitment and activation are strongly implicated in  
1135 the pathogenesis of severe COVID-19 (refs. <sup>78,79</sup>). Thus, BPs may provide therapeutic  
1136 benefits during infections with SARS-CoV-2 through modulation of both innate and adaptive  
1137 immune responses. However, further studies to directly test these pleiotropic immuno-  
1138 modulatory effects of BPs and to assess their relative contribution to the host response to  
1139 SARS-CoV-2 infection are needed.

1140 We conclude that, despite a number of caveats discussed above, the association between  
1141 BP use and decreased odds of COVID-19-related endpoints was robust in analyses  
1142 comparing BP users to BP non-users. Large differences were detected regardless of age,  
1143 sex or geographic location that remained robust when using multiple approaches to address  
1144 unmeasured confounding and/or potential sources of bias. These retrospective findings  
1145 strongly suggest that BPs should be considered for prophylactic and/or therapeutic use in  
1146 individuals at risk of SARS-CoV-2 infection. However, additional well-controlled prospective  
1147 clinical studies will be needed to rigorously assess whether the observed reduction in COVID-  
1148 19-related outcomes is directly caused by BPs and remains true in patient populations not  
1149 commonly prescribed BPs.

1150 A number of BPs are globally available as relatively affordable generics that are generally  
1151 well tolerated and could be prescribed for off-label use. Rare, but severe adverse events that  
1152 have been linked to BP use include osteonecrosis of the jaw<sup>80</sup> and atypical femur fractures<sup>81</sup>,  
1153 which are both associated with long-term BP therapy. In this context, it is important to  
1154 consider the relationship between the timing of BP exposure and COVID-19-related  
1155 outcomes. Remarkably, BP users of alendronic acid whose prescription ended more than  
1156 eight months prior to the observation period, as well as users who initiated alendronic acid  
1157 therapy immediately preceding the observation period, had similarly decreased odds of  
1158 COVID-19-related outcomes (**Figure 3B**). A likely explanation for the observed long-term  
1159 protection after transient BP use may be the well-documented retention of BPs in bone  
1160 resulting in half-lives of several years<sup>20</sup>. Small amounts of stored BPs are continuously  
1161 released, especially in regions of high bone turnover, which may result in persistent exposure  
1162 of immune cells either systemically or preferentially in bone marrow, a site of active immune  
1163 cell trafficking<sup>82,83</sup> where anti-viral immune responses can be initiated in response to  
1164 respiratory infection<sup>84</sup>. Thus, BP use at the time of infection may not be necessary for  
1165 protection against COVID-19. Rather, our results suggest that prophylactic BP therapy may  
1166 be sufficient to achieve a potentially rapid and sustained immune modulation resulting in  
1167 profound mitigation of the incidence and/or severity of infections by SARS-CoV-2.

1168  
1169

1170 **Acknowledgements**

1171

1172 The authors acknowledge Ziqi Chen, Paris Pallis, and Flora Tierney for helpful discussions  
1173 on the interpretation of study results.

1174

1175 We are grateful to Komodo Health who provided all data used in this analysis at no cost, and  
1176 we thank Vicki Guan and Ben Cohen from Komodo Health for facilitating this research.

1177 Special thanks to Kantar Health (now Cerner Enviza) who provided the support needed to  
1178 complete this study with no associated financial requirements.

1179 This study was supported by NIH grants AR068383 and AI155865 (to U.H.v.A.) and a CRI  
1180 Irvington postdoctoral fellowship CRI2453 (to P.H.).

1181

1182 **Competing interests**

1183 JT and TH are full-time employees of Cerner Health. UHvA is paid consultant of Avenge Bio,  
1184 Beam Therapeutics, Bluesphere Bio, DNAlite, Gate Biosciences, Gentibio, Intergalactic,  
1185 intrECate Biotherapeutics, Interon, Mallinckrodt Pharmaceuticals, Moderna, Monopteros  
1186 Biotherapeutics, Morphic Therapeutics, Rubius, Selecta and SQZ.

1187

1188

## 1189 REFERENCES

- 1190 1. Sultana J, Crisafulli S, Gabbay F, Lynn E, Shakir S, Trifiro G. Challenges for Drug Repurposing in  
1191 the COVID-19 Pandemic Era. *Front Pharmacol*. 2020;11:588654.
- 1192 2. Roelofs AJ, Thompson K, Ebetino FH, Rogers MJ, Coxon FP. Bisphosphonates: molecular  
1193 mechanisms of action and effects on bone cells, monocytes and macrophages. *Curr Pharm Des*.  
1194 2010;16(27):2950-2960.
- 1195 3. Dhesy-Thind S, Fletcher GG, Blanchette PS, et al. Use of Adjuvant Bisphosphonates and Other  
1196 Bone-Modifying Agents in Breast Cancer: A Cancer Care Ontario and American Society of  
1197 Clinical Oncology Clinical Practice Guideline. *J Clin Oncol*. 2017;35(18):2062-2081.
- 1198 4. Russell RG, Watts NB, Ebetino FH, Rogers MJ. Mechanisms of action of bisphosphonates:  
1199 similarities and differences and their potential influence on clinical efficacy. *Osteoporos Int*.  
1200 2008;19(6):733-759.
- 1201 5. Brufsky A, Marti JLG, Nasrazadani A, Lotze MT. Boning up: amino-bisphosphonates as  
1202 immunostimulants and endosomal disruptors of dendritic cell in SARS-CoV-2 infection. *J Transl*  
1203 *Med*. 2020;18(1):261.
- 1204 6. Poccia F, Agrati C, Castilletti C, et al. Anti-severe acute respiratory syndrome coronavirus  
1205 immune responses: the role played by V gamma 9V delta 2 T cells. *J Infect Dis*.  
1206 2006;193(9):1244-1249.
- 1207 7. Hewitt RE, Lissina A, Green AE, Slay ES, Price DA, Sewell AK. The bisphosphonate acute phase  
1208 response: rapid and copious production of proinflammatory cytokines by peripheral blood gd  
1209 T cells in response to aminobisphosphonates is inhibited by statins. *Clin Exp Immunol*.  
1210 2005;139(1):101-111.
- 1211 8. Tu W, Zheng J, Liu Y, et al. The aminobisphosphonate pamidronate controls influenza  
1212 pathogenesis by expanding a gammadelta T cell population in humanized mice. *J Exp Med*.  
1213 2011;208(7):1511-1522.
- 1214 9. Favot CL, Forster C, Glogauer M. The effect of bisphosphonate therapy on neutrophil function:  
1215 a potential biomarker. *Int J Oral Maxillofac Surg*. 2013;42(5):619-626.
- 1216 10. Roelofs AJ, Coxon FP, Ebetino FH, et al. Fluorescent risedronate analogues reveal  
1217 bisphosphonate uptake by bone marrow monocytes and localization around osteocytes in  
1218 vivo. *J Bone Miner Res*. 2010;25(3):606-616.
- 1219 11. Rogers TL, Holen I. Tumour macrophages as potential targets of bisphosphonates. *J Transl*  
1220 *Med*. 2011;9:177.
- 1221 12. Wolf AM, Rumpold H, Tilg H, Gastl G, Gunsilius E, Wolf D. The effect of zoledronic acid on the  
1222 function and differentiation of myeloid cells. *Haematologica*. 2006;91(9):1165-1171.
- 1223 13. Xia Y, Xie Y, Yu Z, et al. The Mevalonate Pathway Is a Druggable Target for Vaccine Adjuvant  
1224 Discovery. *Cell*. 2018;175(4):1059-1073 e1021.
- 1225 14. Tonti E, Jimenez de Oya N, Galliverti G, et al. Bisphosphonates target B cells to enhance  
1226 humoral immune responses. *Cell Rep*. 2013;5(2):323-330.
- 1227 15. Lee P, Ng C, Slattey A, Nair P, Eisman JA, Center JR. Preadmission Bisphosphonate and  
1228 Mortality in Critically Ill Patients. *J Clin Endocrinol Metab*. 2016;101(5):1945-1953.
- 1229 16. Sing CW, Kiel DP, Hubbard RB, et al. Nitrogen-Containing Bisphosphonates Are Associated  
1230 With Reduced Risk of Pneumonia in Patients With Hip Fracture. *J Bone Miner Res*.  
1231 2020;35(9):1676-1684.
- 1232 17. Suresh E, Pazianas M, Abrahamsen B. Safety issues with bisphosphonate therapy for  
1233 osteoporosis. *Rheumatology (Oxford)*. 2014;53(1):19-31.

- 1234 18. Sbrocchi AM, Forget S, Laforte D, Azouz EM, Rodd C. Zoledronic acid for the treatment of  
1235 osteopenia in pediatric Crohn's disease. *Pediatr Int*. 2010;52(5):754-761.
- 1236 19. George S, Weber DR, Kaplan P, Hummel K, Monk HM, Levine MA. Short-Term Safety of  
1237 Zoledronic Acid in Young Patients With Bone Disorders: An Extensive Institutional Experience.  
1238 *J Clin Endocrinol Metab*. 2015;100(11):4163-4171.
- 1239 20. Cremers S, Drake MT, Ebetino FH, Bilezikian JP, Russell RGG. Pharmacology of  
1240 bisphosphonates. *Br J Clin Pharmacol*. 2019;85(6):1052-1062.
- 1241 21. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-  
1242 CM and ICD-10 administrative data. *Med Care*. 2005;43(11):1130-1139.
- 1243 22. Parsons LS. Reducing Bias in a Propensity Score Matched-Pair sample Using Greedy Matching  
1244 techniques. . The Twenty-Sixth Annual SAS Users Group International Conference; 2001.
- 1245 23. CDC. United States COVID-19 Cases and Death by State Over Time. [https://data.cdc.gov/Case-](https://data.cdc.gov/Case-Surveillance/United-States-COVID-19-Cases-and-Deaths-by-State-o/9mfq-cb36/data)  
1246 [Surveillance/United-States-COVID-19-Cases-and-Deaths-by-State-o/9mfq-cb36/data](https://data.cdc.gov/Case-Surveillance/United-States-COVID-19-Cases-and-Deaths-by-State-o/9mfq-cb36/data).  
1247 Published 2021. Accessed.
- 1248 24. Rosenthal N, Cao Z, Gundrum J, Sianis J, Safo S. Risk Factors Associated With In-Hospital  
1249 Mortality in a US National Sample of Patients With COVID-19. *JAMA Netw Open*.  
1250 2020;3(12):e2029058.
- 1251 25. Ladova K, Vlcek J, Vytrisalova M, Maly J. Healthy adherer effect - the pitfall in the  
1252 interpretation of the effect of medication adherence on health outcomes. *J Eval Clin Pract*.  
1253 2014;20(2):111-116.
- 1254 26. Birkmeyer JD, Barnato A, Birkmeyer N, Bessler R, Skinner J. The Impact Of The COVID-19  
1255 Pandemic On Hospital Admissions In The United States. *Health Affairs*. 2020;39(11):2010-2017.
- 1256 27. Jeffery MM, D'Onofrio G, Paek H, et al. Trends in Emergency Department Visits and Hospital  
1257 Admissions in Health Care Systems in 5 States in the First Months of the COVID-19 Pandemic  
1258 in the US. *JAMA Internal Medicine*. 2020;180(10).
- 1259 28. Colon-Emeric CS, Mesenbrink P, Lyles KW, et al. Potential mediators of the mortality reduction  
1260 with zoledronic acid after hip fracture. *J Bone Miner Res*. 2010;25(1):91-97.
- 1261 29. Reid IR, Horne AM, Mihov B, Stewart A, Bastin S, Gamble GD. Effect of Zoledronate on Lower  
1262 Respiratory Infections in Older Women: Secondary Analysis of a Randomized Controlled Trial.  
1263 *Calcified Tissue International*. 2021;109(1):12-16.
- 1264 30. Atmaca A, Demirci I, Haymana C, et al. No association of anti-osteoporosis drugs with COVID-  
1265 19-related outcomes in women: a nationwide cohort study. *Osteoporos Int*. 2021.
- 1266 31. Degli Esposti L, Perrone V, Sangiorgi D, et al. The Use of Oral Amino-Bisphosphonates and  
1267 Coronavirus Disease 2019 (COVID-19) Outcomes. *J Bone Miner Res*. 2021.
- 1268 32. Blanch-Rubio J, Soldevila-Domenech N, Tio L, et al. Influence of anti-osteoporosis treatments  
1269 on the incidence of COVID-19 in patients with non-inflammatory rheumatic conditions. *Aging*  
1270 *(Albany NY)*. 2020;12(20):19923-19937.
- 1271 33. Israel A, Schaffer AA, Cicurel A, et al. Identification of drugs associated with reduced severity  
1272 of COVID-19 - a case-control study in a large population. *Elife*. 2021;10.
- 1273 34. Karmakar M, Lantz PM, Tipirneni R. Association of Social and Demographic Factors With  
1274 COVID-19 Incidence and Death Rates in the US. *JAMA Network Open*. 2021;4(1).
- 1275 35. Rogers TN, Rogers CR, VanSant-Webb E, Gu LY, Yan B, Qeadan F. Racial Disparities in COVID-19  
1276 Mortality Among Essential Workers in the United States. *World Med Health Policy*. 2020.
- 1277 36. Kaufman HW, Niles JK, Nash DB. Disparities in SARS-CoV-2 Positivity Rates: Associations with  
1278 Race and Ethnicity. *Population Health Management*. 2021;24(1):20-26.

- 1279 37. Escobar GJ, Adams AS, Liu VX, et al. Racial Disparities in COVID-19 Testing and Outcomes.  
1280 *Annals of Internal Medicine*. 2021;174(6):786-793.
- 1281 38. Jacobson M, Chang TY, Shah M, Pramanik R, Shah SB. Racial and Ethnic Disparities in SARS-  
1282 CoV-2 Testing and COVID-19 Outcomes in a Medicaid Managed Care Cohort. *American Journal*  
1283 *of Preventive Medicine*. 2021.
- 1284 39. Rubin-Miller L. COVID-19 Racial Disparities in Testing, Infection, Hospitalization, and Death:  
1285 Analysis of Epic Patient Data. [https://www.kff.org/coronavirus-covid-19/issue-brief/covid-19-](https://www.kff.org/coronavirus-covid-19/issue-brief/covid-19-racial-disparities-testing-infection-hospitalization-death-analysis-epic-patient-data/)  
1286 [racial-disparities-testing-infection-hospitalization-death-analysis-epic-patient-data/](https://www.kff.org/coronavirus-covid-19/issue-brief/covid-19-racial-disparities-testing-infection-hospitalization-death-analysis-epic-patient-data/). Published  
1287 2020. Updated September 16, 2020. Accessed September 10, 2021.
- 1288 40. Azar KMJ, Shen Z, Romanelli RJ, et al. Disparities In Outcomes Among COVID-19 Patients In A  
1289 Large Health Care System In California. *Health Affairs*. 2020;39(7):1253-1262.
- 1290 41. CDC. Risk for COVID-19 Infection, Hospitalization, and Death By Race/Ethnicity.  
1291 [https://www.cdc.gov/coronavirus/2019-ncov/covid-data/investigations-](https://www.cdc.gov/coronavirus/2019-ncov/covid-data/investigations-discovery/hospitalization-death-by-race-ethnicity.html#footnote03)  
1292 [discovery/hospitalization-death-by-race-ethnicity.html#footnote03](https://www.cdc.gov/coronavirus/2019-ncov/covid-data/investigations-discovery/hospitalization-death-by-race-ethnicity.html#footnote03). Published 2021. Updated  
1293 July 16, 2021. Accessed September 7, 2019.
- 1294 42. Nau C, Bruxvoort K, Navarro RA, et al. COVID-19 Inequities Across Multiple Racial and Ethnic  
1295 Groups: Results From an Integrated Health Care Organization. *Annals of Internal Medicine*.  
1296 2021;174(8):1183-1186.
- 1297 43. Price-Haywood EG, Burton J, Fort D, Seoane L. Hospitalization and Mortality among Black  
1298 Patients and White Patients with Covid-19. *N Engl J Med*. 2020;382(26):2534-2543.
- 1299 44. Muñoz-Price LS, Nattinger AB, Rivera F, et al. Racial Disparities in Incidence and Outcomes  
1300 Among Patients With COVID-19. *JAMA Network Open*. 2020;3(9).
- 1301 45. Statistics UBoL. Labor force characteristics by race and ethnicity, 2018.  
1302 <https://www.bls.gov/opub/reports/race-and-ethnicity/2018/home.htm>. Published 2019.  
1303 Accessed September 7, 2021.
- 1304 46. Selden TM, Berdahl TA. COVID-19 And Racial/Ethnic Disparities In Health Risk, Employment,  
1305 And Household Composition. *Health Affairs*. 2020;39(9):1624-1632.
- 1306 47. QuickStats: Percentage\* of Adults Aged  $\geq 50$  Years with Osteoporosis,<sup>†</sup> by Race and Hispanic  
1307 Origin<sup>§</sup> — United States, 2017–2018. *MMWR Morbidity and Mortality Weekly Report*.  
1308 2021;70(19).
- 1309 48. Black DM, Geiger EJ, Eastell R, et al. Atypical Femur Fracture Risk versus Fragility Fracture  
1310 Prevention with Bisphosphonates. *New England Journal of Medicine*. 2020;383(8):743-753.
- 1311 49. Bureau C. Race and Hispanic Origin. <https://www.census.gov/quickfacts/CA>. Published 2019.  
1312 Accessed September 7, 2019.
- 1313 50. Reitsma MB, Claypool AL, Vargo J, et al. Racial/Ethnic Disparities In COVID-19 Exposure Risk,  
1314 Testing, And Cases At The Subcounty Level In California. *Health Aff (Millwood)*.  
1315 2021;40(6):870-878.
- 1316 51. Salami JA, Warraich H, Valero-Elizondo J, et al. National Trends in Statin Use and Expenditures  
1317 in the US Adult Population From 2002 to 2013: Insights From the Medical Expenditure Panel  
1318 Survey. *JAMA Cardiol*. 2017;2(1):56-65.
- 1319 52. Chen J, Rizzo JA. Racial and ethnic disparities in antidepressant drug use. *J Ment Health Policy*  
1320 *Econ*. 2008;11(4):155-165.
- 1321 53. Gu A, Yue Y, Desai RP, Argulian E. Racial and Ethnic Differences in Antihypertensive  
1322 Medication Use and Blood Pressure Control Among US Adults With Hypertension. *Circulation:*  
1323 *Cardiovascular Quality and Outcomes*. 2017;10(1).



- 1324 54. Hoertel N, Sánchez-Rico M, Vernet R, et al. Association between antidepressant use and  
1325 reduced risk of intubation or death in hospitalized patients with COVID-19: results from an  
1326 observational study. *Molecular Psychiatry*. 2021.
- 1327 55. Zimniak M, Kirschner L, Hilpert H, et al. The serotonin reuptake inhibitor Fluoxetine inhibits  
1328 SARS-CoV-2 in human lung tissue. *Sci Rep*. 2021;11(1):5890.
- 1329 56. Emanuel EJ, Persad G, Upshur R, et al. Fair Allocation of Scarce Medical Resources in the Time  
1330 of Covid-19. *N Engl J Med*. 2020;382(21):2049-2055.
- 1331 57. Kluberg SA, Hou L, Dutcher SK, et al. Validation of diagnosis codes to identify hospitalized  
1332 COVID - 19 patients in health care claims data. *Pharmacoepidemiology and Drug Safety*.  
1333 2022;31(4):476-480.
- 1334 58. Curtis JR, Larson JC, Delzell E, et al. Placebo adherence, clinical outcomes, and mortality in the  
1335 women's health initiative randomized hormone therapy trials. *Med Care*. 2011;49(5):427-435.
- 1336 59. Dormuth CR, Patrick AR, Shrank WH, et al. Statin adherence and risk of accidents: a cautionary  
1337 tale. *Circulation*. 2009;119(15):2051-2057.
- 1338 60. Tolstrup JS, Kristiansen L, Becker U, Gronbaek M. Smoking and risk of acute and chronic  
1339 pancreatitis among women and men: a population-based cohort study. *Arch Intern Med*.  
1340 2009;169(6):603-609.
- 1341 61. Shastri MD, Shukla SD, Chong WC, et al. Smoking and COVID-19: What we know so far. *Respir*  
1342 *Med*. 2021;176:106237.
- 1343 62. Gleeson D, Murphy GM, Dowling RH. Changes in serum calcium levels influence biliary calcium  
1344 levels in humans. *Gastroenterology*. 1994;107(6):1812-1818.
- 1345 63. Kumar A, Kumar PG, Pujahari AK, Sampath S. Hypercalcemia Related Pancreatitis. *Med J*  
1346 *Armed Forces India*. 2010;66(4):385-386.
- 1347 64. Lohia P, Kapur S, Benjaram S, Mir T. Association between antecedent statin use and severe  
1348 disease outcomes in COVID-19: A retrospective study with propensity score matching. *J Clin*  
1349 *Lipidol*. 2021.
- 1350 65. Zhang XJ, Qin JJ, Cheng X, et al. In-Hospital Use of Statins Is Associated with a Reduced Risk of  
1351 Mortality among Individuals with COVID-19. *Cell Metab*. 2020;32(2):176-187 e174.
- 1352 66. Istvan ES, Deisenhofer J. Structural mechanism for statin inhibition of HMG-CoA reductase.  
1353 *Science*. 2001;292(5519):1160-1164.
- 1354 67. Kavanagh KL, Guo K, Dunford JE, et al. The molecular mechanism of nitrogen-containing  
1355 bisphosphonates as antiosteoporosis drugs. *Proceedings of the National Academy of Sciences*.  
1356 2006;103(20):7829-7834.
- 1357 68. Russell RG. Bisphosphonates: mode of action and pharmacology. *Pediatrics*. 2007;119 Suppl  
1358 2:S150-162.
- 1359 69. Wang H, Sarikonda G, Puan KJ, et al. Indirect stimulation of human Vgamma2Vdelta2 T cells  
1360 through alterations in isoprenoid metabolism. *J Immunol*. 2011;187(10):5099-5113.
- 1361 70. Nada MH, Wang H, Workalemahu G, Tanaka Y, Morita CT. Enhancing adoptive cancer  
1362 immunotherapy with Vgamma2Vdelta2 T cells through pulse zoledronate stimulation. *J*  
1363 *Immunother Cancer*. 2017;5:9.
- 1364 71. Ribot JC, Lopes N, Silva-Santos B. gammadelta T cells in tissue physiology and surveillance. *Nat*  
1365 *Rev Immunol*. 2021;21(4):221-232.
- 1366 72. Zheng J, Wu WL, Liu Y, et al. The Therapeutic Effect of Pamidronate on Lethal Avian Influenza  
1367 A H7N9 Virus Infected Humanized Mice. *PLoS One*. 2015;10(8):e0135999.
- 1368 73. Abdullah MI, Abed MN, Richardson A. Inhibition of the mevalonate pathway augments the  
1369 activity of pitavastatin against ovarian cancer cells. *Scientific Reports*. 2017;7(1).

- 1370 74. Sarhan D, Leijonhufvud C, Murray S, et al. Zoledronic acid inhibits NFAT and IL-2 signaling  
1371 pathways in regulatory T cells and diminishes their suppressive function in patients with  
1372 metastatic cancer. *Oncoimmunology*. 2017;6(8):e1338238.
- 1373 75. Liu H, Wang SH, Chen SC, Chen CY, Lo JL, Lin TM. Immune modulation of CD4(+)CD25(+)  
1374 regulatory T cells by zoledronic acid. *BMC Immunol*. 2016;17(1):45.
- 1375 76. Kuiper JW, Forster C, Sun C, Peel S, Glogauer M. Zoledronate and pamidronate depress  
1376 neutrophil functions and survival in mice. *Br J Pharmacol*. 2012;165(2):532-539.
- 1377 77. Chadwick JW, Tenenbaum HC, Sun CX, Wood RE, Glogauer M. The effect of pamidronate  
1378 delivery in bisphosphonate-naive patients on neutrophil chemotaxis and oxidative burst. *Sci*  
1379 *Rep*. 2020;10(1):18309.
- 1380 78. Meizlish ML, Pine AB, Bishai JD, et al. A neutrophil activation signature predicts critical illness  
1381 and mortality in COVID-19. *Blood Adv*. 2021;5(5):1164-1177.
- 1382 79. Reusch N, De Domenico E, Bonaguro L, et al. Neutrophils in COVID-19. *Front Immunol*.  
1383 2021;12:652470.
- 1384 80. Migliorati CA, Siegel MA, Elting LS. Bisphosphonate-associated osteonecrosis: a long-term  
1385 complication of bisphosphonate treatment. *The Lancet Oncology*. 2006;7(6):508-514.
- 1386 81. Saita Y, Ishijima M, Kaneko K. Atypical femoral fractures and bisphosphonate use: current  
1387 evidence and clinical implications. *Therapeutic Advances in Chronic Disease*. 2015;6(4):185-  
1388 193.
- 1389 82. Mazo IB, Honczarenko M, Leung H, et al. Bone marrow is a major reservoir and site of  
1390 recruitment for central memory CD8+ T cells. *Immunity*. 2005;22(2):259-270.
- 1391 83. Zhao E, Xu H, Wang L, et al. Bone marrow and the control of immunity. *Cell Mol Immunol*.  
1392 2012;9(1):11-19.
- 1393 84. Hermesh T, Moltedo B, Moran TM, Lopez CB. Antiviral instruction of bone marrow leukocytes  
1394 during respiratory viral infections. *Cell Host Microbe*. 2010;7(5):343-353.
- 1395
- 1396

## Association Between Bisphosphonate Use and COVID-19-Related Outcomes

1397  
1398  
1399  
1400  
1401  
  
1402  
1403  
1404  
1405  
1406  
1407  
1408  
1409  
1410  
1411  
1412  
1413  
1414  
1415

### APPENDIX Table of Contents

<b>APPENDIX 1: Study Methods</b> .....	<b>A2</b>
<b>Section 1: Variable Assignment</b> .....	<b>A2</b>
<b>Section 2: Sensitivity Analyses Methodologies</b> .....	<b>A6</b>
Sensitivity Analysis 1 .....	<b>A6</b>
Sensitivity Analysis 2 .....	<b>A7</b>
Sensitivity Analysis 3 .....	<b>A8</b>
Sensitivity Analysis 4 .....	<b>A9</b>
Sensitivity Analysis 5 .....	<b>A10</b>
<b>APPENDIX 2: Additional Results</b> .....	<b>A12</b>
<b>APPENDIX 3: Deceased Sensitivity Analysis</b> .....	<b>A23</b>
<b>ADDITIONAL TABLES</b> .....	<b>A28</b>

## 1416 **APPENDIX 1: Study Methods**

1417

### 1418 **Section 1: Variable Assignment**

1419

1420

#### *Outcomes*

1421

The following details the identification algorithms and associated codes that were used to identify outcomes of interest, including COVID-19-related as well as the exploratory outcomes that were assessed during sensitivity analyses.

1422

1423

1424

1425

#### **Primary Outcomes**

1426

##### **SARS-CoV-2 Testing**

1427

- Any medical services claim with a procedure code indicating polymerase chain reaction (PCR) testing for active SARS-CoV-2 infection 3/1/2020-6/30/2020

1428

1429

- Identified using HCPCS codes: 87635, 87636, 87637

1430

##### **COVID-19 Diagnosis**

1431

- Any medical services claim with a diagnosis code indicating COVID-19 3/1/2020-6/30/2020

1432

- Identified using ICD-10 code U07.1x

1433

##### **COVID-19-Related Hospitalization**

1434

- Any medical services claim occurring in an inpatient setting with a diagnosis code indicating COVID-19 3/1/2020-6/30/2020

1435

1436

- Identified using ICD-10 code U07.1x

1437

1438

1439

#### **Exploratory Outcomes** (*study observation period*)

1440

##### **Acute Cholecystitis-Related Service**

1441

- Any medical services claim occurring in an emergency room/inpatient setting with a diagnosis indicating acute cholecystitis 3/1/2020-6/30/2020

1442

1443

- Identified using ICD-10 codes K81.0x

1444

##### **Acute Pancreatitis-Related Service**

1445

- Any medical services claim occurring in an emergency room/inpatient setting with a diagnosis indicating acute pancreatitis 3/1/2020-6/30/2020

1446

1447

- Identified using ICD-10 codes K85.x

1448

1449

1450

#### **Exploratory Outcomes** (*2019*)

1451

##### **Acute Cholecystitis-Related Service**

1452

- Any medical services claim occurring in an emergency room/inpatient setting with a diagnosis indicating acute cholecystitis 7/1/2019-12/31/2019

1453

1454

- Identified using ICD-10 codes K81.0x

1455

##### **Acute Pancreatitis-Related Service**

1456

- Any medical services claim occurring in an emergency room/inpatient setting with a diagnosis indicating acute pancreatitis 7/1/2019-12/31/2019

1457

1458

- Identified using ICD-10 codes K85.x

1459

##### **Acute Bronchitis-Related Service**

1460

- Any medical services claim with a diagnosis indicating acute bronchitis 7/1/2019-12/31/2019

1461

- Identified using ICD-10 codes J20.x-J21.x

1462

##### **Acute Pneumonia-Related Service**

1463

- Any medical services claim with a diagnosis indicating acute bronchitis 7/1/2019-12/31/2019

- 1464 - Identified using ICD-10 codes J13.x-J18.x  
1465  
1466

### Osteonecrosis

#### Osteonecrosis

- 1469 - Any medical services claim with a diagnosis indicating drug-induced osteonecrosis 1/1/2019-  
1470 6/30/2020  
1471 - Identified using ICD-10 codes M87.1x  
1472  
1473  
1474  
1475

### *Drug-Exposure Assignment*

1477 The following details the identification algorithms and associated inputs used for drug-exposure  
1478 classification of study subjects into users/non-users of bisphosphonates, non-bisphosphonates  
1479 osteoporosis medications, statins, antihypertensives, non-insulin antidiabetics, and antidepressants.  
1480

#### Bisphosphonates

- 1482 - Any outpatient prescription or in-office dispensing 1/1/2019-2/29/2020  
1483 - Drugs included: alendronate, alendronic acid, etidronate, ibandronate, ibandronic acid,  
1484 pamidronate, risedronate, and zoledronic acid

#### Non-BP Anti-Resorptive Bone Health Medications

- 1485 - Any outpatient prescription or in-office dispensing 1/1/2019-2/29/2020  
1486 - Drugs included: denosumab, calcitonin, raloxifene, romosozumab-aqqg, teriparatide,  
1487 abaloparatide, or bazedoxifene  
1488

#### Statins

- 1489 - Any outpatient prescription 1/1/2019-2/29/2020  
1490 - Drugs included: pravastatin, rosuvastatin, fluvastatin, atorvastatin, pitavastatin, or  
1491 simvastatin  
1492

#### Antihypertensives

- 1493 - Any non-ophthalmic, non-injection, outpatient prescription claim for a beta-blocker, calcium  
1494 channel blocker, or renin angiotensin system antagonist 1/1/2019-2/29/2020  
1495 - Drugs included: acebutolol, atenolol, betaxolol, bisoprolol, carvedilol, labetalol, metoprolol,  
1496 nadolol, nebivolol, penbutolol, pindolol, propranolol, timolol, amlodipine, diltiazem, felodipine,  
1497 isradipine, nifedipine, nisoldipine, verapamil, aliskiren, azilsartan, benazepril,  
1498 candesartan, captopril, enalapril, eprosartan, fosinopril, irbesartan, lisinopril, losartan,  
1499 moexipril, olmesartan, perindopril, quinapril, ramipril, sacubitril, telmisartan, trandolapril,  
1500 valsartan  
1501

#### Antidiabetics

- 1502 - Any outpatient prescription claim for a non-insulin antidiabetic medication 1/1/2019-  
1503 2/29/2020  
1504 - Drugs included: metformin, chlorpropamide, glimepiride, glipizide, glyburide, tolazamide,  
1505 tolbutamide, pioglitazone, rosiglitazone, alogliptin, linagliptin, saxagliptin, sitagliptin,  
1506 albiglutide, dulaglutide, exenatide, liraglutide, lixisenatide, semaglutide, nateglinide,  
1507 repaglinide, canagliflozin, dapagliflozin, empagliflozin, ertugliflozin  
1508

#### Antidepressants

- 1509 - Any outpatient prescription claim for a selective serotonin reuptake inhibitor, norepinephrine-  
1510 dopamine reuptake inhibitor, serotonin-norepinephrine reuptake inhibitor, tricyclic, tetracyclic,  
1511 modified cyclic, or MAO inhibitor medication 1/1/2019-2/29/2020  
1512

- 1513 - Drugs included: amoxapine, bupropion, citalopram, clomipramine, desipramine,  
1514 desvenlafaxine, doxepin, duloxetine, escitalopram, esketamine, fluoxetine, fluvoxamine,  
1515 imipramine, isocarboxazid, levomilnacipran, maprotiline, mirtazapine, nefazodone,  
1516 nortriptyline, paroxetine, phenelzine, protriptyline, selegiline, sertraline, tranylcypromine,  
1517 trazodone, trimipramine, venlafaxine, vilazodone, vortioxetine

1518  
1519  
1520  
1521

### 1522 *Charlson Comorbidity Condition Assignment*

1523 The following ICD-10 codes were used to assign the CCI condition-specific indicators that are used  
1524 to calculate the overall CCI score. The time period used for identification of condition-specific  
1525 indicators was the entire pre-observation period (1/1/2019-2/29/2020).

1526  
1527  
1528

#### Myocardial infarction

- ICD-10 codes: I21.x, I22.x, I25.2

1529  
1530

#### Congestive heart failure

- ICD-10 codes: I09.9, I11.0, I13.0, I13.2, I25.5, I42.0, I42.5 - I42.9, I43.x, I50.x, P29.0

1531  
1532  
1533

#### Peripheral vascular disease

- ICD-10 codes: I70.x, I71.x, I73.8, I73.9, I77.1, I79.0, I79.2, K55.1, K55.8, K55.9, Z95.8,  
Z95.9

1534  
1535

#### Cerebrovascular disease

- ICD-10 codes: G45.x, G46.x, H34.0, I60.x-I69.x

1536  
1537

#### Dementia

- ICD-10 codes: F00.x - F03.x, F05.1, G30.x, G31.1

1538  
1539

#### Chronic pulmonary disease

- ICD-10 codes: I27.8, I27.9, J40.x - J47.x, J60.x - J67.x, J68.4, J70.1, J70.3

1540  
1541

#### Rheumatologic disease

- ICD-10 codes: M05.x, M06.x, M31.5, M32.x - M34.x, M35.1, M35.3, M36.0

1542  
1543

#### Peptic ulcer disease

- ICD-10 codes: K25.x-K28.x

1544  
1545  
1546

#### Mild liver disease

- ICD-10 codes: B18.x, K70.0 - K70.3, K70.9, K71.3 - K71.5, K71.7, K73.x, K74.x, K76.0,  
K76.2 - K76.4, K76.8, K76.9, Z94.4

1547  
1548

#### Diabetes without chronic complications

- ICD-10 codes: E10.0, E10.1, E10.6, E10.8, E10.9, E11.0, E11.1, E11.6, E11.8, E11.9, E12.0,  
E12.1, E12.6, E12.8, E12.9, E13.0, E13.1, E13.6, E13.8, E13.9, E14.0, E14.1, E14.6, E14.8,  
E14.9

1549  
1550

#### Diabetes with chronic complications

- ICD-10 codes: E10.2 - E10.5, E10.7, E11.2 - E11.5, E11.7, E12.2 - E12.5, E12.7, E13.2 -  
E13.5, E13.7, E14.2 - E14.5, E14.7

1551  
1552  
1553

#### Hemiplegia or paraplegia

- ICD-10 codes: G04.1, G11.4, G80.1, G80.2, G81.x, G82.x, G83.0 - G83.4, G83.9

1554  
1555

#### Renal disease

- ICD-10 codes: I12.0, I13.1, N03.2 - N03.7, N05.2 - N05.7, N18.x, N19.x, N25.0, Z49.0 -  
Z49.2, Z94.0, Z99.2

1556  
1557  
1558  
1559

#### Any tumor, leukemia, or lymphoma

1560 - ICD-10 codes: C00.x - C26.x, C30.x - C34.x, C37.x - C41.x, C43.x, C45.x - C58.x, C60.x -  
1561 C76.x, C81.x - C85.x, C88.x, C90.x - C97.x

1562 Moderate or severe liver disease

1563 - ICD-10 codes: I85.0, I85.9, I86.4, I98.2, K70.4, K71.1, K72.1, K72.9, K76.5, K76.6, K76.7

1564 Metastatic solid tumor

1565 - ICD-10 codes: C77.x - C80.x

1566 AIDS/HIV

1567 - ICD-10 codes: B20.x - B22.x, B24.x

1568

1569

1570 *Additional Condition Covariate Assignment*

1571 The following details the ICD-10 diagnosis codes that were used to identify comorbid conditions.

1572 For all condition indicators classification was based on all medical claims occurring during the pre-  
1573 observation period (1/1/2019-2/29/2020).

1574

1575 Osteoporosis: M80.x, M81.x, M82.x

1576 Cardiovascular Disease Overall: I3x.x-I4x.x, I20.x-I28.x, I50.x-I52.x

1577 Cancer: C0x.x - C9x.x

1578 Chronic Kidney Disease (CKD)/ End-Stage Renal Disease (ESRD): I12.0, I13.1, N03.2 - N03.7,

1579 N05.2 - N05.7, N18.x, N19.x, N25.0, Z49.0 - Z49.2, Z94.0, Z99.2

1580 Chronic Obstructive Pulmonary Disease (COPD): J43.x, J44.x

1581 Dementia: F00.x - F03.x, F05.1, G30.x, G31.1

1582 Depression: F32.x, F33.x

1583 Dyslipidemia: E78.x

1584 Heart Failure: I50.x, I11.0xx, I13.0xx, I13.2xx

1585 HIV/AIDS: B20.x - B22.x, B24.x

1586 Hypertension: I10.x, I12.x, I11.9xx, I13.1xx

1587 Liver Disease: B18.x, K70.0 - K70.3, K70.9, K71.3 - K71.5, K71.7, K73.x, K74.x, K76.0, K76.2 -

1588 K76.4, K76.8, K76.9, Z94.4, I85.0, I85.9, I86.4, I98.2, K70.4, K71.1, K72.1, K72.9,

1589 K76.5, K76.6, K76.7

1590 Obesity: E66.x

1591 Sickle Cell Disease: D57.x

1592 Stroke: I63.x

1593 Type 2 Diabetes: E11.x

1594

1595

1596

1597

1598

1599 **Section 2: Sensitivity Analyses Methodologies**

1600

1601 **Sensitivity Analysis (1): COVID-19-Related Outcomes in “*Bone-Rx*” Cohort**

1602

1603 *Overview & Rationale*

1604 - The first sensitivity analysis was performed to validate the robustness of the primary findings  
1605 by limiting all BP non-users to those who had used non-BP anti-resorptive bone health  
1606 medications during the pre-observation period, thus yielding a more comparable comparator  
1607 cohort that was also receiving bone health medication therapy.

1608 - The use of an active-comparator cohort was done to reduce the impact of unmeasured  
1609 confounding that may have occurred in the primary analysis due to the use of the derived  
1610 Charlson Comorbidity Index composite score as the only comorbidity matching covariate.  
1611 Restriction of the patient population to users of any non-BP anti-resorptive bone health  
1612 medication prior to propensity-score matching improves the probability of having drug  
1613 user/non-user matches with more similar clinical characteristics.

1614 - This sensitivity analysis, further, also acted to increase the robustness and reliability of the  
1615 matched user/non-user outcome comparisons since non-BP anti-resorptive bone health  
1616 medication users represented the smaller portion of the total bone health medication-user  
1617 population (“*Bone-Rx*” cohort) and therefore were matched to their best BP-user pair.  
1618

1619 *Analysis Cohort Definition(s)*

- 1620 - Continuous medical and prescription insurance coverage 1/1/2019-6/30/2020  
1621 - Patients with  $\geq 1$  claim for any anti-resorptive bone health medication 1/1/2019-2/29/2020  
1622

1623 *Exposures of Interest*

- 1624 - Patients were assigned into the BP user cohort if they had any claim 1/1/2019-2/29/2020 for  
1625 one of the following: alendronate, alendronic acid, etidronate, ibandronate, ibandronic acid,  
1626 pamidronate, risedronate, and zoledronic acid.  
1627 - Patients were assigned into the non-BP any anti-resorptive bone health medication user  
1628 cohort if: (1) they had any claim 1/1/2019-2/29/2020 for one of the following: denosumab,  
1629 calcitonin, raloxifene, romosozumab-aqqg, teriparatide, abaloparatide, or bazedoxifene; and (2)  
1630 they had no BP claims 1/1/2019-2/29/2020.  
1631

1632 *Outcomes*

- 1633 - SARS-CoV-2 testing, COVID-19 diagnosis, and COVID-19-related hospitalizations  
1634

1635 *Cohort Matching*

- 1636 - Non-BP anti-resorptive bone health medication users were matched to BP users based on age,  
1637 gender, insurance type, any PCP visit in 2019, and comorbidity score. Matching was  
1638 performed within each region separately (northeast, midwest, south, west) and then combined  
1639 as well as in NY-state alone.  
1640

1641 *Statistical Analyses*

- 1642 - Same as was performed for the primary analysis cohort.



## 1643 **Sensitivity Analysis (2): COVID-19-Related Outcomes in “Osteo-Dx-Rx” Cohort**

1644

### 1645 *Overview & Rationale*

- 1646 - The second sensitivity analysis was performed to further assess the robustness of the primary  
1647 analysis findings by performing a highly restricted comparator cohort matching that included  
1648 patients diagnosed and treated for osteoporosis (“Osteo-Dx-Rx” cohort).
- 1649 - The relationship between COVID-19-related outcomes and BP-exposure was modelled after  
1650 restricting anti-resorptive bone health medication users to those most likely to use BPs and  
1651 matching BP non-users to BP users based on the presence of comorbid diagnoses within  
1652 insurance type in four states with early COVID-19 spread representing each to further reduce  
1653 confounding related to differences in demographic/clinical characteristics amongst BP  
1654 users/non-users, confounding due to socioeconomic status (insurance type as proxy), and  
1655 confounding due to differences in COVID-19-exposure risk based on geography.

1656

### 1657 *Analysis Cohort Definition(s)*

- 1658 - Continuous medical and prescription insurance coverage 1/1/2019-6/30/2020
- 1659 - Patients with  $\geq 1$  claim for any osteoporosis medication 1/1/2019-2/29/2020 who also met  
1660 the following criteria: (i) female; (ii) age 51 or older; (iii) identified as residing in New York,  
1661 Illinois, Florida, or California; and (iv) had  $\geq 1$  medical claim indicating a diagnosis of  
1662 osteoporosis 1/1/2019-2/29/2020

1663

### 1664 *Exposures of Interest*

- 1665 - Patients were assigned into the BP user cohort if they had any claim 1/1/2019-2/29/2020 for  
1666 one of the following: alendronate, alendronic acid, etidronate, ibandronate, ibandronic acid,  
1667 pamidronate, risedronate, and zoledronic acid.
- 1668 - Patients were assigned into the non-BP anti-resorptive bone health medication user cohort if:  
1669 (1) they had any claim 1/1/2019-2/29/2020 for one of the following: denosumab, calcitonin,  
1670 raloxifene, romosozumab-aqqg, teriparatide, abaloparatide, or bazedoxifene; and (2) they had  
1671 no BP claims 1/1/2019-2/29/2020.

1672

### 1673 *Outcomes*

- 1674 - SARS-CoV-2 testing, COVID-19 diagnosis, and COVID-19-related hospitalizations

1675

### 1676 *Cohort Matching*

- 1677 - Non- anti-resorptive bone health medication users were matched to BP users based on age,  
1678 PCP visit in 2019, and the presence of the following comorbid conditions (assigned using ICD-  
1679 10 codes on claims occurring 1/1/2019-2/29/2020): cancer, chronic obstructive pulmonary  
1680 disease, depression, dyslipidaemia, heart failure, hypertension, obesity, and type 2 diabetes.
- 1681 - Matching was performed within each state when stratified by insurance type (commercial, dual,  
1682 Medicaid, Medicare).

1683

### 1684 *Statistical Analyses*

- 1685 - Multivariate logistic regression analyses, modelled separately for each COVID-19-related  
1686 outcome of interest, were performed on the unmatched and matched samples after combining  
1687 all patient observations. In addition to the key exposure variable (indicating BP user versus  
1688 non-BP user), the regression model also included demographic/clinical covariate for age group,  
1689 region, insurance type, PCP visit in 2019, and the following comorbid conditions: osteoporosis,  
1690 cancer, chronic obstructive pulmonary disease, depression, dyslipidaemia, hypertension,  
1691 obesity, type 2 diabetes, cardiovascular disease overall, sickle cell anemia, stroke, dementia,  
1692 HIV/AIDS, chronic kidney disease/end-stage renal disease, and liver disease.

1693

1694 **Sensitivity Analysis (3): Association of BP-use with Exploratory Negative Control**  
1695 **Outcomes**

1696 *Overview & Rationale*

- 1697 - The third sensitivity analysis was performed to assess the relationship between BP-use and  
1698 outcomes not anticipated to be impacted by the pharmacological mechanism of BPs.
- 1699 - This was performed by modelling the relationship between BP-exposure and other outcomes  
1700 occurring (1) during the study observation, and (2) during the second half of 2019 among BP  
1701 users with claims during the first half of 2019 and their previously-assigned BP non-user  
1702 matched pair, in the primary, “*Bone-Rx*”, and “*Osteo-Dx-Rx*” cohorts.
- 1703 - Outcomes modelled included any acute cholecystitis-related or acute pancreatitis-related  
1704 inpatient/emergency-room (ER) service, used as exploratory outcomes not predicted to be  
1705 modulated by BP exposure to assess the validity of the core COVID-19-related outcomes.  
1706

1707 *Analysis Cohort Definition(s)*

- 1708 - Patients who were included in the primary analysis cohort for assessment of (1) outcomes  
1709 occurring during the study observation period; for (2) outcomes assessed during the second  
1710 half of 2019 the cohort was restricted to among BP users with claims during the first half of  
1711 2019 and their previously-assigned BP non-user matched pair.
- 1712 - Patients who met all eligibility criteria to be included in the ‘*Bone-Rx*’ cohort for assessment  
1713 of (1) outcomes occurring during the study observation period; for (2) outcomes assessed  
1714 during the second half of 2019 the cohort was restricted to among BP users with claims  
1715 during the first half of 2019 and their previously-assigned BP non-user matched pair.
- 1716 - Patients who met all eligibility criteria to be included in the ‘*Osteo-Dx-Rx*’ cohort for  
1717 assessment of (1) outcomes occurring during the study observation period; for (2) outcomes  
1718 assessed during the second half of 2019 the cohort was restricted to among BP users with  
1719 claims during the first half of 2019 and their previously-assigned BP non-user matched pair.  
1720

1721 *Exposures of Interest*

- 1722 - For the primary analysis cohort, the BP user / BP non-user assignment was the same as used  
1723 in the core analyses.
- 1724 - For the “*Bone-Rx*” and “*Osteo-Dx-Rx*” cohorts, assignment was the same as used in those  
1725 analyses stratifying medication users into BP users and non-BP medication users.  
1726

1727 *Outcomes*

- 1728 - Any medical claim from an ER/inpatient setting with a diagnosis indicating acute cholecystitis  
1729 (ICD-10 code K81.0x) occurring 3/1/2020-6/30/2020 (observation period)
- 1730 - Any medical claim from an ER/inpatient setting with a diagnosis indicating acute pancreatitis  
1731 (ICD-10 code K85.x) occurring 3/1/2020-6/30/2020 (observation period)
- 1732 - Any medical claim from an ER/inpatient setting with a diagnosis indicating acute cholecystitis  
1733 (ICD-10 code K81.0x) occurring 7/1/2019-12/31/2019 (2019)
- 1734 - Any medical claim from an ER/inpatient setting with a diagnosis indicating acute pancreatitis  
1735 (ICD-10 code K85.x) occurring 7/1/2019-12/31/2019 (2019)  
1736

1737 *Cohort Matching*

- 1738 - NA; all cohorts previously matched.  
1739

1740 *Statistical Analyses*

- 1741 - Multivariate logistic regression analyses were performed using the same methodologies  
1742 employed when assessing COVID-19 outcomes that were cohort-build-specific (i.e. followed  
1743 previous approach detailed for each respective cohort build) to assess the odds of acute  
1744 cholecystitis or acute pancreatitis.

1745 **Sensitivity Analysis (4): Association of BP-use with Exploratory Positive Control Outcomes**  
1746 **in 2019**  
1747

1748 *Overview & Rationale*

- 1749 - The fourth sensitivity analysis was performed to assess the relationship between BP-use and  
1750 select outcomes occurring in 2019 to validate the theorized BP mechanism of action.
- 1751 - This was performed by modelling the relationship between BP-exposure in the first half of  
1752 2019 and other outcomes occurring during the second half of 2019 in the primary, “Bone-Rx”,  
1753 and “Osteo-Dx-Rx” cohorts, specifically medical services for other infectious respiratory  
1754 conditions (acute bronchitis, pneumonia), used to assess the validity of the relationship  
1755 between BP-use and decreased respiratory infections.  
1756

1757 *Analysis Cohort Definition(s)*

- 1758 - The following criteria were applied to all three cohort build variations (primary analysis cohort,  
1759 “Bone-Rx” cohort, “Osteo-Dx-Rx” cohort): (i) BP users were restricted to those with any BP  
1760 claim 1/1/2019-6/30/2019, and the remaining previously-classified BP-user patients with their  
1761 first BP-claim date occurring on/after 7/1/2019 were excluded; (ii) BP non-users were  
1762 restricted to their BP-user matched-pair previously assigned.  
1763

1764 *Exposures of Interest*

- 1765 - In all cohort build variations, the previously-classified BP user cohorts were restricted to those  
1766 with any BP-claim 1/1/2019-6/30/2019; all other previously-classified BP users were excluded.  
1767

1768 *Outcomes*

- 1769 - Any medical claim with a diagnosis indicating acute bronchitis (ICD-10 code J20.x-J21.x)  
1770 occurring 7/1/2019-12/31/2019
- 1771 - Any medical claim with a diagnosis indicating pneumonia (ICD-10 code J13.x-J18.x) occurring  
1772 7/1/2019-12/31/2019  
1773

1774 *Cohort Matching*

- 1775 - NA; all cohorts previously matched.  
1776

1777 *Statistical Analyses*

- 1778 - Multivariate logistic regression analyses were performed using the same methodologies  
1779 employed when assessing COVID-19-related outcomes that were cohort-build-specific (i.e.  
1780 followed previous approach detailed for each respective cohort build) to assess the odds of  
1781 acute bronchitis, or pneumonia.  
1782  
1783

1784 **Sensitivity Analysis (5): Association between use of Other Drug Classes and COVID-19-**  
1785 **Related Outcomes**  
1786

1787 *Overview & Rationale*

- 1788 - The fifth sensitivity analysis was performed to assess whether the observed protective effect of  
1789 BPs may be associated with general healthier behaviours in patients using any medication  
1790 rather than specifically BP use. To assess this unmeasured confounding due to the healthy  
1791 adherer effect, which is a type of potential bias where patients may have better outcomes due  
1792 to their healthier behaviours and not better outcomes related to active drug treatment itself, the  
1793 first sensitivity analysis evaluated the association between use of other preventive medications  
1794 (statin, antihypertensive, antidiabetic, antidepressant) and COVID-19-related outcomes were  
1795 evaluated.
- 1796 - This was performed following the same techniques used in the primary cohort matching and  
1797 analyses but when assigned drug exposure cohorts based on the use of statin,  
1798 antihypertensive, antidiabetic, or antidepressant medications. The consistency of methods was  
1799 done to permit direct comparison on the association between drug-use and COVID-19-related  
1800 outcomes to assess whether the healthy adherer effect alone accounts for the decrease in the  
1801 odds of COVID-19 outcomes when comparing BP users to non-users in the primary analysis.  
1802 Evidence to support the contention that the HAE is a significant source of unmeasured  
1803 confounding would necessitate that other drug classes display a similar statistically significant  
1804 trend and/or magnitude when comparing drug users to non-users. Variability in directional  
1805 impact, magnitude, and/or statistical significance would, conversely, suggest that the healthy  
1806 adherer effect itself does not account for the differences seen when comparing BP users to BP  
1807 non-users.
- 1808 - This sensitivity analysis, additionally, also employed a unique nested-matching technique  
1809 wherein BP users were matched to BP non-users within the other-medication-class matched  
1810 populations when stratified into the already matched but mutually exclusive user/non-user  
1811 cohorts. This was performed to: (1) assess whether the decreased odds of COVID-19-related  
1812 outcomes in BP users compared to BP non-users was robust, even amongst cohorts  
1813 displaying an increase in the odds of COVID-19-related outcomes; and (2) to assess whether  
1814 the magnitude of decrease in odds of COVID-19-related outcomes amongst BP users  
1815 compared to BP non-users seen in the primary analysis is impacted by use of other  
1816 medication classes, including some that have also been identified as being associated with a  
1817 reduced incidence and/or severity of COVID-19-related outcomes.

1818  
1819 *Analysis Cohort Definition(s)*

- 1820 - Continuous medical and prescription insurance coverage 1/1/2019-6/30/2020 (*all*)  
1821 - Patients with any claim for another drug class of interest (statin, antihypertensive,  
1822 antidiabetic, antidepressant) medication 1/1/2019-2/29/2020 were classified users
- 1823 - Among the propensity-score matched drug user/non-user cohorts, a further stratification and  
1824 propensity-score matching based on BP use 1/1/2019-2/29/2020 to yield the following: (i)  
1825 drug user/BP user matched to drug user/BP non-user, (ii) drug non-user/BP user matched to  
1826 drug non-user/BP non-user.

1827  
1828 *Exposures of Interest*

- 1829 - Patients were assigned into the statin user cohort if they had any claim 1/1/2019-2/29/2020 for  
1830 one of the following: pravastatin, rosuvastatin, fluvastatin, atorvastatin, pitavastatin, or  
1831 simvastatin
- 1832 - Patients were assigned into the antihypertensive user cohort if they had any non-ophthalmic,  
1833 non-injection claim 1/1/2019-2/29/2020 for a beta blocker, calcium channel blocker, or renin-  
1834 angiotensin system antagonist medication.

- 1835 - Patients were assigned into the antidiabetic user cohort if they had any claim 1/1/2019-  
1836 2/29/2020 for one of the following non-insulin medications: metformin, chlorpropamide,  
1837 glimepiride, glipizide, glyburide, tolazamide, tolbutamide, pioglitazone, rosiglitazone, alogliptin,  
1838 linagliptin, saxagliptin, sitagliptin, albiglutide, dulaglutide, exenatide, liraglutide, lixisenatide,  
1839 semaglutide, nateglinide, repaglinide, canagliflozin, dapagliflozin, empagliflozin, ertugliflozin
- 1840 - Patients were assigned into the antidepressant user cohort if they had any claim 1/1/2019-  
1841 2/29/2020 for one of the following: amoxapine, bupropion, citalopram, clomipramine,  
1842 desipramine, desvenlafaxine, doxepin, duloxetine, escitalopram, esketamine, fluoxetine,  
1843 fluvoxamine, imipramine, isocarboxazid, levomilnacipran, maprotiline, mirtazapine,  
1844 nefazodone, nortriptyline, paroxetine, phenelzine, protriptyline, selegiline, sertraline,  
1845 tranylcypromine, trazodone, trimipramine, venlafaxine, vilazodone, vortioxetine

1846  
1847 *Outcomes*

- 1848 - SARS-CoV-2 testing, COVID-19 diagnosis, and COVID-19-related hospitalizations  
1849

1850 *Cohort Matching*

- 1851 - For the larger drug-class analyses, matching was performed following the same methods used  
1852 in the primary analysis: users were matched to non-users based on age, gender, insurance  
1853 type, any PCP visit in 2019, and comorbidity score. Matching was performed within each  
1854 region separately (northeast, midwest, south, west) and then combined, as well as in NY-state  
1855 alone.
- 1856 - Following this matching procedure, a nested BP user to BP non-user propensity score match  
1857 was then performed on the aforementioned matched populations (i.e. within the separate and  
1858 already matched statin user and statin non-user populations). Matching was performed using  
1859 the same list of demographic/clinical characteristics, and was also performed within each  
1860 region separately (northeast, midwest, south, west) and then combined as well as in NY-state  
1861 alone.

1862  
1863 *Statistical Analyses*

- 1864 - Same as was performed for the primary analysis cohort.  
1865  
1866  
1867

## 1868 **APPENDIX 2: Additional Study Results; Cohort Characteristics Pre/Post Match**

1869

### 1870 **Primary Analysis Study Population**

1871

#### 1872 *Northeast Region*

1873 A total of 2,152,560 patients identified as residing in the northeast were included in the unmatched  
1874 primary analysis cohort comparisons, of which 119,728 (5.6%) and 2,032,832 (94.4%) were classified  
1875 as BP users and BP non-users, respectively (**Table S2a**). Prior to propensity-score matching, there  
1876 were significant differences across all demographic and clinical characteristics. Compared to BP non-  
1877 users, BP users were older (97.5% age  $\geq 51$  versus 49.8%;  $p < 0.001$ ), predominantly female (90.5%  
1878 versus 57.4%;  $p < 0.001$ ), with higher comorbidity burden (mean CCI=0.93 versus 0.65;  $p < 0.001$ ),  
1879 insured by Medicare (46.5% versus 18.0%;  $p < 0.001$ ), and have had a primary-care physician (PCP)  
1880 visit in 2019 (58.3% versus 42.8%;  $p < 0.001$ ). Propensity-score matching yielded 119,494 BP users  
1881 and 119,494 BP non-users with no significant differences across examined characteristics. A total of  
1882 234 BP users from the northeast region in the unmatched primary analysis cohort were not assigned  
1883 an applicable BP non-user pair during the matching procedure and were excluded from the matched  
1884 BP user population.

1885

#### 1886 *Midwest Region*

1887 A total of 1,467,802 patients identified as residing in the midwest were included in the unmatched  
1888 primary analysis cohort comparisons, of which 75,967 (5.2%) and 1,391,835 (94.8%) were classified  
1889 as BP users and BP non-users, respectively (**Table S2b**). Prior to propensity-score matching, there  
1890 were significant differences across all demographic and clinical characteristics. Compared to BP non-  
1891 users, BP users were older (96.6% age  $\geq 51$  versus 44.0%;  $p < 0.001$ ), predominantly female (90.3%  
1892 versus 57.1%;  $p < 0.001$ ), with higher comorbidity burden (mean CCI=0.99 versus 0.56;  $p < 0.001$ ),  
1893 insured by Medicare (43.6% versus 14.5%;  $p < 0.001$ ), and have had a primary-care physician (PCP)  
1894 visit in 2019 (62.2% versus 51.0%;  $p < 0.001$ ). Propensity-score matching yielded 75,901 BP users and  
1895 75,901 BP non-users with no significant differences across examined characteristics. A total of 66 BP  
1896 users from the midwest region in the unmatched primary analysis cohort were not assigned an  
1897 applicable BP non-user pair during the matching procedure and were excluded from the matched BP  
1898 user population.

1899

#### 1900 *South Region*

1901 A total of 3,042,604 patients identified as residing in the south were included in the unmatched  
1902 primary analysis cohort comparisons, of which 160,886 (5.3%) and 2,881,718 (94.7%) were classified  
1903 as BP users and BP non-users, respectively (**Table S2c**). Prior to propensity-score matching, there  
1904 were significant differences across all demographic and clinical characteristics. Compared to BP non-  
1905 users, BP users were older (96.8% age  $\geq 51$  versus 39.2%;  $p < 0.001$ ), predominantly female (90.6%  
1906 versus 57.4%;  $p < 0.001$ ), with higher comorbidity burden (mean CCI=0.86 versus 0.55;  $p < 0.001$ ),  
1907 insured by Medicare (41.0% versus 11.3%;  $p < 0.001$ ), and have had a primary-care physician (PCP)  
1908 visit in 2019 (66.1% versus 49.2%;  $p < 0.001$ ). Propensity-score matching yielded 159,704 BP users  
1909 and 159,704 BP non-users with no significant differences across examined characteristics. A total of  
1910 1,182 BP users from the south region in the unmatched primary analysis cohort were not assigned an  
1911 applicable BP non-user pair during the matching procedure and were excluded from the matched BP  
1912 user population.

1913

#### 1914 *West Region*

1915 A total of 1,243,637 patients identified as residing in the west were included in the unmatched primary  
1916 analysis cohort comparisons, of which 95,470 (7.7%) and 1,148,167 (92.3%) were classified as BP  
1917 users and BP non-users, respectively (**Table S2d**). Prior to propensity-score matching, there were  
1918 significant differences across all demographic and clinical characteristics. Compared to BP non-users,

1919 BP users were older (97.8% age  $\geq$ 51 versus 43.5%;  $p<0.001$ ), predominantly female (88.7% versus  
1920 56.4%;  $p<0.001$ ), with higher comorbidity burden (mean CCI=1.08 versus 0.66;  $p<0.001$ ), insured by  
1921 Medicare (43.5% versus 11.0%;  $p<0.001$ ), and have had a primary-care physician (PCP) visit in 2019  
1922 (67.7% versus 45.3%;  $p<0.001$ ). Propensity-score matching yielded 95,267 BP users and 95,267 BP  
1923 non-users with no significant differences across examined characteristics. A total of 203 BP users  
1924 from the west region in the unmatched primary analysis cohort were not assigned an applicable BP  
1925 non-user pair during the matching procedure and were excluded from the matched BP user  
1926 population.

1927  
1928 *New York State*

1929 A total of 968,296 patients identified as residing in New York state were included in the unmatched  
1930 primary analysis NY-state restricted cohort, of which 50,035 (5.2%) and 918,261 (94.8%) were  
1931 classified as BP users and BP non-users, respectively (**Table S2e**). Prior to propensity-score  
1932 matching, there were significant differences across all demographic and clinical characteristics.  
1933 Compared to BP non-users, BP users were older (98.1% age  $\geq$ 51 versus 50.7%;  $p<0.001$ ),  
1934 predominantly female (90.9% versus 57.5%;  $p<0.001$ ), with higher comorbidity burden (mean  
1935 CCI=0.95 versus 0.63;  $p<0.001$ ), insured by Medicare (57.7% versus 19.5%;  $p<0.001$ ), and have had  
1936 a primary-care physician (PCP) visit in 2019 (62.7% versus 45.3%;  $p<0.001$ ). Propensity-score  
1937 matching yielded 49,862 BP users and 49,862 BP non-users with no significant differences across  
1938 examined characteristics. A total of 173 BP users from the unmatched New York state primary  
1939 analysis cohort were not assigned an applicable BP non-user pair during the matching procedure and  
1940 were excluded from the matched BP user population.

1941  
1942  
1943

### **Bone-Rx Analysis Study Population**

1944 *All Observations (all regions combined)*

1945 A total of 502,895 patients were included in the unmatched “*Bone-Rx*” analysis cohort comparisons, of  
1946 which 452,051 (89.9%) and 50,844 (10.1%) were classified as BP users and BP non-users,  
1947 respectively (**Table S6a**). Prior to propensity-score matching, there were significant differences across  
1948 all demographic and clinical characteristics. Compared to BP non-users, BP users were younger (47.9%  
1949 age  $\geq$ 71 versus 55.2%;  $p<0.001$ ), predominantly female (90.1% versus 87.2%;  $p<0.001$ ), with a lower  
1950 comorbidity burden (mean CCI=0.95 versus 1.99;  $p<0.001$ ), with a larger proportion of patients  
1951 residing in the west (21.1% versus 15.8%;  $p<0.001$ ), a lower proportion covered by Medicare (43.4%  
1952 versus 47.5%;  $p<0.001$ ), and a lower proportion have had a primary-care physician (PCP) visit in  
1953 2019 (63.8% versus 64.3%;  $p=0.009$ ). Propensity-score matching yielded 50,498 BP users and  
1954 50,498 BP non-users with no significant differences across examined characteristics. A total of 346  
1955 BP non-users from the unmatched “*Bone-Rx*” analysis cohort were not assigned an applicable BP  
1956 user pair during the matching procedure and were excluded from the matched BP non-user  
1957 population.

1958  
1959 *Northeast Region*

1960 A total of 135,867 patients identified as residing in the northeast were included in the unmatched  
1961 “*Bone-Rx*” analysis cohort comparisons, of which 119,728 (88.1%) and 16,139 (11.9%) were  
1962 classified as BP users and BP non-users, respectively (**Table S6b**). Prior to propensity-score  
1963 matching based on BP-use, there were significant differences across all demographic and clinical  
1964 characteristics except for any PCP visit in 2019 ( $p=0.95$ ). Compared to BP non-users, BP users were  
1965 younger (48.1% age  $\geq$ 71 versus 54.8%;  $p<0.001$ ), predominantly female (90.5% versus 87.5%;  
1966  $p<0.001$ ), with a lower comorbidity burden (mean CCI=0.93 versus 1.97;  $p<0.001$ ), and a lower  
1967 proportion insured by Medicare (46.5% versus 54.0%;  $p<0.001$ ). Propensity-score matching yielded  
1968 15,993 BP users and 15,993 BP non-users with no significant differences across examined  
1969 characteristics. A total of 146 BP non-users from the northeast region in the unmatched “*Bone-Rx*”

1970 analysis cohort were not assigned an applicable BP user pair during the matching procedure and  
1971 were excluded from the matched BP non-user population.

1972

### 1973 *Midwest Region*

1974 A total of 85,391 patients identified as residing in the midwest were included in the unmatched “*Bone-*  
1975 *Rx*” analysis cohort comparisons, of which 75,967 (89.0%) and 9,424 (11.0%) were classified as BP  
1976 users and BP non-users, respectively (**Table S6c**). Prior to propensity-score matching, there were  
1977 significant differences across all demographic and clinical characteristics. Compared to BP non-users,  
1978 BP users were younger (43.0% age  $\geq 71$  versus 54.1%;  $p < 0.001$ ), predominantly female (90.3%  
1979 versus 86.1%;  $p < 0.001$ ), with a lower comorbidity burden (mean CCI=0.99 versus 2.12;  $p < 0.001$ ), had  
1980 a lower proportion insured by Medicare (43.6% versus 51.9%;  $p < 0.001$ ), with a lower proportion  
1981 having a primary-care physician (PCP) visit in 2019 (62.2% versus 64.7%;  $p < 0.001$ ). Propensity-score  
1982 matching yielded 9,360 BP users and 9,360 BP non-users with no significant differences across  
1983 examined characteristics. A total of 64 BP non-users from the midwest region in the unmatched  
1984 “*Bone-Rx*” analysis cohort were not assigned an applicable BP user pair during the matching  
1985 procedure and were excluded from the matched BP non-user population.

1986

### 1987 *South Region*

1988 A total of 178,118 patients identified as residing in the south were included in the unmatched “*Bone-*  
1989 *Rx*” analysis cohort comparisons, of which 160,886 (90.3%) and 17,232 (9.7%) were classified as BP  
1990 users and BP non-users, respectively (**Table S6d**). Prior to propensity-score matching, there were  
1991 significant differences across all demographic and clinical characteristics except for any PCP visit in  
1992 2019 ( $p = 0.45$ ). Compared to BP non-users, BP users were younger (46.6% age  $\geq 71$  versus 53.3%;  
1993  $p < 0.001$ ), predominantly female (90.6% versus 88.1%;  $p < 0.001$ ), with a lower comorbidity burden  
1994 (mean CCI=0.86 versus 1.86;  $p < 0.001$ ), and a lower proportion insured by Medicare (41.0% versus  
1995 44.0%;  $p < 0.001$ ). Propensity-score matching yielded 17,140 BP users and 17,140 BP non-users with  
1996 no significant differences across examined characteristics. A total of 92 BP non-users from the south  
1997 region in the unmatched “*Bone-Rx*” analysis cohort were not assigned an applicable BP user pair  
1998 during the matching procedure and were excluded from the matched BP non-user population.

1999

### 2000 *West Region*

2001 A total of 103,519 patients identified as residing in the west were included in the unmatched “*Bone-Rx*”  
2002 analysis cohort comparisons, of which 95,470 (92.2%) and 8,049 (7.8%) were classified as BP users  
2003 and BP non-users, respectively (**Table S6e**). Prior to propensity-score matching, there were  
2004 significant differences across all demographic and clinical characteristics. Compared to BP non-users,  
2005 BP users were younger (54.1% age  $\geq 71$  versus 61.6%;  $p < 0.001$ ), predominantly female (88.7%  
2006 versus 86.2%;  $p < 0.001$ ), with a lower comorbidity burden (mean CCI=1.08 versus 2.17;  $p < 0.001$ ),  
2007 insured by Medicare (43.5% versus 36.9%;  $p < 0.001$ ), with a lower proportion having a primary-care  
2008 physician (PCP) visit in 2019 (67.7% versus 71.6%;  $p < 0.001$ ). Propensity-score matching yielded  
2009 8,005 BP users and 8,005 BP non-users with no significant differences across examined  
2010 characteristics. A total of 44 BP non-users from the west region in the unmatched “*Bone-Rx*” analysis  
2011 cohort were not assigned an applicable BP user pair during the matching procedure and were  
2012 excluded from the matched BP non-user population.

2013

### 2014 *New York State*

2015 A total of 57,397 patients identified as residing in New York state were included in the unmatched  
2016 “*Bone-Rx*” analysis NY-state restricted cohort, of which 50,035 (87.2%) and 7,362 (12.8%) were  
2017 classified as BP users and BP non-users, respectively (**Table S6f**). Prior to propensity-score matching,  
2018 there were significant differences across all demographic and clinical characteristics except for any  
2019 PCP visit in 2019 ( $p = 0.35$ ). Compared to BP non-users, BP users were younger (53.2% age  $\geq 71$   
2020 versus 54.5%;  $p < 0.001$ ), predominantly female (90.9% versus 89.5%;  $p < 0.001$ ), with a lower



2021 comorbidity burden (mean CCI=0.95 versus 1.81;  $p<0.001$ ), and a higher proportion insured by  
2022 Medicaid (18.3% versus 13.8%;  $p<0.001$ ). Propensity-score matching yielded 7,254 BP users and  
2023 7,254 BP non-users with no significant differences across examined characteristics. A total of 108 BP  
2024 non-users from the unmatched New York state “Bone-Rx” analysis cohort were not assigned an  
2025 applicable BP user pair during the matching procedure and were excluded from the matched BP non-  
2026 user population.

2027

### 2028 **Osteo-Dx-Rx Analysis Study Population**

2029 A total of 60,043 female patients age  $\geq 51$  with a diagnosis of osteoporosis who resided in New York  
2030 (NY), Illinois (IL), Florida (FL), or California (CA) were included in the unmatched “Osteo-Dx-Rx”  
2031 analysis cohort comparison, of which 51,651 (86.0%) and 8,392 (14.0%) were classified as BP users  
2032 and BP non-users, respectively (**Table S7**). Prior to propensity-score matching, which was performed  
2033 within each state by insurance type, there were significant differences across all demographic and  
2034 clinical characteristics except the proportion of patients with a diagnosis of dyslipidemia ( $p=0.08$ ).  
2035 Compared to BP non-users, BP users were younger (18.8% age  $\geq 81$  versus 26.0%;  $p<0.001$ ), with a  
2036 larger proportion of patients residing in CA (42.5% versus 30.5%;  $p<0.001$ ), insured by Medicaid (23.1%  
2037 versus 21.3%;  $p<0.001$ ), have had a primary-care physician (PCP) visit in 2019 (77.4% versus 71.1%;  
2038  $p<0.001$ ), had a higher proportion with a diagnosis of obesity (11.2% versus 9.6%;  $p<0.001$ , and had  
2039 a lower proportion diagnosed with the following: cancer (11.8% versus 19.4%;  $p<0.001$ ), COPD (10.1%  
2040 versus 16.2%;  $p<0.001$ ), heart failure (6.1% versus 10.7%;  $p<0.001$ ), hypertension (58.0% versus  
2041 60.9%;  $p<0.001$ ), type 2 diabetes (25.6% versus 26.9%;  $p<0.01$ ), and depression (13.9% versus  
2042 15.2%;  $p<0.001$ ). Propensity-score matching yielded 7,949 BP users and 7,949 BP non-users with no  
2043 significant differences across examined characteristics. A total of 443 BP non-users from the  
2044 unmatched “Osteo-Dx-Rx” analysis cohort were not assigned an applicable BP user pair during the  
2045 matching procedure and were excluded from the matched BP non-user population.

2046

2047

2048

2049

2050

### **Statin User/Non-User Analysis**

2051 *Statin-Use Comparison: All Observations (all regions combined)*

2052 A total of 7,906,603 patients were included in the unmatched analysis cohort comparison of statin-use,  
2053 of which 1,503,395 (19.0%) and 6,403,208 (81.0%) were classified as statin users and statin non-  
2054 users, respectively (**Table S8a**). Prior to propensity-score matching, there were significant differences  
2055 across all demographic and clinical characteristics. Compared to statin non-users, statin users were  
2056 older (87.9% age  $\geq 51$  versus 37.1%;  $p<0.001$ ), with a higher proportion of males (41.1% versus  
2057 40.9%;  $p<0.001$ ), from the northeast (29.7% versus 26.6%;  $p<0.001$ ), with higher comorbidity burden  
2058 (mean CCI=1.15 versus 0.49;  $p<0.001$ ), insured by Medicare (32.7% versus 11.3%;  $p<0.001$ ), and  
2059 have had a primary-care physician (PCP) visit in 2019 (66.1% versus 44.1%;  $p<0.001$ ). Propensity-  
2060 score matching yielded 1,436,300 statin users and 1,436,300 statin non-users with no significant  
2061 differences across age group, region, insurance type, and having had any PCP visit in 2019. The final  
2062 matched population did, however, display statistically significant differences between statin users and  
2063 statin non-users for gender (58.7% versus 58.4% male;  $p<0.001$ ) and mean CCI (1.11 versus 1.12;  
2064  $p<0.001$ ). These differences, however, are small in magnitude, and were statistically significant due to  
2065 the underlying statistical power associated with the large sample size. A total of 67,095 statin users  
2066 from the unmatched analysis cohort were not assigned an applicable statin non-user pair during the  
2067 matching procedure and were excluded from the matched statin user population.

2068

2069 *Statin-Use Comparison: New York State*

2070 A total of 968,296 patients identified as residing in New York state were included in the unmatched  
2071 analysis cohort comparison of statin-use, of which 206,301 (21.3%) and 761,995 (78.7%) were  
2072 classified as statin users and statin non-users, respectively (**Table S8b**). Prior to propensity-score

2073 matching, there were significant differences across all demographic and clinical characteristics.  
2074 Compared to statin non-users, statin users were older (90.3% age  $\geq 51$  versus 43.1%;  $p < 0.001$ ), with a  
2075 higher proportion of males (42.0% versus 40.4%;  $p < 0.001$ ), with higher comorbidity burden (mean  
2076 CCI=1.17 versus 0.51;  $p < 0.001$ ), insured by Medicare (47.4% versus 14.5%;  $p < 0.001$ ), and have had  
2077 a primary-care physician (PCP) visit in 2019 (64.0% versus 41.3%;  $p < 0.001$ ). Propensity-score  
2078 matching yielded 185,536 statin users and 185,536 statin non-users with no significant differences  
2079 across age group, gender, insurance type, and having had any PCP visit in 2019. The final matched  
2080 population did, however, display statistically significant differences between statin users and statin  
2081 non-users for mean CCI (1.06 versus 1.08;  $p < 0.001$ ). This difference, however, is small in magnitude,  
2082 and was statistically significant due to the underlying statistical power associated with the large  
2083 sample size. A total of 20,765 statin users from the unmatched analysis cohort were not assigned an  
2084 applicable statin non-user pair during the matching procedure and were excluded from the matched  
2085 statin user population.  
2086

#### 2087 *BP-Use Comparison within Statin Users: All Regions Combined*

2088 Of the 1,436,300 statin users from the statin user/non-user propensity-score matching analysis, a total  
2089 of 217,981 (15.2%) and 1,218,319 (84.8%) were classified as BP users and BP non-users,  
2090 respectively (**Table S8c**). Prior to propensity-score matching based on BP-use, there were significant  
2091 differences across all demographic and clinical characteristics except for any PCP visit in 2019  
2092 ( $p = 0.27$ ). Compared to BP non-users, BP users were older (98.9% age  $\geq 51$  versus 85.3%;  $p < 0.001$ ),  
2093 with a higher proportion of females (90.1% versus 53.1%;  $p < 0.001$ ), from the west (21.7% versus  
2094 14.0%;  $p < 0.001$ ), with lower comorbidity burden (mean CCI=0.95 versus 1.13;  $p < 0.001$ ), and insured  
2095 by Medicare (50.8% versus 29.7%;  $p < 0.001$ ). Propensity-score matching yielded 213,480 BP users  
2096 and 213,480 BP non-users with no significant differences across examined characteristics. A total of  
2097 4,501 BP users were not assigned an applicable BP non-user pair during the matching procedure and  
2098 were excluded from the matched BP user population.  
2099

#### 2100 *BP-Use Comparison within Statin Users: New York State*

2101 Of the 185,536 statin users from the statin user/non-user propensity-score matching analysis on  
2102 patients residing in New York state, a total of 23,863 (12.9%) and 161,673 (87.1%) were classified as  
2103 BP users and BP non-users, respectively (**Table S8d**). Prior to propensity-score matching based on  
2104 BP-use, there were significant differences across all demographic and clinical characteristics except  
2105 for any PCP visit in 2019 ( $p = 0.33$ ). Compared to BP non-users, BP users were older (99.3% age  $\geq 51$   
2106 versus 87.7%;  $p < 0.001$ ), with a higher proportion of females (91.2% versus 53.3%;  $p < 0.001$ ), with  
2107 lower comorbidity burden (mean CCI=0.92 versus 1.08;  $p < 0.001$ ), and insured by Medicare (66.4%  
2108 versus 41.9%;  $p < 0.001$ ). Propensity-score matching yielded 23,736 BP users and 23,736 BP non-  
2109 users with no significant differences across examined characteristics. A total of 127 BP users were  
2110 not assigned an applicable BP non-user pair during the matching procedure and were excluded from  
2111 the matched BP user population.  
2112

#### 2113 *BP-Use Comparison within Statin Non-users: All Regions Combined*

2114 Of the 1,436,300 statin non-users from the statin user/non-user propensity-score matching analysis, a  
2115 total of 124,843 (8.7%) and 1,311,457 (91.3%) were classified as BP users and BP non-users,  
2116 respectively (**Table S8e**). Prior to propensity-score matching based on BP-use, there were significant  
2117 differences across all demographic and clinical characteristics. Compared to BP non-users, BP users  
2118 were older (98.7% age  $\geq 51$  versus 86.3%;  $p < 0.001$ ), with a higher proportion of females (89.6%  
2119 versus 55.5%;  $p < 0.001$ ), from the west (21.4% versus 14.6%;  $p < 0.001$ ), with lower comorbidity  
2120 burden (mean CCI=1.02 versus 1.13;  $p < 0.001$ ), insured by Medicare (45.8% versus 31.7%;  $p < 0.001$ ),  
2121 and have had a primary-care physician (PCP) visit in 2019 (71.7% versus 63.9%;  $p < 0.001$ ).  
2122 Propensity-score matching yielded 124,716 BP users and 124,716 BP non-users with no significant  
2123 differences across examined characteristics. A total of 127 BP users were not assigned an applicable  
2124 BP non-user pair during the matching procedure and were excluded from the matched BP user  
2125 population.

2126  
2127  
2128  
2129  
2130  
2131  
2132  
2133  
2134  
2135  
2136  
2137  
2138  
2139  
2140  
2141

*BP-Use Comparison within Statin Non-users: New York State*

Of the 185,536 statin non-users from the statin user/non-user propensity-score matching analysis on patients residing in New York state, a total of 14,546 (7.8%) and 170,990 (92.2%) were classified as BP users and BP non-users, respectively (**Table S8f**). Prior to propensity-score matching based on BP-use, there were significant differences across all demographic and clinical characteristics. Compared to BP non-users, BP users were older (99.2% age  $\geq 51$  versus 88.4%;  $p < 0.001$ ), with a higher proportion of females (90.6% versus 55.1%;  $p < 0.001$ ), with lower comorbidity burden (mean CCI=0.95 versus 1.09;  $p < 0.001$ ), insured by Medicare (59.7% versus 43.7%;  $p < 0.001$ ), and have had a primary-care physician (PCP) visit in 2019 (70.5% versus 59.4%;  $p < 0.001$ ). Propensity-score matching yielded 14,521 BP users and 14,521 BP non-users with no significant differences across examined characteristics. A total of 25 BP users were not assigned an applicable BP non-user pair during the matching procedure and were excluded from the matched BP user population.

**Antihypertensive User/Non-User Analysis**

2142 *Antihypertensive-Use Comparison: All Observations (all regions combined)*

2143 A total of 7,906,603 patients were included in the unmatched analysis cohort comparison of  
2144 antihypertensive-use, of which 2,101,120 (26.6%) and 5,805,483 (73.4%) were classified as  
2145 antihypertensive users and antihypertensive non-users, respectively (**Table S9a**). Prior to propensity-  
2146 score matching, there were significant differences across all demographic and clinical characteristics.  
2147 Compared to antihypertensive non-users, antihypertensive users were older (80.8% age  $\geq 51$  versus  
2148 34.4%;  $p < 0.001$ ), with a higher proportion of females (60.4% versus 58.6%;  $p < 0.001$ ), from the  
2149 northeast (27.8% versus 27.0%;  $p < 0.001$ ), with higher comorbidity burden (mean CCI=1.13 versus  
2150 0.43;  $p < 0.001$ ), insured by Medicare (29.5% versus 10.3%;  $p < 0.001$ ), and have had a primary-care  
2151 physician (PCP) visit in 2019 (64.2% versus 39.2%;  $p < 0.001$ ). Propensity-score matching yielded  
2152 1,786,001 antihypertensive users and 1,786,001 antihypertensive non-users with no significant  
2153 differences across age group, gender, region, insurance type, and having had any PCP visit in 2019.  
2154 The final matched population did, however, display statistically significant difference between  
2155 antihypertensive users and antihypertensive non-users for mean CCI (1.64 versus 1.66;  $p < 0.05$ ). This  
2156 difference, however, is small in magnitude, and was statistically significant due to the underlying  
2157 statistical power associated with the large sample size. A total of 315,119 antihypertensive users from  
2158 the unmatched analysis cohort were not assigned an applicable antihypertensive non-user pair during  
2159 the matching procedure and were excluded from the matched antihypertensive user population.

2160  
2161 *Antihypertensive-Use Comparison: New York State*

2162 A total of 968,296 patients identified as residing in New York state were included in the unmatched  
2163 analysis cohort comparison of antihypertensive-use, of which 258,652 (26.7%) and 709,644 (73.3%)  
2164 were classified as antihypertensive users and antihypertensive non-users, respectively (**Table S9b**).  
2165 Prior to propensity-score matching, there were significant differences across all demographic and  
2166 clinical characteristics. Compared to antihypertensive non-users, antihypertensive users were older  
2167 (86.6% age  $\geq 51$  versus 40.9%;  $p < 0.001$ ), with a higher proportion of females (59.4% versus 59.2%;  
2168  $p = 0.02$ ), with higher comorbidity burden (mean CCI=1.17 versus 0.46;  $p < 0.001$ ), insured by Medicare  
2169 (45.9% versus 12.6%;  $p < 0.001$ ), and have had a primary-care physician (PCP) visit in 2019 (62.4%  
2170 versus 40.3%;  $p < 0.001$ ). Propensity-score matching yielded 203,624 antihypertensive users and  
2171 203,624 antihypertensive non-users with no significant differences across examined characteristics. A  
2172 total of 55,028 antihypertensive users from the unmatched analysis cohort were not assigned an  
2173 applicable antihypertensive non-user pair during the matching procedure and were excluded from the  
2174 matched antihypertensive user population.

2175  
2176 *BP-Use Comparison within Antihypertensive Users: All Regions Combined*

2177 Of the 1,786,001 antihypertensive users from the antihypertensive user/non-user propensity-score  
2178 matching analysis, a total of 206,613 (11.6%) and 1,579,388 (88.4%) were classified as BP users and  
2179 BP non-users, respectively (**Table S9c**). Prior to propensity-score matching based on BP-use, there  
2180 were significant differences across all demographic and clinical characteristics. Compared to BP non-  
2181 users, BP users were older (98.2% age  $\geq 51$  versus 75.2%;  $p < 0.001$ ), with a higher proportion of  
2182 females (89.7% versus 56.6%;  $p < 0.001$ ), from the west (22.0% versus 14.3%;  $p < 0.001$ ), with lower  
2183 comorbidity burden (mean CCI=0.94 versus 0.95;  $p = 0.02$ ), insured by Medicare (48.6% versus 24.4%;  
2184  $p < 0.001$ ), and have not had a primary-care physician (PCP) visit in 2019 (41.2% versus 40.1%;  
2185  $p < 0.001$ ). Propensity-score matching yielded 204,396 BP users and 204,396 BP non-users with no  
2186 significant differences across examined characteristics. A total of 2,217 BP users were not assigned  
2187 an applicable BP non-user pair during the matching procedure and were excluded from the matched  
2188 BP user population.

#### 2189 *BP-Use Comparison within Antihypertensive Users: New York State*

2191 Of the 203,624 antihypertensive users from the antihypertensive user/non-user propensity-score  
2192 matching analysis on patients residing in New York state, a total of 21,213 (10.4%) and 182,411  
2193 (89.6%) were classified as BP users and BP non-users, respectively (**Table S9d**). Prior to propensity-  
2194 score matching based on BP-use, there were significant differences across all demographic and  
2195 clinical characteristics. Compared to BP non-users, BP users were older (98.8% age  $\geq 51$  versus  
2196 81.4%;  $p < 0.001$ ), with a higher proportion of females (90.9% versus 55.5%;  $p < 0.001$ ), with lower  
2197 comorbidity burden (mean CCI=0.88 versus 0.95;  $p < 0.001$ ), insured by Medicare (64.1% versus  
2198 35.9%;  $p < 0.001$ ), and have not had a primary-care physician (PCP) visit in 2019 (53.4% versus 55.7%;  
2199  $p < 0.001$ ). Propensity-score matching yielded 21,126 BP users and 21,126 BP non-users with no  
2200 significant differences across examined characteristics. A total of 87 BP users were not assigned an  
2201 applicable BP non-user pair during the matching procedure and were excluded from the matched BP  
2202 user population.

#### 2203 *BP-Use Comparison within Antihypertensive Non-users: All Regions Combined*

2205 Of the 1,786,001 antihypertensive non-users from the antihypertensive user/non-user propensity-  
2206 score matching analysis, a total of 136,016 (7.6%) and 1,649,985 (92.4%) were classified as BP users  
2207 and BP non-users, respectively (**Table S9e**). Prior to propensity-score matching based on BP-use,  
2208 there were significant differences across all demographic and clinical characteristics. Compared to BP  
2209 non-users, BP users were older (97.7% age  $\geq 51$  versus 76.3%;  $p < 0.001$ ), with a higher proportion of  
2210 females (90.5% versus 58.0%;  $p < 0.001$ ), from the west (20.3% versus 14.8%;  $p < 0.001$ ), with lower  
2211 comorbidity burden (mean CCI=0.88 versus 0.96;  $p < 0.001$ ), insured by Medicare (40.7% versus  
2212 26.0%;  $p < 0.001$ ), and have had a primary-care physician (PCP) visit in 2019 (68.0% versus 59.0%;  
2213  $p < 0.001$ ). Propensity-score matching yielded 135,724 BP users and 135,724 BP non-users with no  
2214 significant differences across examined characteristics. A total of 292 BP users were not assigned an  
2215 applicable BP non-user pair during the matching procedure and were excluded from the matched BP  
2216 user population.

#### 2217 *BP-Use Comparison within Antihypertensive Non-users: New York State*

2219 Of the 203,624 antihypertensive non-users from the antihypertensive user/non-user propensity-score  
2220 matching analysis on patients residing in New York state, a total of 14,051 (6.9%) and 189,573  
2221 (93.1%) were classified as BP users and BP non-users, respectively (**Table S9f**). Prior to propensity-  
2222 score matching based on BP-use, there were significant differences across all demographic and  
2223 clinical characteristics. Compared to BP non-users, BP users were older (98.7% age  $\geq 51$  versus  
2224 82.1%;  $p < 0.001$ ), with a higher proportion of females (91.3% versus 56.8%;  $p < 0.001$ ), with lower  
2225 comorbidity burden (mean CCI=0.81 versus 0.96;  $p < 0.001$ ), insured by Medicare (54.9% versus  
2226 37.7%;  $p < 0.001$ ), and have had a primary-care physician (PCP) visit in 2019 (66.3% versus 54.7%;  
2227  $p < 0.001$ ). Propensity-score matching yielded 13,983 BP users and 13,983 BP non-users with no  
2228 significant differences across examined characteristics. A total of 68 BP users were not assigned an

2229 applicable BP non-user pair during the matching procedure and were excluded from the matched BP  
2230 user population.

2231  
2232  
2233

### **Antidiabetic User/Non-User Analysis**

2234 *Antidiabetic-Use Comparison: All Observations (all regions combined)*

2235 A total of 7,906,603 patients were included in the unmatched analysis cohort comparison of  
2236 antidiabetic-use, of which 755,252 (9.6%) and 7,151,351 (90.4%) were classified as antidiabetic users  
2237 and antidiabetic non-users, respectively (**Table S10a**). Prior to propensity-score matching, there were  
2238 significant differences across all demographic and clinical characteristics. Compared to antidiabetic  
2239 non-users, antidiabetic users were older (79.4% age  $\geq$ 51 versus 43.3%;  $p < 0.001$ ), with a higher  
2240 proportion of females (60.8% versus 58.9%;  $p < 0.001$ ), from the northeast (28.8% versus 27.1%;  
2241  $p < 0.001$ ), with higher comorbidity burden (mean CCI=1.25 versus 0.55;  $p < 0.001$ ), insured by  
2242 Medicare (26.2% versus 14.2%;  $p < 0.001$ ), and have had a primary-care physician (PCP) visit in 2019  
2243 (66.5% versus 43.6%;  $p < 0.001$ ). Propensity-score matching yielded 754,553 antidiabetic users and  
2244 754,553 antidiabetic non-users with no significant differences across examined characteristics. A total  
2245 of 699 antidiabetic users from the unmatched analysis cohort were not assigned an applicable  
2246 antidiabetic non-user pair during the matching procedure and were excluded from the matched  
2247 antidiabetic user population.

2248  
2249

*Antidiabetic-Use Comparison: New York State*

2250 A total of 968,296 patients identified as residing in New York state were included in the unmatched  
2251 analysis cohort comparison of antidiabetic-use, of which 105,117 (10.9%) and 863,179 (89.1%) were  
2252 classified as antidiabetic users and antidiabetic non-users, respectively (**Table S10b**). Prior to  
2253 propensity-score matching, there were significant differences across all demographic and clinical  
2254 characteristics. Compared to antidiabetic non-users, antidiabetic users were older (83.8% age  $\geq$ 51  
2255 versus 49.4%;  $p < 0.001$ ), with a higher proportion of males (42.2% versus 40.6%;  $p < 0.001$ ), with  
2256 higher comorbidity burden (mean CCI=1.34 versus 0.56;  $p < 0.001$ ), insured by Medicare (40.5%  
2257 versus 19.2%;  $p < 0.001$ ), and have had a primary-care physician (PCP) visit in 2019 (64.6% versus  
2258 43.9%;  $p < 0.001$ ). Propensity-score matching yielded 104,691 antidiabetic users and 104,691  
2259 antidiabetic non-users with no significant differences across examined characteristics. A total of 426  
2260 antidiabetic users from the unmatched analysis cohort were not assigned an applicable antidiabetic  
2261 non-user pair during the matching procedure and were excluded from the matched antidiabetic user  
2262 population.

2263  
2264

*BP-Use Comparison within Antidiabetic Users: All Regions Combined*

2265 Of the 754,553 antidiabetic users from the antidiabetic user/non-user propensity-score matching  
2266 analysis, a total of 80,529 (10.7%) and 674,024 (89.3%) were classified as BP users and BP non-  
2267 users, respectively (**Table S10c**). Prior to propensity-score matching based on BP-use, there were  
2268 significant differences across all demographic and clinical characteristics. Compared to BP non-users,  
2269 BP users were older (98.2% age  $\geq$ 51 versus 75.2%;  $p < 0.001$ ), with a higher proportion of females  
2270 (98.5% versus 77.1%;  $p < 0.001$ ), from the west (22.2% versus 14.2%;  $p < 0.001$ ), with a higher  
2271 comorbidity burden (mean CCI=1.32 versus 1.23;  $p < 0.001$ ), insured by Medicare (45.2% versus  
2272 24.0%;  $p < 0.001$ ), and have had a primary-care physician (PCP) visit in 2019 (69.5% versus 66.1%;  
2273  $p < 0.001$ ). Propensity-score matching yielded 79,500 BP users and 79,500 BP non-users with no  
2274 significant differences across examined characteristics. A total of 1,029 BP users were not assigned  
2275 an applicable BP non-user pair during the matching procedure and were excluded from the matched  
2276 BP user population.

2277  
2278

*BP-Use Comparison within Antidiabetic Users: New York State*

2279 Of the 104,691 antidiabetic users from the antidiabetic user/non-user propensity-score matching  
2280 analysis on patients residing in New York state, a total of 9,529 (9.1%) and 95,162 (90.9%) were

2281 classified as BP users and BP non-users, respectively (**Table S10d**). Prior to propensity-score  
2282 matching based on BP-use, there were significant differences across all demographic and clinical  
2283 characteristics. Compared to BP non-users, BP users were older (99.1% age  $\geq 51$  versus 82.2%;  
2284  $p < 0.001$ ), with a higher proportion of females (90.1% versus 54.5%;  $p < 0.001$ ), with a higher  
2285 comorbidity burden (mean CCI=1.46 versus 1.31;  $p < 0.001$ ), insured by Medicare (64.6% versus  
2286 38.2%;  $p < 0.001$ ), and have had a primary-care physician (PCP) visit in 2019 (66.3% versus 64.4%;  
2287  $p < 0.001$ ). Propensity-score matching yielded 9,456 BP users and 9,456 BP non-users with no  
2288 significant differences across examined characteristics. A total of 73 BP users were not assigned an  
2289 applicable BP non-user pair during the matching procedure and were excluded from the matched BP  
2290 user population.

#### 2291 2292 *BP-Use Comparison within Antidiabetic Non-users: All Regions Combined*

2293 Of the 754,553 antidiabetic non-users from the antidiabetic user/non-user propensity-score matching  
2294 analysis, a total of 73,173 (9.7%) and 681,380 (90.3%) were classified as BP users and BP non-users,  
2295 respectively (**Table S10e**). Prior to propensity-score matching based on BP-use, there were  
2296 significant differences across all demographic characteristics, but no difference was seen in mean  
2297 CCI (1.24 versus 1.24;  $p = 0.92$ ). Compared to BP non-users, BP users were older (98.0% age  $\geq 51$   
2298 versus 77.3%;  $p < 0.001$ ), with a higher proportion of females (88.9% versus 57.7%;  $p < 0.001$ ), from the  
2299 west (20.1% versus 14.5%;  $p < 0.001$ ), insured by Medicare (40.0% versus 24.8%;  $p < 0.001$ ), and have  
2300 had a primary-care physician (PCP) visit in 2019 (74.1% versus 65.7%;  $p < 0.001$ ). Propensity-score  
2301 matching yielded 72,514 BP users and 72,514 BP non-users with no significant differences across  
2302 examined characteristics. A total of 659 BP users were not assigned an applicable BP non-user pair  
2303 during the matching procedure and were excluded from the matched BP user population.

#### 2304 2305 *BP-Use Comparison within Antidiabetic Non-users: New York State*

2306 Of the 104,691 antidiabetic non-users from the antidiabetic user/non-user propensity-score matching  
2307 analysis on patients residing in New York state, a total of 9,275 (8.9%) and 95,416 (91.1%) were  
2308 classified as BP users and BP non-users, respectively (**Table S10f**). Prior to propensity-score  
2309 matching based on BP-use, there were significant differences across all demographic and clinical  
2310 characteristics. Compared to BP non-users, BP users were older (99.0% age  $\geq 51$  versus 82.2%;  
2311  $p < 0.001$ ), with a higher proportion of females (89.2% versus 54.7%;  $p < 0.001$ ), with a higher  
2312 comorbidity burden (mean CCI=1.37 versus 1.32;  $p < 0.01$ ), insured by Medicare (57.7% versus 38.9%;  
2313  $p < 0.001$ ), and have had a primary-care physician (PCP) visit in 2019 (72.5% versus 63.8%;  $p < 0.001$ ).  
2314 Propensity-score matching yielded 13,983 BP users and 13,983 BP non-users with no significant  
2315 differences across examined characteristics. A total of 131 BP users were not assigned an applicable  
2316 BP non-user pair during the matching procedure and were excluded from the matched BP user  
2317 population.

#### 2318 2319 2320 **Antidepressant User/Non-User Analysis**

##### 2321 *Antidepressant-Use Comparison: All Observations (all regions combined)*

2322 A total of 7,906,603 patients were included in the unmatched analysis cohort comparison of  
2323 antidepressant-use, of which 1,571,005 (19.9%) and 6,335,598 (80.1%) were classified as  
2324 antidepressant users and antidepressant non-users, respectively (**Table S11a**). Prior to propensity-  
2325 score matching, there were significant differences across all demographic and clinical characteristics.  
2326 Compared to antidepressant non-users, antidepressant users were older (58.6% age  $\geq 51$  versus  
2327 43.8%;  $p < 0.001$ ), with a higher proportion of females (72.8% versus 55.7%;  $p < 0.001$ ), from the  
2328 midwest (22.1% versus 17.7%;  $p < 0.001$ ), with higher comorbidity burden (mean CCI=0.90 versus  
2329 0.55;  $p < 0.001$ ), insured by Medicare (18.5% versus 14.6%;  $p < 0.001$ ), and have had a primary-care  
2330 physician (PCP) visit in 2019 (61.1% versus 42.0%;  $p < 0.001$ ). Propensity-score matching yielded  
2331 1,536,048 antidepressant users and 1,536,048 antidepressant non-users with no significant  
2332 differences across examined characteristics. A total of 34,957 antidepressant users from the

2333 unmatched analysis cohort were not assigned an applicable antidepressant non-user pair during the  
2334 matching procedure and were excluded from the matched antidepressant user population.

2335  
2336 *Antidepressant-Use Comparison: New York State*

2337 A total of 968,296 patients identified as residing in New York state were included in the unmatched  
2338 analysis cohort comparison of antidepressant-use, of which 136,081 (14.1%) and 832,215 (85.9%)  
2339 were classified as antidepressant users and antidepressant non-users, respectively (**Table S11b**).  
2340 Prior to propensity-score matching, there were significant differences across all demographic and  
2341 clinical characteristics. Compared to antidepressant non-users, antidepressant users were older (66.3%  
2342 age  $\geq 51$  versus 51.0%;  $p < 0.001$ ), with a higher proportion of females (71.2% versus 57.3%;  $p < 0.001$ ),  
2343 with higher comorbidity burden (mean CCI=0.98 versus 0.59;  $p < 0.001$ ), insured by Medicare (32.2%  
2344 versus 19.8%;  $p < 0.001$ ), and have had a primary-care physician (PCP) visit in 2019 (60.7% versus  
2345 43.8%;  $p < 0.001$ ). Propensity-score matching yielded 135,516 antidepressant users and 135,516  
2346 antidepressant non-users with no significant differences across examined characteristics. A total of  
2347 565 antidepressant users from the unmatched analysis cohort were not assigned an applicable  
2348 antidepressant non-user pair during the matching procedure and were excluded from the matched  
2349 antidepressant user population.

2350  
2351 *BP-Use Comparison within Antidepressant Users: All Regions Combined*

2352 Of the 1,536,048 antidepressant users from the antidepressant user/non-user propensity-score  
2353 matching analysis, a total of 145,109 (9.4%) and 1,390,939 (90.6%) were classified as BP users and  
2354 BP non-users, respectively (**Table S11c**). Prior to propensity-score matching based on BP-use, there  
2355 were significant differences across all demographic and clinical characteristics. Compared to BP non-  
2356 users, BP users were older (96.7% age  $\geq 51$  versus 54.4%;  $p < 0.001$ ), with a higher proportion of  
2357 females (91.9% versus 70.2%;  $p < 0.001$ ), from the west (19.6% versus 13.9%;  $p < 0.001$ ), with a higher  
2358 comorbidity burden (mean CCI=1.09 versus 0.84;  $p < 0.001$ ), insured by Medicare (42.4% versus  
2359 16.2%;  $p < 0.001$ ), and have had a primary-care physician (PCP) visit in 2019 (64.6% versus 60.2%;  
2360  $p < 0.001$ ). Propensity-score matching yielded 144,282 BP users and 144,282 BP non-users with no  
2361 significant differences across examined characteristics. A total of 827 BP users were not assigned an  
2362 applicable BP non-user pair during the matching procedure and were excluded from the matched BP  
2363 user population.

2364  
2365 *BP-Use Comparison within Antidepressant Users: New York State*

2366 Of the 135,516 antidepressant users from the antidepressant user/non-user propensity-score  
2367 matching analysis on patients residing in New York state, a total of 12,950 (9.6%) and 122,566  
2368 (90.4%) were classified as BP users and BP non-users, respectively (**Table S11d**). Prior to  
2369 propensity-score matching based on BP-use, there were significant differences across all  
2370 demographic and clinical characteristics. Compared to BP non-users, BP users were older (97.8%  
2371 age  $\geq 51$  versus 63.0%;  $p < 0.001$ ), with a higher proportion of females (92.6% versus 68.9%;  $p < 0.001$ ),  
2372 with a higher comorbidity burden (mean CCI=1.13 versus 0.95;  $p < 0.001$ ), insured by Medicare (60.8%  
2373 versus 29.1%;  $p < 0.001$ ), and have had a primary-care physician (PCP) visit in 2019 (65.3% versus  
2374 60.1%;  $p < 0.001$ ). Propensity-score matching yielded 12,859 BP users and 12,859 BP non-users with  
2375 no significant differences across examined characteristics. A total of 91 BP users were not assigned  
2376 an applicable BP non-user pair during the matching procedure and were excluded from the matched  
2377 BP user population.

2378  
2379 *BP-Use Comparison within Antidepressant Non-users: All Regions Combined*

2380 Of the 1,536,048 antidepressant non-users from the antidepressant user/non-user propensity-score  
2381 matching analysis, a total of 113,110 (7.4%) and 1,422,938 (92.6%) were classified as BP users and  
2382 BP non-users, respectively (**Table S11e**). Prior to propensity-score matching based on BP-use, there  
2383 were significant differences across all demographic characteristics. Compared to BP non-users, BP  
2384 users were older (97.1% age  $\geq 51$  versus 55.4%;  $p < 0.001$ ), with a higher proportion of females (93.2%

2385 versus 70.6%;  $p < 0.001$ ), from the west (20.0% versus 14.0%;  $p < 0.001$ ), with a higher comorbidity  
2386 burden (mean CCI=1.06 versus 0.85;  $p < 0.001$ ), insured by Medicare (40.4% versus 17.0%;  $p < 0.001$ ),  
2387 and have had a primary-care physician (PCP) visit in 2019 (71.2% versus 59.8%;  $p < 0.001$ ).  
2388 Propensity-score matching yielded 112,402 BP users and 112,402 BP non-users with no significant  
2389 differences across examined characteristics. A total of 708 BP users were not assigned an applicable  
2390 BP non-user pair during the matching procedure and were excluded from the matched BP user  
2391 population.

2392  
2393 *BP-Use Comparison within Antidepressant Non-users: New York State*

2394 Of the 135,516 antidepressant non-users from the antidepressant user/non-user propensity-score  
2395 matching analysis on patients residing in New York state, a total of 10,174 (7.5%) and 125,342  
2396 (92.5%) were classified as BP users and BP non-users, respectively (**Table S11f**). Prior to propensity-  
2397 score matching based on BP-use, there were significant differences across all demographic and  
2398 clinical characteristics. Compared to BP non-users, BP users were older (98.4% age  $\geq 51$  versus  
2399 63.7%;  $p < 0.001$ ), with a higher proportion of females (93.6% versus 69.4%;  $p < 0.001$ ), with a higher  
2400 comorbidity burden (mean CCI=1.13 versus 0.95;  $p < 0.01$ ), insured by Medicare (60.0% versus 29.9%;  
2401  $p < 0.001$ ), and have had a primary-care physician (PCP) visit in 2019 (71.7% versus 59.7%;  $p < 0.001$ ).  
2402 Propensity-score matching yielded 10,091 BP users and 10,091 BP non-users with no significant  
2403 differences across examined characteristics. A total of 83 BP users were not assigned an applicable  
2404 BP non-user pair during the matching procedure and were excluded from the matched BP user  
2405 population.  
2406



## 2407 **APPENDIX 3: Post-hoc Analysis on the Impact of Censoring due to Death**

2408

### 2409 *Background*

2410 Following completion of all core study analyses, an additional post-hoc investigation was performed to  
2411 assess whether censoring bias due to patient death could impact our current findings of a decrease in  
2412 the odds of COVID-19 outcomes seen amongst BP users. Typically, it is very difficult to perform  
2413 assessments on this type of bias due to the fact that insurance claims databases in the United States  
2414 do not include this information. Some claims database providers, including Komodo Health, do have  
2415 the capability to 'link' their de-identified claims data with external sources on decedent enrollees, but  
2416 at the time of study initiation and data extraction there were enhanced HIPAA constraints associated  
2417 with claims datasets that included COVID-identifying diagnosis/treatment codes due to the heightened  
2418 risk of patient re-identification due to the then lower prevalence and high visibility associated for  
2419 patients with COVID-19. Eventually the increased prevalence of COVID-19 reduced the HIPAA  
2420 concerns on working with claims data that include COVID-19-identifiers, and in support of this  
2421 analysis and the potentially significant public health implications of our findings, Komodo Health linked  
2422 their COVID-identifiable dataset with mortality data sources that account for roughly 80-85% of  
2423 available death records. In conjunction with Komodo Health, queries on this mortality-linked COVID-  
2424 19-identifiable dataset were performed to determine whether bias caused by patient censoring due to  
2425 death could have impacted the validity and/or reliability of our current findings

2426

2427

### 2428 *Methodological Concerns of Patient Censoring due to Death*

2429 The single motivating factor for initiation of this post-hoc analysis was the fact that the decrease in  
2430 odds of COVID-19 outcomes among BP users in this study was found to be statistically significant,  
2431 large in magnitude, and robust across almost all analysis variations performed. The exhaustive use of  
2432 methodological techniques to control for unmeasured confounding and/or outside sources of bias  
2433 employed in this current study were undertaken not in search of statistical significance, but in search  
2434 of non-significance. This was undertaken because the consistency seen in statistical significance, in  
2435 addition to the magnitude of the decrease in the odds of our outcomes of interest, are typically not  
2436 seen to this degree. As such, the next logical step after exhausting all methodological techniques is to  
2437 search for other sources that could induce a large-enough bias on the underlying patient population  
2438 itself, such as censoring of the target study cohort, that could drastically alter the typical composition  
2439 of the overall sample and thus impact the reliability and validity of outcomes measured.

2440 The high rate of death associated with COVID-19 infection, which was even worse during the early  
2441 months of the pandemic, represents such an instance where outside influences could impact the  
2442 underlying data, and as such, the validity of research performed on that data. The primary concern is  
2443 whether patients who have died are censored from the analytical sample due to the application of one  
2444 of the most fundamental inclusion/exclusion criteria used in claims-based research, the requirement  
2445 for continuous insurance eligibility over the entire study period that is needed so that healthcare  
2446 resource utilization events from all subjects are captured and available in the data for analysis. If in  
2447 our current sample, a larger number of BP users died after contracting COVID-19 and were censored  
2448 due to insurance eligibility, and a lower number of BP non-users survived and thus met the insurance  
2449 eligibility criteria, then the remaining study sample would be comprised of healthier-looking BP users  
2450 and a higher number of BP non-users with COVID-19 related healthcare services.

2451 The potential for such a censoring bias in this current study sample, and the impact of that bias on the  
2452 magnitude and statistical significance of our core study findings, was assessed in this post-hoc  
2453 analysis by: (1) adjusting eligibility criteria to prevent the censoring of patients that may have died  
2454 during the first half of 2020; (2) replicating key exposure (BP-use, use of other non-BP bone health  
2455 medications) and outcomes (COVID-19 diagnosis) in this expanded sample that aligns with the core  
2456 study methods; (3) analysing the impact on study findings that would result from the retention and  
2457 inclusion of deceased-patient observations in the core study sample on the odds of COVID-19

2458 diagnosis; and (4) calculating the number of missing patient observations censored due to death that  
2459 would be required to reach a statistically non-significant difference in the odds of COVID-19.  
2460

2461

## 2462 **Post-Hoc Analysis**

2463

### 2464 Methods

2465

#### 2466 *Cohort Definition*

- 2467 - Continuous insurance eligibility 1/1/2019-12/31/2019; used to ensure that any censoring due  
2468 to death occurs during the observation period of 1/1/2020-6/30/2020
- 2469 - BP users compared to BP non-users to produce a cohort comparison similar to the primary  
2470 analysis cohort
- 2471 - BP users compared to users of non-BP anti-resorptive bone health medications to produce a  
2472 cohort comparison similar to the “*Bone-Rx*” active comparator analysis  
2473

2474

#### 2474 *Exposures of Interest*

- 2475 - Patients were assigned into the BP user cohort if they had any claim 1/1/2019-2/29/2020 for  
2476 one of the following: alendronate, alendronic acid, etidronate, ibandronate, ibandronic acid,  
2477 pamidronate, risedronate, and zoledronic acid; for the cohort comparison of all osteoporosis  
2478 medication users BP users were further restricted to those that had no claims for a non-BP  
2479 anti-resorptive bone health medication 1/1/2019-2/29/2020.
- 2480 - Patients were assigned into the non-BP anti-resorptive bone health medication user cohort if:  
2481 (1) they had any claim 1/1/2019-2/29/2020 for one of the following: denosumab, calcitonin,  
2482 raloxifene, romosozumab-aqqg, teriparatide, abaloparatide, or bazedoxifene; and (2) they had  
2483 no BP claims  
2484

2485

#### 2485 *Outcomes / Endpoints*

- 2486 - Patients were assigned into the COVID-19 diagnosis cohort based on any medical service  
2487 claim with an ICD-10 diagnosis code of U07.1 occurring 1/1/2020-6/30/2020
- 2488 - Patients with a date-of-death between 1/1/2020-6/30/2020 were classified into the deceased  
2489 cohort  
2490

2491

#### 2491 *Statistical Analysis*

- 2492 - Chi-square testing was used to assess whether statistically significant differences exist  
2493 between BP users and BP non-users in the unadjusted odds of having any COVID-19  
2494 diagnosis during the first half of 2020 among cohorts that approximate the primary analysis  
2495 and “*Bone-Rx*” study cohorts for the following:
  - 2496 1. Among all patient-observations with a COVID-19 diagnosis to assess the potential ‘true’  
2497 comparison that would occur
  - 2498 2. With deceased patient-observations that had a known COVID-19 diagnosis removed  
2499 prior to testing to replicate findings that would occur if these observations were  
2500 censored
  - 2501 3. When making the assumption that all patients who died during this period died due to  
2502 COVID-19, and thus should be classified as having a COVID-19 diagnosis  
2503
- 2504 - An additional analysis was performed on the last variation modelled (assuming all patients  
2505 died due to COVID-19) to determine the additional BP user patient observations that would be  
2506 needed to be classified as having had a COVID-19 diagnosis to yield a similar distribution of  
2507 COVID-19 diagnosis (yes/no) as was seen in the BP non-user cohort to yield an odds ratio  
2508 ~1.0

- 2509 - Finally, the impact on odds ratio testing results comparing BP users to BP non-users was  
2510 modelled based on the additional number of BP users needed to be classified as having been  
2511 diagnosed with COVID-19 to reach statistical non-significance  
2512

2513

## 2514 Results

2515

### 2516 *Patient Count Distribution*

- 2517 - Among the full sample a decreased rate of COVID-19 among BP users compared to BP non-  
2518 users was seen in both the full sample population (1.2% versus 4.7%) as well as when  
2519 restricted to users of non-BP anti-resorptive bone health medications (1.2% versus 4.3%)  
2520 (**Table S12a**)  
2521

2522

### 2523 *Unadjusted Chi-Square Comparison Inclusive of Deceased Patients*

- 2524 - The decrease in the odds of any COVID-19 diagnosis amongst BP users compared to BP non-  
2525 users was found to be robust in both the full (OR=0.24) and “*Bone-Rx*” (OR=0.35)  
2526 comparisons when including deceased patients with a known COVID-19 diagnosis (**Table**  
2527 **S12b**)  
2528

2529

### 2530 *Unadjusted Chi-Square Comparison with Deceased Patients Removed*

- 2531 - The decrease in the odds of any COVID-19 diagnosis amongst BP users compared to BP non-  
2532 users was found to be robust in both the full (OR=0.23) and “*Bone-Rx*” (OR=0.26)  
2533 comparisons when removing deceased patients with a known COVID-19 diagnosis (**Table**  
2534 **S12c**)  
2535

2536

2537

### 2538 *Unadjusted Chi-Square Comparison Assuming all Deceased Patients had COVID-19*


- 2539 - The decrease in the odds of any COVID-19 diagnosis amongst BP users compared to BP non-  
2540 users was found to be robust in both the full (OR=0.39) and “*Bone-Rx*” (OR=0.29)  
2541 comparisons when assuming that all deceased patients had a COVID-19 diagnosis (**Table**  
2542 **S12d**)  
2543 - Among this final analysis that assumes all deceased patients had a diagnosis of COVID-19,  
2544 the percentage of BP non-users with an assumed COVID-19 diagnosis was 5.5% and 7.2% for  
2545 the full and OPRX comparisons, respectively.  
2546 - These proportions were then used to estimate the number of additional BP users with a  
2547 COVID-19 diagnosis that would be needed to have the same distribution and thus an odds  
2548 ratio ~1.0 (**Table S12e**)  
2549 - It would require an additional 22,235 (37,095-14,860) BP-user patient observations from the  
2550 full cohort comparison to be classified as having a COVID-19 diagnosis to have an equivalent  
2551 odds of being diagnosed with COVID-19 as was seen among the BP non-user cohort  
2552 - It would require an additional 32,598 (46,637-14,039) BP-user patient observations from the  
2553 “*Bone-Rx*” cohort comparison to be classified as having a COVID-19 diagnosis to have an  
2554 equivalent odds of being diagnosed with COVID-19 as was seen among the BP non-user  
2555 cohort  
2556

2557

2558 - In the full (all observations) comparison, the minimum number of additional BP users classified  
2559 as having a COVID-19 diagnosis needed to reach statistical non-significance for the calculated  
2560 unadjusted odds ratio was 21,860 (Figure S1)

2561  
2562  
2563  
2564

**Figure S1: Full Cohort: Odds Ratio by Additional Number of BP Users Classified as having COVID-19 Diagnosis**




2565  
2566  
2567  
2568  
2569  
2570  
2571  
2572

Legend: Shown in Figure S1 is the forest plot of the change in the crude odds ratio (OR) of BP users having a COVID-19 diagnosis as a factor of the additional number of BP users needed to be classified as having a COVID-19 diagnosis to reach statistical non-significance for all observations.

2573 - In the “*Bone-Rx*” comparison, the minimum number of additional BP users classified as having  
2574 a COVID-19 diagnosis needed to reach statistical non-significance for the calculated  
2575 unadjusted odds ratio was 31,360 (**Figure S2**)  
2576

2577  
2578 **Figure S2: Bone-Rx Cohort: Odds Ratio by Additional Number of BP Users Classified as**  
2579 **having COVID-19 Diagnosis**  
2580



BP: bisphosphonate

2581 Legend: Shown in Figure S2 is the forest plot of the change in the crude odds ratio (OR) of BP  
2582 users having a COVID-19 diagnosis as a factor of the additional number of BP users needed to  
2583 be classified as having a COVID-19 diagnosis to reach statistical non-significance when  
2584 comparing BP users to users of non-BP anti-resorptive bone medications.  
2585  
2586  
2587  
2588

2589 **APPENDIX TABLES**

2590  
2591 **Table S1: Most Recent Bisphosphonate Claim Among all Users**

2592

<b>Drug (route)</b>	<b>N</b>	<b>%</b>
alendronate / alendronic acid (oral)	340,810	75.4%
etidronate (oral)	14	0.0%
ibandronate / ibandronic acid (oral)	37,988	8.4%
ibandronic acid (injection/infusion)	1,169	0.3%
pamidronate (injection/infusion)	1,121	0.2%
risedronate (oral)	18,991	4.2%
zoledronic acid (injection/infusion)	51,958	11.5%

2593

2594  
2595

**Table S2a: Primary Analysis Cohort (Region=Northeast), Patient Characteristics Pre/Post Match**

	Region=Northeast Unmatched							Region=Northeast Matched						
	All		BP Non-users		BP Users		p-value	All		BP Non-users		BP Users		p-value
	N	%	N	%	N	%		N	%	N	%	N	%	
<b>All Patients</b>	<b>2,152,560</b>	<b>100.0%</b>	<b>2,032,832</b>	<b>94.4%</b>	<b>119,728</b>	<b>5.6%</b>		<b>238,988</b>	<b>100.0%</b>	<b>119,494</b>	<b>50.0%</b>	<b>119,494</b>	<b>50.0%</b>	
<b>Age</b>														
≤20	363,637	16.9%	363,401	17.9%	236	0.2%	<0.001	474	0.2%	238	0.2%	236	0.2%	1.00
21-40	397,377	18.5%	396,613	19.5%	764	0.6%		1,528	0.6%	764	0.6%	764	0.6%	
41-50	261,570	12.2%	259,528	12.8%	2,042	1.7%		4,084	1.7%	2,042	1.7%	2,042	1.7%	
51-60	372,238	17.3%	354,228	17.4%	18,010	15.0%		36,020	15.1%	18,010	15.1%	18,010	15.1%	
61-70	354,331	16.5%	313,237	15.4%	41,094	34.3%		82,233	34.4%	41,139	34.4%	41,094	34.4%	
71-80	252,712	11.7%	215,151	10.6%	37,561	31.4%		74,831	31.3%	37,393	31.3%	37,438	31.3%	
≥81	150,695	7.0%	130,674	6.4%	20,021	16.7%		39,818	16.7%	19,908	16.7%	19,910	16.7%	
<b>Gender</b>														
Female	1,275,611	59.3%	1,167,241	57.4%	108,370	90.5%	<0.001	216,273	90.5%	108,137	90.5%	108,136	90.5%	0.99
Male	876,949	40.7%	865,591	42.6%	11,358	9.5%		22,715	9.5%	11,357	9.5%	11,358	9.5%	
<b>Insurance</b>														
Commercial	1,050,795	48.8%	1,017,502	50.1%	33,293	27.8%	<0.001	66,552	27.8%	33,259	27.8%	33,293	27.9%	0.99
Dual	47,773	2.2%	40,168	2.0%	7,605	6.4%		15,114	6.3%	7,576	6.3%	7,538	6.3%	
Medicaid	631,863	29.4%	608,649	29.9%	23,214	19.4%		46,094	19.3%	23,047	19.3%	23,047	19.3%	
Medicare	422,129	19.6%	366,513	18.0%	55,616	46.5%		111,228	46.5%	55,612	46.5%	55,616	46.5%	
<b>PCP Visit 2019</b>														
No	1,212,394	56.3%	1,162,527	57.2%	49,867	41.7%	<0.001	99,741	41.7%	49,874	41.7%	49,867	41.7%	0.98
Yes	940,166	43.7%	870,305	42.8%	69,861	58.3%		139,247	58.3%	69,620	58.3%	69,627	58.3%	
<b>Continuous Outcomes</b>														
	mean	SD	mean	SD	mean	SD	p-value	mean	SD	mean	SD	mean	SD	p-value
<b>CCI</b>	0.67	1.42	0.65	1.40	0.93	1.71	<0.001	0.93	1.71	0.93	1.71	0.93	1.71	0.96

2596

BP: bisphosphonate; CCI: Charlson Comorbidity Index; PCP: primary care physician; SD: standard deviation

2597  
2598

**Table S2b: Primary Analysis Cohort (Region=Midwest), Patient Characteristics Pre/Post Match**

	Region=Midwest Unmatched							Region=Midwest Matched						
	All		BP Non-users		BP Users		p-value	All		BP Non-users		BP Users		p-value
	N	%	N	%	N	%		N	%	N	%	N	%	
<b>All Patients</b>	<b>1,467,802</b>	<b>100.0%</b>	<b>1,391,835</b>	<b>94.8%</b>	<b>75,967</b>	<b>5.2%</b>		<b>151,802</b>	<b>100.0%</b>	<b>75,901</b>	<b>50.0%</b>	<b>75,901</b>	<b>50.0%</b>	
<b>Age</b>														
≤20	310,027	21.1%	309,759	22.3%	268	0.4%	<0.001	537	0.4%	269	0.4%	268	0.4%	1.00
21-40	287,236	19.6%	286,643	20.6%	593	0.8%		1,188	0.8%	595	0.8%	593	0.8%	
41-50	185,240	12.6%	183,556	13.2%	1,684	2.2%		3,367	2.2%	1,683	2.2%	1,684	2.2%	
51-60	246,230	16.8%	233,992	16.8%	12,238	16.1%		24,478	16.1%	12,240	16.1%	12,238	16.1%	
61-70	224,668	15.3%	196,172	14.1%	28,496	37.5%		56,991	37.5%	28,495	37.5%	28,496	37.5%	
71-80	130,563	8.9%	109,442	7.9%	21,121	27.8%		42,153	27.8%	21,075	27.8%	21,078	27.8%	
≥81	83,838	5.7%	72,271	5.2%	11,567	15.2%		23,088	15.2%	11,544	15.2%	11,544	15.2%	
<b>Gender</b>														
Female	863,156	58.8%	794,578	57.1%	68,578	90.3%	<0.001	137,028	90.3%	68,516	90.3%	68,512	90.3%	0.97
Male	604,646	41.2%	597,257	42.9%	7,389	9.7%		14,774	9.7%	7,385	9.7%	7,389	9.7%	
<b>Insurance</b>														
Commercial	885,651	60.3%	854,518	61.4%	31,133	41.0%	<0.001	62,243	41.0%	31,110	41.0%	31,133	41.0%	1.00
Dual	28,190	1.9%	24,584	1.8%	3,606	4.7%		7,211	4.8%	3,605	4.7%	3,606	4.8%	
Medicaid	318,596	21.7%	310,473	22.3%	8,123	10.7%		16,136	10.6%	8,079	10.6%	8,057	10.6%	
Medicare	235,365	16.0%	202,260	14.5%	33,105	43.6%		66,212	43.6%	33,107	43.6%	33,105	43.6%	
<b>PCP Visit 2019</b>														
No	711,308	48.5%	682,601	49.0%	28,707	37.8%	<0.001	57,398	37.8%	28,691	37.8%	28,707	37.8%	0.93
Yes	756,494	51.5%	709,234	51.0%	47,260	62.2%		94,404	62.2%	47,210	62.2%	47,194	62.2%	
<b>Continuous Outcomes</b>														
	mean	SD	mean	SD	mean	SD	p-value	mean	SD	mean	SD	mean	SD	p-value
<b>CCI</b>	0.59	1.37	0.56	1.34	0.99	1.86	<0.001	0.99	1.86	0.99	1.85	1.00	1.86	0.77

2599

BP: bisphosphonate; CCI: Charlson Comorbidity Index; PCP: primary care physician; SD: standard deviation



2600  
2601

**Table S2c: Primary Analysis Cohort (Region=South), Patient Characteristics Pre/Post Match**

	Region=South Unmatched							Region=South Matched						
	All		BP Non-users		BP Users		p-value	All		BP Non-users		BP Users		p-value
	N	%	N	%	N	%		N	%	N	%	N	%	
<b>All Patients</b>	<b>3,042,604</b>	<b>100.0%</b>	<b>2,881,718</b>	<b>94.7%</b>	<b>160,886</b>	<b>5.3%</b>		<b>319,408</b>	<b>100.0%</b>	<b>159,704</b>	<b>50.0%</b>	<b>159,704</b>	<b>50.0%</b>	
<b>Age</b>														
≤20	890,677	29.3%	890,203	30.9%	474	0.3%	<0.001	943	0.3%	469	0.3%	474	0.3%	1.00
21-40	527,971	17.4%	526,794	18.3%	1,177	0.7%		2,364	0.7%	1,187	0.7%	1,177	0.7%	
41-50	338,262	11.1%	334,841	11.6%	3,421	2.1%		6,839	2.1%	3,418	2.1%	3,421	2.1%	
51-60	442,757	14.6%	417,664	14.5%	25,093	15.6%		50,186	15.7%	25,093	15.7%	25,093	15.7%	
61-70	409,854	13.5%	353,958	12.3%	55,896	34.7%		111,800	35.0%	55,904	35.0%	55,896	35.0%	
71-80	272,761	9.0%	222,156	7.7%	50,605	31.5%		99,223	31.1%	49,605	31.1%	49,618	31.1%	
≥81	160,322	5.3%	136,102	4.7%	24,220	15.1%		48,053	15.0%	24,028	15.0%	24,025	15.0%	
<b>Gender</b>														
Female	1,800,166	59.2%	1,654,351	57.4%	145,815	90.6%	<0.001	289,263	90.6%	144,630	90.6%	144,633	90.6%	0.99
Male	1,242,438	40.8%	1,227,367	42.6%	15,071	9.4%		30,145	9.4%	15,074	9.4%	15,071	9.4%	
<b>Insurance</b>														
Commercial	1,475,456	48.5%	1,416,166	49.1%	59,290	36.9%	<0.001	118,587	37.1%	59,297	37.1%	59,290	37.1%	1.00
Dual	53,474	1.8%	39,414	1.4%	14,060	8.7%		25,752	8.1%	12,874	8.1%	12,878	8.1%	
Medicaid	1,121,606	36.9%	1,099,957	38.2%	21,649	13.5%		43,299	13.6%	21,650	13.6%	21,649	13.6%	
Medicare	392,068	12.9%	326,181	11.3%	65,887	41.0%		131,770	41.3%	65,883	41.3%	65,887	41.3%	
<b>PCP Visit 2019</b>														
No	1,701,040	55.9%	1,646,572	57.1%	54,468	33.9%	<0.001	108,601	34.0%	54,275	34.0%	54,326	34.0%	0.85
Yes	1,341,564	44.1%	1,235,146	42.9%	106,418	66.1%		210,807	66.0%	105,429	66.0%	105,378	66.0%	
<b>Continuous Outcomes</b>														
	mean	SD	mean	SD	mean	SD	p-value	mean	SD	mean	SD	mean	SD	p-value
<b>CCI</b>	0.57	1.31	0.55	1.28	0.86	1.70	<0.001	0.86	1.70	0.86	1.70	0.86	1.71	0.84

2602

BP: bisphosphonate; CCI: Charlson Comorbidity Index; PCP: primary care physician; SD: standard deviation

2603  
2604

**Table S2d: Primary Analysis Cohort (Region=West), Patient Characteristics Pre/Post Match**

	Region=West Unmatched							Region=West Matched						
	All		BP Non-users		BP Users		p-value	All		BP Non-users		BP Users		p-value
	N	%	N	%	N	%		N	%	N	%	N	%	
<b>All Patients</b>	<b>1,243,637</b>	<b>100.0%</b>	<b>1,148,167</b>	<b>92.3%</b>	<b>95,470</b>	<b>7.7%</b>		<b>190,534</b>	<b>100.0%</b>	<b>95,267</b>	<b>50.0%</b>	<b>95,267</b>	<b>50.0%</b>	
<b>Age</b>														
≤20	275,709	22.2%	275,559	24.0%	150	0.2%	<0.001	299	0.2%	149	0.2%	150	0.2%	1.00
21-40	234,415	18.8%	233,858	20.4%	557	0.6%		1,115	0.6%	558	0.6%	557	0.6%	
41-50	140,237	11.3%	138,833	12.1%	1,404	1.5%		2,806	1.5%	1,402	1.5%	1,404	1.5%	
51-60	188,965	15.2%	178,585	15.6%	10,380	10.9%		20,761	10.9%	10,381	10.9%	10,380	10.9%	
61-70	192,408	15.5%	161,016	14.0%	31,392	32.9%		62,798	33.0%	31,406	33.0%	31,392	33.0%	
71-80	127,739	10.3%	95,301	8.3%	32,438	34.0%		64,596	33.9%	32,293	33.9%	32,303	33.9%	
≥81	84,164	6.8%	65,015	5.7%	19,149	20.1%		38,159	20.0%	19,078	20.0%	19,081	20.0%	
<b>Gender</b>														
Female	732,027	58.9%	647,354	56.4%	84,673	88.7%	<0.001	168,933	88.7%	84,463	88.7%	84,470	88.7%	0.96
Male	511,610	41.1%	500,813	43.6%	10,797	11.3%		21,601	11.3%	10,804	11.3%	10,797	11.3%	
<b>Insurance</b>														
Commercial	526,701	42.4%	503,359	43.8%	23,342	24.4%	<0.001	46,688	24.5%	23,346	24.5%	23,342	24.5%	1.00
Dual	27,060	2.2%	20,924	1.8%	6,136	6.4%		11,859	6.2%	5,925	6.2%	5,934	6.2%	
Medicaid	522,435	42.0%	497,941	43.4%	24,494	25.7%		48,990	25.7%	24,496	25.7%	24,494	25.7%	
Medicare	167,441	13.5%	125,943	11.0%	41,498	43.5%		82,997	43.6%	41,500	43.6%	41,497	43.6%	
<b>PCP Visit 2019</b>														
No	658,955	53.0%	628,131	54.7%	30,824	32.3%	<0.001	61,643	32.4%	30,819	32.4%	30,824	32.4%	0.98
Yes	584,682	47.0%	520,036	45.3%	64,646	67.7%		128,891	67.6%	64,448	67.6%	64,443	67.6%	
<b>Continuous Outcomes</b>														
	mean	SD	mean	SD	mean	SD	p-value	mean	SD	mean	SD	mean	SD	p-value
<b>CCI</b>	0.69	1.46	0.66	1.42	1.08	1.84	<0.001	1.09	1.83	1.08	1.83	1.09	1.84	0.73

2605

BP: bisphosphonate; CCI: Charlson Comorbidity Index; PCP: primary care physician; SD: standard deviation

2606  
2607

**Table S2e: Primary Analysis Cohort (Region=New York State), Patient Characteristics Pre/Post Match**

	Region=New York State Unmatched							Region=New York State Matched						
	All		BP Non-users		BP Users		p-value	All		BP Non-users		BP Users		p-value
	N	%	N	%	N	%		N	%	N	%	N	%	
<b>All Patients</b>	<b>968,296</b>	<b>100.0%</b>	<b>918,261</b>	<b>94.8%</b>	<b>50,035</b>	<b>5.2%</b>		<b>99,724</b>	<b>100.0%</b>	<b>49,862</b>	<b>50.0%</b>	<b>49,862</b>	<b>50.0%</b>	
<b>Age</b>														
≤20	133,178	13.8%	133,128	14.5%	50	0.1%	<0.001	102	0.1%	52	0.1%	50	0.1%	1.00
21-40	192,959	19.9%	192,731	21.0%	228	0.5%		453	0.5%	225	0.5%	228	0.5%	
41-50	127,794	13.2%	127,139	13.8%	655	1.3%		1,311	1.3%	656	1.3%	655	1.3%	
51-60	172,444	17.8%	166,080	18.1%	6,364	12.7%		12,732	12.8%	6,368	12.8%	6,364	12.8%	
61-70	159,912	16.5%	143,776	15.7%	16,136	32.2%		32,265	32.4%	16,129	32.3%	16,136	32.4%	
71-80	120,117	12.4%	102,655	11.2%	17,462	34.9%		34,693	34.8%	17,352	34.8%	17,341	34.8%	
≥81	61,892	6.4%	52,752	5.7%	9,140	18.3%		18,168	18.2%	9,080	18.2%	9,088	18.2%	
<b>Gender</b>														
Female	573,610	59.2%	528,152	57.5%	45,458	90.9%	<0.001	90,567	90.8%	45,282	90.8%	45,285	90.8%	0.97
Male	394,686	40.8%	390,109	42.5%	4,577	9.1%		9,157	9.2%	4,580	9.2%	4,577	9.2%	
<b>Insurance</b>														
Commercial	500,918	51.7%	490,503	53.4%	10,415	20.8%	<0.001	20,830	20.9%	10,415	20.9%	10,415	20.9%	1.00
Dual	6,814	0.7%	5,218	0.6%	1,596	3.2%		3,154	3.2%	1,581	3.2%	1,573	3.2%	
Medicaid	252,366	26.1%	243,191	26.5%	9,175	18.3%		18,044	18.1%	9,019	18.1%	9,025	18.1%	
Medicare	208,198	21.5%	179,349	19.5%	28,849	57.7%		57,696	57.9%	28,847	57.9%	28,849	57.9%	
<b>PCP Visit 2019</b>														
No	521,282	53.8%	502,609	54.7%	18,673	37.3%	<0.001	37,253	37.4%	18,616	37.3%	18,637	37.4%	0.89
Yes	447,014	46.2%	415,652	45.3%	31,362	62.7%		62,471	62.6%	31,246	62.7%	31,225	62.6%	
<b>Continuous Outcomes</b>														
	<b>mean</b>	<b>SD</b>	<b>mean</b>	<b>SD</b>	<b>mean</b>	<b>SD</b>	<b>p-value</b>	<b>mean</b>	<b>SD</b>	<b>mean</b>	<b>SD</b>	<b>mean</b>	<b>SD</b>	<b>p-value</b>
<b>CCI</b>	0.65	1.39	0.63	1.37	0.95	1.68	<0.001	0.95	1.68	0.95	1.67	0.95	1.68	0.93

2608

BP: bisphosphonate; CCI: Charlson Comorbidity Index; PCP: primary care physician; SD: standard deviation

2609  
2610  
2611

**Table S3a: Unadjusted COVID-19-Related Outcomes Stratified by Age, Sex, & Age by Sex; Matched Primary Analysis Cohort, All-Regions Combined**

Primary Analysis Cohort, All Regions Matched																	
	All		SARS-CoV-2 Test				COVID-19 Diagnosis				COVID-19 Hospitalization						
	N	%	N	%	OR		p-value	N	%	OR		p-value	N	%	OR		p-value
					LL	UL				LL	UL				LL	UL	
<b>All Patients</b>	<b>900,732</b>	<b>100.0%</b>	<b>28,137</b>	<b>3.1%</b>				<b>16,289</b>	<b>1.8%</b>				<b>3,710</b>	<b>0.4%</b>			
BP User	450,366	50.0%	5,189	1.2%	0.22		<0.001	3,024	0.7%	0.22		<0.001	715	0.2%	0.24		<0.001
BP Non-user	450,366	50.0%	22,948	5.1%	0.21	0.22		13,265	2.9%	0.21	0.23		2,995	0.7%	0.22	0.26	
<b>By Age</b>																	
Age ≤20	2,253	100.0%	67	3.0%				14	0.6%				2	0.1%			
BP User	1,128	50.1%	29	2.6%	0.75		0.26	2	0.2%	0.16		0.007	2	0.2%	NA		NA
BP Non-user	1,125	49.9%	38	3.4%	0.46	1.23		12	1.1%	0.04	0.74		0	0.0%	NA	NA	
Age 21-40	6,195	100.0%	335	5.4%				115	1.9%				13	0.2%			
BP User	3,091	49.9%	58	1.9%	0.20		<0.001	15	0.5%	0.15		<0.001	4	0.1%	0.45		0.27
BP Non-user	3,104	50.1%	277	8.9%	0.15	0.26		100	3.2%	0.08	0.25		9	0.3%	0.14	1.45	
Age 41-50	17,096	100.0%	894	5.2%				270	1.6%				54	0.3%			
BP User	8,551	50.0%	188	2.2%	0.25		<0.001	48	0.6%	0.21		<0.001	14	0.2%	0.35		<0.001
BP Non-user	8,545	50.0%	706	8.3%	0.21	0.29		222	2.6%	0.15	0.29		40	0.5%	0.19	0.64	
Age 51-60	131,445	100.0%	5,765	4.4%				2,371	1.8%				397	0.3%			
BP User	65,721	50.0%	1,104	1.7%	0.22		<0.001	456	0.7%	0.23		<0.001	83	0.1%	0.26		<0.001
BP Non-user	65,724	50.0%	4,661	7.1%	0.21	0.24		1,915	2.9%	0.21	0.26		314	0.5%	0.21	0.34	
Age 61-70	313,822	100.0%	10,438	3.3%				5,029	1.6%				1,035	0.3%			
BP User	156,878	50.0%	1,843	1.2%	0.21		<0.001	939	0.6%	0.23		<0.001	173	0.1%	0.20		<0.001
BP Non-user	156,944	50.0%	8,595	5.5%	0.20	0.22		4,090	2.6%	0.21	0.24		862	0.5%	0.17	0.24	
Age 71-80	280,803	100.0%	7,179	2.6%				4,827	1.7%				1,212	0.4%			
BP User	140,437	50.0%	1,309	0.9%	0.22		<0.001	877	0.6%	0.22		<0.001	234	0.2%	0.24		<0.001
BP Non-user	140,366	50.0%	5,870	4.2%	0.20	0.23		3,950	2.8%	0.20	0.23		978	0.7%	0.21	0.27	
Age ≥81	149,118	100.0%	3,459	2.3%				3,663	2.5%				997	0.7%			
BP User	74,560	50.0%	658	0.9%	0.23		<0.001	687	0.9%	0.22		<0.001	205	0.3%	0.26		<0.001
BP Non-user	74,558	50.0%	2,801	3.8%	0.21	0.25		2,976	4.0%	0.21	0.24		792	1.1%	0.22	0.30	
<b>Female Patients</b>	<b>811,497</b>	<b>100.0%</b>	<b>24,936</b>	<b>3.1%</b>				<b>14,367</b>	<b>1.8%</b>				<b>3,127</b>	<b>0.4%</b>			
BP User	405,751	50.0%	4,519	1.1%	0.21		<0.001	2,667	0.7%	0.22		<0.001	593	0.1%	0.23		<0.001
BP Non-user	405,746	50.0%	20,417	5.0%	0.21	0.22		11,700	2.9%	0.21	0.23		2,534	0.6%	0.21	0.25	
<b>By Age</b>																	
Age ≤20	885	100.0%	26	2.9%				7	0.8%				1	0.1%			
BP User	442	49.9%	11	2.5%	0.73		0.43	1	0.2%	0.17		0.12	1	0.2%	NA		NA
BP Non-user	443	50.1%	15	3.4%	0.33	1.60		6	1.4%	0.02	1.38		0	0.0%	NA	NA	
Age 21-40	3,765	100.0%	218	5.8%				64	1.7%				9	0.2%			
BP User	1,879	49.9%	40	2.1%	0.21		<0.001	12	0.6%	0.23		<0.001	3	0.2%	0.50		0.51
BP Non-user	1,886	50.1%	178	9.4%	0.15	0.30		52	2.8%	0.12	0.43		6	0.3%	0.13	2.01	
Age 41-50	13,542	100.0%	730	5.4%				206	1.5%				37	0.3%			
BP User	6,774	50.0%	157	2.3%	0.26		<0.001	43	0.6%	0.26		<0.001	11	0.2%	0.42		0.01
BP Non-user	6,768	50.0%	573	8.5%	0.21	0.31		163	2.4%	0.18	0.36		26	0.4%	0.21	0.85	
Age 51-60	119,205	100.0%	5,200	4.4%				2,093	1.8%				327	0.3%			
BP User	59,602	50.0%	973	1.6%	0.22		<0.001	399	0.7%	0.23		<0.001	64	0.1%	0.24		<0.001
BP Non-user	59,603	50.0%	4,227	7.1%	0.20	0.23		1,694	2.8%	0.21	0.26		263	0.4%	0.18	0.32	
Age 61-70	290,276	100.0%	9,474	3.3%				4,506	1.6%				885	0.3%			

BP User	145,131	50.0%	1,639	1.1%	0.20		<0.001	851	0.6%	0.23		<0.001	144	0.1%	0.19		<0.001
BP Non-user	145,145	50.0%	7,835	5.4%	0.19	0.21		3,655	2.5%	0.21	0.25		741	0.5%	0.16	0.23	
Age 71-80	253,094	100.0%	6,304	2.5%			<0.001	4,254	1.7%			<0.001	1,026	0.4%			<0.001
BP User	126,559	50.0%	1,140	0.9%	0.21			769	0.6%	0.22			193	0.2%	0.23		
BP Non-user	126,535	50.0%	5,164	4.1%	0.20	0.23	<0.001	3,485	2.8%	0.20	0.23	<0.001	833	0.7%	0.20	0.27	<0.001
Age ≥81	130,730	100.0%	2,984	2.3%				3,237	2.5%				842	0.6%			
BP User	65,364	50.0%	559	0.9%	0.22		<0.001	592	0.9%	0.22		<0.001	177	0.3%	0.26		<0.001
BP Non-user	65,366	50.0%	2,425	3.7%	0.20	0.25		2,645	4.0%	0.20	0.24		665	1.0%	0.22	0.31	
<b>Male Patients</b>	<b>89,235</b>	<b>100.0%</b>	<b>3,201</b>	<b>3.6%</b>				<b>1,922</b>	<b>2.2%</b>				<b>583</b>	<b>0.7%</b>			
BP User	44,615	50.0%	670	1.5%	0.25		<0.001	357	0.8%	0.22		<0.001	122	0.3%	0.26		<0.001
BP Non-user	44,620	50.0%	2,531	5.7%	0.23	0.28		1,565	3.5%	0.20	0.25		461	1.0%	0.22	0.32	
<b>By Age</b>																	
Age ≤20	1,368	100.0%	41	3.0%			0.42	7	0.5%			0.07	1	0.1%			NA
BP User	686	50.1%	18	2.6%	0.77			1	0.1%	0.16			1	0.1%	NA		
BP Non-user	682	49.9%	23	3.4%	0.41	1.44	<0.001	6	0.9%	0.02	1.37	<0.001	0	0.0%	NA	NA	0.63
Age 21-40	2,430	100.0%	117	4.8%				51	2.1%				4	0.2%			
BP User	1,212	49.9%	18	1.5%	0.17		<0.001	3	0.2%	0.06		<0.001	1	0.1%	0.33		0.63
BP Non-user	1,218	50.1%	99	8.1%	0.10	0.28		48	3.9%	0.02	0.19		3	0.2%	0.03	3.22	
Age 41-50	3,554	100.0%	164	4.6%			<0.001	64	1.8%			<0.001	17	0.5%			0.01
BP User	1,777	50.0%	31	1.7%	0.22			5	0.3%	0.08			3	0.2%	0.21		
BP Non-user	1,777	50.0%	133	7.5%	0.15	0.33	<0.001	59	3.3%	0.03	0.21	<0.001	14	0.8%	0.06	0.74	0.01
Age 51-60	12,240	100.0%	565	4.6%				278	2.3%				70	0.6%			
BP User	6,119	50.0%	131	2.1%	0.29		<0.001	57	0.9%	0.25		<0.001	19	0.3%	0.37		<0.001
BP Non-user	6,121	50.0%	434	7.1%	0.24	0.35		221	3.6%	0.19	0.34		51	0.8%	0.22	0.63	
Age 61-70	23,546	100.0%	964	4.1%			<0.001	523	2.2%			<0.001	150	0.6%			<0.001
BP User	11,747	49.9%	204	1.7%	0.26			88	0.7%	0.20			29	0.2%	0.24		
BP Non-user	11,799	50.1%	760	6.4%	0.22	0.30	<0.001	435	3.7%	0.16	0.25	<0.001	121	1.0%	0.16	0.36	<0.001
Age 71-80	27,709	100.0%	875	3.2%				573	2.1%				186	0.7%			
BP User	13,878	50.1%	169	1.2%	0.23		<0.001	108	0.8%	0.23		<0.001	41	0.3%	0.28		<0.001
BP Non-user	13,831	49.9%	706	5.1%	0.19	0.27		465	3.4%	0.18	0.28		145	1.0%	0.20	0.40	
Age ≥81	18,388	100.0%	475	2.6%			<0.001	426	2.3%			<0.001	155	0.8%			<0.001
BP User	9,196	50.0%	99	1.1%	0.26			95	1.0%	0.28			28	0.3%	0.22		
BP Non-user	9,192	50.0%	376	4.1%	0.20	0.32	<0.001	331	3.6%	0.22	0.35	<0.001	127	1.4%	0.14	0.33	<0.001

BP: bisphosphonate; LL: lower 95% confidence interval level; NA: not applicable; OR: odds ratio; UL: upper 95% confidence interval level

2612  
2613  
2614

2615  
2616  
2617

**Table S3b: Unadjusted COVID-19-Related Outcomes Stratified by Age, Sex, & Age by Sex; Matched Primary Analysis Cohort, Region=Northeast**

Region=Northeast Matched																	
	All		SARS-CoV-2 Test				COVID-19 Diagnosis				COVID-19 Hospitalization						
	N	%	N	%	OR		p-value	N	%	OR		p-value	N	%	OR		p-value
					LL	UL				LL	UL				LL	UL	
<b>All Patients</b>	<b>238,988</b>	<b>100.0%</b>	<b>8,831</b>	<b>3.7%</b>				<b>7,820</b>	<b>3.3%</b>				<b>1,505</b>	<b>0.6%</b>			
BP User	119,494	50.0%	1,684	1.4%	0.22		<0.001	1,578	1.3%	0.24		<0.001	314	0.3%	0.26		<0.001
BP Non-user	119,494	50.0%	7,147	6.0%	0.21	0.24		6,242	5.2%	0.23	0.26		1,191	1.0%	0.23	0.30	
<b>By Age</b>																	
Age ≤20	474	100.0%	14	3.0%				7	1.5%				2	0.4%			
BP User	236	49.8%	7	3.0%	1.01		0.99	2	0.8%	0.40		0.45	2	0.8%	NA		NA
BP Non-user	238	50.2%	7	2.9%	0.35	2.92		5	2.1%	0.08	2.07		0	0.0%	NA	NA	
Age 21-40	1,528	100.0%	93	6.1%				55	3.6%				5	0.3%			
BP User	764	50.0%	14	1.8%	0.16		<0.001	7	0.9%	0.14		<0.001	1	0.1%	0.25		0.37
BP Non-user	764	50.0%	79	10.3%	0.09	0.29		48	6.3%	0.06	0.31		4	0.5%	0.03	2.23	
Age 41-50	4,084	100.0%	234	5.7%				118	2.9%				18	0.4%			
BP User	2,042	50.0%	53	2.6%	0.27		<0.001	17	0.8%	0.16		<0.001	6	0.3%	0.50		0.16
BP Non-user	2,042	50.0%	181	8.9%	0.20	0.37		101	4.9%	0.10	0.27		12	0.6%	0.19	1.33	
Age 51-60	36,020	100.0%	1,863	5.2%				1,190	3.3%				160	0.4%			
BP User	18,010	50.0%	353	2.0%	0.22		<0.001	237	1.3%	0.24		<0.001	38	0.2%	0.31		<0.001
BP Non-user	18,010	50.0%	1,510	8.4%	0.19	0.25		953	5.3%	0.21	0.28		122	0.7%	0.22	0.45	
Age 61-70	82,233	100.0%	3,200	3.9%				2,424	2.9%				403	0.5%			
BP User	41,094	50.0%	597	1.5%	0.22		<0.001	507	1.2%	0.26		<0.001	79	0.2%	0.24		<0.001
BP Non-user	41,139	50.0%	2,603	6.3%	0.20	0.24		1,917	4.7%	0.23	0.28		324	0.8%	0.19	0.31	
Age 71-80	74,831	100.0%	2,266	3.0%				2,306	3.1%				493	0.7%			
BP User	37,438	50.0%	442	1.2%	0.23		<0.001	475	1.3%	0.25		<0.001	99	0.3%	0.25		<0.001
BP Non-user	37,393	50.0%	1,824	4.9%	0.21	0.26		1,831	4.9%	0.23	0.28		394	1.1%	0.20	0.31	
Age ≥81	39,818	100.0%	1,161	2.9%				1,720	4.3%				424	1.1%			
BP User	19,910	50.0%	218	1.1%	0.22		<0.001	333	1.7%	0.23		<0.001	89	0.4%	0.26		<0.001
BP Non-user	19,908	50.0%	943	4.7%	0.19	0.26		1,387	7.0%	0.20	0.26		335	1.7%	0.21	0.33	
<b>Female Patients</b>	<b>216,273</b>	<b>100.0%</b>	<b>7,897</b>	<b>3.7%</b>				<b>6,941</b>	<b>3.2%</b>				<b>1,263</b>	<b>0.6%</b>			
BP User	108,136	50.0%	1,483	1.4%	0.22		<0.001	1,392	1.3%	0.24		<0.001	255	0.2%	0.25		<0.001
BP Non-user	108,137	50.0%	6,414	5.9%	0.21	0.23		5,549	5.1%	0.23	0.26		1,008	0.9%	0.22	0.29	
<b>By Age</b>																	
Age ≤20	180	100.0%	4	2.2%				3	1.7%				1	0.6%			
BP User	90	50.0%	2	2.2%	1.00		1.00	1	1.1%	0.49		1.00	1	1.1%	NA		NA
BP Non-user	90	50.0%	2	2.2%	0.14	7.26		2	2.2%	0.04	5.55		0	0.0%	NA	NA	
Age 21-40	864	100.0%	59	6.8%				32	3.7%				4	0.5%			
BP User	431	49.9%	10	2.3%	0.19		<0.001	6	1.4%	0.22		<0.001	1	0.2%	0.33		0.62
BP Non-user	433	50.1%	49	11.3%	0.09	0.37		26	6.0%	0.09	0.54		3	0.7%	0.03	3.22	
Age 41-50	3,176	100.0%	176	5.5%				87	2.7%				13	0.4%			
BP User	1,588	50.0%	40	2.5%	0.28		<0.001	15	0.9%	0.20		<0.001	5	0.3%	0.62		0.40
BP Non-user	1,588	50.0%	136	8.6%	0.19	0.40		72	4.5%	0.11	0.35		8	0.5%	0.20	1.91	
Age 51-60	32,612	100.0%	1,690	5.2%				1,048	3.2%				125	0.4%			
BP User	16,306	50.0%	310	1.9%	0.21		<0.001	206	1.3%	0.24		<0.001	31	0.2%	0.33		<0.001
BP Non-user	16,306	50.0%	1,380	8.5%	0.18	0.24		842	5.2%	0.20	0.27		94	0.6%	0.22	0.49	
Age 61-70	76,403	100.0%	2,933	3.8%				2,181	2.9%				343	0.4%			

BP User	38,200	50.0%	536	1.4%	0.21		<0.001	456	1.2%	0.26		<0.001	63	0.2%	0.22		<0.001
BP Non-user	38,203	50.0%	2,397	6.3%	0.19	0.23		1,725	4.5%	0.23	0.28		280	0.7%	0.17	0.29	
Age 71-80	67,857	100.0%	2,021	3.0%				2,063	3.0%				416	0.6%			
BP User	33,930	50.0%	393	1.2%	0.23		<0.001	413	1.2%	0.24		<0.001	77	0.2%	0.23		<0.001
BP Non-user	33,927	50.0%	1,628	4.8%	0.21	0.26		1,650	4.9%	0.22	0.27		339	1.0%	0.18	0.29	
Age ≥81	35,181	100.0%	1,014	2.9%				1,527	4.3%				361	1.0%			
BP User	17,591	50.0%	192	1.1%	0.23		<0.001	295	1.7%	0.23		<0.001	77	0.4%	0.27		<0.001
BP Non-user	17,590	50.0%	822	4.7%	0.19	0.26		1,232	7.0%	0.20	0.26		284	1.6%	0.21	0.34	
<b>Male Patients</b>	<b>22,715</b>	<b>100.0%</b>	<b>934</b>	<b>4.1%</b>				<b>879</b>	<b>3.9%</b>				<b>242</b>	<b>1.1%</b>			
BP User	11,358	50.0%	201	1.8%	0.26		<0.001	186	1.6%	0.26		<0.001	59	0.5%	0.32		<0.001
BP Non-user	11,357	50.0%	733	6.5%	0.22	0.31		693	6.1%	0.22	0.30		183	1.6%	0.24	0.43	
<b>By Age</b>																	
Age ≤20	294	100.0%	10	3.4%				4	1.4%				1	0.3%			
BP User	146	49.7%	5	3.4%	1.01		0.98	1	0.7%	0.33		0.62	1	0.7%	NA		NA
BP Non-user	148	50.3%	5	3.4%	0.29	3.58		3	2.0%	0.03	3.24		0	0.0%	NA	NA	
Age 21-40	664	100.0%	34	5.1%				23	3.5%				1	0.2%			
BP User	333	50.2%	4	1.2%	0.12		<0.001	1	0.3%	0.04		<0.001	0	0.0%	NA		NA
BP Non-user	331	49.8%	30	9.1%	0.04	0.35		22	6.6%	0.01	0.32		1	0.3%	NA	NA	
Age 41-50	908	100.0%	58	6.4%				31	3.4%				5	0.6%			
BP User	454	50.0%	13	2.9%	0.27		<0.001	2	0.4%	0.06		<0.001	1	0.2%	0.25		0.37
BP Non-user	454	50.0%	45	9.9%	0.14	0.50		29	6.4%	0.02	0.27		4	0.9%	0.03	2.23	
Age 51-60	3,408	100.0%	173	5.1%				142	4.2%				35	1.0%			
BP User	1,704	50.0%	43	2.5%	0.31		<0.001	31	1.8%	0.27		<0.001	7	0.4%	0.25		<0.001
BP Non-user	1,704	50.0%	130	7.6%	0.22	0.45		111	6.5%	0.18	0.40		28	1.6%	0.11	0.57	
Age 61-70	5,830	100.0%	267	4.6%				243	4.2%				60	1.0%			
BP User	2,894	49.6%	61	2.1%	0.29		<0.001	51	1.8%	0.26		<0.001	16	0.6%	0.37		<0.001
BP Non-user	2,936	50.4%	206	7.0%	0.21	0.38		192	6.5%	0.19	0.35		44	1.5%	0.21	0.65	
Age 71-80	6,974	100.0%	245	3.5%				243	3.5%				77	1.1%			
BP User	3,508	50.3%	49	1.4%	0.24		<0.001	62	1.8%	0.33		<0.001	22	0.6%	0.39		<0.001
BP Non-user	3,466	49.7%	196	5.7%	0.17	0.32		181	5.2%	0.24	0.44		55	1.6%	0.24	0.64	
Age ≥81	4,637	100.0%	147	3.2%				193	4.2%				63	1.4%			
BP User	2,319	50.0%	26	1.1%	0.21		<0.001	38	1.6%	0.23		<0.001	12	0.5%	0.23		<0.001
BP Non-user	2,318	50.0%	121	5.2%	0.13	0.32		155	6.7%	0.16	0.33		51	2.2%	0.12	0.43	

BP: bisphosphonate; LL: lower 95% confidence interval level; NA: not applicable; OR: odds ratio; UL: upper 95% confidence interval level

2618  
2619

2620  
2621  
2622

**Table S3c: Unadjusted COVID-19-Related Outcomes Stratified by Age, Sex, & Age by Sex; Matched Primary Analysis Cohort, Region=Midwest**

Region=Midwest Matched																	
	All		SARS-CoV-2 Test				COVID-19 Diagnosis				COVID-19 Hospitalization						
	N	%	N	%	OR		p-value	N	%	OR		p-value	N	%	OR		p-value
					LL	UL				LL	UL				LL	UL	
<b>All Patients</b>	<b>151,802</b>	<b>100.0%</b>	<b>4,451</b>	<b>2.9%</b>				<b>2,099</b>	<b>1.4%</b>				<b>636</b>	<b>0.4%</b>			
BP User	75,901	50.0%	868	1.1%	0.23		<0.001	383	0.5%	0.22		<0.001	121	0.2%	0.23		<0.001
BP Non-user	75,901	50.0%	3,583	4.7%	0.22	0.25		1,716	2.3%	0.20	0.25		515	0.7%	0.19	0.29	
<b>By Age</b>																	
Age ≤20	537	100.0%	15	2.8%			0.44	2	0.4%			NA	0	0.0%			NA
BP User	268	49.9%	6	2.2%	0.66			0	0.0%	NA			0	0.0%	NA		
BP Non-user	269	50.1%	9	3.3%	0.23	1.89		2	0.7%	NA	NA		0	0.0%	NA	NA	
Age 21-40	1,188	100.0%	62	5.2%			<0.001	17	1.4%			0.002	1	0.1%			NA
BP User	593	49.9%	7	1.2%	0.12			2	0.3%	0.13			0	0.0%	NA		
BP Non-user	595	50.1%	55	9.2%	0.05	0.26		15	2.5%	0.03	0.57		1	0.2%	NA	NA	
Age 41-50	3,367	100.0%	184	5.5%			<0.001	46	1.4%			<0.001	16	0.5%			0.002
BP User	1,684	50.0%	36	2.1%	0.23			10	0.6%	0.27			2	0.1%	0.14		
BP Non-user	1,683	50.0%	148	8.8%	0.16	0.33		36	2.1%	0.14	0.55		14	0.8%	0.03	0.62	
Age 51-60	24,478	100.0%	951	3.9%			<0.001	293	1.2%			<0.001	80	0.3%			<0.001
BP User	12,238	50.0%	180	1.5%	0.22			52	0.4%	0.21			15	0.1%	0.23		
BP Non-user	12,240	50.0%	771	6.3%	0.19	0.26		241	2.0%	0.16	0.29		65	0.5%	0.13	0.40	
Age 61-70	56,991	100.0%	1,764	3.1%			<0.001	671	1.2%			<0.001	189	0.3%			<0.001
BP User	28,496	50.0%	322	1.1%	0.21			123	0.4%	0.22			35	0.1%	0.23		
BP Non-user	28,495	50.0%	1,442	5.1%	0.19	0.24		548	1.9%	0.18	0.27		154	0.5%	0.16	0.33	
Age 71-80	42,153	100.0%	1,009	2.4%			<0.001	577	1.4%			<0.001	200	0.5%			<0.001
BP User	21,078	50.0%	209	1.0%	0.25			95	0.5%	0.19			37	0.2%	0.23		
BP Non-user	21,075	50.0%	800	3.8%	0.22	0.30		482	2.3%	0.16	0.24		163	0.8%	0.16	0.32	
Age ≥81	23,088	100.0%	466	2.0%			<0.001	493	2.1%			<0.001	150	0.6%			<0.001
BP User	11,544	50.0%	108	0.9%	0.30			101	0.9%	0.25			32	0.3%	0.27		
BP Non-user	11,544	50.0%	358	3.1%	0.24	0.37		392	3.4%	0.20	0.31		118	1.0%	0.18	0.40	
<b>Female Patients</b>	<b>137,028</b>	<b>100.0%</b>	<b>3,945</b>	<b>2.9%</b>				<b>1,828</b>	<b>1.3%</b>				<b>543</b>	<b>0.4%</b>			
BP User	68,512	50.0%	762	1.1%	0.23		<0.001	333	0.5%	0.22		<0.001	103	0.2%	0.23		<0.001
BP Non-user	68,516	50.0%	3,183	4.6%	0.21	0.25		1,495	2.2%	0.19	0.25		440	0.6%	0.19	0.29	
<b>By Age</b>																	
Age ≤20	226	100.0%	7	3.1%			1.00	1	0.4%			NA	0	0.0%			NA
BP User	113	50.0%	3	2.7%	0.74			0	0.0%	NA			0	0.0%	NA		
BP Non-user	113	50.0%	4	3.5%	0.16	3.40		1	0.9%	NA	NA		0	0.0%	NA	NA	
Age 21-40	700	100.0%	34	4.9%			<0.001	7	1.0%			0.12	0	0.0%			NA
BP User	349	49.9%	6	1.7%	0.20			1	0.3%	0.17			0	0.0%	NA		
BP Non-user	351	50.1%	28	8.0%	0.08	0.49		6	1.7%	0.02	1.38		0	0.0%	NA	NA	
Age 41-50	2,639	100.0%	157	5.9%			<0.001	32	1.2%			0.005	10	0.4%			0.02
BP User	1,319	50.0%	31	2.4%	0.23			8	0.6%	0.33			1	0.1%	0.11		
BP Non-user	1,320	50.0%	126	9.5%	0.15	0.34		24	1.8%	0.15	0.74		9	0.7%	0.01	0.87	
Age 51-60	22,101	100.0%	856	3.9%			<0.001	260	1.2%			<0.001	70	0.3%			<0.001
BP User	11,050	50.0%	159	1.4%	0.22			47	0.4%	0.22			13	0.1%	0.23		
BP Non-user	11,051	50.0%	697	6.3%	0.18	0.26		213	1.9%	0.16	0.30		57	0.5%	0.12	0.42	
Age 61-70	52,520	100.0%	1,594	3.0%				591	1.1%				165	0.3%			



BP User	26,260	50.0%	286	1.1%	0.21		<0.001	107	0.4%	0.22		<0.001	29	0.1%	0.21		<0.001
BP Non-user	26,260	50.0%	1,308	5.0%	0.18	0.24		484	1.8%	0.18	0.27		136	0.5%	0.14	0.32	
Age 71-80	38,367	100.0%	877	2.3%				501	1.3%				172	0.4%			
BP User	19,184	50.0%	180	0.9%	0.25		<0.001	85	0.4%	0.20		<0.001	33	0.2%	0.24		<0.001
BP Non-user	19,183	50.0%	697	3.6%	0.21	0.30		416	2.2%	0.16	0.25		139	0.7%	0.16	0.35	
Age ≥81	20,475	100.0%	420	2.1%				436	2.1%				126	0.6%			
BP User	10,237	50.0%	97	0.9%	0.29		<0.001	85	0.8%	0.24		<0.001	27	0.3%	0.27		<0.001
BP Non-user	10,238	50.0%	323	3.2%	0.23	0.37		351	3.4%	0.19	0.30		99	1.0%	0.18	0.41	
<b>Male Patients</b>	<b>14,774</b>	<b>100.0%</b>	<b>506</b>	<b>3.4%</b>				<b>271</b>	<b>1.8%</b>				<b>93</b>	<b>0.6%</b>			
BP User	7,389	50.0%	106	1.4%	0.25		<0.001	50	0.7%	0.22		<0.001	18	0.2%	0.24		<0.001
BP Non-user	7,385	50.0%	400	5.4%	0.20	0.32		221	3.0%	0.16	0.30		75	1.0%	0.14	0.40	
<b>By Age</b>																	
Age ≤20	311	100.0%	8	2.6%				1	0.3%				0	0.0%			
BP User	155	49.8%	3	1.9%	0.60		0.72	0	0.0%	NA		NA	0	0.0%	NA		NA
BP Non-user	156	50.2%	5	3.2%	0.14	2.54		1	0.6%	NA	NA		0	0.0%	NA	NA	
Age 21-40	488	100.0%	28	5.7%				10	2.0%				1	0.2%			
BP User	244	50.0%	1	0.4%	0.03		<0.001	1	0.4%	0.11		0.02	0	0.0%	NA		NA
BP Non-user	244	50.0%	27	11.1%	0.00	0.25		9	3.7%	0.01	0.85		1	0.4%	NA	NA	
Age 41-50	728	100.0%	27	3.7%				14	1.9%				6	0.8%			
BP User	365	50.1%	5	1.4%	0.22		<0.001	2	0.5%	0.16		0.007	1	0.3%	0.20		0.12
BP Non-user	363	49.9%	22	6.1%	0.08	0.57		12	3.3%	0.04	0.73		5	1.4%	0.02	1.69	
Age 51-60	2,377	100.0%	95	4.0%				33	1.4%				10	0.4%			
BP User	1,188	50.0%	21	1.8%	0.27		<0.001	5	0.4%	0.18		<0.001	2	0.2%	0.25		0.11
BP Non-user	1,189	50.0%	74	6.2%	0.17	0.44		28	2.4%	0.07	0.46		8	0.7%	0.05	1.17	
Age 61-70	4,471	100.0%	170	3.8%				80	1.8%				24	0.5%			
BP User	2,236	50.0%	36	1.6%	0.26		<0.001	16	0.7%	0.24		<0.001	6	0.3%	0.33		0.01
BP Non-user	2,235	50.0%	134	6.0%	0.18	0.37		64	2.9%	0.14	0.42		18	0.8%	0.13	0.84	
Age 71-80	3,786	100.0%	132	3.5%				76	2.0%				28	0.7%			
BP User	1,894	50.0%	29	1.5%	0.27		<0.001	10	0.5%	0.15		<0.001	4	0.2%	0.16		<0.001
BP Non-user	1,892	50.0%	103	5.4%	0.18	0.41		66	3.5%	0.08	0.29		24	1.3%	0.06	0.48	
Age ≥81	2,613	100.0%	46	1.8%				57	2.2%				24	0.9%			
BP User	1,307	50.0%	11	0.8%	0.31		<0.001	16	1.2%	0.38		<0.001	5	0.4%	0.26		0.004
BP Non-user	1,306	50.0%	35	2.7%	0.16	0.61		41	3.1%	0.21	0.69		19	1.5%	0.10	0.70	

BP: bisphosphonate; LL: lower 95% confidence interval level; NA: not applicable; OR: odds ratio; UL: upper 95% confidence interval level

2623  
2624  
2625

2626  
2627  
2628

**Table S3d: Unadjusted COVID-19-Related Outcomes Stratified by Age, Sex, & Age by Sex; Matched Primary Analysis Cohort, Region=South**

Region=South Matched																	
	All		SARS-CoV-2 Test				COVID-19 Diagnosis				COVID-19 Hospitalization						
	N	%	N	%	OR		p-value	N	%	OR		p-value	N	%	OR		p-value
					LL	UL				LL	UL				LL	UL	
<b>All Patients</b>	<b>319,408</b>	<b>100.0%</b>	<b>8,418</b>	<b>2.6%</b>				<b>3,535</b>	<b>1.1%</b>				<b>849</b>	<b>0.3%</b>			
BP User	159,704	50.0%	1,553	1.0%	0.22		<0.001	624	0.4%	0.21		<0.001	167	0.1%	0.24		<0.001
BP Non-user	159,704	50.0%	6,865	4.3%	0.21	0.23		2,911	1.8%	0.19	0.23		682	0.4%	0.21	0.29	
<b>By Age</b>																	
Age ≤20	943	100.0%	29	3.1%			0.87	4	0.4%			NA	0	0.0%			NA
BP User	474	50.3%	15	3.2%	1.06			0	0.0%	NA			0	0.0%	NA		
BP Non-user	469	49.7%	14	3.0%	0.51	2.23		4	0.9%	NA	NA		0	0.0%	NA	NA	
Age 21-40	2,364	100.0%	113	4.8%			<0.001	25	1.1%			<0.001	4	0.2%			1.00
BP User	1,177	49.8%	20	1.7%	0.20			4	0.3%	0.19			2	0.2%	1.01		
BP Non-user	1,187	50.2%	93	7.8%	0.12	0.33		21	1.8%	0.06	0.55		2	0.2%	0.14	7.17	
Age 41-50	6,839	100.0%	329	4.8%			<0.001	73	1.1%			<0.001	10	0.1%			0.99
BP User	3,421	50.0%	72	2.1%	0.26			18	0.5%	0.32			5	0.1%	1.00		
BP Non-user	3,418	50.0%	257	7.5%	0.20	0.34		55	1.6%	0.19	0.55		5	0.1%	0.29	3.45	
Age 51-60	50,186	100.0%	1,999	4.0%			<0.001	584	1.2%			<0.001	103	0.2%			<0.001
BP User	25,093	50.0%	393	1.6%	0.23			114	0.5%	0.24			23	0.1%	0.29		
BP Non-user	25,093	50.0%	1,606	6.4%	0.21	0.26		470	1.9%	0.19	0.29		80	0.3%	0.18	0.46	
Age 61-70	111,800	100.0%	3,246	2.9%			<0.001	1,106	1.0%			<0.001	247	0.2%			<0.001
BP User	55,896	50.0%	583	1.0%	0.21			191	0.3%	0.21			38	0.1%	0.18		
BP Non-user	55,904	50.0%	2,663	4.8%	0.19	0.23		915	1.6%	0.18	0.24		209	0.4%	0.13	0.26	
Age 71-80	99,223	100.0%	1,942	2.0%			<0.001	1,029	1.0%			<0.001	260	0.3%			<0.001
BP User	49,618	50.0%	322	0.6%	0.19			170	0.3%	0.20			55	0.1%	0.27		
BP Non-user	49,605	50.0%	1,620	3.3%	0.17	0.22		859	1.7%	0.17	0.23		205	0.4%	0.20	0.36	
Age ≥81	48,053	100.0%	760	1.6%			<0.001	714	1.5%			<0.001	225	0.5%			<0.001
BP User	24,025	50.0%	148	0.6%	0.24			127	0.5%	0.21			44	0.2%	0.24		
BP Non-user	24,028	50.0%	612	2.5%	0.20	0.28		587	2.4%	0.18	0.26		181	0.8%	0.17	0.34	
<b>Female Patients</b>	<b>289,263</b>	<b>100.0%</b>	<b>7,519</b>	<b>2.6%</b>				<b>3,159</b>	<b>1.1%</b>				<b>745</b>	<b>0.3%</b>			
BP User	144,633	50.0%	1,365	0.9%	0.21		<0.001	562	0.4%	0.21		<0.001	143	0.1%	0.24		<0.001
BP Non-user	144,630	50.0%	6,154	4.3%	0.20	0.23		2,597	1.8%	0.19	0.23		602	0.4%	0.20	0.28	
<b>By Age</b>																	
Age ≤20	372	100.0%	11	3.0%			0.75	3	0.8%			NA	0	0.0%			NA
BP User	185	49.7%	6	3.2%	1.22			0	0.0%	NA			0	0.0%	NA		
BP Non-user	187	50.3%	5	2.7%	0.37	4.07		3	1.6%	NA	NA		0	0.0%	NA	NA	
Age 21-40	1,543	100.0%	81	5.2%			<0.001	16	1.0%			0.08	3	0.2%			0.62
BP User	770	49.9%	14	1.8%	0.20			4	0.5%	0.33			2	0.3%	2.01		
BP Non-user	773	50.1%	67	8.7%	0.11	0.35		12	1.6%	0.11	1.03		1	0.1%	0.18	22.22	
Age 41-50	5,569	100.0%	273	4.9%			<0.001	66	1.2%			<0.001	9	0.2%			1.00
BP User	2,787	50.0%	65	2.3%	0.30			18	0.6%	0.37			5	0.2%	1.25		
BP Non-user	2,782	50.0%	208	7.5%	0.22	0.39		48	1.7%	0.21	0.64		4	0.1%	0.33	4.65	
Age 51-60	46,012	100.0%	1,819	4.0%			<0.001	521	1.1%			<0.001	89	0.2%			<0.001
BP User	23,007	50.0%	358	1.6%	0.23			100	0.4%	0.23			16	0.1%	0.22		
BP Non-user	23,005	50.0%	1,461	6.4%	0.21	0.26		421	1.8%	0.19	0.29		73	0.3%	0.13	0.38	
Age 61-70	103,825	100.0%	2,948	2.8%				1,007	1.0%				218	0.2%			

BP User	51,910	50.0%	517	1.0%	0.20		<0.001	177	0.3%	0.21		<0.001	33	0.1%	0.18		<0.001
BP Non-user	51,915	50.0%	2,431	4.7%	0.19	0.23		830	1.6%	0.18	0.25		185	0.4%	0.12	0.26	
Age 71-80	89,474	100.0%	1,729	1.9%				915	1.0%				230	0.3%			
BP User	44,742	50.0%	283	0.6%	0.19		<0.001	153	0.3%	0.20		<0.001	47	0.1%	0.26		<0.001
BP Non-user	44,732	50.0%	1,446	3.2%	0.17	0.22		762	1.7%	0.17	0.24		183	0.4%	0.19	0.35	
Age ≥81	42,468	100.0%	658	1.5%				631	1.5%				196	0.5%			
BP User	21,232	50.0%	122	0.6%	0.22		<0.001	110	0.5%	0.21		<0.001	40	0.2%	0.26		<0.001
BP Non-user	21,236	50.0%	536	2.5%	0.18	0.27		521	2.5%	0.17	0.25		156	0.7%	0.18	0.36	
<b>Male Patients</b>	<b>30,145</b>	<b>100.0%</b>	<b>899</b>	<b>3.0%</b>				<b>376</b>	<b>1.2%</b>				<b>104</b>	<b>0.3%</b>			
BP User	15,071	50.0%	188	1.2%	0.26		<0.001	62	0.4%	0.19		<0.001	24	0.2%	0.30		<0.001
BP Non-user	15,074	50.0%	711	4.7%	0.22	0.30		314	2.1%	0.15	0.26		80	0.5%	0.19	0.47	
<b>By Age</b>																	
Age ≤20	571	100.0%	18	3.2%				1	0.2%				0	0.0%			
BP User	289	50.6%	9	3.1%	0.98		0.96	0	0.0%	NA		NA	0	0.0%	NA		NA
BP Non-user	282	49.4%	9	3.2%	0.38	2.49		1	0.4%	NA	NA		0	0.0%	NA	NA	
Age 21-40	821	100.0%	32	3.9%				9	1.1%				1	0.1%			
BP User	407	49.6%	6	1.5%	0.22		<0.001	0	0.0%	NA		NA	0	0.0%	NA		NA
BP Non-user	414	50.4%	26	6.3%	0.09	0.55		9	2.2%	NA	NA		1	0.2%	NA	NA	
Age 41-50	1,270	100.0%	56	4.4%				7	0.6%				1	0.1%			
BP User	634	49.9%	7	1.1%	0.13		<0.001	0	0.0%	NA		NA	0	0.0%	NA		NA
BP Non-user	636	50.1%	49	7.7%	0.06	0.30		7	1.1%	NA	NA		1	0.2%	NA	NA	
Age 51-60	4,174	100.0%	180	4.3%				63	1.5%				14	0.3%			
BP User	2,086	50.0%	35	1.7%	0.23		<0.001	14	0.7%	0.28		<0.001	7	0.3%	1.00		0.99
BP Non-user	2,088	50.0%	145	6.9%	0.16	0.33		49	2.3%	0.15	0.51		7	0.3%	0.35	2.86	
Age 61-70	7,975	100.0%	298	3.7%				99	1.2%				29	0.4%			
BP User	3,986	50.0%	66	1.7%	0.27		<0.001	14	0.4%	0.16		<0.001	5	0.1%	0.21		<0.001
BP Non-user	3,989	50.0%	232	5.8%	0.21	0.36		85	2.1%	0.09	0.29		24	0.6%	0.08	0.54	
Age 71-80	9,749	100.0%	213	2.2%				114	1.2%				30	0.3%			
BP User	4,876	50.0%	39	0.8%	0.22		<0.001	17	0.3%	0.17		<0.001	8	0.2%	0.36		0.01
BP Non-user	4,873	50.0%	174	3.6%	0.15	0.31		97	2.0%	0.10	0.29		22	0.5%	0.16	0.81	
Age ≥81	5,585	100.0%	102	1.8%				83	1.5%				29	0.5%			
BP User	2,793	50.0%	26	0.9%	0.34		<0.001	17	0.6%	0.25		<0.001	4	0.1%	0.16		<0.001
BP Non-user	2,792	50.0%	76	2.7%	0.21	0.53		66	2.4%	0.15	0.43		25	0.9%	0.06	0.46	

BP: bisphosphonate; LL: lower 95% confidence interval level; NA: not applicable; OR: odds ratio; UL: upper 95% confidence interval level

2629

2630

2631

2632  
2633  
2634

**Table S3e: Unadjusted COVID-19-Related Outcomes Stratified by Age, Sex, & Age by Sex; Matched Primary Analysis Cohort, Region=West**

Region=West Matched																	
	All		SARS-CoV-2 Test				COVID-19 Diagnosis				COVID-19 Hospitalization						
	N	%	N	%	OR		p-value	N	%	OR		p-value	N	%	OR		p-value
					LL	UL				LL	UL				LL	UL	
<b>All Patients</b>	<b>190,534</b>	<b>100.0%</b>	<b>6,437</b>	<b>3.4%</b>				<b>2,835</b>	<b>1.5%</b>				<b>720</b>	<b>0.4%</b>			
BP User	95,267	50.0%	1,084	1.1%	0.19		<0.001	439	0.5%	0.18		<0.001	113	0.1%	0.19		<0.001
BP Non-user	95,267	50.0%	5,353	5.6%	0.18	0.21		2,396	2.5%	0.16	0.20		607	0.6%	0.15	0.23	
<b>By Age</b>																	
Age ≤20	299	100.0%	9	3.0%			0.02	1	0.3%			NA	0	0.0%			NA
BP User	150	50.2%	1	0.7%	0.12			0	0.0%	NA			0	0.0%	NA		
BP Non-user	149	49.8%	8	5.4%	0.01	0.96		1	0.7%	NA	NA		0	0.0%	NA	NA	
Age 21-40	1,115	100.0%	67	6.0%			<0.001	18	1.6%			0.001	3	0.3%			1.00
BP User	557	50.0%	17	3.1%	0.32			2	0.4%	0.12			1	0.2%	0.50		
BP Non-user	558	50.0%	50	9.0%	0.18	0.56		16	2.9%	0.03	0.53		2	0.4%	0.05	5.53	
Age 41-50	2,806	100.0%	147	5.2%			<0.001	33	1.2%			<0.001	10	0.4%			0.01
BP User	1,404	50.0%	27	1.9%	0.21			3	0.2%	0.10			1	0.1%	0.11		
BP Non-user	1,402	50.0%	120	8.6%	0.14	0.32		30	2.1%	0.03	0.32		9	0.6%	0.01	0.87	
Age 51-60	20,761	100.0%	952	4.6%			<0.001	304	1.5%			<0.001	54	0.3%			<0.001
BP User	10,380	50.0%	178	1.7%	0.22			53	0.5%	0.21			7	0.1%	0.15		
BP Non-user	10,381	50.0%	774	7.5%	0.18	0.26		251	2.4%	0.15	0.28		47	0.5%	0.07	0.33	
Age 61-70	62,798	100.0%	2,228	3.5%			<0.001	828	1.3%			<0.001	196	0.3%			<0.001
BP User	31,392	50.0%	341	1.1%	0.17			118	0.4%	0.16			21	0.1%	0.12		
BP Non-user	31,406	50.0%	1,887	6.0%	0.15	0.19		710	2.3%	0.13	0.20		175	0.6%	0.08	0.19	
Age 71-80	64,596	100.0%	1,962	3.0%			<0.001	915	1.4%			<0.001	259	0.4%			<0.001
BP User	32,303	50.0%	336	1.0%	0.20			137	0.4%	0.17			43	0.1%	0.20		
BP Non-user	32,293	50.0%	1,626	5.0%	0.18	0.22		778	2.4%	0.14	0.21		216	0.7%	0.14	0.27	
Age ≥81	38,159	100.0%	1,072	2.8%			<0.001	736	1.9%			<0.001	198	0.5%			<0.001
BP User	19,081	50.0%	184	1.0%	0.20			126	0.7%	0.20			40	0.2%	0.25		
BP Non-user	19,078	50.0%	888	4.7%	0.17	0.23		610	3.2%	0.17	0.24		158	0.8%	0.18	0.36	
<b>Female Patients</b>	<b>168,933</b>	<b>100.0%</b>	<b>5,575</b>	<b>3.3%</b>				<b>2,439</b>	<b>1.4%</b>				<b>576</b>	<b>0.3%</b>			
BP User	84,470	50.0%	909	1.1%	0.19		<0.001	380	0.4%	0.18		<0.001	92	0.1%	0.19		<0.001
BP Non-user	84,463	50.0%	4,666	5.5%	0.17	0.20		2,059	2.4%	0.16	0.20		484	0.6%	0.15	0.24	
<b>By Age</b>																	
Age ≤20	107	100.0%	4	3.7%			NA	0	0.0%			NA	0	0.0%			NA
BP User	54	50.5%	0	0.0%	NA			0	0.0%	NA			0	0.0%	NA		
BP Non-user	53	49.5%	4	7.5%	NA	NA		0	0.0%	NA	NA		0	0.0%	NA	NA	
Age 21-40	658	100.0%	44	6.7%			<0.001	9	1.4%			0.04	2	0.3%			NA
BP User	329	50.0%	10	3.0%	0.27			1	0.3%	0.12			0	0.0%	NA		
BP Non-user	329	50.0%	34	10.3%	0.13	0.56		8	2.4%	0.02	0.98		2	0.6%	NA	NA	
Age 41-50	2,158	100.0%	124	5.7%			<0.001	21	1.0%			<0.001	5	0.2%			NA
BP User	1,080	50.0%	21	1.9%	0.19			2	0.2%	0.10			0	0.0%	NA		
BP Non-user	1,078	50.0%	103	9.6%	0.12	0.30		19	1.8%	0.02	0.45		5	0.5%	NA	NA	
Age 51-60	18,480	100.0%	835	4.5%			<0.001	264	1.4%			<0.001	43	0.2%			<0.001
BP User	9,239	50.0%	146	1.6%	0.20			46	0.5%	0.21			4	0.0%	0.10		
BP Non-user	9,241	50.0%	689	7.5%	0.17	0.24		218	2.4%	0.15	0.29		39	0.4%	0.04	0.29	
Age 61-70	57,528	100.0%	1,999	3.5%				727	1.3%				159	0.3%			

BP User	28,761	50.0%	300	1.0%	0.17		<0.001	111	0.4%	0.18		<0.001	19	0.1%	0.14		<0.001
BP Non-user	28,767	50.0%	1,699	5.9%	0.15	0.19		616	2.1%	0.14	0.22		140	0.5%	0.08	0.22	
Age 71-80	57,396	100.0%	1,677	2.9%				775	1.4%				208	0.4%			
BP User	28,703	50.0%	284	1.0%	0.20		<0.001	118	0.4%	0.18		<0.001	36	0.1%	0.21		<0.001
BP Non-user	28,693	50.0%	1,393	4.9%	0.17	0.22		657	2.3%	0.14	0.21		172	0.6%	0.15	0.30	
Age ≥81	32,606	100.0%	892	2.7%				643	2.0%				159	0.5%			
BP User	16,304	50.0%	148	0.9%	0.19		<0.001	102	0.6%	0.18		<0.001	33	0.2%	0.26		<0.001
BP Non-user	16,302	50.0%	744	4.6%	0.16	0.23		541	3.3%	0.15	0.23		126	0.8%	0.18	0.38	
<b>Male Patients</b>	<b>21,601</b>	<b>100.0%</b>	<b>862</b>	<b>4.0%</b>				<b>396</b>	<b>1.8%</b>				<b>144</b>	<b>0.7%</b>			
BP User	10,797	50.0%	175	1.6%	0.24		<0.001	59	0.5%	0.17		<0.001	21	0.2%	0.17		<0.001
BP Non-user	10,804	50.0%	687	6.4%	0.21	0.29		337	3.1%	0.13	0.23		123	1.1%	0.11	0.27	
<b>By Age</b>																	
Age ≤20	192	100.0%	5	2.6%				1	0.5%				0	0.0%			
BP User	96	50.0%	1	1.0%	0.24		0.37	0	0.0%	NA		NA	0	0.0%	NA		NA
BP Non-user	96	50.0%	4	4.2%	0.03	2.21		1	1.0%	NA	NA		0	0.0%	NA	NA	
Age 21-40	457	100.0%	23	5.0%				9	2.0%				1	0.2%			
BP User	228	49.9%	7	3.1%	0.42		0.06	1	0.4%	0.12		0.04	1	0.4%	NA		NA
BP Non-user	229	50.1%	16	7.0%	0.17	1.05		8	3.5%	0.02	0.98		0	0.0%	NA	NA	
Age 41-50	648	100.0%	23	3.5%				12	1.9%				5	0.8%			
BP User	324	50.0%	6	1.9%	0.34		0.02	1	0.3%	0.09		0.006	1	0.3%	0.25		0.37
BP Non-user	324	50.0%	17	5.2%	0.13	0.88		11	3.4%	0.01	0.69		4	1.2%	0.03	2.23	
Age 51-60	2,281	100.0%	117	5.1%				40	1.8%				11	0.5%			
BP User	1,141	50.0%	32	2.8%	0.36		<0.001	7	0.6%	0.21		<0.001	3	0.3%	0.37		0.15
BP Non-user	1,140	50.0%	85	7.5%	0.24	0.54		33	2.9%	0.09	0.47		8	0.7%	0.10	1.41	
Age 61-70	5,270	100.0%	229	4.3%				101	1.9%				37	0.7%			
BP User	2,631	49.9%	41	1.6%	0.21		<0.001	7	0.3%	0.07		<0.001	2	0.1%	0.06		<0.001
BP Non-user	2,639	50.1%	188	7.1%	0.15	0.29		94	3.6%	0.03	0.16		35	1.3%	0.01	0.24	
Age 71-80	7,200	100.0%	285	4.0%				140	1.9%				51	0.7%			
BP User	3,600	50.0%	52	1.4%	0.21		<0.001	19	0.5%	0.15		<0.001	7	0.2%	0.16		<0.001
BP Non-user	3,600	50.0%	233	6.5%	0.16	0.29		121	3.4%	0.09	0.25		44	1.2%	0.07	0.35	
Age ≥81	5,553	100.0%	180	3.2%				93	1.7%				39	0.7%			
BP User	2,777	50.0%	36	1.3%	0.24		<0.001	24	0.9%	0.34		<0.001	7	0.3%	0.22		<0.001
BP Non-user	2,776	50.0%	144	5.2%	0.17	0.35		69	2.5%	0.21	0.55		32	1.2%	0.10	0.49	

BP: bisphosphonate; LL: lower 95% confidence interval level; NA: not applicable; OR: odds ratio; UL: upper 95% confidence interval level

2635  
2636

2637  
2638  
2639

**Table S3f: Unadjusted COVID-19-Related Outcomes Stratified by Age, Sex, & Age by Sex; Matched Primary Analysis Cohort, Region=New York State**

Region=New York State Matched																	
	All		SARS-CoV-2 Test				COVID-19 Diagnosis				COVID-19 Hospitalization						
	N	%	N	%	OR		p-value	N	%	OR		p-value	N	%	OR		p-value
					LL	UL				LL	UL				LL	UL	
<b>All Patients</b>	<b>99,724</b>	<b>100.0%</b>	<b>3,598</b>	<b>3.6%</b>				<b>3,607</b>	<b>3.6%</b>				<b>622</b>	<b>0.6%</b>			
BP User	49,862	50.0%	772	1.5%	0.26		<0.001	811	1.6%	0.28		<0.001	136	0.3%	0.28		<0.001
BP Non-user	49,862	50.0%	2,826	5.7%	0.24	0.28		2,796	5.6%	0.26	0.30		486	1.0%	0.23	0.34	
<b>By Age</b>																	
Age ≤20	102	100.0%	4	3.9%				2	2.0%				1	1.0%			
BP User	50	49.0%	2	4.0%	1.04		1.00	1	2.0%	1.04		1.00	1	2.0%	NA		NA
BP Non-user	52	51.0%	2	3.8%	0.14	7.69		1	1.9%	0.06	17.11		0	0.0%	NA	NA	
Age 21-40	453	100.0%	21	4.6%				15	3.3%				1	0.2%			
BP User	228	50.3%	3	1.3%	0.15		<0.001	2	0.9%	0.14		0.004	1	0.4%	NA		NA
BP Non-user	225	49.7%	18	8.0%	0.04	0.53		13	5.8%	0.03	0.65		0	0.0%	NA	NA	
Age 41-50	1,311	100.0%	77	5.9%				36	2.7%				4	0.3%			
BP User	655	50.0%	22	3.4%	0.38		<0.001	8	1.2%	0.28		<0.001	1	0.2%	0.33		0.62
BP Non-user	656	50.0%	55	8.4%	0.23	0.63		28	4.3%	0.13	0.61		3	0.5%	0.03	3.21	
Age 51-60	12,732	100.0%	688	5.4%				527	4.1%				58	0.5%			
BP User	6,364	50.0%	155	2.4%	0.27		<0.001	118	1.9%	0.28		<0.001	17	0.3%	0.41		0.002
BP Non-user	6,368	50.0%	533	8.4%	0.23	0.33		409	6.4%	0.22	0.34		41	0.6%	0.23	0.73	
Age 61-70	32,265	100.0%	1,294	4.0%				1,150	3.6%				141	0.4%			
BP User	16,136	50.0%	277	1.7%	0.26		<0.001	267	1.7%	0.29		<0.001	27	0.2%	0.24		<0.001
BP Non-user	16,129	50.0%	1,017	6.3%	0.23	0.30		883	5.5%	0.25	0.33		114	0.7%	0.15	0.36	
Age 71-80	34,693	100.0%	957	2.8%				1,196	3.4%				240	0.7%			
BP User	17,341	50.0%	204	1.2%	0.26		<0.001	257	1.5%	0.26		<0.001	45	0.3%	0.23		<0.001
BP Non-user	17,352	50.0%	753	4.3%	0.22	0.31		939	5.4%	0.23	0.30		195	1.1%	0.17	0.32	
Age ≥81	18,168	100.0%	557	3.1%				681	3.7%				177	1.0%			
BP User	9,088	50.0%	109	1.2%	0.23		<0.001	158	1.7%	0.29		<0.001	44	0.5%	0.33		<0.001
BP Non-user	9,080	50.0%	448	4.9%	0.19	0.29		523	5.8%	0.24	0.35		133	1.5%	0.23	0.46	
<b>Female Patients</b>	<b>90,567</b>	<b>100.0%</b>	<b>3,255</b>	<b>3.6%</b>				<b>3,235</b>	<b>3.6%</b>				<b>537</b>	<b>0.6%</b>			
BP User	45,285	50.0%	687	1.5%	0.26		<0.001	726	1.6%	0.28		<0.001	108	0.2%	0.25		<0.001
BP Non-user	45,282	50.0%	2,568	5.7%	0.24	0.28		2,509	5.5%	0.26	0.30		429	0.9%	0.20	0.31	
<b>By Age</b>																	
Age ≤20	33	100.0%	0	0.0%				1	3.0%				1	3.0%			
BP User	16	48.5%	0	0.0%	NA		NA	1	6.3%	NA		NA	1	6.3%	NA		NA
BP Non-user	17	51.5%	0	0.0%	NA	NA		0	0.0%	NA	NA		0	0.0%	NA	NA	
Age 21-40	261	100.0%	16	6.1%				8	3.1%				1	0.4%			
BP User	132	50.6%	2	1.5%	0.13		0.002	2	1.5%	0.32		0.17	1	0.8%	NA		NA
BP Non-user	129	49.4%	14	10.9%	0.03	0.57		6	4.7%	0.06	1.59		0	0.0%	NA	NA	
Age 41-50	1,032	100.0%	58	5.6%				28	2.7%				3	0.3%			
BP User	516	50.0%	18	3.5%	0.43		0.003	7	1.4%	0.32		0.007	0	0.0%	NA		NA
BP Non-user	516	50.0%	40	7.8%	0.24	0.76		21	4.1%	0.14	0.77		3	0.6%	NA	NA	
Age 51-60	11,699	100.0%	637	5.4%				482	4.1%				47	0.4%			
BP User	5,849	50.0%	138	2.4%	0.26		<0.001	110	1.9%	0.28		<0.001	14	0.2%	0.42		0.006
BP Non-user	5,850	50.0%	499	8.5%	0.21	0.31		372	6.4%	0.23	0.35		33	0.6%	0.23	0.79	
Age 61-70	30,115	100.0%	1,204	4.0%				1,070	3.6%				126	0.4%			

BP User	15,060	50.0%	257	1.7%	0.26		<0.001	248	1.6%	0.29		<0.001	23	0.2%	0.22		<0.001
BP Non-user	15,055	50.0%	947	6.3%	0.22	0.30		822	5.5%	0.25	0.33		103	0.7%	0.14	0.35	
Age 71-80	31,385	100.0%	858	2.7%				1,052	3.4%				208	0.7%			
BP User	15,688	50.0%	176	1.1%	0.25		<0.001	221	1.4%	0.26		<0.001	33	0.2%	0.19		<0.001
BP Non-user	15,697	50.0%	682	4.3%	0.21	0.30		831	5.3%	0.22	0.30		175	1.1%	0.13	0.27	
Age ≥81	16,042	100.0%	482	3.0%				594	3.7%				151	0.9%			
BP User	8,024	50.0%	96	1.2%	0.24		<0.001	137	1.7%	0.29		<0.001	36	0.4%	0.31		<0.001
BP Non-user	8,018	50.0%	386	4.8%	0.19	0.30		457	5.7%	0.24	0.35		115	1.4%	0.21	0.45	
<b>Male Patients</b>	<b>9,157</b>	<b>100.0%</b>	<b>343</b>	<b>3.7%</b>				<b>372</b>	<b>4.1%</b>				<b>85</b>	<b>0.9%</b>			
BP User	4,577	50.0%	85	1.9%	0.32		<0.001	85	1.9%	0.28		<0.001	28	0.6%	0.49		0.002
BP Non-user	4,580	50.0%	258	5.6%	0.25	0.41		287	6.3%	0.22	0.36		57	1.2%	0.31	0.77	
<b>By Age</b>																	
Age ≤20	69	100.0%	4	5.8%				1	1.4%				0	0.0%			
BP User	34	49.3%	2	5.9%	1.03		1.00	0	0.0%	NA		NA	0	0.0%	NA		NA
BP Non-user	35	50.7%	2	5.7%	0.14	7.77		1	2.9%	NA	NA		0	0.0%	NA	NA	
Age 21-40	192	100.0%	5	2.6%				7	3.6%				0	0.0%			
BP User	96	50.0%	1	1.0%	0.24		0.37	0	0.0%	NA		NA	0	0.0%	NA		NA
BP Non-user	96	50.0%	4	4.2%	0.03	2.21		7	7.3%	NA	NA		0	0.0%	NA	NA	
Age 41-50	279	100.0%	19	6.8%				8	2.9%				1	0.4%			
BP User	139	49.8%	4	2.9%	0.25		0.02	1	0.7%	0.14		0.07	1	0.7%	NA		NA
BP Non-user	140	50.2%	15	10.7%	0.08	0.76		7	5.0%	0.02	1.13		0	0.0%	NA	NA	
Age 51-60	1,033	100.0%	51	4.9%				45	4.4%				11	1.1%			
BP User	515	49.9%	17	3.3%	0.49		0.02	8	1.6%	0.21		<0.001	3	0.6%	0.37		0.22
BP Non-user	518	50.1%	34	6.6%	0.27	0.88		37	7.1%	0.09	0.44		8	1.5%	0.10	1.42	
Age 61-70	2,150	100.0%	90	4.2%				80	3.7%				15	0.7%			
BP User	1,076	50.0%	20	1.9%	0.27		<0.001	19	1.8%	0.30		<0.001	4	0.4%	0.36		0.08
BP Non-user	1,074	50.0%	70	6.5%	0.16	0.45		61	5.7%	0.18	0.50		11	1.0%	0.11	1.14	
Age 71-80	3,308	100.0%	99	3.0%				144	4.4%				32	1.0%			
BP User	1,653	50.0%	28	1.7%	0.38		<0.001	36	2.2%	0.32		<0.001	12	0.7%	0.60		0.16
BP Non-user	1,655	50.0%	71	4.3%	0.25	0.60		108	6.5%	0.22	0.47		20	1.2%	0.29	1.23	
Age ≥81	2,126	100.0%	75	3.5%				87	4.1%				26	1.2%			
BP User	1,064	50.0%	13	1.2%	0.20		<0.001	21	2.0%	0.30		<0.001	8	0.8%	0.44		0.05
BP Non-user	1,062	50.0%	62	5.8%	0.11	0.37		66	6.2%	0.18	0.50		18	1.7%	0.19	1.02	

BP: bisphosphonate; LL: lower 95% confidence interval level; NA: not applicable; OR: odds ratio; UL: upper 95% confidence interval level

2640  
2641

2642  
2643  
2644

**Table S4: ‘Bone-Rx’ Cohort Unadjusted/Adjusted Odds Ratio for COVID-19-Related Outcomes, Stratified by Region and New York State**

		SARS-CoV-2 Test				COVID-19 Diagnosis				COVID-19 Hospitalization			
		OR	LL	UL	p value	OR	LL	UL	p value	OR	LL	UL	p value
All	Unadjusted	0.22	0.21	0.22	<0.001	0.22	0.21	0.23	<0.001	0.24	0.22	0.26	<0.001
	Adjusted	0.22	0.21	0.23	<0.001	0.23	0.22	0.24	<0.001	0.26	0.24	0.29	<0.001
Northeast	Unadjusted	0.22	0.21	0.24	<0.001	0.24	0.23	0.26	<0.001	0.26	0.23	0.30	<0.001
	Adjusted	0.23	0.21	0.24	<0.001	0.25	0.23	0.26	<0.001	0.29	0.26	0.33	<0.001
Midwest	Unadjusted	0.23	0.22	0.25	<0.001	0.22	0.20	0.25	<0.001	0.23	0.19	0.29	<0.001
	Adjusted	0.24	0.22	0.26	<0.001	0.24	0.22	0.27	<0.001	0.26	0.21	0.32	<0.001
South	Unadjusted	0.22	0.21	0.23	<0.001	0.21	0.19	0.23	<0.001	0.24	0.21	0.29	<0.001
	Adjusted	0.22	0.21	0.23	<0.001	0.22	0.20	0.24	<0.001	0.26	0.23	0.30	<0.001
West	Unadjusted	0.19	0.18	0.21	<0.001	0.18	0.16	0.20	<0.001	0.19	0.15	0.23	<0.001
	Adjusted	0.20	0.18	0.21	<0.001	0.19	0.17	0.21	<0.001	0.20	0.16	0.25	<0.001
New York	Unadjusted	0.26	0.24	0.28	<0.001	0.28	0.26	0.30	<0.001	0.28	0.23	0.34	<0.001
	Adjusted	0.26	0.24	0.28	<0.001	0.28	0.26	0.31	<0.001	0.33	0.27	0.40	<0.001

2645

LL: lower 95% confidence interval level; OR: odds ratio; UL: upper 95% confidence interval level



2646  
2647  
2648

**Table S5a: Statin Use Sensitivity Analysis, Unadjusted/Adjusted Odds Ratio for COVID-19-Related Outcomes, Stratified by Region and New York State**

		SARS-CoV-2 Test				COVID-19 Diagnosis				COVID-19 Hospitalization			
		Statin Uses versus Non-users											
		OR	LL	UL	p value	OR	LL	UL	p value	OR	LL	UL	p value
All	Unadjusted	0.90	0.89	0.91	<0.001	0.91	0.90	0.92	<0.001	1.12	1.09	1.15	<0.001
	Adjusted	0.87	0.86	0.87	<0.001	0.79	0.78	0.81	<0.001	0.99	0.96	1.02	0.48
Northeast	Unadjusted	0.87	0.85	0.88	<0.001	0.88	0.86	0.90	<0.001	1.16	1.11	1.21	<0.001
	Adjusted	0.85	0.84	0.87	<0.001	0.77	0.75	0.78	<0.001	1.03	0.98	1.07	0.22
Midwest	Unadjusted	0.97	0.95	0.99	0.02	1.10	1.07	1.14	<0.001	1.27	1.19	1.36	<0.001
	Adjusted	0.92	0.90	0.94	<0.001	0.99	0.96	1.03	0.75	1.15	1.08	1.23	<0.001
South	Unadjusted	0.90	0.88	0.91	<0.001	0.90	0.88	0.93	<0.001	1.00	0.95	1.06	0.90
	Adjusted	0.85	0.84	0.87	<0.001	0.80	0.78	0.83	<0.001	0.88	0.83	0.94	<0.001
West	Unadjusted	0.88	0.86	0.90	<0.001	0.83	0.80	0.86	<0.001	1.02	0.95	1.10	0.58
	Adjusted	0.86	0.83	0.88	<0.001	0.71	0.68	0.74	<0.001	0.87	0.80	0.94	<0.001
New York	Unadjusted	0.91	0.89	0.93	<0.001	0.93	0.91	0.96	<0.001	1.21	1.14	1.29	<0.001
	Adjusted	0.92	0.90	0.95	<0.001	0.79	0.77	0.82	<0.001	1.05	0.98	1.13	0.15
		BP Users versus BP Non-users among Statin Users											
		OR	LL	UL	p value	OR	LL	UL	p value	OR	LL	UL	p value
All	Unadjusted	0.23	0.22	0.24	<0.001	0.26	0.25	0.28	<0.001	0.26	0.23	0.29	<0.001
	Adjusted	0.23	0.22	0.24	<0.001	0.27	0.25	0.29	<0.001	0.28	0.25	0.32	<0.001
Northeast	Unadjusted	0.25	0.23	0.27	<0.001	0.29	0.27	0.31	<0.001	0.28	0.24	0.34	<0.001
	Adjusted	0.25	0.23	0.27	<0.001	0.29	0.27	0.32	<0.001	0.32	0.26	0.38	<0.001
Midwest	Unadjusted	0.24	0.22	0.27	<0.001	0.22	0.19	0.25	<0.001	0.21	0.16	0.27	<0.001
	Adjusted	0.25	0.23	0.29	<0.001	0.23	0.22	0.25	<0.001	0.22	0.17	0.30	<0.001
South	Unadjusted	0.22	0.21	0.24	<0.001	0.26	0.23	0.29	<0.001	0.26	0.21	0.33	<0.001
	Adjusted	0.22	0.20	0.24	<0.001	0.27	0.24	0.31	<0.001	0.28	0.22	0.36	<0.001
West	Unadjusted	0.20	0.18	0.22	<0.001	0.22	0.19	0.25	<0.001	0.25	0.20	0.33	<0.001
	Adjusted	0.20	0.18	0.22	<0.001	0.23	0.20	0.27	<0.001	0.28	0.21	0.36	<0.001
New York	Unadjusted	0.27	0.24	0.30	<0.001	0.31	0.28	0.35	<0.001	0.30	0.23	0.39	<0.001
	Adjusted	0.28	0.25	0.32	<0.001	0.31	0.28	0.35	<0.001	0.33	0.25	0.44	<0.001
		BP Users versus BP Non-users among Statin Non-users											
		OR	LL	UL	p value	OR	LL	UL	p value	OR	LL	UL	p value
All	Unadjusted	0.23	0.21	0.24	<0.001	0.21	0.19	0.23	<0.001	0.21	0.17	0.25	<0.001
	Adjusted	0.24	0.22	0.25	<0.001	0.23	0.21	0.25	<0.001	0.25	0.21	0.30	<0.001
Northeast	Unadjusted	0.25	0.22	0.27	<0.001	0.22	0.20	0.25	<0.001	0.24	0.19	0.31	<0.001
	Adjusted	0.26	0.23	0.29	<0.001	0.25	0.22	0.28	<0.001	0.29	0.22	0.37	<0.001
Midwest	Unadjusted	0.24	0.21	0.28	<0.001	0.22	0.18	0.27	<0.001	0.21	0.14	0.31	<0.001
	Adjusted	0.24	0.20	0.28	<0.001	0.25	0.20	0.32	<0.001	0.26	0.17	0.39	<0.001
South	Unadjusted	0.23	0.21	0.25	<0.001	0.19	0.15	0.22	<0.001	0.18	0.12	0.27	<0.001
	Adjusted	0.24	0.21	0.27	<0.001	0.21	0.17	0.25	<0.001	0.22	0.15	0.33	<0.001
West	Unadjusted	0.19	0.17	0.22	<0.001	0.18	0.15	0.22	<0.001	0.16	0.11	0.25	<0.001
	Adjusted	0.20	0.17	0.23	<0.001	0.19	0.18	0.21	<0.001	0.18	0.11	0.29	<0.001
New York	Unadjusted	0.26	0.23	0.30	<0.001	0.26	0.22	0.30	<0.001	0.27	0.19	0.39	<0.001
	Adjusted	0.26	0.22	0.31	<0.001	0.25	0.21	0.30	<0.001	0.35	0.23	0.52	<0.001

2649

LL: lower 95% confidence interval level; OR: odds ratio; UL: upper 95% confidence interval level

2650  
2651  
2652

**Table S5b: Antihypertensive Use Sensitivity Analysis, Unadjusted/Adjusted Odds Ratio for COVID-19-Related Outcomes, Stratified by Region and New York State**

		Odds of SARS-CoV-2 Test				Odds of COVID-19 Diagnosis				Odds of COVID-19 Hospitalization			
		Antihypertensive Users versus Non-users											
		OR	LL	UL	p value	OR	LL	UL	p value	OR	LL	UL	p value
All	Unadjusted	0.91	0.90	0.92	<0.001	0.86	0.85	0.87	<0.001	1.13	1.10	1.17	<0.001
	Adjusted	0.87	0.86	0.88	<0.001	0.75	0.74	0.76	<0.001	0.98	0.95	1.00	0.10
Northeast	Unadjusted	0.86	0.84	0.87	<0.001	0.83	0.82	0.85	<0.001	1.20	1.15	1.25	<0.001
	Adjusted	0.82	0.81	0.83	<0.001	0.72	0.71	0.73	<0.001	1.04	0.99	1.08	0.10
Midwest	Unadjusted	1.00	0.98	1.02	0.98	1.06	1.03	1.10	<0.001	1.28	1.20	1.36	<0.001
	Adjusted	0.94	0.91	0.96	<0.001	0.94	0.90	0.97	<0.001	1.11	1.04	1.19	0.002
South	Unadjusted	0.93	0.92	0.94	<0.001	0.88	0.86	0.90	<0.001	1.02	0.96	1.07	0.58
	Adjusted	0.88	0.87	0.89	<0.001	0.78	0.76	0.80	<0.001	0.89	0.84	0.94	<0.001
West	Unadjusted	0.90	0.88	0.92	<0.001	0.75	0.73	0.78	<0.001	0.99	0.92	1.06	0.83
	Adjusted	0.87	0.85	0.89	<0.001	0.65	0.62	0.67	<0.001	0.84	0.78	0.90	<0.001
New York	Unadjusted	0.92	0.90	0.94	<0.001	0.90	0.87	0.92	<0.001	1.23	1.15	1.31	<0.001
	Adjusted	0.90	0.87	0.92	<0.001	0.75	0.73	0.77	<0.001	1.01	0.95	1.09	0.70
		BP Users versus BP Non-users among Antihypertensive Users											
		OR	LL	UL	p value	OR	LL	UL	p value	OR	LL	UL	p value
All	Unadjusted	0.23	0.22	0.24	<0.001	0.26	0.25	0.28	<0.001	0.26	0.23	0.29	<0.001
	Adjusted	0.23	0.22	0.24	<0.001	0.26	0.25	0.28	<0.001	0.27	0.24	0.30	<0.001
Northeast	Unadjusted	0.24	0.22	0.26	<0.001	0.28	0.26	0.31	<0.001	0.27	0.22	0.32	<0.001
	Adjusted	0.23	0.21	0.26	<0.001	0.28	0.26	0.31	<0.001	0.29	0.24	0.34	<0.001
Midwest	Unadjusted	0.26	0.23	0.29	<0.001	0.27	0.23	0.31	<0.001	0.27	0.21	0.35	<0.001
	Adjusted	0.27	0.24	0.30	<0.001	0.28	0.26	0.30	<0.001	0.27	0.20	0.35	<0.001
South	Unadjusted	0.23	0.21	0.25	<0.001	0.24	0.22	0.28	<0.001	0.26	0.20	0.32	<0.001
	Adjusted	0.23	0.21	0.25	<0.001	0.24	0.21	0.28	<0.001	0.25	0.20	0.32	<0.001
West	Unadjusted	0.20	0.18	0.22	<0.001	0.21	0.18	0.25	<0.001	0.24	0.18	0.31	<0.001
	Adjusted	0.20	0.18	0.22	<0.001	0.22	0.18	0.25	<0.001	0.24	0.18	0.33	<0.001
New York	Unadjusted	0.26	0.23	0.29	<0.001	0.30	0.26	0.33	<0.001	0.29	0.22	0.38	<0.001
	Adjusted	0.25	0.22	0.29	<0.001	0.30	0.26	0.34	<0.001	0.33	0.24	0.44	<0.001
		BP Users versus BP Non-users among Antihypertensive Non-users											
		OR	LL	UL	p value	OR	LL	UL	p value	OR	LL	UL	p value
All	Unadjusted	0.21	0.20	0.22	<0.001	0.20	0.18	0.22	<0.001	0.21	0.17	0.25	<0.001
	Adjusted	0.21	0.20	0.22	<0.001	0.22	0.20	0.24	<0.001	0.27	0.22	0.32	<0.001
Northeast	Unadjusted	0.21	0.19	0.23	<0.001	0.22	0.19	0.24	<0.001	0.23	0.18	0.31	<0.001
	Adjusted	0.22	0.20	0.25	<0.001	0.25	0.22	0.28	<0.001	0.30	0.22	0.40	<0.001
Midwest	Unadjusted	0.22	0.19	0.25	<0.001	0.16	0.12	0.20	<0.001	0.20	0.13	0.31	<0.001
	Adjusted	0.21	0.18	0.25	<0.001	0.18	0.14	0.23	<0.001	0.26	0.16	0.42	<0.001
South	Unadjusted	0.20	0.18	0.22	<0.001	0.19	0.16	0.22	<0.001	0.22	0.15	0.32	<0.001
	Adjusted	0.20	0.18	0.22	<0.001	0.21	0.17	0.25	<0.001	0.28	0.19	0.41	<0.001
West	Unadjusted	0.19	0.17	0.22	<0.001	0.18	0.15	0.22	<0.001	0.15	0.09	0.24	<0.001
	Adjusted	0.20	0.17	0.22	<0.001	0.20	0.16	0.25	<0.001	0.19	0.11	0.32	<0.001
New York	Unadjusted	0.26	0.23	0.31	<0.001	0.25	0.21	0.29	<0.001	0.23	0.15	0.36	<0.001
	Adjusted	0.27	0.23	0.32	<0.001	0.26	0.22	0.31	<0.001	0.26	0.16	0.43	<0.001

LL: lower 95% confidence interval level; OR: odds ratio; UL: upper 95% confidence interval level

2653  
2654

2655  
2656  
2657

**Table S5c: Antidiabetic Use Sensitivity Analysis, Unadjusted/Adjusted Odds Ratio for COVID-19-Related Outcomes, Stratified by Region and New York State**

		Odds of SARS-CoV-2 Test				Odds of COVID-19 Diagnosis				Odds of COVID-19 Hospitalization			
		Antidiabetic Users versus Non-users											
		OR	LL	UL	p value	OR	LL	UL	p value	OR	LL	UL	p value
All	Unadjusted	0.98	0.97	0.99	0.01	1.15	1.13	1.18	<0.001	1.50	1.45	1.56	<0.001
	Adjusted	0.92	0.90	0.93	<0.001	0.88	0.86	0.90	<0.001	1.13	1.08	1.18	<0.001
Northeast	Unadjusted	1.00	0.98	1.02	0.92	1.11	1.09	1.14	<0.001	1.55	1.47	1.64	<0.001
	Adjusted	0.94	0.92	0.97	<0.001	0.84	0.81	0.86	<0.001	1.18	1.11	1.27	<0.001
Midwest	Unadjusted	1.04	1.01	1.08	0.01	1.39	1.33	1.46	<0.001	1.61	1.47	1.76	<0.001
	Adjusted	0.95	0.91	0.99	0.01	1.11	1.04	1.17	<0.001	1.30	1.17	1.44	<0.001
South	Unadjusted	0.97	0.95	0.99	0.01	1.16	1.12	1.21	<0.001	1.39	1.29	1.50	<0.001
	Adjusted	0.90	0.88	0.93	<0.001	0.91	0.87	0.95	<0.001	1.04	0.95	1.14	0.40
West	Unadjusted	0.91	0.88	0.94	<0.001	1.07	1.01	1.12	0.01	1.43	1.30	1.58	<0.001
	Adjusted	0.86	0.82	0.89	<0.001	0.80	0.75	0.85	<0.001	0.97	0.86	1.09	0.60
New York	Unadjusted	1.06	1.03	1.10	<0.001	1.15	1.11	1.19	<0.001	1.59	1.46	1.72	<0.001
	Adjusted	1.06	1.02	1.10	0.007	0.87	0.83	0.90	<0.001	1.18	1.07	1.30	0.001
		BP Users versus BP Non-users among Antidiabetic Users											
		OR	LL	UL	p value	OR	LL	UL	p value	OR	LL	UL	p value
All	Unadjusted	0.26	0.24	0.28	<0.001	0.29	0.27	0.32	<0.001	0.28	0.24	0.33	<0.001
	Adjusted	0.26	0.24	0.28	<0.001	0.29	0.27	0.32	<0.001	0.29	0.25	0.34	<0.001
Northeast	Unadjusted	0.28	0.24	0.32	<0.001	0.32	0.28	0.35	<0.001	0.29	0.23	0.36	<0.001
	Adjusted	0.28	0.24	0.32	<0.001	0.31	0.27	0.35	<0.001	0.30	0.24	0.39	<0.001
Midwest	Unadjusted	0.27	0.22	0.33	<0.001	0.30	0.24	0.38	<0.001	0.28	0.19	0.41	<0.001
	Adjusted	0.27	0.22	0.34	<0.001	0.32	0.26	0.41	<0.001	0.29	0.19	0.42	<0.001
South	Unadjusted	0.29	0.26	0.33	<0.001	0.31	0.26	0.36	<0.001	0.35	0.26	0.47	<0.001
	Adjusted	0.30	0.26	0.34	<0.001	0.30	0.25	0.36	<0.001	0.36	0.26	0.48	<0.001
West	Unadjusted	0.19	0.16	0.22	<0.001	0.20	0.17	0.25	<0.001	0.21	0.15	0.30	<0.001
	Adjusted	0.19	0.16	0.23	<0.001	0.21	0.17	0.26	<0.001	0.22	0.15	0.31	<0.001
New York	Unadjusted	0.33	0.27	0.40	<0.001	0.34	0.29	0.39	<0.001	0.35	0.26	0.49	<0.001
	Adjusted	0.32	0.26	0.40	<0.001	0.32	0.28	0.36	<0.001	0.40	0.28	0.56	<0.001
		BP Users versus BP Non-users among Antidiabetic Non-users											
		OR	LL	UL	p value	OR	LL	UL	p value	OR	LL	UL	p value
All	Unadjusted	0.24	0.23	0.26	<0.001	0.24	0.22	0.26	<0.001	0.24	0.20	0.29	<0.001
	Adjusted	0.25	0.23	0.27	<0.001	0.25	0.23	0.28	<0.001	0.27	0.22	0.33	<0.001
Northeast	Unadjusted	0.24	0.22	0.28	<0.001	0.26	0.22	0.29	<0.001	0.25	0.19	0.34	<0.001
	Adjusted	0.25	0.22	0.29	<0.001	0.27	0.24	0.32	<0.001	0.28	0.20	0.39	<0.001
Midwest	Unadjusted	0.27	0.22	0.32	<0.001	0.22	0.17	0.30	<0.001	0.26	0.16	0.42	<0.001
	Adjusted	0.28	0.24	0.31	<0.001	0.23	0.17	0.31	<0.001	0.26	0.16	0.45	<0.001
South	Unadjusted	0.24	0.21	0.27	<0.001	0.25	0.20	0.30	<0.001	0.29	0.20	0.43	<0.001
	Adjusted	0.24	0.21	0.27	<0.001	0.24	0.21	0.28	<0.001	0.33	0.22	0.49	<0.001
West	Unadjusted	0.23	0.20	0.27	<0.001	0.18	0.14	0.24	<0.001	0.13	0.07	0.23	<0.001
	Adjusted	0.23	0.20	0.28	<0.001	0.20	0.15	0.26	<0.001	0.15	0.08	0.28	<0.001
New York	Unadjusted	0.30	0.25	0.37	<0.001	0.30	0.25	0.36	<0.001	0.22	0.14	0.36	<0.001
	Adjusted	0.30	0.25	0.37	<0.001	0.31	0.25	0.37	<0.001	0.24	0.14	0.41	<0.001

LL: lower 95% confidence interval level; OR: odds ratio; UL: upper 95% confidence interval level

2658  
2659

2660  
2661  
2662

**Table S5d: Antidepressant Use Sensitivity Analysis, Unadjusted/Adjusted Odds Ratio for COVID-19-Related Outcomes, Stratified by Region and New York State**

		Odds of SARS-CoV-2 Test				Odds of COVID-19 Diagnosis				Odds of COVID-19 Hospitalization			
		Antidepressant Users versus Non-users											
		OR	LL	UL	p value	OR	LL	UL	p value	OR	LL	UL	p value
All	Unadjusted	1.04	1.03	1.05	<0.001	0.71	0.70	0.72	<0.001	0.81	0.78	0.83	<0.001
	Adjusted	1.00	0.99	1.01	0.61	0.65	0.64	0.66	<0.001	0.75	0.73	0.78	<0.001
Northeast	Unadjusted	1.01	0.99	1.02	0.54	0.71	0.69	0.72	<0.001	0.84	0.80	0.88	<0.001
	Adjusted	0.97	0.95	0.99	0.001	0.65	0.63	0.66	<0.001	0.77	0.73	0.82	<0.001
Midwest	Unadjusted	1.10	1.08	1.12	<0.001	0.75	0.72	0.78	<0.001	0.84	0.78	0.90	<0.001
	Adjusted	1.05	1.03	1.07	<0.001	0.69	0.66	0.71	<0.001	0.78	0.73	0.84	<0.001
South	Unadjusted	1.04	1.02	1.05	<0.001	0.68	0.66	0.70	<0.001	0.74	0.70	0.79	<0.001
	Adjusted	0.99	0.98	1.01	0.49	0.64	0.62	0.66	<0.001	0.72	0.68	0.77	<0.001
West	Unadjusted	1.04	1.02	1.06	0.00	0.70	0.67	0.73	<0.001	0.77	0.70	0.84	<0.001
	Adjusted	0.99	0.97	1.02	0.46	0.64	0.61	0.66	<0.001	0.70	0.64	0.77	<0.001
New York	Unadjusted	1.00	0.97	1.03	0.86	0.77	0.74	0.80	<0.001	0.83	0.76	0.91	<0.001
	Adjusted	0.98	0.95	1.01	0.27	0.72	0.70	0.75	<0.001	0.77	0.70	0.85	<0.001
		BP Users versus BP Non-users among Antidepressant Users											
		OR	LL	UL	p value	OR	LL	UL	p value	OR	LL	UL	p value
All	Unadjusted	0.27	0.26	0.28	<0.001	0.30	0.28	0.32	<0.001	0.31	0.27	0.36	<0.001
	Adjusted	0.27	0.25	0.28	<0.001	0.30	0.28	0.32	<0.001	0.33	0.28	0.38	<0.001
Northeast	Unadjusted	0.28	0.26	0.31	<0.001	0.33	0.30	0.37	<0.001	0.36	0.29	0.45	<0.001
	Adjusted	0.28	0.25	0.30	<0.001	0.32	0.29	0.36	<0.001	0.37	0.29	0.47	<0.001
Midwest	Unadjusted	0.30	0.27	0.34	<0.001	0.26	0.22	0.31	<0.001	0.25	0.18	0.34	<0.001
	Adjusted	0.30	0.26	0.34	<0.001	0.27	0.22	0.33	<0.001	0.26	0.18	0.36	<0.001
South	Unadjusted	0.26	0.24	0.29	<0.001	0.27	0.23	0.31	<0.001	0.32	0.24	0.41	<0.001
	Adjusted	0.26	0.24	0.28	<0.001	0.27	0.23	0.32	<0.001	0.32	0.24	0.43	<0.001
West	Unadjusted	0.25	0.22	0.28	<0.001	0.27	0.22	0.32	<0.001	0.29	0.20	0.41	<0.001
	Adjusted	0.24	0.21	0.27	<0.001	0.29	0.28	0.30	<0.001	0.33	0.23	0.48	<0.001
New York	Unadjusted	0.30	0.26	0.34	<0.001	0.33	0.28	0.38	<0.001	0.24	0.16	0.36	<0.001
	Adjusted	0.30	0.25	0.34	<0.001	0.31	0.27	0.37	<0.001	0.25	0.16	0.39	<0.001
		BP Users versus BP Non-users among Antidepressant Non-users											
		OR	LL	UL	p value	OR	LL	UL	p value	OR	LL	UL	p value
All	Unadjusted	0.20	0.19	0.22	<0.001	0.22	0.20	0.24	<0.001	0.24	0.20	0.28	<0.001
	Adjusted	0.21	0.19	0.22	<0.001	0.23	0.21	0.25	<0.001	0.27	0.22	0.32	<0.001
Northeast	Unadjusted	0.21	0.19	0.24	<0.001	0.23	0.20	0.26	<0.001	0.25	0.19	0.32	<0.001
	Adjusted	0.22	0.19	0.25	<0.001	0.24	0.22	0.25	<0.001	0.29	0.22	0.39	<0.001
Midwest	Unadjusted	0.22	0.19	0.26	<0.001	0.23	0.18	0.28	<0.001	0.28	0.19	0.39	<0.001
	Adjusted	0.21	0.18	0.25	<0.001	0.26	0.24	0.27	<0.001	0.32	0.22	0.47	<0.001
South	Unadjusted	0.20	0.18	0.22	<0.001	0.21	0.18	0.25	<0.001	0.21	0.15	0.30	<0.001
	Adjusted	0.20	0.18	0.23	<0.001	0.23	0.19	0.27	<0.001	0.22	0.16	0.32	<0.001
West	Unadjusted	0.18	0.16	0.21	<0.001	0.20	0.16	0.25	<0.001	0.20	0.13	0.30	<0.001
	Adjusted	0.19	0.16	0.22	<0.001	0.20	0.20	0.21	<0.001	0.22	0.14	0.35	<0.001
New York	Unadjusted	0.26	0.22	0.32	<0.001	0.27	0.23	0.32	<0.001	0.29	0.19	0.43	<0.001
	Adjusted	0.26	0.23	0.30	<0.001	0.26	0.22	0.32	<0.001	0.35	0.22	0.54	<0.001

LL: lower 95% confidence interval level; OR: odds ratio; UL: upper 95% confidence interval level

2663  
2664

2665  
2666

**Table S6a: “Bone-Rx” Cohort (All Regions), Patient Characteristics Pre/Post Match**

	"Bone-Rx" Cohort / All Observations Unmatched							"Bone-Rx" Cohort / All Observations Matched						
	All		BP Non-user		BP User		p-value	All		BP Non-user		BP User		p-value
	N	%	N	%	N	%		N	%	N	%	N	%	
<b>All Patients</b>	<b>502,895</b>	<b>100.0%</b>	<b>50,844</b>	<b>10.1%</b>	<b>452,051</b>	<b>89.9%</b>		<b>100,996</b>	<b>100.0%</b>	<b>50,498</b>	<b>50.0%</b>	<b>50,498</b>	<b>50.0%</b>	
<b>Age</b>														
≤20	1,164	0.2%	36	0.1%	1,128	0.2%	<0.001	67	0.1%	36	0.1%	31	0.1%	0.97
21-40	3,501	0.7%	410	0.8%	3,091	0.7%		790	0.8%	403	0.8%	387	0.8%	
41-50	9,631	1.9%	1,080	2.1%	8,551	1.9%		2,107	2.1%	1,069	2.1%	1,038	2.1%	
51-60	72,139	14.3%	6,418	12.6%	65,721	14.5%		12,777	12.7%	6,395	12.7%	6,382	12.6%	
61-70	171,687	34.1%	14,809	29.1%	156,878	34.7%		29,509	29.2%	14,751	29.2%	14,758	29.2%	
71-80	157,877	31.4%	16,152	31.8%	141,725	31.4%		32,129	31.8%	16,055	31.8%	16,074	31.8%	
≥81	86,896	17.3%	11,939	23.5%	74,957	16.6%		23,617	23.4%	11,789	23.3%	11,828	23.4%	
<b>Gender</b>														
Female	451,790	89.8%	44,354	87.2%	407,436	90.1%	<0.001	88,552	87.7%	44,235	87.6%	44,317	87.8%	0.43
Male	51,105	10.2%	6,490	12.8%	44,615	9.9%		12,444	12.3%	6,263	12.4%	6,181	12.2%	
<b>Region</b>														
Midwest	85,391	17.0%	9,424	18.5%	75,967	16.8%	<0.001	18,720	18.5%	9,360	18.5%	9,360	18.5%	1.00
Northeast	135,867	27.0%	16,139	31.7%	119,728	26.5%		31,986	31.7%	15,993	31.7%	15,993	31.7%	
South	178,118	35.4%	17,232	33.9%	160,886	35.6%		34,280	33.9%	17,140	33.9%	17,140	33.9%	
West	103,519	20.6%	8,049	15.8%	95,470	21.1%		16,010	15.9%	8,005	15.9%	8,005	15.9%	
<b>Insurance</b>														
Commercial	164,150	32.6%	17,092	33.6%	147,058	32.5%	<0.001	33,977	33.6%	16,963	33.6%	17,014	33.7%	0.91
Dual	33,969	6.8%	2,562	5.0%	31,407	6.9%		5,056	5.0%	2,547	5.0%	2,509	5.0%	
Medicaid	84,514	16.8%	7,034	13.8%	77,480	17.1%		13,925	13.8%	6,986	13.8%	6,939	13.7%	
Medicare	220,262	43.8%	24,156	47.5%	196,106	43.4%		48,038	47.6%	24,002	47.5%	24,036	47.6%	
<b>PCP Visit 2019</b>														
No	181,996	36.2%	18,130	35.7%	163,866	36.2%	0.009	35,943	35.6%	17,979	35.6%	17,964	35.6%	0.92
Yes	320,899	63.8%	32,714	64.3%	288,185	63.8%		65,053	64.4%	32,519	64.4%	32,534	64.4%	
<b>Continuous Outcomes</b>														
	<b>mean</b>	<b>SD</b>	<b>mean</b>	<b>SD</b>	<b>mean</b>	<b>SD</b>	<b>p-value</b>	<b>mean</b>	<b>SD</b>	<b>mean</b>	<b>SD</b>	<b>mean</b>	<b>SD</b>	<b>p-value</b>
<b>CCI</b>	1.05	1.91	1.99	2.71	0.95	1.76	<0.001	1.93	2.59	1.93	2.60	1.92	2.59	0.76

BP: bisphosphonate; CCI: Charlson Comorbidity Index; PCP: primary care physician; SD: standard deviation

2667  
2668

2669  
2670

**Table S6b: “Bone-Rx” Cohort (Region=Northeast), Patient Characteristics Pre/Post Match**

	"Bone-Rx" Cohort / Region=Northeast Unmatched							"Bone-Rx" Cohort / Region=Northeast Matched						
	All		BP Non-user		BP User		p-value	All		BP Non-user		BP User		p-value
	N	%	N	%	N	%		N	%	N	%	N	%	
<b>All Patients</b>	<b>135,867</b>	<b>100.0%</b>	<b>16,139</b>	<b>11.9%</b>	<b>119,728</b>	<b>88.1%</b>		<b>31,986</b>	<b>100.0%</b>	<b>15,993</b>	<b>50.0%</b>	<b>15,993</b>	<b>50.0%</b>	
<b>Age</b>														
≤20	245	0.2%	≤10	0.1%	236	0.2%	<0.001	15	0.0%	≤10	0.1%	≤10	0.0%	0.99
21-40	891	0.7%	127	0.8%	764	0.6%		250	0.8%	124	0.8%	126	0.8%	
41-50	2,340	1.7%	298	1.8%	2,042	1.7%		570	1.8%	290	1.8%	280	1.8%	
51-60	20,069	14.8%	2,059	12.8%	18,010	15.0%		4,088	12.8%	2,049	12.8%	2,039	12.7%	
61-70	45,896	33.8%	4,802	29.8%	41,094	34.3%		9,526	29.8%	4,767	29.8%	4,759	29.8%	
71-80	42,828	31.5%	5,267	32.6%	37,561	31.4%		10,465	32.7%	5,226	32.7%	5,239	32.8%	
≥81	23,598	17.4%	3,577	22.2%	20,021	16.7%		7,072	22.1%	3,528	22.1%	3,544	22.2%	
<b>Gender</b>														
Female	122,485	90.2%	14,115	87.5%	108,370	90.5%	<0.001	28,157	88.0%	14,062	87.9%	14,095	88.1%	0.57
Male	13,382	9.8%	2,024	12.5%	11,358	9.5%		3,829	12.0%	1,931	12.1%	1,898	11.9%	
<b>Insurance</b>														
Commercial	37,810	27.8%	4,517	28.0%	33,293	27.8%	<0.001	8,927	27.9%	4,459	27.9%	4,468	27.9%	0.99
Dual	8,434	6.2%	829	5.1%	7,605	6.4%		1,637	5.1%	824	5.2%	813	5.1%	
Medicaid	25,296	18.6%	2,082	12.9%	23,214	19.4%		4,122	12.9%	2,067	12.9%	2,055	12.8%	
Medicare	64,327	47.3%	8,711	54.0%	55,616	46.5%		17,300	54.1%	8,643	54.0%	8,657	54.1%	
<b>PCP Visit 2019</b>														
No	56,593	41.7%	6,726	41.7%	49,867	41.7%	0.95	13,307	41.6%	6,654	41.6%	6,653	41.6%	0.99
Yes	79,274	58.3%	9,413	58.3%	69,861	58.3%		18,679	58.4%	9,339	58.4%	9,340	58.4%	
<b>Continuous Outcomes</b>														
	<b>mean</b>	<b>SD</b>	<b>mean</b>	<b>SD</b>	<b>mean</b>	<b>SD</b>	<b>p-value</b>	<b>mean</b>	<b>SD</b>	<b>mean</b>	<b>SD</b>	<b>mean</b>	<b>SD</b>	<b>p-value</b>
<b>CCI</b>	1.06	1.89	1.97	2.70	0.93	1.71	<0.001	1.89	2.57	1.89	2.58	1.89	2.57	0.91

2671

BP: bisphosphonate; CCI: Charlson Comorbidity Index; PCP: primary care physician; SD: standard deviation

2672  
2673

**Table S6c: “Bone-Rx” Cohort (Region=Midwest), Patient Characteristics Pre/Post Match**

	"Bone-Rx" Cohort / Region=Midwest Unmatched							"Bone-Rx" Cohort / Region=Midwest Matched						
	All		BP Non-user		BP User		p-value	All		BP Non-user		BP User		p-value
	N	%	N	%	N	%		N	%	N	%	N	%	
<b>All Patients</b>	<b>85,391</b>	<b>100.0%</b>	<b>9,424</b>	<b>11.0%</b>	<b>75,967</b>	<b>89.0%</b>		<b>18,720</b>	<b>100.0%</b>	<b>9,360</b>	<b>50.0%</b>	<b>9,360</b>	<b>50.0%</b>	
<b>Age</b>														
≤20	274	0.3%	≤10	0.1%	268	0.4%	<0.001	13	0.1%	≤10	0.1%	≤10	0.1%	1.00
21-40	672	0.8%	79	0.8%	593	0.8%		154	0.8%	78	0.8%	76	0.8%	
41-50	1,886	2.2%	202	2.1%	1,684	2.2%		389	2.1%	200	2.1%	189	2.0%	
51-60	13,522	15.8%	1,284	13.6%	12,238	16.1%		2,559	13.7%	1,280	13.7%	1,279	13.7%	
61-70	31,256	36.6%	2,760	29.3%	28,496	37.5%		5,512	29.4%	2,754	29.4%	2,758	29.5%	
71-80	23,887	28.0%	2,766	29.4%	21,121	27.8%		5,492	29.3%	2,748	29.4%	2,744	29.3%	
≥81	13,894	16.3%	2,327	24.7%	11,567	15.2%		4,601	24.6%	2,294	24.5%	2,307	24.6%	
<b>Gender</b>														
Female	76,696	89.8%	8,118	86.1%	68,578	90.3%	<0.001	16,223	86.7%	8,102	86.6%	8,121	86.8%	0.68
Male	8,695	10.2%	1,306	13.9%	7,389	9.7%		2,497	13.3%	1,258	13.4%	1,239	13.2%	
<b>Insurance</b>														
Commercial	34,494	40.4%	3,361	35.7%	31,133	41.0%	<0.001	6,699	35.8%	3,345	35.7%	3,354	35.8%	0.96
Dual	4,042	4.7%	436	4.6%	3,606	4.7%		852	4.6%	429	4.6%	423	4.5%	
Medicaid	8,856	10.4%	733	7.8%	8,123	10.7%		1,441	7.7%	729	7.8%	712	7.6%	
Medicare	37,999	44.5%	4,894	51.9%	33,105	43.6%		9,728	52.0%	4,857	51.9%	4,871	52.0%	
<b>PCP Visit 2019</b>														
No	32,037	37.5%	3,330	35.3%	28,707	37.8%	<0.001	6,628	35.4%	3,312	35.4%	3,316	35.4%	0.95
Yes	53,354	62.5%	6,094	64.7%	47,260	62.2%		12,092	64.6%	6,048	64.6%	6,044	64.6%	
<b>Continuous Outcomes</b>														
	<b>mean</b>	<b>SD</b>	<b>mean</b>	<b>SD</b>	<b>mean</b>	<b>SD</b>	<b>p-value</b>	<b>mean</b>	<b>SD</b>	<b>mean</b>	<b>SD</b>	<b>mean</b>	<b>SD</b>	<b>p-value</b>
<b>CCI</b>	1.12	2.02	2.12	2.83	0.99	1.86	<0.001	2.05	2.72	2.06	2.72	2.05	2.72	0.91

2674  
2675

BP: bisphosphonate; CCI: Charlson Comorbidity Index; PCP: primary care physician; SD: standard deviation

2676  
2677

**Table S6d: "Bone-Rx" Cohort (Region=South), Patient Characteristics Pre/Post Match**

	"Bone-Rx" Cohort / Region=South Unmatched							"Bone-Rx" Cohort / Region=South Matched						
	All		BP Non-user		BP User		p-value	All		BP Non-user		BP User		p-value
	N	%	N	%	N	%		N	%	N	%	N	%	
<b>All Patients</b>	<b>178,118</b>	<b>100.0%</b>	<b>17,232</b>	<b>9.7%</b>	<b>160,886</b>	<b>90.3%</b>		<b>34,280</b>	<b>100.0%</b>	<b>17,140</b>	<b>50.0%</b>	<b>17,140</b>	<b>50.0%</b>	
<b>Age</b>														
≤20	490	0.3%	16	0.1%	474	0.3%	<0.001	31	0.1%	16	0.1%	15	0.1%	1.00
21-40	1,313	0.7%	136	0.8%	1,177	0.7%		262	0.8%	134	0.8%	128	0.7%	
41-50	3,866	2.2%	445	2.6%	3,421	2.1%		884	2.6%	444	2.6%	440	2.6%	
51-60	27,389	15.4%	2,296	13.3%	25,093	15.6%		4,574	13.3%	2,290	13.4%	2,284	13.3%	
61-70	61,038	34.3%	5,142	29.8%	55,896	34.7%		10,271	30.0%	5,129	29.9%	5,142	30.0%	
71-80	56,126	31.5%	5,521	32.0%	50,605	31.5%		10,990	32.1%	5,493	32.0%	5,497	32.1%	
≥81	27,896	15.7%	3,676	21.3%	24,220	15.1%		7,268	21.2%	3,634	21.2%	3,634	21.2%	
<b>Gender</b>														
Female	160,994	90.4%	15,179	88.1%	145,815	90.6%	<0.001	30,322	88.5%	15,149	88.4%	15,173	88.5%	0.69
Male	17,124	9.6%	2,053	11.9%	15,071	9.4%		3,958	11.5%	1,991	11.6%	1,967	11.5%	
<b>Insurance</b>														
Commercial	66,332	37.2%	7,042	40.9%	59,290	36.9%	<0.001	14,052	41.0%	7,007	40.9%	7,045	41.1%	0.95
Dual	14,829	8.3%	769	4.5%	14,060	8.7%		1,523	4.4%	769	4.5%	754	4.4%	
Medicaid	23,492	13.2%	1,843	10.7%	21,649	13.5%		3,639	10.6%	1,829	10.7%	1,810	10.6%	
Medicare	73,465	41.2%	7,578	44.0%	65,887	41.0%		15,066	43.9%	7,535	44.0%	7,531	43.9%	
<b>PCP Visit 2019</b>														
No	60,253	33.8%	5,785	33.6%	54,468	33.9%	0.454	11,462	33.4%	5,736	33.5%	5,726	33.4%	0.91
Yes	117,865	66.2%	11,447	66.4%	106,418	66.1%		22,818	66.6%	11,404	66.5%	11,414	66.6%	
<b>Continuous Outcomes</b>														
	<b>mean</b>	<b>SD</b>	<b>mean</b>	<b>SD</b>	<b>mean</b>	<b>SD</b>	<b>p-value</b>	<b>mean</b>	<b>SD</b>	<b>mean</b>	<b>SD</b>	<b>mean</b>	<b>SD</b>	<b>p-value</b>
<b>CCI</b>	0.95	1.84	1.86	2.65	0.86	1.70	<0.001	1.80	2.54	1.80	2.54	1.79	2.53	0.78

2678  
2679  
2680

BP: bisphosphonate; CCI: Charlson Comorbidity Index; PCP: primary care physician; SD: standard deviation



2681  
2682

**Table S6e: “Bone-Rx” Cohort (Region=West), Patient Characteristics Pre/Post Match**

	"Bone-Rx" Cohort / Region=West Unmatched							"Bone-Rx" Cohort / Region=West Matched						
	All		BP Non-user		BP User		p-value	All		BP Non-user		BP User		p-value
	N	%	N	%	N	%		N	%	N	%	N	%	
<b>All Patients</b>	<b>103,519</b>	<b>100.0%</b>	<b>8,049</b>	<b>7.8%</b>	<b>95,470</b>	<b>92.2%</b>		<b>16,010</b>	<b>100.0%</b>	<b>8,005</b>	<b>50.0%</b>	<b>8,005</b>	<b>50.0%</b>	
<b>Age</b>														
≤20	155	0.1%	≤10	0.1%	150	0.2%	<0.001	≤10	0.0%	≤10	0.1%	≤10	0.0%	0.96
21-40	625	0.6%	68	0.8%	557	0.6%		124	0.8%	67	0.8%	57	0.7%	
41-50	1,539	1.5%	135	1.7%	1,404	1.5%		264	1.6%	135	1.7%	129	1.6%	
51-60	11,159	10.8%	779	9.7%	10,380	10.9%		1,556	9.7%	776	9.7%	780	9.7%	
61-70	33,497	32.4%	2,105	26.2%	31,392	32.9%		4,200	26.2%	2,101	26.2%	2,099	26.2%	
71-80	35,036	33.8%	2,598	32.3%	32,438	34.0%		5,182	32.4%	2,588	32.3%	2,594	32.4%	
≥81	21,508	20.8%	2,359	29.3%	19,149	20.1%		4,676	29.2%	2,333	29.1%	2,343	29.3%	
<b>Gender</b>														
Female	91,615	88.5%	6,942	86.2%	84,673	88.7%	<0.001	13,850	86.5%	6,922	86.5%	6,928	86.5%	0.89
Male	11,904	11.5%	1,107	13.8%	10,797	11.3%		2,160	13.5%	1,083	13.5%	1,077	13.5%	
<b>Insurance</b>														
Commercial	25,514	24.6%	2,172	27.0%	23,342	24.4%	<0.001	4,299	26.9%	2,152	26.9%	2,147	26.8%	1.00
Dual	6,664	6.4%	528	6.6%	6,136	6.4%		1,044	6.5%	525	6.6%	519	6.5%	
Medicaid	26,870	26.0%	2,376	29.5%	24,494	25.7%		4,723	29.5%	2,361	29.5%	2,362	29.5%	
Medicare	44,471	43.0%	2,973	36.9%	41,498	43.5%		5,944	37.1%	2,967	37.1%	2,977	37.2%	
<b>PCP Visit 2019</b>														
No	33,113	32.0%	2,289	28.4%	30,824	32.3%	<0.001	4,546	28.4%	2,277	28.4%	2,269	28.3%	0.89
Yes	70,406	68.0%	5,760	71.6%	64,646	67.7%		11,464	71.6%	5,728	71.6%	5,736	71.7%	
<b>Continuous Outcomes</b>														
	<b>mean</b>	<b>SD</b>	<b>mean</b>	<b>SD</b>	<b>mean</b>	<b>SD</b>	<b>p-value</b>	<b>mean</b>	<b>SD</b>	<b>mean</b>	<b>SD</b>	<b>mean</b>	<b>SD</b>	<b>p-value</b>
<b>CCI</b>	1.17	1.94	2.17	2.67	1.08	1.84	<0.001	2.12	2.59	2.12	2.59	2.12	2.59	0.93

2683  
2684  
2685

BP: bisphosphonate; CCI: Charlson Comorbidity Index; PCP: primary care physician; SD: standard deviation

2686  
2687

**Table S6f: “Bone-Rx” Cohort (Region=New York State), Patient Characteristics Pre/Post Match**

	"Bone-Rx" Cohort / Region=New York State Unmatched							"Bone-Rx" Cohort / Region=New York State Matched						
	All		BP Non-user		BP User		p-value	All		BP Non-user		BP User		p-value
	N	%	N	%	N	%		N	%	N	%	N	%	
<b>All Patients</b>	<b>57,397</b>	<b>100.0%</b>	<b>7,362</b>	<b>12.8%</b>	<b>50,035</b>	<b>87.2%</b>		<b>14,508</b>	<b>100.0%</b>	<b>7,254</b>	<b>50.0%</b>	<b>7,254</b>	<b>50.0%</b>	
<b>Age</b>														
≤20	56	0.1%	≤10	0.1%	50	0.1%	<0.001	11	0.1%	≤10	0.1%	≤10	0.1%	0.96
21-40	272	0.5%	44	0.6%	228	0.5%		76	0.5%	42	0.6%	34	0.5%	
41-50	775	1.4%	120	1.6%	655	1.3%		207	1.4%	107	1.5%	100	1.4%	
51-60	7,249	12.6%	885	12.0%	6,364	12.7%		1,744	12.0%	871	12.0%	873	12.0%	
61-70	18,433	32.1%	2,297	31.2%	16,136	32.2%		4,540	31.3%	2,264	31.2%	2,276	31.4%	
71-80	19,944	34.7%	2,482	33.7%	17,462	34.9%		4,934	34.0%	2,455	33.8%	2,479	34.2%	
≥81	10,668	18.6%	1,528	20.8%	9,140	18.3%		2,996	20.7%	1,509	20.8%	1,487	20.5%	
<b>Gender</b>														
Female	52,047	90.7%	6,589	89.5%	45,458	90.9%	<.001	13,106	90.3%	6,526	90.0%	6,580	90.7%	0.13
Male	5,350	9.3%	773	10.5%	4,577	9.1%		1,402	9.7%	728	10.0%	674	9.3%	
<b>Insurance</b>														
Commercial	12,309	21.4%	1,894	25.7%	10,415	20.8%	<0.001	3,706	25.5%	1,850	25.5%	1,856	25.6%	1.00
Dual	1,750	3.0%	154	2.1%	1,596	3.2%		307	2.1%	153	2.1%	154	2.1%	
Medicaid	10,191	17.8%	1,016	13.8%	9,175	18.3%		1,968	13.6%	987	13.6%	981	13.5%	
Medicare	33,147	57.8%	4,298	58.4%	28,849	57.7%		8,527	58.8%	4,264	58.8%	4,263	58.8%	
<b>PCP Visit 2019</b>														
No	21,462	37.4%	2,789	37.9%	18,673	37.3%	0.35	5,468	37.7%	2,744	37.8%	2,724	37.6%	0.73
Yes	35,935	62.6%	4,573	62.1%	31,362	62.7%		9,040	62.3%	4,510	62.2%	4,530	62.4%	
<b>Continuous Outcomes</b>														
	<b>mean</b>	<b>SD</b>	<b>mean</b>	<b>SD</b>	<b>mean</b>	<b>SD</b>	<b>p-value</b>	<b>mean</b>	<b>SD</b>	<b>mean</b>	<b>SD</b>	<b>mean</b>	<b>SD</b>	<b>p-value</b>
<b>CCI</b>	1.06	1.84	1.81	2.56	0.95	1.68	<0.001	1.69	2.35	1.69	2.36	1.69	2.35	0.98

2688  
2689  
2690

BP: bisphosphonate; CCI: Charlson Comorbidity Index; PCP: primary care physician; SD: standard deviation

2691 Table S7: "Osteo-Dx-Rx" Cohort, Patient Characteristics Pre/Post Match

	"Osteo-Dx-Rx" Cohort / All Observations Unmatched							"Osteo-Dx-Rx" Cohort / All Observations Matched						
	All		BP Non-user		BP User		p-value	All		BP Non-user		BP User		p-value
	N	%	N	%	N	%		N	%	N	%	N	%	
<b>All Patients</b>	<b>60,043</b>	<b>100.0%</b>	<b>8,392</b>	<b>14.0%</b>	<b>51,651</b>	<b>86.0%</b>		<b>15,898</b>	<b>100.0%</b>	<b>7,949</b>	<b>50.0%</b>	<b>7,949</b>	<b>50.0%</b>	
<b>Age</b>														
51-60	6,443	10.7%	753	9.0%	5,690	11.0%	<0.001	1,430	9.0%	723	9.1%	707	8.9%	0.95
61-70	20,187	33.6%	2,492	29.7%	17,695	34.3%		4,821	30.3%	2,397	30.2%	2,424	30.5%	
71-80	21,545	35.9%	2,964	35.3%	18,581	36.0%		5,677	35.7%	2,841	35.7%	2,836	35.7%	
≥81	11,868	19.8%	2,183	26.0%	9,685	18.8%		3,970	25.0%	1,988	25.0%	1,982	24.9%	
<b>State</b>														
CA	24,489	40.8%	2,558	30.5%	21,931	42.5%	<0.001	4,886	30.7%	2,443	30.7%	2,443	30.7%	1.00
FL	11,904	19.8%	1,767	21.1%	10,137	19.6%		3,256	20.5%	1,628	20.5%	1,628	20.5%	
IL	4,447	7.4%	678	8.1%	3,769	7.3%		1,168	7.3%	584	7.3%	584	7.3%	
NY	19,203	32.0%	3,389	40.4%	15,814	30.6%		6,588	41.4%	3,294	41.4%	3,294	41.4%	
<b>Insurance</b>														
Commercial	12,990	21.6%	2,048	24.4%	10,942	21.2%	<0.001	3,736	23.5%	1,868	23.5%	1,868	23.5%	1.00
Dual	3,652	6.1%	313	3.7%	3,339	6.5%		554	3.5%	277	3.5%	277	3.5%	
Medicaid	13,698	22.8%	1,785	21.3%	11,913	23.1%		3,392	21.3%	1,696	21.3%	1,696	21.3%	
Medicare	29,703	49.5%	4,246	50.6%	25,457	49.3%		8,216	51.7%	4,108	51.7%	4,108	51.7%	
<b>PCP Visit 2019</b>														
No	14,089	23.5%	2,427	28.9%	11,662	22.6%	<0.001	4,487	28.2%	2,243	28.2%	2,244	28.2%	0.99
Yes	45,954	76.5%	5,965	71.1%	39,989	77.4%		11,411	71.8%	5,706	71.8%	5,705	71.8%	
<b>Cancer Dx</b>														
No	52,301	87.1%	6,765	80.6%	45,536	88.2%	<0.001	13,116	82.5%	6,548	82.4%	6,568	82.6%	0.68
Yes	7,742	12.9%	1,627	19.4%	6,115	11.8%		2,782	17.5%	1,401	17.6%	1,381	17.4%	
<b>COPD Dx</b>														
No	53,446	89.0%	7,035	83.8%	46,411	89.9%	<0.001	13,705	86.2%	6,834	86.0%	6,871	86.4%	0.39
Yes	6,597	11.0%	1,357	16.2%	5,240	10.1%		2,193	13.8%	1,115	14.0%	1,078	13.6%	
<b>Heart Failure Dx</b>														
No	56,005	93.3%	7,492	89.3%	48,513	93.9%	<0.001	14,475	91.0%	7,218	90.8%	7,257	91.3%	0.28
Yes	4,038	6.7%	900	10.7%	3,138	6.1%		1,423	9.0%	731	9.2%	692	8.7%	
<b>Hypertension Dx</b>														
No	24,966	41.6%	3,281	39.1%	21,685	42.0%	<0.001	6,268	39.4%	3,137	39.5%	3,131	39.4%	0.92
Yes	35,077	58.4%	5,111	60.9%	29,966	58.0%		9,630	60.6%	4,812	60.5%	4,818	60.6%	
<b>Dyslipidemia Dx</b>														
No	24,095	40.1%	3,295	39.3%	20,800	40.3%	0.08	6,187	38.9%	3,101	39.0%	3,086	38.8%	0.81
Yes	35,948	59.9%	5,097	60.7%	30,851	59.7%		9,711	61.1%	4,848	61.0%	4,863	61.2%	
<b>Obesity Dx</b>														
No	53,453	89.0%	7,583	90.4%	45,870	88.8%	<0.001	14,468	91.0%	7,217	90.8%	7,251	91.2%	0.35
Yes	6,590	11.0%	809	9.6%	5,781	11.2%		1,430	9.0%	732	9.2%	698	8.8%	
<b>Type 2 Diabetes Dx</b>														
No	44,565	74.2%	6,132	73.1%	38,433	74.4%	0.009	11,759	74.0%	5,859	73.7%	5,900	74.2%	0.46
Yes	15,478	25.8%	2,260	26.9%	13,218	25.6%		4,139	26.0%	2,090	26.3%	2,049	25.8%	
<b>Depression Dx</b>														
No	51,609	86.0%	7,114	84.8%	44,495	86.1%	0.001	13,697	86.2%	6,844	86.1%	6,853	86.2%	0.84
Yes	8,434	14.0%	1,278	15.2%	7,156	13.9%		2,201	13.8%	1,105	13.9%	1,096	13.8%	

2692 BP: bisphosphonate; CCI: Charlson Comorbidity Index; CA: California; Dx: diagnosis; FL: Florida; IL: Illinois; NY: New York; PCP: primary care physician

2693  
2694

**Table S8a: Statin Cohort (All Regions), Patient Characteristics Pre/Post Match**

	All Observations by Statin Use: Unmatched							All Observations by Statin Use: Matched						
	All		Statin Non-users		Statin Users		p-value	All		Statin Non-users		Statin Users		p-value
	N	%	N	%	N	%		N	%	N	%	N	%	
<b>All Patients</b>	<b>7,906,603</b>	<b>100.0%</b>	<b>6,403,208</b>	<b>81.0%</b>	<b>1,503,395</b>	<b>19.0%</b>		<b>2,872,600</b>	<b>100.0%</b>	<b>1,436,300</b>	<b>50.0%</b>	<b>1,436,300</b>	<b>50.0%</b>	
<b>Age</b>														
≤20	1,840,050	23.3%	1,838,665	28.7%	1,385	0.1%	<0.001	2,772	0.1%	1,387	0.1%	1,385	0.1%	0.11
21-40	1,446,999	18.3%	1,402,606	21.9%	44,393	3.0%		88,760	3.1%	44,371	3.1%	44,389	3.1%	
41-50	925,309	11.7%	789,385	12.3%	135,924	9.0%		271,615	9.5%	135,748	9.5%	135,867	9.5%	
51-60	1,250,190	15.8%	888,510	13.9%	361,680	24.1%		710,481	24.7%	354,449	24.7%	356,032	24.8%	
61-70	1,181,261	14.9%	728,702	11.4%	452,559	30.1%		857,269	29.8%	428,326	29.8%	428,943	29.9%	
71-80	783,775	9.9%	452,267	7.1%	331,508	22.1%		605,360	21.1%	303,279	21.1%	302,081	21.0%	
≥81	479,019	6.1%	303,073	4.7%	175,946	11.7%		336,343	11.7%	168,740	11.7%	167,603	11.7%	
<b>Gender</b>														
Female	4,670,960	59.1%	3,785,061	59.1%	885,899	58.9%	<0.001	1,682,354	58.6%	839,207	58.4%	843,147	58.7%	<0.001
Male	3,235,643	40.9%	2,618,147	40.9%	617,496	41.1%		1,190,246	41.4%	597,093	41.6%	593,153	41.3%	
<b>Region</b>														
Midwest	1,467,802	18.6%	1,188,569	18.6%	279,233	18.6%	<0.001	542,638	18.9%	271,319	18.9%	271,319	18.9%	1.00
Northeast	2,152,560	27.2%	1,706,021	26.6%	446,539	29.7%		847,868	29.5%	423,934	29.5%	423,934	29.5%	
South	3,042,604	38.5%	2,490,630	38.9%	551,974	36.7%		1,046,224	36.4%	523,112	36.4%	523,112	36.4%	
West	1,243,637	15.7%	1,017,988	15.9%	225,649	15.0%		435,870	15.2%	217,935	15.2%	217,935	15.2%	
<b>Insurance</b>														
Commercial	3,938,603	49.8%	3,350,332	52.3%	588,271	39.1%	<0.001	1,175,472	40.9%	587,847	40.9%	587,625	40.9%	0.34
Dual	156,497	2.0%	73,532	1.1%	82,965	5.5%		110,207	3.8%	54,851	3.8%	55,356	3.9%	
Medicaid	2,594,500	32.8%	2,254,531	35.2%	339,969	22.6%		641,345	22.3%	320,434	22.3%	320,911	22.3%	
Medicare	1,217,003	15.4%	724,813	11.3%	492,190	32.7%		945,576	32.9%	473,168	32.9%	472,408	32.9%	
<b>PCP Visit 2019</b>														
No	4,283,697	54.2%	3,773,784	58.9%	509,913	33.9%	<0.001	1,016,313	35.4%	508,587	35.4%	507,726	35.3%	0.29
Yes	3,622,906	45.8%	2,629,424	41.1%	993,482	66.1%		1,856,287	64.6%	927,713	64.6%	928,574	64.7%	
<b>Continuous Outcomes</b>														
	<b>mean</b>	<b>SD</b>	<b>mean</b>	<b>SD</b>	<b>mean</b>	<b>SD</b>	<b>p-value</b>	<b>mean</b>	<b>SD</b>	<b>mean</b>	<b>SD</b>	<b>mean</b>	<b>SD</b>	<b>p-value</b>
<b>CCI</b>	0.62	1.38	0.49	1.23	1.15	1.79	<0.001	1.11	1.77	1.12	1.79	1.11	1.75	<0.001

2695 CCI: Charlson Comorbidity Index; PCP: primary care physician; SD: standard deviation

2696

2697

2698  
2699

**Table S8b: Statin Cohort (Region=New York State), Patient Characteristics Pre/Post Match**

	Region=NY by Statin Use: Unmatched							Region=NY by Statin Use: Matched						
	All		Statin Non-users		Statin Users		p-value	All		Statin Non-users		Statin Users		p-value
	N	%	N	%	N	%		N	%	N	%	N	%	
<b>All Patients</b>	<b>968,296</b>	<b>100.0%</b>	<b>761,995</b>	<b>78.7%</b>	<b>206,301</b>	<b>21.3%</b>		<b>371,072</b>	<b>100.0%</b>	<b>185,536</b>	<b>50.0%</b>	<b>185,536</b>	<b>50.0%</b>	
<b>Age</b>														
≤20	133,178	13.8%	133,111	17.5%	67	0.0%	<0.001	134	0.0%	67	0.0%	67	0.0%	1.00
21-40	192,959	19.9%	188,446	24.7%	4,513	2.2%		9,019	2.4%	4,508	2.4%	4,511	2.4%	
41-50	127,794	13.2%	112,342	14.7%	15,452	7.5%		30,860	8.3%	15,420	8.3%	15,440	8.3%	
51-60	172,444	17.8%	128,472	16.9%	43,972	21.3%		86,136	23.2%	43,068	23.2%	43,068	23.2%	
61-70	159,912	16.5%	100,884	13.2%	59,028	28.6%		106,460	28.7%	53,233	28.7%	53,227	28.7%	
71-80	120,117	12.4%	64,549	8.5%	55,568	26.9%		91,337	24.6%	45,675	24.6%	45,662	24.6%	
≥81	61,892	6.4%	34,191	4.5%	27,701	13.4%		47,126	12.7%	23,565	12.7%	23,561	12.7%	
<b>Gender</b>														
Female	573,610	59.2%	454,050	59.6%	119,560	58.0%	<0.001	215,375	58.0%	107,420	57.9%	107,955	58.2%	0.08
Male	394,686	40.8%	307,945	40.4%	86,741	42.0%		155,697	42.0%	78,116	42.1%	77,581	41.8%	
<b>Insurance</b>														
Commercial	500,918	51.7%	442,990	58.1%	57,928	28.1%	<0.001	116,123	31.3%	58,206	31.4%	57,917	31.2%	0.57
Dual	6,814	0.7%	2,410	0.3%	4,404	2.1%		4,447	1.2%	2,190	1.2%	2,257	1.2%	
Medicaid	252,366	26.1%	206,109	27.0%	46,257	22.4%		83,550	22.5%	41,703	22.5%	41,847	22.6%	
Medicare	208,198	21.5%	110,486	14.5%	97,712	47.4%		166,952	45.0%	83,437	45.0%	83,515	45.0%	
<b>PCP Visit 2019</b>														
No	521,282	53.8%	446,929	58.7%	74,353	36.0%	<0.001	146,967	39.6%	73,675	39.7%	73,292	39.5%	0.20
Yes	447,014	46.2%	315,066	41.3%	131,948	64.0%		224,105	60.4%	111,861	60.3%	112,244	60.5%	
<b>Continuous Outcomes</b>														
	<b>mean</b>	<b>SD</b>	<b>mean</b>	<b>SD</b>	<b>mean</b>	<b>SD</b>	<b>p-value</b>	<b>mean</b>	<b>SD</b>	<b>mean</b>	<b>SD</b>	<b>mean</b>	<b>SD</b>	<b>p-value</b>
<b>CCI</b>	0.65	1.39	0.51	1.24	1.17	1.77	<0.001	1.07	1.73	1.08	1.76	1.06	1.70	<0.001

CCI: Charlson Comorbidity Index; PCP: primary care physician; SD: standard deviation

2700  
2701  
2702

2703  
2704

**Table S8c: Statin User Cohort (All Regions) by BP Use, Patient Characteristics Pre/Post Match of BP Users/Non-users**

	All Statin Users by BP: Unmatched							All Statin Users by BP: Matched						
	All		BP Non-user		BP User		p-value	All		BP Non-user		BP User		p-value
	N	%	N	%	N	%		N	%	N	%	N	%	
<b>All Patients</b>	<b>1,436,300</b>	<b>100.0%</b>	<b>1,218,319</b>	<b>84.8%</b>	<b>217,981</b>	<b>15.2%</b>		<b>426,960</b>	<b>100.0%</b>	<b>213,480</b>	<b>50.0%</b>	<b>213,480</b>	<b>50.0%</b>	
<b>Age</b>														
≤20	1,385	0.1%	1,365	0.1%	20	0.0%	<0.001	42	0.0%	22	0.0%	20	0.0%	1.00
21-40	44,389	3.1%	44,042	3.6%	347	0.2%		704	0.2%	357	0.2%	347	0.2%	
41-50	135,867	9.5%	133,850	11.0%	2,017	0.9%		4,033	0.9%	2,016	0.9%	2,017	0.9%	
51-60	356,032	24.8%	333,325	27.4%	22,707	10.4%		45,439	10.6%	22,732	10.6%	22,707	10.6%	
61-70	428,943	29.9%	356,208	29.2%	72,735	33.4%		144,861	33.9%	72,341	33.9%	72,520	34.0%	
71-80	302,081	21.0%	223,651	18.4%	78,430	36.0%		150,527	35.3%	75,316	35.3%	75,211	35.2%	
≥81	167,603	11.7%	125,878	10.3%	41,725	19.1%		81,354	19.1%	40,696	19.1%	40,658	19.0%	
<b>Gender</b>														
Female	843,147	58.7%	646,846	53.1%	196,301	90.1%	<0.001	383,586	89.8%	191,786	89.8%	191,800	89.8%	0.94
Male	593,153	41.3%	571,473	46.9%	21,680	9.9%		43,374	10.2%	21,694	10.2%	21,680	10.2%	
<b>Region</b>														
Midwest	271,319	18.9%	237,718	19.5%	33,601	15.4%	<0.001	67,050	15.7%	33,525	15.7%	33,525	15.7%	1.00
Northeast	423,934	29.5%	366,936	30.1%	56,998	26.1%		113,308	26.5%	56,654	26.5%	56,654	26.5%	
South	523,112	36.4%	442,996	36.4%	80,116	36.8%		157,838	37.0%	78,919	37.0%	78,919	37.0%	
West	217,935	15.2%	170,669	14.0%	47,266	21.7%		88,764	20.8%	44,382	20.8%	44,382	20.8%	
<b>Insurance</b>														
Commercial	587,625	40.9%	533,843	43.8%	53,782	24.7%	<0.001	107,552	25.2%	53,774	25.2%	53,778	25.2%	1.00
Dual	55,356	3.9%	42,041	3.5%	13,315	6.1%		24,380	5.7%	12,183	5.7%	12,197	5.7%	
Medicaid	320,911	22.3%	280,799	23.0%	40,112	18.4%		76,121	17.8%	38,050	17.8%	38,071	17.8%	
Medicare	472,408	32.9%	361,636	29.7%	110,772	50.8%		218,907	51.3%	109,473	51.3%	109,434	51.3%	
<b>PCP Visit 2019</b>														
No	507,726	35.3%	430,446	35.3%	77,280	35.5%	0.27	151,395	35.5%	75,614	35.4%	75,781	35.5%	0.59
Yes	928,574	64.7%	787,873	64.7%	140,701	64.5%		275,565	64.5%	137,866	64.6%	137,699	64.5%	
<b>Continuous Outcomes</b>														
	<b>mean</b>	<b>SD</b>	<b>mean</b>	<b>SD</b>	<b>mean</b>	<b>SD</b>	<b>p-value</b>	<b>mean</b>	<b>SD</b>	<b>mean</b>	<b>SD</b>	<b>mean</b>	<b>SD</b>	<b>p-value</b>
<b>CCI</b>	1.11	1.75	1.13	1.77	0.95	1.66	<0.001	0.97	1.66	0.97	1.66	0.97	1.67	0.79

2705

BP: bisphosphonate; CCI: Charlson Comorbidity Index; PCP: primary care physician; SD: standard deviation

2706  
2707  
2708

**Table S8d: Statin User Cohort (Region=New York State) by BP Use, Patient Characteristics Pre/Post Match of BP Users/Non-users**

	Region=NY Statin Users by BP: Unmatched							Region=NY Statin Users by BP: Matched						
	All		BP Non-user		BP User		p-value	All		BP Non-user		BP User		p-value
	N	%	N	%	N	%		N	%	N	%	N	%	
<b>All Patients</b>	<b>185,536</b>	<b>100.0%</b>	<b>161,673</b>	<b>87.1%</b>	<b>23,863</b>	<b>12.9%</b>		<b>47,472</b>	<b>100.0%</b>	<b>23,736</b>	<b>50.0%</b>	<b>23,736</b>	<b>50.0%</b>	
<b>Age</b>														
≤20	67	0.0%	67	0.0%	0	0.0%	<0.001	52	0.1%	26	0.1%	26	0.1%	1.00
21-40	4,511	2.4%	4,485	2.8%	26	0.1%		304	0.6%	152	0.6%	152	0.6%	
41-50	15,440	8.3%	15,288	9.5%	152	0.6%		4,381	9.2%	2,192	9.2%	2,189	9.2%	
51-60	43,068	23.2%	40,879	25.3%	2,189	9.2%		14,717	31.0%	7,358	31.0%	7,359	31.0%	
61-70	53,227	28.7%	45,861	28.4%	7,366	30.9%		18,189	38.3%	9,092	38.3%	9,097	38.3%	
71-80	45,662	24.6%	36,474	22.6%	9,188	38.5%		9,829	20.7%	4,916	20.7%	4,913	20.7%	
≥81	23,561	12.7%	18,619	11.5%	4,942	20.7%		0	0.0%		0.0%		0.0%	
<b>Gender</b>														
Female	107,955	58.2%	86,194	53.3%	21,761	91.2%	<0.001	43,265	91.1%	21,631	91.1%	21,634	91.1%	0.96
Male	77,581	41.8%	75,479	46.7%	2,102	8.8%		4,207	8.9%	2,105	8.9%	2,102	8.9%	
<b>Insurance</b>														
Commercial	57,917	31.2%	54,411	33.7%	3,506	14.7%	<0.001	7,008	14.8%	3,502	14.8%	3,506	14.8%	1.00
Dual	2,257	1.2%	1,664	1.0%	593	2.5%		1,128	2.4%	564	2.4%	564	2.4%	
Medicaid	41,847	22.6%	37,926	23.5%	3,921	16.4%		7,644	16.1%	3,821	16.1%	3,823	16.1%	
Medicare	83,515	45.0%	67,672	41.9%	15,843	66.4%		31,692	66.8%	15,849	66.8%	15,843	66.7%	
<b>PCP Visit 2019</b>														
No	73,292	39.5%	63,797	39.5%	9,495	39.8%	0.33	18,870	39.7%	9,434	39.7%	9,436	39.8%	0.99
Yes	112,244	60.5%	97,876	60.5%	14,368	60.2%		28,602	60.3%	14,302	60.3%	14,300	60.2%	
<b>Continuous Outcomes</b>														
	<b>mean</b>	<b>SD</b>	<b>mean</b>	<b>SD</b>	<b>mean</b>	<b>SD</b>	<b>p-value</b>	<b>mean</b>	<b>SD</b>	<b>mean</b>	<b>SD</b>	<b>mean</b>	<b>SD</b>	<b>p-value</b>
<b>CCI</b>	1.06	1.70	1.08	1.71	0.92	1.59	<0.001	0.92	1.58	0.92	1.57	0.93	1.59	0.64

BP: bisphosphonate; CCI: Charlson Comorbidity Index; PCP: primary care physician; SD: standard deviation

2709  
2710  
2711

2712  
2713

**Table S8e: Statin Non-user Cohort (All Regions) by BP Use, Patient Characteristics Pre/Post Match of BP Users/Non-users**

	All Statin Non-users by BP Use: Unmatched							All Statin Non-users by BP: Matched						
	All		BP Non-users		BP Users		p-value	All		BP Non-users		BP Users		p-value
	N	%	N	%	N	%		N	%	N	%	N	%	
<b>All Patients</b>	<b>1,436,300</b>	<b>100.0%</b>	<b>1,311,457</b>	<b>91.3%</b>	<b>124,843</b>	<b>8.7%</b>		<b>249,432</b>	<b>100.0%</b>	<b>124,716</b>	<b>50.0%</b>	<b>124,716</b>	<b>50.0%</b>	
<b>Age</b>														
≤20	1,387	0.1%	1,383	0.1%	4	0.0%	<0.001	6	0.0%	2	0.0%	4	0.0%	0.99
21-40	44,371	3.1%	44,170	3.4%	201	0.2%		413	0.2%	212	0.2%	201	0.2%	
41-50	135,748	9.5%	134,305	10.2%	1,443	1.2%		2,880	1.2%	1,437	1.2%	1,443	1.2%	
51-60	354,449	24.7%	336,779	25.7%	17,670	14.2%		35,335	14.2%	17,665	14.2%	17,670	14.2%	
61-70	428,326	29.8%	381,936	29.1%	46,390	37.2%		92,791	37.2%	46,401	37.2%	46,390	37.2%	
71-80	303,279	21.1%	264,157	20.1%	39,122	31.3%		78,077	31.3%	39,037	31.3%	39,040	31.3%	
≥81	168,740	11.7%	148,727	11.3%	20,013	16.0%		39,930	16.0%	19,962	16.0%	19,968	16.0%	
<b>Gender</b>														
Female	839,207	58.4%	727,324	55.5%	111,883	89.6%	<0.001	223,501	89.6%	111,745	89.6%	111,756	89.6%	0.94
Male	597,093	41.6%	584,133	44.5%	12,960	10.4%		25,931	10.4%	12,971	10.4%	12,960	10.4%	
<b>Region</b>														
Midwest	271,319	18.9%	249,383	19.0%	21,936	17.6%	<0.001	43,870	17.6%	21,935	17.6%	21,935	17.6%	1.00
Northeast	423,934	29.5%	390,134	29.7%	33,800	27.1%		67,594	27.1%	33,797	27.1%	33,797	27.1%	
South	523,112	36.4%	480,680	36.7%	42,432	34.0%		84,618	33.9%	42,309	33.9%	42,309	33.9%	
West	217,935	15.2%	191,260	14.6%	26,675	21.4%		53,350	21.4%	26,675	21.4%	26,675	21.4%	
<b>Insurance</b>														
Commercial	587,847	40.9%	552,487	42.1%	35,360	28.3%	<0.001	70,725	28.4%	35,365	28.4%	35,360	28.4%	1.00
Dual	54,851	3.8%	46,371	3.5%	8,480	6.8%		16,696	6.7%	8,342	6.7%	8,354	6.7%	
Medicaid	320,434	22.3%	296,591	22.6%	23,843	19.1%		47,674	19.1%	23,832	19.1%	23,842	19.1%	
Medicare	473,168	32.9%	416,008	31.7%	57,160	45.8%		114,337	45.8%	57,177	45.8%	57,160	45.8%	
<b>PCP Visit 2019</b>														
No	508,587	35.4%	473,241	36.1%	35,346	28.3%	<0.001	70,689	28.3%	35,343	28.3%	35,346	28.3%	0.99
Yes	927,713	64.6%	838,216	63.9%	89,497	71.7%		178,743	71.7%	89,373	71.7%	89,370	71.7%	
<b>Continuous Outcomes</b>														
	<b>mean</b>	<b>SD</b>	<b>mean</b>	<b>SD</b>	<b>mean</b>	<b>SD</b>	<b>p-value</b>	<b>mean</b>	<b>SD</b>	<b>mean</b>	<b>SD</b>	<b>mean</b>	<b>SD</b>	<b>p-value</b>
<b>CCI</b>	1.12	1.79	1.13	1.79	1.02	1.86	<0.001	1.02	1.85	1.02	1.84	1.02	1.86	0.49

BP: bisphosphonate; CCI: Charlson Comorbidity Index; PCP: primary care physician; SD: standard deviation

2714  
2715  
2716  
2717



2718  
2719  
2720

**Table S8f: Statin Non-user Cohort (Region=New York State) by BP Use, Patient Characteristics Pre/Post Match of BP Users/Non-users**

	Region=NY Statin Non-users by BP: Unmatched							Region=NY Statin Non-users by BP: Matched						
	All		BP Non-users		BP Users		p-value	All		BP Non-users		BP Users		p-value
	N	%	N	%	N	%		N	%	N	%	N	%	
<b>All Patients</b>	<b>185,536</b>	<b>100.0%</b>	<b>170,990</b>	<b>92.2%</b>	<b>14,546</b>	<b>7.8%</b>		<b>29,042</b>	<b>100.0%</b>	<b>14,521</b>	<b>50.0%</b>	<b>14,521</b>	<b>50.0%</b>	
<b>Age</b>														
≤20	67	0.0%	67	0.0%	0	0.0%	<0.001	0	0.0%	0	0.0%	0	0.0%	1.00
21-40	4,508	2.4%	4,498	2.6%	10	0.1%		23	0.1%	13	0.1%	10	0.1%	
41-50	15,420	8.3%	15,314	9.0%	106	0.7%		211	0.7%	105	0.7%	106	0.7%	
51-60	43,068	23.2%	41,317	24.2%	1,751	12.0%		3,502	12.1%	1,751	12.1%	1,751	12.1%	
61-70	53,233	28.7%	48,148	28.2%	5,085	35.0%		10,174	35.0%	5,089	35.0%	5,085	35.0%	
71-80	45,675	24.6%	40,731	23.8%	4,944	34.0%		9,877	34.0%	4,937	34.0%	4,940	34.0%	
≥81	23,565	12.7%	20,915	12.2%	2,650	18.2%		5,255	18.1%	2,626	18.1%	2,629	18.1%	
<b>Gender</b>														
Female	107,420	57.9%	94,242	55.1%	13,178	90.6%	<0.001	26,304	90.6%	13,151	90.6%	13,153	90.6%	0.97
Male	78,116	42.1%	76,748	44.9%	1,368	9.4%		2,738	9.4%	1,370	9.4%	1,368	9.4%	
<b>Insurance</b>														
Commercial	58,206	31.4%	56,313	32.9%	1,893	13.0%	<0.001	3,785	13.0%	1,892	13.0%	1,893	13.0%	0.96
Dual	2,190	1.2%	1,754	1.0%	436	3.0%		883	3.0%	449	3.1%	434	3.0%	
Medicaid	41,703	22.5%	38,177	22.3%	3,526	24.2%		6,994	24.1%	3,491	24.0%	3,503	24.1%	
Medicare	83,437	45.0%	74,746	43.7%	8,691	59.7%		17,380	59.8%	8,689	59.8%	8,691	59.9%	
<b>PCP Visit 2019</b>														
No	73,675	39.7%	69,382	40.6%	4,293	29.5%	<0.001	8,564	29.5%	4,280	29.5%	4,284	29.5%	0.96
Yes	111,861	60.3%	101,608	59.4%	10,253	70.5%		20,478	70.5%	10,241	70.5%	10,237	70.5%	
<b>Continuous Outcomes</b>														
	<b>mean</b>	<b>SD</b>	<b>mean</b>	<b>SD</b>	<b>mean</b>	<b>SD</b>	<b>p-value</b>	<b>mean</b>	<b>SD</b>	<b>mean</b>	<b>SD</b>	<b>mean</b>	<b>SD</b>	<b>p-value</b>
<b>CCI</b>	1.08	1.76	1.09	1.76	0.95	1.75	<0.001	0.95	1.74	0.95	1.73	0.95	1.75	0.82

BP: bisphosphonate; CCI: Charlson Comorbidity Index; PCP: primary care physician; SD: standard deviation

2721  
2722  
2723

2724  
2725

**Table S9a: Antihypertensive Cohort (All Regions), Patient Characteristics Pre/Post Match**

	All Observations by Antihypertensive Use: Unmatched							All Observations by Antihypertensive Use: Matched						
	All		HTN Non-users		HTN Users		p-value	All		HTN Non-users		HTN Users		p-value
	N	%	N	%	N	%		N	%	N	%	N	%	
<b>All Patients</b>	<b>7,906,603</b>	<b>100.0%</b>	<b>5,805,483</b>	<b>73.4%</b>	<b>2,101,120</b>	<b>26.6%</b>		<b>3,572,002</b>	<b>100.0%</b>	<b>1,786,001</b>	<b>50.0%</b>	<b>1,786,001</b>	<b>50.0%</b>	
<b>Age</b>														
≤20	1,840,050	23.3%	1,823,229	31.4%	16,821	0.8%	<0.001	33,574	0.9%	16,785	0.9%	16,789	0.9%	0.44
21-40	1,446,999	18.3%	1,299,520	22.4%	147,479	7.0%		293,445	8.2%	146,712	8.2%	146,733	8.2%	
41-50	925,309	11.7%	685,931	11.8%	239,378	11.4%		463,130	13.0%	231,312	13.0%	231,818	13.0%	
51-60	1,250,190	15.8%	759,987	13.1%	490,203	23.3%		870,549	24.4%	434,995	24.4%	435,554	24.4%	
61-70	1,181,261	14.9%	626,235	10.8%	555,026	26.4%		918,823	25.7%	459,192	25.7%	459,631	25.7%	
71-80	783,775	9.9%	381,957	6.6%	401,818	19.1%		619,578	17.3%	309,898	17.4%	309,680	17.3%	
≥81	479,019	6.1%	228,624	3.9%	250,395	11.9%		372,903	10.4%	187,107	10.5%	185,796	10.4%	
<b>Gender</b>														
Female	4,670,960	59.1%	3,402,357	58.6%	1,268,603	60.4%	<0.001	2,159,365	60.5%	1,079,468	60.4%	1,079,897	60.5%	0.64
Male	3,235,643	40.9%	2,403,126	41.4%	832,517	39.6%		1,412,637	39.5%	706,533	39.6%	706,104	39.5%	
<b>Region</b>														
Midwest	1,467,802	18.6%	1,065,772	18.4%	402,030	19.1%	<0.001	694,206	19.4%	347,103	19.4%	347,103	19.4%	1.00
Northeast	2,152,560	27.2%	1,568,239	27.0%	584,321	27.8%		997,132	27.9%	498,566	27.9%	498,566	27.9%	
South	3,042,604	38.5%	2,240,163	38.6%	802,441	38.2%		1,338,570	37.5%	669,285	37.5%	669,285	37.5%	
West	1,243,637	15.7%	931,309	16.0%	312,328	14.9%		542,094	15.2%	271,047	15.2%	271,047	15.2%	
<b>Insurance</b>														
Commercial	3,938,603	49.8%	3,060,354	52.7%	878,249	41.8%	<0.001	1,695,516	47.5%	848,106	47.5%	847,410	47.4%	0.80
Dual	156,497	2.0%	55,827	1.0%	100,670	4.8%		93,467	2.6%	46,774	2.6%	46,693	2.6%	
Medicaid	2,594,500	32.8%	2,091,349	36.0%	503,151	23.9%		812,737	22.8%	406,012	22.7%	406,725	22.8%	
Medicare	1,217,003	15.4%	597,953	10.3%	619,050	29.5%		970,282	27.2%	485,109	27.2%	485,173	27.2%	
<b>PCP Visit 2019</b>														
No	4,283,697	54.2%	3,531,914	60.8%	751,783	35.8%	<0.001	1,438,005	40.3%	719,756	40.3%	718,249	40.2%	0.10
Yes	3,622,906	45.8%	2,273,569	39.2%	1,349,337	64.2%		2,133,997	59.7%	1,066,245	59.7%	1,067,752	59.8%	
<b>Continuous Outcomes</b>														
	<b>mean</b>	<b>SD</b>	<b>mean</b>	<b>SD</b>	<b>mean</b>	<b>SD</b>	<b>p-value</b>	<b>mean</b>	<b>SD</b>	<b>mean</b>	<b>SD</b>	<b>mean</b>	<b>SD</b>	<b>p-value</b>
<b>CCI</b>	0.62	1.38	0.43	1.14	1.13	1.80	<0.001	0.95	1.65	0.96	1.66	0.95	1.64	<0.05

CCI: Charlson Comorbidity Index; HTN: antihypertensive; PCP: primary care physician; SD: standard deviation

2726  
2727  
2728

2729  
2730

**Table S9b: Antihypertensive Cohort (Region=New York State), Patient Characteristics Pre/Post Match**

	Region=NY by Antihypertensive Use: Unmatched							Region=NY by Antihypertensive Use: Matched						
	All		HTN Non-users		HTN Users		p-value	All		HTN Non-users		HTN Users		p-value
	N	%	N	%	N	%		N	%	N	%	N	%	
<b>All Patients</b>	<b>968,296</b>	<b>100.0%</b>	<b>709,644</b>	<b>73.3%</b>	<b>258,652</b>	<b>26.7%</b>		<b>407,248</b>	<b>100.0%</b>	<b>203,624</b>	<b>50.0%</b>	<b>203,624</b>	<b>50.0%</b>	
<b>Age</b>														
≤20	133,178	13.8%	132,352	18.7%	826	0.3%	<0.001	1,622	0.4%	811	0.4%	811	0.4%	1.00
21-40	192,959	19.9%	181,447	25.6%	11,512	4.5%		22,930	5.6%	11,465	5.6%	11,465	5.6%	
41-50	127,794	13.2%	105,490	14.9%	22,304	8.6%		43,846	10.8%	21,923	10.8%	21,923	10.8%	
51-60	172,444	17.8%	119,643	16.9%	52,801	20.4%		96,318	23.7%	48,159	23.7%	48,159	23.7%	
61-70	159,912	16.5%	92,103	13.0%	67,809	26.2%		109,858	27.0%	54,929	27.0%	54,929	27.0%	
71-80	120,117	12.4%	54,076	7.6%	66,041	25.5%		88,734	21.8%	44,367	21.8%	44,367	21.8%	
≥81	61,892	6.4%	24,533	3.5%	37,359	14.4%		43,940	10.8%	21,970	10.8%	21,970	10.8%	
<b>Gender</b>														
Female	573,610	59.2%	419,901	59.2%	153,709	59.4%	0.02	240,930	59.2%	120,465	59.2%	120,465	59.2%	1.00
Male	394,686	40.8%	289,743	40.8%	104,943	40.6%		166,318	40.8%	83,159	40.8%	83,159	40.8%	
<b>Insurance</b>														
Commercial	500,918	51.7%	425,181	59.9%	75,737	29.3%	<0.001	150,918	37.1%	75,459	37.1%	75,459	37.1%	1.00
Dual	6,814	0.7%	1,659	0.2%	5,155	2.0%		2,986	0.7%	1,493	0.7%	1,493	0.7%	
Medicaid	252,366	26.1%	193,207	27.2%	59,159	22.9%		95,032	23.3%	47,516	23.3%	47,516	23.3%	
Medicare	208,198	21.5%	89,597	12.6%	118,601	45.9%		158,312	38.9%	79,156	38.9%	79,156	38.9%	
<b>PCP Visit 2019</b>														
No	521,282	53.8%	423,952	59.7%	97,330	37.6%	<0.001	181,234	44.5%	90,617	44.5%	90,617	44.5%	1.00
Yes	447,014	46.2%	285,692	40.3%	161,322	62.4%		226,014	55.5%	113,007	55.5%	113,007	55.5%	
<b>Continuous Outcomes</b>														
	<b>mean</b>	<b>SD</b>	<b>mean</b>	<b>SD</b>	<b>mean</b>	<b>SD</b>	<b>p-value</b>	<b>mean</b>	<b>SD</b>	<b>mean</b>	<b>SD</b>	<b>mean</b>	<b>SD</b>	<b>p-value</b>
<b>CCI</b>	0.65	1.39	0.46	1.16	1.17	1.80	<0.001	0.95	1.60	0.95	1.60	0.95	1.60	1.00

CCI: Charlson Comorbidity Index; HTN: antihypertensive; PCP: primary care physician; SD: standard deviation

2731  
2732  
2733

2734  
2735

**Table S9c: Antihypertensive User Cohort (All Regions) by BP Use, Patient Characteristics Pre/Post Match of BP Users/Non-users**

	All Antihypertensive Users by BP: Unmatched							All Antihypertensive Users by BP: Matched						
	All		BP Non-user		BP User		p-value	All		BP Non-user		BP User		p-value
	N	%	N	%	N	%		N	%	N	%	N	%	
<b>All Patients</b>	<b>1,786,001</b>	<b>100.0%</b>	<b>1,579,388</b>	<b>88.4%</b>	<b>206,613</b>	<b>11.6%</b>		<b>408,792</b>	<b>100.0%</b>	<b>204,396</b>	<b>50.0%</b>	<b>204,396</b>	<b>50.0%</b>	
<b>Age</b>														
≤20	16,789	0.9%	16,586	1.1%	203	0.1%	<0.001	411	0.1%	208	0.1%	203	0.1%	1.00
21-40	146,733	8.2%	145,872	9.2%	861	0.4%		1,728	0.4%	868	0.4%	860	0.4%	
41-50	231,818	13.0%	229,150	14.5%	2,668	1.3%		5,333	1.3%	2,667	1.3%	2,666	1.3%	
51-60	435,554	24.4%	413,155	26.2%	22,399	10.8%		44,796	11.0%	22,399	11.0%	22,397	11.0%	
61-70	459,631	25.7%	390,664	24.7%	68,967	33.4%		137,730	33.7%	68,862	33.7%	68,868	33.7%	
71-80	309,680	17.3%	237,749	15.1%	71,931	34.8%		140,882	34.5%	70,439	34.5%	70,443	34.5%	
≥81	185,796	10.4%	146,212	9.3%	39,584	19.2%		77,912	19.1%	38,953	19.1%	38,959	19.1%	
<b>Gender</b>														
Female	1,079,897	60.5%	894,472	56.6%	185,425	89.7%	<0.001	366,424	89.6%	183,212	89.6%	183,212	89.6%	1.00
Male	706,104	39.5%	684,916	43.4%	21,188	10.3%		42,368	10.4%	21,184	10.4%	21,184	10.4%	
<b>Region</b>														
Midwest	347,103	19.4%	313,523	19.9%	33,580	16.3%	<0.001	67,058	16.4%	33,529	16.4%	33,529	16.4%	1.00
Northeast	498,566	27.9%	444,828	28.2%	53,738	26.0%		107,150	26.2%	53,575	26.2%	53,575	26.2%	
South	669,285	37.5%	595,410	37.7%	73,875	35.8%		146,890	35.9%	73,445	35.9%	73,445	35.9%	
West	271,047	15.2%	225,627	14.3%	45,420	22.0%		87,694	21.5%	43,847	21.5%	43,847	21.5%	
<b>Insurance</b>														
Commercial	847,410	47.4%	787,519	49.9%	59,891	29.0%	<0.001	119,737	29.3%	59,863	29.3%	59,874	29.3%	1.00
Dual	46,693	2.6%	37,153	2.4%	9,540	4.6%		17,884	4.4%	8,945	4.4%	8,939	4.4%	
Medicaid	406,725	22.8%	369,893	23.4%	36,832	17.8%		70,769	17.3%	35,387	17.3%	35,382	17.3%	
Medicare	485,173	27.2%	384,823	24.4%	100,350	48.6%		200,402	49.0%	100,201	49.0%	100,201	49.0%	
<b>PCP Visit 2019</b>														
No	718,249	40.2%	633,042	40.1%	85,207	41.2%	<0.001	168,255	41.2%	84,128	41.2%	84,127	41.2%	1.00
Yes	1,067,752	59.8%	946,346	59.9%	121,406	58.8%		240,537	58.8%	120,268	58.8%	120,269	58.8%	
<b>Continuous Outcomes</b>														
	<b>mean</b>	<b>SD</b>	<b>mean</b>	<b>SD</b>	<b>mean</b>	<b>SD</b>	<b>p-value</b>	<b>mean</b>	<b>SD</b>	<b>mean</b>	<b>SD</b>	<b>mean</b>	<b>SD</b>	<b>p-value</b>
<b>CCI</b>	0.95	1.64	0.95	1.64	0.94	1.68	0.02	0.95	1.67	0.95	1.67	0.95	1.68	0.68

BP: bisphosphonate; CCI: Charlson Comorbidity Index; PCP: primary care physician; SD: standard deviation

2736  
2737  
2738

2739  
2740  
2741

**Table S9d: Antihypertensive User Cohort (Region=New York State) by BP Use, Patient Characteristics Pre/Post Match of BP Users/Non-users**

	Region=NY Antihypertensive Users by BP: Unmatched							Region=NY Antihypertensive Users by BP: Matched						
	All		BP Non-user		BP User		p-value	All		BP Non-user		BP User		p-value
	N	%	N	%	N	%		N	%	N	%	N	%	
<b>All Patients</b>	203,624	100.0%	182,411	89.6%	21,213	10.4%		42,252	100.0%	21,126	50.0%	21,126	50.0%	
<b>Age</b>														
≤20	811	0.4%	798	0.4%	13	0.1%	<0.001	27	0.1%	14	0.1%	13	0.1%	1.00
21-40	11,465	5.6%	11,396	6.2%	69	0.3%		137	0.3%	68	0.3%	69	0.3%	
41-50	21,923	10.8%	21,747	11.9%	176	0.8%		354	0.8%	178	0.8%	176	0.8%	
51-60	48,159	23.7%	46,047	25.2%	2,112	10.0%		4,218	10.0%	2,108	10.0%	2,110	10.0%	
61-70	54,929	27.0%	48,022	26.3%	6,907	32.6%		13,804	32.7%	6,902	32.7%	6,902	32.7%	
71-80	44,367	21.8%	36,409	20.0%	7,958	37.5%		15,777	37.3%	7,886	37.3%	7,891	37.4%	
≥81	21,970	10.8%	17,992	9.9%	3,978	18.8%		7,935	18.8%	3,970	18.8%	3,965	18.8%	
<b>Gender</b>														
Female	120,465	59.2%	101,190	55.5%	19,275	90.9%	<0.001	38,380	90.8%	19,190	90.8%	19,190	90.8%	1.00
Male	83,159	40.8%	81,221	44.5%	1,938	9.1%		3,872	9.2%	1,936	9.2%	1,936	9.2%	
<b>Insurance</b>														
Commercial	75,459	37.1%	71,460	39.2%	3,999	18.9%	<0.001	7,993	18.9%	3,997	18.9%	3,996	18.9%	1.00
Dual	1,493	0.7%	1,151	0.6%	342	1.6%		643	1.5%	322	1.5%	321	1.5%	
Medicaid	47,516	23.3%	44,248	24.3%	3,268	15.4%		6,414	15.2%	3,207	15.2%	3,207	15.2%	
Medicare	79,156	38.9%	65,552	35.9%	13,604	64.1%		27,202	64.4%	13,600	64.4%	13,602	64.4%	
<b>PCP Visit 2019</b>														
No	90,617	44.5%	80,739	44.3%	9,878	46.6%	<0.001	19,672	46.6%	9,837	46.6%	9,835	46.6%	0.98
Yes	113,007	55.5%	101,672	55.7%	11,335	53.4%		22,580	53.4%	11,289	53.4%	11,291	53.4%	
<b>Continuous Outcomes</b>														
	mean	SD	mean	SD	mean	SD	p-value	mean	SD	mean	SD	mean	SD	p-value
<b>CCI</b>	0.95	1.60	0.95	1.61	0.88	1.54	<0.001	0.87	1.53	0.87	1.52	0.87	1.53	0.87

BP: bisphosphonate; CCI: Charlson Comorbidity Index; PCP: primary care physician; SD: standard deviation

2742  
2743  
2744

2745  
2746  
2747

**Table S9e: Antihypertensive Non-user Cohort (All Regions) by BP Use, Patient Characteristics Pre/Post Match of BP Users/Non-users**

	All Antihypertensive Non-users by BP: Unmatched							All Antihypertensive Non-users by BP: Matched						
	All		BP Non-user		BP User		p-value	All		BP Non-user		BP User		p-value
	N	%	N	%	N	%		N	%	N	%	N	%	
<b>All Patients</b>	<b>1,786,001</b>	<b>100.0%</b>	<b>1,649,985</b>	<b>92.4%</b>	<b>136,016</b>	<b>7.6%</b>		<b>271,448</b>	<b>100.0%</b>	<b>135,724</b>	<b>50.0%</b>	<b>135,724</b>	<b>50.0%</b>	
<b>Age</b>														
≤20	16,785	0.9%	16,767	1.0%	18	0.0%	<0.001	34	0.0%	16	0.0%	18	0.0%	1.00
21-40	146,712	8.2%	146,210	8.9%	502	0.4%		1,009	0.4%	507	0.4%	502	0.4%	
41-50	231,312	13.0%	228,725	13.9%	2,587	1.9%		5,163	1.9%	2,577	1.9%	2,586	1.9%	
51-60	434,995	24.4%	410,636	24.9%	24,359	17.9%		48,700	17.9%	24,349	17.9%	24,351	17.9%	
61-70	459,192	25.7%	404,445	24.5%	54,747	40.3%		109,415	40.3%	54,711	40.3%	54,704	40.3%	
71-80	309,898	17.4%	271,617	16.5%	38,281	28.1%		76,139	28.0%	38,070	28.0%	38,069	28.0%	
≥81	187,107	10.5%	171,585	10.4%	15,522	11.4%		30,988	11.4%	15,494	11.4%	15,494	11.4%	
<b>Gender</b>														
Female	1,079,468	60.4%	956,403	58.0%	123,065	90.5%	<0.001	245,537	90.5%	122,762	90.4%	122,775	90.5%	0.93
Male	706,533	39.6%	693,582	42.0%	12,951	9.5%		25,911	9.5%	12,962	9.6%	12,949	9.5%	
<b>Region</b>														
Midwest	347,103	19.4%	321,267	19.5%	25,836	19.0%	<0.001	51,638	19.0%	25,819	19.0%	25,819	19.0%	1.00
Northeast	498,566	27.9%	463,273	28.1%	35,293	25.9%		70,544	26.0%	35,272	26.0%	35,272	26.0%	
South	669,285	37.5%	622,064	37.7%	47,221	34.7%		93,980	34.6%	46,990	34.6%	46,990	34.6%	
West	271,047	15.2%	243,381	14.8%	27,666	20.3%		55,286	20.4%	27,643	20.4%	27,643	20.4%	
<b>Insurance</b>														
Commercial	848,106	47.5%	798,579	48.4%	49,527	36.4%	<0.001	99,039	36.5%	49,523	36.5%	49,516	36.5%	1.00
Dual	46,774	2.6%	40,212	2.4%	6,562	4.8%		12,645	4.7%	6,319	4.7%	6,326	4.7%	
Medicaid	406,012	22.7%	381,472	23.1%	24,540	18.0%		49,025	18.1%	24,516	18.1%	24,509	18.1%	
Medicare	485,109	27.2%	429,722	26.0%	55,387	40.7%		110,739	40.8%	55,366	40.8%	55,373	40.8%	
<b>PCP Visit 2019</b>														
No	719,756	40.3%	676,255	41.0%	43,501	32.0%	<0.001	86,956	32.0%	43,478	32.0%	43,478	32.0%	1.00
Yes	1,066,245	59.7%	973,730	59.0%	92,515	68.0%		184,492	68.0%	92,246	68.0%	92,246	68.0%	
<b>Continuous Outcomes</b>														
	<b>mean</b>	<b>SD</b>	<b>mean</b>	<b>SD</b>	<b>mean</b>	<b>SD</b>	<b>p-value</b>	<b>mean</b>	<b>SD</b>	<b>mean</b>	<b>SD</b>	<b>mean</b>	<b>SD</b>	<b>p-value</b>
<b>CCI</b>	0.96	1.66	0.96	1.65	0.88	1.76	<0.001	0.88	1.75	0.88	1.74	0.88	1.75	0.76

BP: bisphosphonate; CCI: Charlson Comorbidity Index; PCP: primary care physician; SD: standard deviation

2748  
2749  
2750

2751  
2752  
2753

**Table S9f: Antihypertensive Non-user Cohort (Region=New York State) by BP Use, Patient Characteristics Pre/Post Match of BP Users/Non-users**

	Region=NY Antihypertensive Non-Users by BP: Unmatched							Region=NY Antihypertensive Non-users by BP: Matched						
	All		BP Non-user		BP User		p-value	All		BP Non-user		BP User		p-value
	N	%	N	%	N	%		N	%	N	%	N	%	
<b>All Patients</b>	203,624	100.0%	189,573	93.1%	14,051	6.9%		27,966	100.0%	13,983	50.0%	13,983	50.0%	
<b>Age</b>														
≤20	811	0.4%	810	0.4%	1	0.0%	<0.001	2	0.0%	1	0.0%	1	0.0%	1.00
21-40	11,465	5.6%	11,451	6.0%	14	0.1%		28	0.1%	14	0.1%	14	0.1%	
41-50	21,923	10.8%	21,762	11.5%	161	1.1%		324	1.2%	163	1.2%	161	1.2%	
51-60	48,159	23.7%	46,035	24.3%	2,124	15.1%		4,245	15.2%	2,121	15.2%	2,124	15.2%	
61-70	54,929	27.0%	49,409	26.1%	5,520	39.3%		11,027	39.4%	5,512	39.4%	5,515	39.4%	
71-80	44,367	21.8%	39,789	21.0%	4,578	32.6%		9,054	32.4%	4,528	32.4%	4,526	32.4%	
≥81	21,970	10.8%	20,317	10.7%	1,653	11.8%		3,286	11.7%	1,644	11.8%	1,642	11.7%	
<b>Gender</b>														
Female	120,465	59.2%	107,632	56.8%	12,833	91.3%	<0.001	25,530	91.3%	12,764	91.3%	12,766	91.3%	0.97
Male	83,159	40.8%	81,941	43.2%	1,218	8.7%		2,436	8.7%	1,219	8.7%	1,217	8.7%	
<b>Insurance</b>														
Commercial	75,459	37.1%	73,115	38.6%	2,344	16.7%	<0.001	4,683	16.7%	2,342	16.7%	2,341	16.7%	1.00
Dual	1,493	0.7%	1,211	0.6%	282	2.0%		554	2.0%	277	2.0%	277	2.0%	
Medicaid	47,516	23.3%	43,809	23.1%	3,707	26.4%		7,295	26.1%	3,648	26.1%	3,647	26.1%	
Medicare	79,156	38.9%	71,438	37.7%	7,718	54.9%		15,434	55.2%	7,716	55.2%	7,718	55.2%	
<b>PCP Visit 2019</b>														
No	90,617	44.5%	85,875	45.3%	4,742	33.7%	<0.001	9,461	33.8%	4,728	33.8%	4,733	33.8%	0.95
Yes	113,007	55.5%	103,698	54.7%	9,309	66.3%		18,505	66.2%	9,255	66.2%	9,250	66.2%	
<b>Continuous Outcomes</b>														
	mean	SD	mean	SD	mean	SD	p-value	mean	SD	mean	SD	mean	SD	p-value
<b>CCI</b>	0.95	1.60	0.96	1.60	0.81	1.60	<0.001	0.81	1.59	0.81	1.58	0.81	1.59	0.92

BP: bisphosphonate; CCI: Charlson Comorbidity Index; PCP: primary care physician; SD: standard deviation

2754  
2755  
2756

2757  
2758

**Table S10a: Antidiabetic Cohort (All Regions), Patient Characteristics Pre/Post Match**

	All Observations by Antidiabetic Use: Unmatched							All Observations by Antidiabetic Use: Matched						
	All		DIAB Non-users		DIAB Users		p-value	All		DIAB Non-users		DIAB Users		p-value
	N	%	N	%	N	%		N	%	N	%	N	%	
<b>All Patients</b>	<b>7,906,603</b>	<b>100.0%</b>	<b>7,151,351</b>	<b>90.4%</b>	<b>755,252</b>	<b>9.6%</b>		<b>1,509,106</b>	<b>100.0%</b>	<b>754,553</b>	<b>50.0%</b>	<b>754,553</b>	<b>50.0%</b>	
<b>Age</b>														
≤20	1,840,050	23.3%	1,833,838	25.6%	6,212	0.8%	<0.001	12,422	0.8%	6,211	0.8%	6,211	0.8%	1.00
21-40	1,446,999	18.3%	1,389,243	19.4%	57,756	7.6%		115,448	7.7%	57,723	7.6%	57,725	7.7%	
41-50	925,309	11.7%	833,333	11.7%	91,976	12.2%		183,810	12.2%	91,905	12.2%	91,905	12.2%	
51-60	1,250,190	15.8%	1,058,878	14.8%	191,312	25.3%		382,390	25.3%	191,196	25.3%	191,194	25.3%	
61-70	1,181,261	14.9%	973,670	13.6%	207,591	27.5%		414,869	27.5%	207,435	27.5%	207,434	27.5%	
71-80	783,775	9.9%	645,256	9.0%	138,519	18.3%		276,619	18.3%	138,310	18.3%	138,309	18.3%	
≥81	479,019	6.1%	417,133	5.8%	61,886	8.2%		123,548	8.2%	61,773	8.2%	61,775	8.2%	
<b>Gender</b>														
Female	4,670,960	59.1%	4,212,086	58.9%	458,874	60.8%	<0.001	916,914	60.8%	458,455	60.8%	458,459	60.8%	0.99
Male	3,235,643	40.9%	2,939,265	41.1%	296,378	39.2%		592,192	39.2%	296,098	39.2%	296,094	39.2%	
<b>Region</b>														
Midwest	1,467,802	18.6%	1,333,631	18.6%	134,171	17.8%	<0.001	268,044	17.8%	134,022	17.8%	134,022	17.8%	1.00
Northeast	2,152,560	27.2%	1,935,311	27.1%	217,249	28.8%		434,080	28.8%	217,040	28.8%	217,040	28.8%	
South	3,042,604	38.5%	2,752,618	38.5%	289,986	38.4%		579,562	38.4%	289,781	38.4%	289,781	38.4%	
West	1,243,637	15.7%	1,129,791	15.8%	113,846	15.1%		227,420	15.1%	113,710	15.1%	113,710	15.1%	
<b>Insurance</b>														
Commercial	3,938,603	49.8%	3,631,514	50.8%	307,089	40.7%	<0.001	614,045	40.7%	307,022	40.7%	307,023	40.7%	1.00
Dual	156,497	2.0%	113,496	1.6%	43,001	5.7%		85,209	5.6%	42,603	5.6%	42,606	5.6%	
Medicaid	2,594,500	32.8%	2,387,519	33.4%	206,981	27.4%		413,743	27.4%	206,875	27.4%	206,868	27.4%	
Medicare	1,217,003	15.4%	1,018,822	14.2%	198,181	26.2%		396,109	26.2%	198,053	26.2%	198,056	26.2%	
<b>PCP Visit 2019</b>														
No	4,283,697	54.2%	4,030,804	56.4%	252,893	33.5%	<0.001	505,500	33.5%	252,752	33.5%	252,748	33.5%	0.99
Yes	3,622,906	45.8%	3,120,547	43.6%	502,359	66.5%		1,003,606	66.5%	501,801	66.5%	501,805	66.5%	
<b>Continuous Outcomes</b>														
	<b>mean</b>	<b>SD</b>	<b>mean</b>	<b>SD</b>	<b>mean</b>	<b>SD</b>	<b>p-value</b>	<b>mean</b>	<b>SD</b>	<b>mean</b>	<b>SD</b>	<b>mean</b>	<b>SD</b>	<b>p-value</b>
<b>CCI</b>	0.62	1.38	0.55	1.30	1.25	1.84	<0.001	1.24	1.82	1.24	1.82	1.24	1.82	0.99

2759

CCI: Charlson Comorbidity Index; DIAB: antidiabetic; PCP: primary care physician; SD: standard deviation



2760  
2761

**Table S10b: Antidiabetic Cohort (Region=New York State), Patient Characteristics Pre/Post Match**

	Region=NY by Antidiabetic Use: Unmatched							Region=NY by Antidiabetic Use: Matched						
	All		DIAB Non-users		DIAB Users		p-value	All		DIAB Non-users		DIAB Users		p-value
	N	%	N	%	N	%		N	%	N	%	N	%	
<b>All Patients</b>	<b>968,296</b>	<b>100.0%</b>	<b>863,179</b>	<b>89.1%</b>	<b>105,117</b>	<b>10.9%</b>		<b>209,382</b>	<b>100.0%</b>	<b>104,691</b>	<b>50.0%</b>	<b>104,691</b>	<b>50.0%</b>	
<b>Age</b>														
≤20	133,178	13.8%	132,723	15.4%	455	0.4%	<0.001	910	0.4%	455	0.4%	455	0.4%	1.00
21-40	192,959	19.9%	186,785	21.6%	6,174	5.9%		12,328	5.9%	6,164	5.9%	6,164	5.9%	
41-50	127,794	13.2%	117,342	13.6%	10,452	9.9%		20,880	10.0%	10,440	10.0%	10,440	10.0%	
51-60	172,444	17.8%	148,040	17.2%	24,404	23.2%		48,735	23.3%	24,369	23.3%	24,366	23.3%	
61-70	159,912	16.5%	130,968	15.2%	28,944	27.5%		57,638	27.5%	28,819	27.5%	28,819	27.5%	
71-80	120,117	12.4%	95,621	11.1%	24,496	23.3%		48,625	23.2%	24,311	23.2%	24,314	23.2%	
≥81	61,892	6.4%	51,700	6.0%	10,192	9.7%		20,266	9.7%	10,133	9.7%	10,133	9.7%	
<b>Gender</b>														
Female	573,610	59.2%	512,889	59.4%	60,721	57.8%	<0.001	120,937	57.8%	60,467	57.8%	60,470	57.8%	0.99
Male	394,686	40.8%	350,290	40.6%	44,396	42.2%		88,445	42.2%	44,224	42.2%	44,221	42.2%	
<b>Insurance</b>														
Commercial	500,918	51.7%	468,804	54.3%	32,114	30.6%	<0.001	64,200	30.7%	32,100	30.7%	32,100	30.7%	1.00
Dual	6,814	0.7%	4,408	0.5%	2,406	2.3%		4,389	2.1%	2,196	2.1%	2,193	2.1%	
Medicaid	252,366	26.1%	224,334	26.0%	28,032	26.7%		55,853	26.7%	27,925	26.7%	27,928	26.7%	
Medicare	208,198	21.5%	165,633	19.2%	42,565	40.5%		84,940	40.6%	42,470	40.6%	42,470	40.6%	
<b>PCP Visit 2019</b>														
No	521,282	53.8%	484,071	56.1%	37,211	35.4%	<0.001	74,215	35.4%	37,106	35.4%	37,109	35.4%	0.99
Yes	447,014	46.2%	379,108	43.9%	67,906	64.6%		135,167	64.6%	67,585	64.6%	67,582	64.6%	
<b>Continuous Outcomes</b>														
	<b>mean</b>	<b>SD</b>	<b>mean</b>	<b>SD</b>	<b>mean</b>	<b>SD</b>	<b>p-value</b>	<b>mean</b>	<b>SD</b>	<b>mean</b>	<b>SD</b>	<b>mean</b>	<b>SD</b>	<b>p-value</b>
<b>CCI</b>	0.65	1.39	0.56	1.30	1.34	1.84	<0.001	1.32	1.79	1.32	1.79	1.32	1.79	0.98

CCI: Charlson Comorbidity Index; DIAB: antidiabetic; PCP: primary care physician; SD: standard deviation

2762  
2763  
2764

2765  
2766

**Table S10c: Antidiabetic User Cohort (All Regions) by BP Use, Patient Characteristics Pre/Post Match of BP Users/Non-users**

	All Antidiabetic Users by BP: Unmatched						All Antidiabetic Users by BP: Matched							
	All		BP Non-user		BP User		p-value	All		BP Non-user		BP User		p-value
	N	%	N	%	N	%		N	%	N	%	N	%	
<b>All Patients</b>	<b>754,553</b>	<b>100.0%</b>	<b>674,024</b>	<b>89.3%</b>	<b>80,529</b>	<b>10.7%</b>		<b>159,000</b>	<b>100.0%</b>	<b>79,500</b>	<b>50.0%</b>	<b>79,500</b>	<b>50.0%</b>	
<b>Age</b>														
≤20	6,211	0.8%	6,169	0.9%	42	0.1%	<0.001	83	0.1%	41	0.1%	42	0.1%	1.00
21-40	57,725	7.7%	57,535	8.5%	190	0.2%		380	0.2%	190	0.2%	190	0.2%	
41-50	91,905	12.2%	90,952	13.5%	953	1.2%		1,905	1.2%	952	1.2%	953	1.2%	
51-60	191,194	25.3%	182,922	27.1%	8,272	10.3%		16,536	10.4%	8,268	10.4%	8,268	10.4%	
61-70	207,434	27.5%	180,895	26.8%	26,539	33.0%		53,028	33.4%	26,512	33.3%	26,516	33.4%	
71-80	138,309	18.3%	107,467	15.9%	30,842	38.3%		60,240	37.9%	30,121	37.9%	30,119	37.9%	
≥81	61,775	8.2%	48,084	7.1%	13,691	17.0%		26,828	16.9%	13,416	16.9%	13,412	16.9%	
<b>Gender</b>														
Female	458,459	60.8%	386,400	57.3%	72,059	89.5%	<0.001	142,068	89.4%	71,027	89.3%	71,041	89.4%	0.91
Male	296,094	39.2%	287,624	42.7%	8,470	10.5%		16,932	10.6%	8,473	10.7%	8,459	10.6%	
<b>Region</b>														
Midwest	134,022	17.8%	123,909	18.4%	10,113	12.6%	<0.001	20,168	12.7%	10,084	12.7%	10,084	12.7%	1.00
Northeast	217,040	28.8%	196,723	29.2%	20,317	25.2%		40,446	25.4%	20,223	25.4%	20,223	25.4%	
South	289,781	38.4%	257,599	38.2%	32,182	40.0%		63,740	40.1%	31,870	40.1%	31,870	40.1%	
West	113,710	15.1%	95,793	14.2%	17,917	22.2%		34,646	21.8%	17,323	21.8%	17,323	21.8%	
<b>Insurance</b>														
Commercial	307,023	40.7%	290,957	43.2%	16,066	20.0%	<0.001	32,086	20.2%	16,043	20.2%	16,043	20.2%	1.00
Dual	42,606	5.6%	32,797	4.9%	9,809	12.2%		18,653	11.7%	9,321	11.7%	9,332	11.7%	
Medicaid	206,868	27.4%	188,638	28.0%	18,230	22.6%		35,513	22.3%	17,759	22.3%	17,754	22.3%	
Medicare	198,056	26.2%	161,632	24.0%	36,424	45.2%		72,748	45.8%	36,377	45.8%	36,371	45.7%	
<b>PCP Visit 2019</b>														
No	252,748	33.5%	228,203	33.9%	24,545	30.5%	<0.001	48,374	30.4%	24,184	30.4%	24,190	30.4%	0.97
Yes	501,805	66.5%	445,821	66.1%	55,984	69.5%		110,626	69.6%	55,316	69.6%	55,310	69.6%	
<b>Continuous Outcomes</b>														
	<b>mean</b>	<b>SD</b>	<b>mean</b>	<b>SD</b>	<b>mean</b>	<b>SD</b>	<b>p-value</b>	<b>mean</b>	<b>SD</b>	<b>mean</b>	<b>SD</b>	<b>mean</b>	<b>SD</b>	<b>p-value</b>
<b>CCI</b>	1.24	1.82	1.23	1.81	1.32	1.90	<0.001	1.31	1.88	1.31	1.87	1.32	1.88	0.75

BP: bisphosphonate; CCI: Charlson Comorbidity Index; PCP: primary care physician; SD: standard deviation

2767  
2768  
2769

2770  
2771  
2772

**Table S10d: Antidiabetic User Cohort (Region=New York State) by BP Use, Patient Characteristics Pre/Post Match of BP Users/Non-users**

	Region=NY Antidiabetic Users by BP: Unmatched							Region=NY Antidiabetic Users by BP: Matched						
	All		BP Non-user		BP User		p-value	All		BP Non-user		BP User		p-value
	N	%	N	%	N	%		N	%	N	%	N	%	
<b>All Patients</b>	<b>104,691</b>	<b>100.0%</b>	<b>95,162</b>	<b>90.9%</b>	<b>9,529</b>	<b>9.1%</b>		<b>18,912</b>	<b>100.0%</b>	<b>9,456</b>	<b>50.0%</b>	<b>9,456</b>	<b>50.0%</b>	
<b>Age</b>														
≤20	455	0.4%	454	0.5%	1	0.0%	<0.001	2	0.0%	1	0.0%	1	0.0%	1.00
21-40	6,164	5.9%	6,152	6.5%	12	0.1%		25	0.1%	13	0.1%	12	0.1%	
41-50	10,440	10.0%	10,363	10.9%	77	0.8%		151	0.8%	75	0.8%	76	0.8%	
51-60	24,366	23.3%	23,532	24.7%	834	8.8%		1,665	8.8%	831	8.8%	834	8.8%	
61-70	28,819	27.5%	25,939	27.3%	2,880	30.2%		5,741	30.4%	2,870	30.4%	2,871	30.4%	
71-80	24,314	23.2%	20,338	21.4%	3,976	41.7%		7,880	41.7%	3,941	41.7%	3,939	41.7%	
≥81	10,133	9.7%	8,384	8.8%	1,749	18.4%		3,448	18.2%	1,725	18.2%	1,723	18.2%	
<b>Gender</b>														
Female	60,470	57.8%	51,884	54.5%	8,586	90.1%	<0.001	17,022	90.0%	8,509	90.0%	8,513	90.0%	0.92
Male	44,221	42.2%	43,278	45.5%	943	9.9%		1,890	10.0%	947	10.0%	943	10.0%	
<b>Insurance</b>														
Commercial	32,100	30.7%	31,172	32.8%	928	9.7%	<0.001	1,849	9.8%	924	9.8%	925	9.8%	1.00
Dual	2,193	2.1%	1,693	1.8%	500	5.2%		978	5.2%	490	5.2%	488	5.2%	
Medicaid	27,928	26.7%	25,978	27.3%	1,950	20.5%		3,793	20.1%	1,897	20.1%	1,896	20.1%	
Medicare	42,470	40.6%	36,319	38.2%	6,151	64.6%		12,292	65.0%	6,145	65.0%	6,147	65.0%	
<b>PCP Visit 2019</b>														
No	37,109	35.4%	33,894	35.6%	3,215	33.7%	<.001	6,363	33.6%	3,182	33.7%	3,181	33.6%	0.99
Yes	67,582	64.6%	61,268	64.4%	6,314	66.3%		12,549	66.4%	6,274	66.3%	6,275	66.4%	
<b>Continuous Outcomes</b>														
	<b>mean</b>	<b>SD</b>	<b>mean</b>	<b>SD</b>	<b>mean</b>	<b>SD</b>	<b>p-value</b>	<b>mean</b>	<b>SD</b>	<b>mean</b>	<b>SD</b>	<b>mean</b>	<b>SD</b>	<b>p-value</b>
<b>CCI</b>	1.32	1.79	1.31	1.79	1.46	1.87	<0.001	1.44	1.83	1.44	1.82	1.45	1.84	0.75

BP: bisphosphonate; CCI: Charlson Comorbidity Index; PCP: primary care physician; SD: standard deviation

2773  
2774  
2775

2776  
2777

**Table S10e: Antidiabetic Non-user Cohort (All Regions) by BP Use, Patient Characteristics Pre/Post Match of BP Users/Non-users**

	All Antidiabetic Non-users by BP: Unmatched							All Antidiabetic Non-users by BP: Matched						
	All		BP Non-user		BP User		p-value	All		BP Non-user		BP User		p-value
	N	%	N	%	N	%		N	%	N	%	N	%	
<b>All Patients</b>	<b>754,553</b>	<b>100.0%</b>	<b>681,380</b>	<b>90.3%</b>	<b>73,173</b>	<b>9.7%</b>		<b>145,028</b>	<b>100.0%</b>	<b>72,514</b>	<b>50.0%</b>	<b>72,514</b>	<b>50.0%</b>	
<b>Age</b>														
≤20	6,211	0.8%	6,199	0.9%	12	0.0%	<0.001	24	0.0%	12	0.0%	12	0.0%	1.00
21-40	57,723	7.6%	57,497	8.4%	226	0.3%		455	0.3%	229	0.3%	226	0.3%	
41-50	91,905	12.2%	90,693	13.3%	1,212	1.7%		2,421	1.7%	1,209	1.7%	1,212	1.7%	
51-60	191,196	25.3%	180,332	26.5%	10,864	14.8%		21,721	15.0%	10,860	15.0%	10,861	15.0%	
61-70	207,435	27.5%	180,825	26.5%	26,610	36.4%		53,115	36.6%	26,558	36.6%	26,557	36.6%	
71-80	138,310	18.3%	114,018	16.7%	24,292	33.2%		47,723	32.9%	23,861	32.9%	23,862	32.9%	
≥81	61,773	8.2%	51,816	7.6%	9,957	13.6%		19,569	13.5%	9,785	13.5%	9,784	13.5%	
<b>Gender</b>														
Female	458,455	60.8%	393,376	57.7%	65,079	88.9%	<0.001	128,836	88.8%	64,411	88.8%	64,425	88.8%	0.91
Male	296,098	39.2%	288,004	42.3%	8,094	11.1%		16,192	11.2%	8,103	11.2%	8,089	11.2%	
<b>Region</b>														
Midwest	134,022	17.8%	123,283	18.1%	10,739	14.7%	<0.001	21,390	14.7%	10,695	14.7%	10,695	14.7%	1.00
Northeast	217,040	28.8%	197,710	29.0%	19,330	26.4%		38,510	26.6%	19,255	26.6%	19,255	26.6%	
South	289,781	38.4%	261,382	38.4%	28,399	38.8%		55,812	38.5%	27,906	38.5%	27,906	38.5%	
West	113,710	15.1%	99,005	14.5%	14,705	20.1%		29,316	20.2%	14,658	20.2%	14,658	20.2%	
<b>Insurance</b>														
Commercial	307,022	40.7%	289,018	42.4%	18,004	24.6%	<0.001	35,983	24.8%	17,988	24.8%	17,995	24.8%	1.00
Dual	42,603	5.6%	33,444	4.9%	9,159	12.5%		17,221	11.9%	8,611	11.9%	8,610	11.9%	
Medicaid	206,875	27.4%	190,166	27.9%	16,709	22.8%		33,264	22.9%	16,636	22.9%	16,628	22.9%	
Medicare	198,053	26.2%	168,752	24.8%	29,301	40.0%		58,560	40.4%	29,279	40.4%	29,281	40.4%	
<b>PCP Visit 2019</b>														
No	252,752	33.5%	233,775	34.3%	18,977	25.9%	<0.001	37,812	26.1%	18,903	26.1%	18,909	26.1%	0.97
Yes	501,801	66.5%	447,605	65.7%	54,196	74.1%		107,216	73.9%	53,611	73.9%	53,605	73.9%	
<b>Continuous Outcomes</b>														
	<b>mean</b>	<b>SD</b>	<b>mean</b>	<b>SD</b>	<b>mean</b>	<b>SD</b>	<b>p-value</b>	<b>mean</b>	<b>SD</b>	<b>mean</b>	<b>SD</b>	<b>mean</b>	<b>SD</b>	<b>p-value</b>
<b>CCI</b>	1.24	1.82	1.24	1.81	1.24	1.89	0.92	1.24	1.87	1.24	1.87	1.25	1.88	0.63

BP: bisphosphonate; CCI: Charlson Comorbidity Index; PCP: primary care physician; SD: standard deviation

2778  
2779  
2780

2781  
2782  
2783

**Table S10f: Antidiabetic Non-user Cohort (Region=New York State) by BP Use, Patient Characteristics Pre/Post Match of BP Users/Non-users**

	Region=NY Antidiabetic Non-users by BP: Unmatched							Region=NY Antidiabetic Non-users by BP: Matched						
	All		BP Non-user		BP User		p-value	All		BP Non-user		BP User		p-value
	N	%	N	%	N	%		N	%	N	%	N	%	
<b>All Patients</b>	104,691	100.0%	95,416	91.1%	9,275	8.9%		18,288	100.0%	9,144	50.0%	9,144	50.0%	
<b>Age</b>														
≤20	455	0.4%	455	0.5%	0	0.0%	<0.001	0	0.0%	0	0.0%	0	0.0%	1.00
21-40	6,164	5.9%	6,146	6.4%	18	0.2%		36	0.2%	18	0.2%	18	0.2%	
41-50	10,440	10.0%	10,367	10.9%	73	0.8%		147	0.8%	74	0.8%	73	0.8%	
51-60	24,369	23.3%	23,304	24.4%	1,065	11.5%		2,128	11.6%	1,064	11.6%	1,064	11.6%	
61-70	28,819	27.5%	25,720	27.0%	3,099	33.4%		6,190	33.8%	3,097	33.9%	3,093	33.8%	
71-80	24,311	23.2%	20,826	21.8%	3,485	37.6%		6,839	37.4%	3,419	37.4%	3,420	37.4%	
≥81	10,133	9.7%	8,598	9.0%	1,535	16.5%		2,948	16.1%	1,472	16.1%	1,476	16.1%	
<b>Gender</b>														
Female	60,467	57.8%	52,194	54.7%	8,273	89.2%	<0.001	16,291	89.1%	8,146	89.1%	8,145	89.1%	0.98
Male	44,224	42.2%	43,222	45.3%	1,002	10.8%		1,997	10.9%	998	10.9%	999	10.9%	
<b>Insurance</b>														
Commercial	32,100	30.7%	31,095	32.6%	1,005	10.8%	<0.001	2,002	10.9%	1,000	10.9%	1,002	11.0%	1.00
Dual	2,196	2.1%	1,675	1.8%	521	5.6%		1,006	5.5%	502	5.5%	504	5.5%	
Medicaid	27,925	26.7%	25,530	26.8%	2,395	25.8%		4,575	25.0%	2,289	25.0%	2,286	25.0%	
Medicare	42,470	40.6%	37,116	38.9%	5,354	57.7%		10,705	58.5%	5,353	58.5%	5,352	58.5%	
<b>PCP Visit 2019</b>														
No	37,106	35.4%	34,553	36.2%	2,553	27.5%	<0.001	5,039	27.6%	2,518	27.5%	2,521	27.6%	0.96
Yes	67,585	64.6%	60,863	63.8%	6,722	72.5%		13,249	72.4%	6,626	72.5%	6,623	72.4%	
<b>Continuous Outcomes</b>														
	mean	SD	mean	SD	mean	SD	p-value	mean	SD	mean	SD	mean	SD	p-value
<b>CCI</b>	1.32	1.79	1.32	1.79	1.37	1.81	0.007	1.37	1.78	1.36	1.78	1.37	1.79	0.92

2784  
2785  
2786

BP: bisphosphonate; CCI: Charlson Comorbidity Index; PCP: primary care physician; SD: standard deviation

2787  
2788

**Table S11a: Antidepressant Cohort (All Regions), Patient Characteristics Pre/Post Match**

	All Observations by Antidepressant Use: Unmatched							All Observations by Antidepressant Use: Matched						
	All		DEPR Non-users		DEPR Users		p-value	All		DEPR Non-users		DEPR Users		p-value
	N	%	N	%	N	%		N	%	N	%	N	%	
<b>All Patients</b>	<b>7,906,603</b>	<b>100.0%</b>	<b>6,335,598</b>	<b>80.1%</b>	<b>1,571,005</b>	<b>19.9%</b>		<b>3,072,096</b>	<b>100.0%</b>	<b>1,536,048</b>	<b>50.0%</b>	<b>1,536,048</b>	<b>50.0%</b>	
<b>Age</b>														
≤20	1,840,050	23.3%	1,750,435	27.6%	89,615	5.7%	<0.001	179,136	5.8%	89,565	5.8%	89,571	5.8%	1.00
21-40	1,446,999	18.3%	1,128,316	17.8%	318,683	20.3%		631,186	20.5%	315,593	20.5%	315,593	20.5%	
41-50	925,309	11.7%	683,455	10.8%	241,854	15.4%		466,681	15.2%	233,336	15.2%	233,345	15.2%	
51-60	1,250,190	15.8%	899,512	14.2%	350,678	22.3%		667,305	21.7%	333,650	21.7%	333,655	21.7%	
61-70	1,181,261	14.9%	879,560	13.9%	301,701	19.2%		592,345	19.3%	296,182	19.3%	296,163	19.3%	
71-80	783,775	9.9%	613,922	9.7%	169,853	10.8%		338,594	11.0%	169,295	11.0%	169,299	11.0%	
≥81	479,019	6.1%	380,398	6.0%	98,621	6.3%		196,849	6.4%	98,427	6.4%	98,422	6.4%	
<b>Gender</b>														
Female	4,670,960	59.1%	3,527,859	55.7%	1,143,101	72.8%	<0.001	2,219,179	72.2%	1,109,580	72.2%	1,109,599	72.2%	0.98
Male	3,235,643	40.9%	2,807,739	44.3%	427,904	27.2%		852,917	27.8%	426,468	27.8%	426,449	27.8%	
<b>Region</b>														
Midwest	1,467,802	18.6%	1,120,969	17.7%	346,833	22.1%	<0.001	671,016	21.8%	335,508	21.8%	335,508	21.8%	1.00
Northeast	2,152,560	27.2%	1,765,134	27.9%	387,426	24.7%		766,046	24.9%	383,023	24.9%	383,023	24.9%	
South	3,042,604	38.5%	2,428,383	38.3%	614,221	39.1%		1,192,058	38.8%	596,029	38.8%	596,029	38.8%	
West	1,243,637	15.7%	1,021,112	16.1%	222,525	14.2%		442,976	14.4%	221,488	14.4%	221,488	14.4%	
<b>Insurance</b>														
Commercial	3,938,603	49.8%	3,230,475	51.0%	708,128	45.1%	<0.001	1,415,351	46.1%	707,675	46.1%	707,676	46.1%	1.00
Dual	156,497	2.0%	94,682	1.5%	61,815	3.9%		109,676	3.6%	54,836	3.6%	54,840	3.6%	
Medicaid	2,594,500	32.8%	2,083,688	32.9%	510,812	32.5%		972,897	31.7%	486,446	31.7%	486,451	31.7%	
Medicare	1,217,003	15.4%	926,753	14.6%	290,250	18.5%		574,172	18.7%	287,091	18.7%	287,081	18.7%	
<b>PCP Visit 2019</b>														
No	4,283,697	54.2%	3,672,879	58.0%	610,818	38.9%	<0.001	1,210,520	39.4%	605,256	39.4%	605,264	39.4%	0.99
Yes	3,622,906	45.8%	2,662,719	42.0%	960,187	61.1%		1,861,576	60.6%	930,792	60.6%	930,784	60.6%	
<b>Continuous Outcomes</b>														
	<b>mean</b>	<b>SD</b>	<b>mean</b>	<b>SD</b>	<b>mean</b>	<b>SD</b>	<b>p-value</b>	<b>mean</b>	<b>SD</b>	<b>mean</b>	<b>SD</b>	<b>mean</b>	<b>SD</b>	<b>p-value</b>
<b>CCI</b>	0.62	1.38	0.55	1.29	0.90	1.65	<0.001	0.87	1.60	0.87	1.60	0.87	1.60	0.98

CCI: Charlson Comorbidity Index; DEPR: antidepressant; PCP: primary care physician; SD: standard deviation

2789  
2790  
2791

2792  
2793

**Table S11b: Antidepressant Cohort (Region=New York State), Patient Characteristics Pre/Post Match**

	Region=NY by Antidepressant Use: Unmatched							Region=NY by Antidepressant Use: Matched						
	All		DEPR Non-users		DEPR Users		p-value	All		DEPR Non-users		DEPR Users		p-value
	N	%	N	%	N	%		N	%	N	%	N	%	
<b>All Patients</b>	<b>968,296</b>	<b>100.0%</b>	<b>832,215</b>	<b>85.9%</b>	<b>136,081</b>	<b>14.1%</b>		<b>271,032</b>	<b>100.0%</b>	<b>135,516</b>	<b>50.0%</b>	<b>135,516</b>	<b>50.0%</b>	
<b>Age</b>														
≤20	133,178	13.8%	128,810	15.5%	4,368	3.2%	<0.001	8,728	3.2%	4,365	3.2%	4,363	3.2%	1.00
21-40	192,959	19.9%	170,076	20.4%	22,883	16.8%		45,666	16.8%	22,832	16.8%	22,834	16.8%	
41-50	127,794	13.2%	109,184	13.1%	18,610	13.7%		36,965	13.6%	18,483	13.6%	18,482	13.6%	
51-60	172,444	17.8%	142,702	17.1%	29,742	21.9%		58,966	21.8%	29,481	21.8%	29,485	21.8%	
61-70	159,912	16.5%	132,317	15.9%	27,595	20.3%		55,083	20.3%	27,543	20.3%	27,540	20.3%	
71-80	120,117	12.4%	99,040	11.9%	21,077	15.5%		42,076	15.5%	21,038	15.5%	21,038	15.5%	
≥81	61,892	6.4%	50,086	6.0%	11,806	8.7%		23,548	8.7%	11,774	8.7%	11,774	8.7%	
<b>Gender</b>														
Female	573,610	59.2%	476,684	57.3%	96,926	71.2%	<0.001	192,930	71.2%	96,468	71.2%	96,462	71.2%	0.98
Male	394,686	40.8%	355,531	42.7%	39,155	28.8%		78,102	28.8%	39,048	28.8%	39,054	28.8%	
<b>Insurance</b>														
Commercial	500,918	51.7%	449,071	54.0%	51,847	38.1%	<0.001	103,658	38.2%	51,829	38.2%	51,829	38.2%	1.00
Dual	6,814	0.7%	5,072	0.6%	1,742	1.3%		3,191	1.2%	1,591	1.2%	1,600	1.2%	
Medicaid	252,366	26.1%	213,705	25.7%	38,661	28.4%		77,136	28.5%	38,569	28.5%	38,567	28.5%	
Medicare	208,198	21.5%	164,367	19.8%	43,831	32.2%		87,047	32.1%	43,527	32.1%	43,520	32.1%	
<b>PCP Visit 2019</b>														
No	521,282	53.8%	467,739	56.2%	53,543	39.3%	<0.001	106,797	39.4%	53,397	39.4%	53,400	39.4%	0.99
Yes	447,014	46.2%	364,476	43.8%	82,538	60.7%		164,235	60.6%	82,119	60.6%	82,116	60.6%	
<b>Continuous Outcomes</b>														
	<b>mean</b>	<b>SD</b>	<b>mean</b>	<b>SD</b>	<b>mean</b>	<b>SD</b>	<b>p-value</b>	<b>mean</b>	<b>SD</b>	<b>mean</b>	<b>SD</b>	<b>mean</b>	<b>SD</b>	<b>p-value</b>
<b>CCI</b>	0.65	1.39	0.59	1.32	0.98	1.71	<0.001	0.96	1.68	0.96	1.68	0.96	1.68	0.99

CCI: Charlson Comorbidity Index; DEPR: antidepressant; PCP: primary care physician; SD: standard deviation

2794  
2795  
2796

2797  
2798

**Table S11c: Antidepressant User Cohort (All Regions) by BP Use, Patient Characteristics Pre/Post Match of BP Users/Non-users**

	All Antidepressant Users by BP: Unmatched							All Antidepressant Users by BP: Matched						
	All		BP Non-user		BP User		p-value	All		BP Non-user		BP User		p-value
	N	%	N	%	N	%		N	%	N	%	N	%	
<b>All Patients</b>	<b>1,536,048</b>	<b>100.0%</b>	<b>1,390,939</b>	<b>90.6%</b>	<b>145,109</b>	<b>9.4%</b>		<b>288,564</b>	<b>100.0%</b>	<b>144,282</b>	<b>50.0%</b>	<b>144,282</b>	<b>50.0%</b>	
<b>Age</b>														
≤20	89,571	5.8%	89,415	6.4%	156	0.1%	<0.001	313	0.1%	157	0.1%	156	0.1%	1.00
21-40	315,593	20.5%	314,429	22.6%	1,164	0.8%		2,326	0.8%	1,162	0.8%	1,164	0.8%	
41-50	233,345	15.2%	229,878	16.5%	3,467	2.4%		6,933	2.4%	3,467	2.4%	3,466	2.4%	
51-60	333,655	21.7%	310,316	22.3%	23,339	16.1%		46,674	16.2%	23,339	16.2%	23,335	16.2%	
61-70	296,163	19.3%	244,247	17.6%	51,916	35.8%		103,798	36.0%	51,905	36.0%	51,893	36.0%	
71-80	169,299	11.0%	126,089	9.1%	43,210	29.8%		85,292	29.6%	42,643	29.6%	42,649	29.6%	
≥81	98,422	6.4%	76,565	5.5%	21,857	15.1%		43,228	15.0%	21,609	15.0%	21,619	15.0%	
<b>Gender</b>														
Female	1,109,599	72.2%	976,214	70.2%	133,385	91.9%	<0.001	265,123	91.9%	132,553	91.9%	132,570	91.9%	0.91
Male	426,449	27.8%	414,725	29.8%	11,724	8.1%		23,441	8.1%	11,729	8.1%	11,712	8.1%	
<b>Region</b>														
Midwest	335,508	21.8%	309,597	22.3%	25,911	17.9%	<0.001	51,754	17.9%	25,877	17.9%	25,877	17.9%	1.00
Northeast	383,023	24.9%	347,944	25.0%	35,079	24.2%		70,010	24.3%	35,005	24.3%	35,005	24.3%	
South	596,029	38.8%	540,382	38.9%	55,647	38.3%		110,518	38.3%	55,259	38.3%	55,259	38.3%	
West	221,488	14.4%	193,016	13.9%	28,472	19.6%		56,282	19.5%	28,141	19.5%	28,141	19.5%	
<b>Insurance</b>														
Commercial	707,676	46.1%	664,625	47.8%	43,051	29.7%	<0.001	86,053	29.8%	43,023	29.8%	43,030	29.8%	1.00
Dual	54,840	3.6%	43,171	3.1%	11,669	8.0%		22,384	7.8%	11,193	7.8%	11,191	7.8%	
Medicaid	486,451	31.7%	457,656	32.9%	28,795	19.8%		56,959	19.7%	28,479	19.7%	28,480	19.7%	
Medicare	287,081	18.7%	225,487	16.2%	61,594	42.4%		123,168	42.7%	61,587	42.7%	61,581	42.7%	
<b>PCP Visit 2019</b>														
No	605,264	39.4%	553,886	39.8%	51,378	35.4%	<0.001	102,148	35.4%	51,064	35.4%	51,084	35.4%	0.94
Yes	930,784	60.6%	837,053	60.2%	93,731	64.6%		186,416	64.6%	93,218	64.6%	93,198	64.6%	
<b>Continuous Outcomes</b>														
	<b>mean</b>	<b>SD</b>	<b>mean</b>	<b>SD</b>	<b>mean</b>	<b>SD</b>	<b>p-value</b>	<b>mean</b>	<b>SD</b>	<b>mean</b>	<b>SD</b>	<b>mean</b>	<b>SD</b>	<b>p-value</b>
<b>CCI</b>	0.87	1.60	0.84	1.58	1.09	1.81	<0.001	1.09	1.79	1.08	1.78	1.09	1.79	0.56

BP: bisphosphonate; CCI: Charlson Comorbidity Index; PCP: primary care physician; SD: standard deviation

2799  
2800  
2801



2802  
2803  
2804

**Table S11d: Antidepressant User Cohort (Region=New York State) by BP Use, Patient Characteristics Pre/Post Match of BP Users/Non-users**

	Region=NY Antidepressant Users by BP: Unmatched							Region=NY Antidepressant Users by BP: Matched						
	All		BP Non-user		BP User		p-value	All		BP Non-user		BP User		p-value
	N	%	N	%	N	%		N	%	N	%	N	%	
<b>All Patients</b>	<b>135,516</b>	<b>100.0%</b>	<b>122,566</b>	<b>90.4%</b>	<b>12,950</b>	<b>9.6%</b>		<b>25,718</b>	<b>100.0%</b>	<b>12,859</b>	<b>50.0%</b>	<b>12,859</b>	<b>50.0%</b>	
<b>Age</b>														
≤20	4,363	3.2%	4,357	3.6%	6	0.0%	<0.001	12	0.0%	6	0.0%	6	0.0%	1.00
21-40	22,834	16.8%	22,770	18.6%	64	0.5%		126	0.5%	62	0.5%	64	0.5%	
41-50	18,482	13.6%	18,263	14.9%	219	1.7%		440	1.7%	221	1.7%	219	1.7%	
51-60	29,485	21.8%	27,702	22.6%	1,783	13.8%		3,570	13.9%	1,788	13.9%	1,782	13.9%	
61-70	27,540	20.3%	23,385	19.1%	4,155	32.1%		8,292	32.2%	4,146	32.2%	4,146	32.2%	
71-80	21,038	15.5%	16,548	13.5%	4,490	34.7%		8,863	34.5%	4,430	34.5%	4,433	34.5%	
≥81	11,774	8.7%	9,541	7.8%	2,233	17.2%		4,415	17.2%	2,206	17.2%	2,209	17.2%	
<b>Gender</b>														
Female	96,462	71.2%	84,469	68.9%	11,993	92.6%	<0.001	23,810	92.6%	11,906	92.6%	11,904	92.6%	0.96
Male	39,054	28.8%	38,097	31.1%	957	7.4%		1,908	7.4%	953	7.4%	955	7.4%	
<b>Insurance</b>														
Commercial	51,829	38.2%	49,332	40.2%	2,497	19.3%	<0.001	4,991	19.4%	2,495	19.4%	2,496	19.4%	1.00
Dual	1,600	1.2%	1,221	1.0%	379	2.9%		710	2.8%	356	2.8%	354	2.8%	
Medicaid	38,567	28.5%	36,366	29.7%	2,201	17.0%		4,269	16.6%	2,131	16.6%	2,138	16.6%	
Medicare	43,520	32.1%	35,647	29.1%	7,873	60.8%		15,748	61.2%	7,877	61.3%	7,871	61.2%	
<b>PCP Visit 2019</b>														
No	53,400	39.4%	48,911	39.9%	4,489	34.7%	<0.001	8,901	34.6%	4,449	34.6%	4,452	34.6%	0.97
Yes	82,116	60.6%	73,655	60.1%	8,461	65.3%		16,817	65.4%	8,410	65.4%	8,407	65.4%	
<b>Continuous Outcomes</b>														
	<b>mean</b>	<b>SD</b>	<b>mean</b>	<b>SD</b>	<b>mean</b>	<b>SD</b>	<b>p-value</b>	<b>mean</b>	<b>SD</b>	<b>mean</b>	<b>SD</b>	<b>mean</b>	<b>SD</b>	<b>p-value</b>
<b>CCI</b>	0.96	1.68	0.95	1.66	1.13	1.78	<0.001	1.12	1.76	1.12	1.75	1.12	1.77	0.86

2805  
2806

BP: bisphosphonate; CCI: Charlson Comorbidity Index; PCP: primary care physician; SD: standard deviation

2807  
2808  
2809

**Table S11e: Antidepressant Non-user Cohort (All Regions) by BP Use, Patient Characteristics Pre/Post Match of BP Users/Non-users**

	All Antidepressant Non-users by BP: Unmatched							All Antidepressant Non-users by BP: Matched						
	All		BP Non-user		BP User		p-value	All		BP Non-user		BP User		p-value
	N	%	N	%	N	%		N	%	N	%	N	%	
<b>All Patients</b>	<b>1,536,048</b>	<b>100.0%</b>	<b>1,422,938</b>	<b>92.6%</b>	<b>113,110</b>	<b>7.4%</b>		<b>224,804</b>	<b>100.0%</b>	<b>112,402</b>	<b>50.0%</b>	<b>112,402</b>	<b>50.0%</b>	
<b>Age</b>														
≤20	89,565	5.8%	89,486	6.3%	79	0.1%	<0.001	155	0.1%	76	0.1%	79	0.1%	1.00
21-40	315,593	20.5%	314,815	22.1%	778	0.7%		1,562	0.7%	784	0.7%	778	0.7%	
41-50	233,336	15.2%	230,961	16.2%	2,375	2.1%		4,746	2.1%	2,371	2.1%	2,375	2.1%	
51-60	333,650	21.7%	314,109	22.1%	19,541	17.3%		39,072	17.4%	19,536	17.4%	19,536	17.4%	
61-70	296,182	19.3%	254,286	17.9%	41,896	37.0%		83,664	37.2%	41,834	37.2%	41,830	37.2%	
71-80	169,295	11.0%	136,746	9.6%	32,549	28.8%		64,163	28.5%	32,073	28.5%	32,090	28.5%	
≥81	98,427	6.4%	82,535	5.8%	15,892	14.1%		31,442	14.0%	15,728	14.0%	15,714	14.0%	
<b>Gender</b>														
Female	1,109,580	72.2%	1,004,112	70.6%	105,468	93.2%	<0.001	209,510	93.2%	104,743	93.2%	104,767	93.2%	0.84
Male	426,468	27.8%	418,826	29.4%	7,642	6.8%		15,294	6.8%	7,659	6.8%	7,635	6.8%	
<b>Region</b>														
Midwest	335,508	21.8%	315,179	22.1%	20,329	18.0%	<0.001	40,548	18.0%	20,274	18.0%	20,274	18.0%	1.00
Northeast	383,023	24.9%	356,184	25.0%	26,839	23.7%		53,590	23.8%	26,795	23.8%	26,795	23.8%	
South	596,029	38.8%	552,754	38.8%	43,275	38.3%		85,440	38.0%	42,720	38.0%	42,720	38.0%	
West	221,488	14.4%	198,821	14.0%	22,667	20.0%		45,226	20.1%	22,613	20.1%	22,613	20.1%	
<b>Insurance</b>														
Commercial	707,675	46.1%	672,990	47.3%	34,685	30.7%	<0.001	69,354	30.9%	34,675	30.8%	34,679	30.9%	1.00
Dual	54,836	3.6%	44,281	3.1%	10,555	9.3%		19,871	8.8%	9,927	8.8%	9,944	8.8%	
Medicaid	486,446	31.7%	463,857	32.6%	22,589	20.0%		45,057	20.0%	22,537	20.1%	22,520	20.0%	
Medicare	287,091	18.7%	241,810	17.0%	45,281	40.0%		90,522	40.3%	45,263	40.3%	45,259	40.3%	
<b>PCP Visit 2019</b>														
No	605,256	39.4%	572,701	40.2%	32,555	28.8%	<0.001	64,959	28.9%	32,483	28.9%	32,476	28.9%	0.97
Yes	930,792	60.6%	850,237	59.8%	80,555	71.2%		159,845	71.1%	79,919	71.1%	79,926	71.1%	
<b>Continuous Outcomes</b>														
	<b>mean</b>	<b>SD</b>	<b>mean</b>	<b>SD</b>	<b>mean</b>	<b>SD</b>	<b>p-value</b>	<b>mean</b>	<b>SD</b>	<b>mean</b>	<b>SD</b>	<b>mean</b>	<b>SD</b>	<b>p-value</b>
<b>CCI</b>	0.87	1.60	0.85	1.58	1.06	1.84	<0.001	1.06	1.82	1.05	1.81	1.06	1.83	0.57

BP: bisphosphonate; CCI: Charlson Comorbidity Index; PCP: primary care physician; SD: standard deviation

2810  
2811

2812  
2813  
2814

**Table S11f: Antidepressant Non-user Cohort (Region=New York State) by BP Use, Patient Characteristics Pre/Post Match of BP Users/Non-users**

	Region=NY Antidepressant Non-users by BP: Unadjusted							Region=NY Antidepressant Non-users by BP: Matched						
	All		BP Non-user		BP User		p-value	All		BP Non-user		BP User		p-value
	N	%	N	%	N	%		N	%	N	%	N	%	
<b>All Patients</b>	<b>135,516</b>	<b>100.0%</b>	<b>125,342</b>	<b>92.5%</b>	<b>10,174</b>	<b>7.5%</b>		<b>20,182</b>	<b>100.0%</b>	<b>10,091</b>	<b>50.0%</b>	<b>10,091</b>	<b>50.0%</b>	
<b>Age</b>														
≤20	4,365	3.2%	4,364	3.5%	1	0.0%	<0.001	2	0.0%	1	0.0%	1	0.0%	1.00
21-40	22,832	16.8%	22,799	18.2%	33	0.3%		66	0.3%	33	0.3%	33	0.3%	
41-50	18,483	13.6%	18,350	14.6%	133	1.3%		267	1.3%	134	1.3%	133	1.3%	
51-60	29,481	21.8%	28,038	22.4%	1,443	14.2%		2,879	14.3%	1,440	14.3%	1,439	14.3%	
61-70	27,543	20.3%	24,197	19.3%	3,346	32.9%		6,686	33.1%	3,345	33.1%	3,341	33.1%	
71-80	21,038	15.5%	17,695	14.1%	3,343	32.9%		6,589	32.6%	3,294	32.6%	3,295	32.7%	
≥81	11,774	8.7%	9,899	7.9%	1,875	18.4%		3,693	18.3%	1,844	18.3%	1,849	18.3%	
<b>Gender</b>														
Female	96,468	71.2%	86,945	69.4%	9,523	93.6%	<0.001	18,892	93.6%	9,446	93.6%	9,446	93.6%	1.00
Male	39,048	28.8%	38,397	30.6%	651	6.4%		1,290	6.4%	645	6.4%	645	6.4%	
<b>Insurance</b>														
Commercial	51,829	38.2%	50,405	40.2%	1,424	14.0%	<0.001	2,848	14.1%	1,425	14.1%	1,423	14.1%	1.00
Dual	1,591	1.2%	1,210	1.0%	381	3.7%		690	3.4%	345	3.4%	345	3.4%	
Medicaid	38,569	28.5%	36,303	29.0%	2,266	22.3%		4,449	22.0%	2,226	22.1%	2,223	22.0%	
Medicare	43,527	32.1%	37,424	29.9%	6,103	60.0%		12,195	60.4%	6,095	60.4%	6,100	60.4%	
<b>PCP Visit 2019</b>														
No	53,397	39.4%	50,515	40.3%	2,882	28.3%	<0.001	5,723	28.4%	2,863	28.4%	2,860	28.3%	0.96
Yes	82,119	60.6%	74,827	59.7%	7,292	71.7%		14,459	71.6%	7,228	71.6%	7,231	71.7%	
<b>Continuous Outcomes</b>														
	mean	SD	mean	SD	mean	SD	p-value	mean	SD	mean	SD	mean	SD	p-value
<b>CCI</b>	0.96	1.68	0.95	1.66	1.13	1.81	<0.001	1.11	1.77	1.11	1.76	1.12	1.78	0.78

2815  
2816  
2817

BP: bisphosphonate; CCI: Charlson Comorbidity Index; PCP: primary care physician; SD: standard deviation

2818 **Table S12a: Patient Count Distribution Inclusive of Deceased Enrollees**

	All Observations		All Bone Health Rx Users ("Bone-Rx")	
	BP Users	BP Non-users	BP Users	BP Non-users
Total (N)	672,913	10,978,373	645,118	75,195
Deceased (N) [any reason]	7,364	101,282	6,922	2,450
COVID-19 Dx (N)	7,927	519,387	7,527	3,201
COVID-19 Dx (%)	1.2%	4.7%	1.2%	4.3%
COVID-19 Dx & Deceased (N)	431	15,470	410	215
COVID-19 Dx & Deceased (%)	5.4%	3.0%	5.4%	6.7%

2819 Dx: diagnosis

2820

2821

**Table S12b: Unadjusted Chi-Square Comparison Inclusive of Deceased Patients**

	All Observations (with deceased)		"Bone-Rx" Observations (with deceased)	
	COVID-19 Dx	No COVID-19 Dx	COVID-19 Dx	No COVID-19 Dx
BP users	7,927	664,986	7,527	637,591
BP Non-users	519,387	10,458,986	2,450	71,994
Odds Ratio	0.24		Odds Ratio 0.35	
95 % CI:	0.2347 to 0.2455		95 % CI: 0.3312 to 0.3633	
p-value	P < 0.0001		p-value P < 0.0001	

2822 BP: bisphosphonate; CI: confidence interval; Dx: diagnosis

2823

2824

**Table S12c: Unadjusted Chi-Square Comparison with Deceased Patients Removed**

	All Observations (without deceased)		"Bone-Rx" Observations (without deceased)	
	COVID-19 Dx	No COVID-19 Dx	COVID-19 Dx	No COVID-19 Dx
BP users	7,496	657,622	7,117	630,669
BP Non-users	503,917	10,357,704	2,986	69,544
Odds Ratio	0.23		Odds Ratio 0.26	
95 % CI:	0.2290 to 0.2397		95 % CI: 0.2516 to 0.2745	
p-value	P < 0.0001		p-value P < 0.0001	

2825 BP: bisphosphonate; CI: confidence interval; Dx: diagnosis

2826

2827

2828

**Table S12d: Unadjusted Chi-Square Comparison Assuming all Deceased Patients had COVID-19**

	All Observations (assume deceased = COVID-19)		"Bone-Rx" Observations (assume deceased = COVID-19)	
	COVID-19 Dx	No COVID-19 Dx	COVID-19 Dx	No COVID-19 Dx
BP users	14,860	658,053	14,039	631,079
BP Non-users	605,199	10,373,174	5,436	69,759
Odds Ratio	0.39		Odds Ratio 0.29	
95 % CI:	0.3807 to 0.3935		95 % CI: 0.2764 to 0.2948	
p-value	P < 0.0001		p-value P < 0.0001	

2829 BP: bisphosphonate; CI: confidence interval; Dx: diagnosis

2830

2831

**Table S12e: Unadjusted Chi-Square Comparison to Yield Odds Ratio = 1.00 (no difference)**

	All Observations (assume deceased = COVID-19)		"Bone-Rx" Observations (assume deceased = COVID-19)	
	COVID-19 Dx	No COVID-19 Dx	COVID-19 Dx	No COVID-19 Dx
BP users	37,095	635,818	46,637	598,481
BP Non-users	605,199	10,373,174	5,436	69,759
Odds Ratio	1.00		Odds Ratio 1.00	
95 % CI:	0.9893 to 1.0108		95 % CI: 0.9713 to 1.0296	
p-value	P = 0.9987		p-value P = 0.9999	

2832 BP: bisphosphonate; CI: confidence interval; Dx: diagnosis

2832